Five years of daily statins extends life by an average of 3.2 days for people with no diagnosed heart disease and 4.1 days for those who already have it. Those figures sit underneath Pfizer’s advertised claim that Lipitor “reduces risk of heart attack by 36%,” a relative number resting on a 1.1 percent absolute difference, and underneath the Heart Protection Study press release that promised a thousand lives saved every week. In A Statin Nation (2018), Malcolm Kendrick works through the trials that built the cholesterol hypothesis and finds the same result repeating. Drugs that drove LDL lower than statins ever managed produced no reduction in deaths. In the FOURIER trial of the PCSK9 injection evolocumab, 251 people died of cardiovascular causes on the drug and 240 on placebo, and total deaths ran 444 against 426.

Kendrick is a Scottish-born general practitioner working in Cheshire, a graduate of Aberdeen University, and the author of The Great Cholesterol Con (2007) and Doctoring Data, a dissection of how trial results are presented to doctors and the public. He writes as a clinician who has watched patients regain the ability to stand and walk after stopping statins, and as a member of The International Network of Cholesterol Sceptics, founded by the Swedish physician Uffe Ravnskov. By his own account, the arrival of statins briefly made him reconsider his rejection of the cholesterol hypothesis. He co-authored a BMJ Open review finding that people over sixty with higher LDL live as long as, or longer than, those with lower levels; it was the journal’s most-read paper for five consecutive months and drew a public rebuttal from Oxford’s Colin Baigent. Steven Nissen, among the most prominent figures in American cardiology, answered Kendrick and his colleagues in JAMA with an article titled “Statin Denial: An Internet-Driven Cult With Deadly Consequences.”

The book arrived as the treatment net was being thrown wider. UK guidance had cut the ten-year risk threshold for statins from 20 to 10 percent, a change the British Medical Association’s GP conference rejected unanimously, to no effect. In 2017 the American Heart Association redefined hypertension as a systolic reading of 130, reclassifying about half the population, and issued a Presidential Advisory against saturated fat. PCSK9 injections had been approved in 2015 at around $14,000 a year, and within two years the stated prevalence of familial hypercholesterolemia, their target market, had doubled from 1 in 500 to 1 in 250. A Lancet paper had declared statin side effects a nocebo phenomenon. Much of what contradicted this consensus was already on record and had been set aside: Framingham’s own 1987 finding that falling cholesterol predicted higher mortality, John Yudkin’s 1972 warning about sugar, the Sugar Association’s 1964 payment to Harvard researchers to blame fat, and G.C. Willis’s vitamin C experiments from nearly sixty years earlier.

Kendrick writes from inside conventional medicine, and his evidence converges with the terrain principle that the body repairs itself: he describes infarcted heart muscle as a tightly controlled conversion to scar tissue, and the macrophages found in plaques as cleaners arriving to remove them. The full summary sets out Willis’s finding that guinea pigs deprived of vitamin C developed human-type plaques within days, which disappeared within days once vitamin C returned. It traces how IMPROVE-IT nearly doubled its enrollment mid-trial, kept its revised calculations secret, recorded 1,215 deaths against 1,231, and still lost an FDA advisory vote 10 to 5. It examines the 1985 study of familial hypercholesterolemia in which patients with heart disease and those without had the same lipid levels and differed in their clotting factors. The largest trial ever run on replacing saturated fat with vegetable oil found that every 0.78 mmol/l fall in cholesterol carried a 22 percent higher risk of death; its data spent decades in a garage, and its lead researcher was Ancel Keys.

Other Books by Dr. Malcolm Kendrick

Audio Deep Dive (for Paid Subscribers)

Read more

Colonialism is a known operating system. Identify a resource. Build the infrastructure to extract it. Capture the local elites who police the extraction. Dress the whole thing as a civilising mission. The pattern ran against India for two centuries, against the Congo for a generation, against Latin America for a hundred years. Every historian recognises it.

What has not been treated at book length, until now, is that the same operating system has been turned around and pointed at the middle class of the developed world. The resource is a middle-class lifetime of health and savings. The infrastructure is the medical system: pharma, hospitals, insurers, medical schools, the regulatory and professional bodies that service them. The captured local elites are the physicians, the researchers, the health reporters, the parents who defend what harmed their children. The civilising mission is “care.”

Extraction brings every part of the extractive machinery into view at the same time, because the pattern only resolves when the whole machinery is visible.

That is why the book is long. 578 pages, twenty-five essays, three appendices, the largest book in the catalogue to date. The length is the argument.

The seed idea, and the person who planted it

The frame that made this pattern visible came from . Rogers named the operating logic “biological colonialism” and did the foundational work of showing how it applies to the pharmaceutical industry’s relationship with children in the developed world. Extraction is the full-length treatment of that frame, extended across every part of the medical system and across a middle-class lifetime. The debt is foundational, and belongs at the top of the post.

What the book shows

Part One: The paradigm. What is being extracted, and what are the mechanisms of extraction at the biological level. The opening chapters put the vaccine schedule where the evidence places it: as the single largest contributor to the chronic disease epidemic in children. The Joy Garner Control Group Survey (2.64 percent chronic illness in the fully unvaccinated, 60 percent in the vaccinated). The particles in the vial that Antonietta Gatti and Stefano Montanari documented across hundreds of samples in high-resolution electron microscopy. The negative synergies between concurrent injections. The clearest single-part statement in the catalogue of the terrain case against the schedule.

Part Two: The architecture. How the infrastructure was built, and how it is defended. The Flexner Report of 1910, funded by Carnegie and Rockefeller, which reduced American medical education from 162 schools to 66 and killed the terrain tradition inside the United States. The institutional machinery that keeps the right questions from being funded (the streetlight effect) and that converts the survivors into the dataset the entire profession reasons from (survivorship bias). The 1986 Act that gave the pharmaceutical industry statutory immunity for vaccine injury, documented through Aaron Siri’s federal court work: the admission in writing from HHS that no placebo-controlled safety review of the schedule has ever been conducted. The scattered fragments of this story, put together in one place.

Part Three: The instruments. The specific tools of extraction, catalogued. Three parallel chapters: the 12 diagnostic thresholds lowered to create millions of new patients at a stroke (blood pressure, cholesterol, diabetes, osteoporosis), each one with the committee that voted and the industry money that funded the committee; the 12 recommended ages lowered to make more patients earlier; the 12 screening programs that manufacture the patients they claim to find. Then: Incurable and Progressive, the framing that converts a resource into a lifetime customer. The HPV lie: Gardasil, the Pap smear industry, and a cancer caused by something other than what you have been told. The Genetic Cover, taken apart over ten specific conditions (Alzheimer’s, Parkinson’s, Type 1 diabetes, cystic fibrosis, autism, Down’s syndrome, sickle cell, Huntington’s, Dravet syndrome, breast cancer), each with the environmental cause the genetic framing is used to conceal. And the medicalisation of ageing and death, where the extraction lands on your parents, nine medications in.

Part Four: The capture. Why the captured population defends the extraction. How the psychological capture works. Why the loudest defenders of the schedule are often the parents of the most obviously injured children. The guards who love you. The gratitude of the captured. These are the hardest chapters in the book because they describe something people recognise in people they love.

Part Five: The refusal. The proof of what the extraction has taken. The closing chapter sits with the Garner cohort, the Mawson studies, the Amish communities, and the Homefirst practice in Chicago. It describes what a chronic illness rate of 2.64 percent looks like in actual children. The counterfactual that was never meant to exist. The body of people who prove what we have lost.

What is at the back

Three appendices. The full Garner Control Group Survey data tables, reproduced with permission. The Gatti-Montanari and Davidson forensic catalogues of vial contents, element by element. And 25 Questions They Never Fund, a chapter-length list of the studies that would resolve every open question in a single calendar year if the institutions wanted them resolved.

Full back-of-book index. Key Numbers reference page. Timeline of the architecture from Flexner (1910) to the present. Glossary. Bibliography. Further Reading. Everything cross-referenced.

Who this book is for

If you have been reading me on Substack for a while and you have been waiting for the one book that holds the whole pattern together, this is that book.

If you are new, start here. You do not need to have read anything else to follow it.

If someone you love is still inside the system and you have been looking for the single volume to put in their hands, this is the one I would send.

Extraction on Lulu

The companion piece: The Genetic Deception, now in print

Chapter 19 of Extraction is called “The Ten Genetic Diseases That Aren’t Genetic.” A short treatment of a problem that needed its own full-length book, and that book came out one week ago.

The Genetic Deception traces how a failed science continues to shape the way disease is diagnosed, named, and treated. It examines the conditions where the genetic framework collapses on inspection. Cystic fibrosis, where the environmental trigger is omitted. Down’s syndrome, where the toxic exposures are known but not acknowledged. Dravet syndrome, where vaccine injury is renamed as inherited fate.

The second edition in print adds three new chapters, a full back-of-book index, and expanded Notes and Sources drawn from the primary literature. If Extraction is the architecture, The Genetic Deception is one of the load-bearing walls examined up close.

Readers who want the whole structure should read Extraction. Readers who want the genetic cover taken apart in detail should read The Genetic Deception. Readers who want both will find the pair reinforcing.

The Genetic Deception on Lulu

Audio Deep Dive (for Paid Subscribers)

Digital Edition

Platinum Supporters - immediate access

Want access now? Upgrade to Platinum Supporter to receive digital editions on paperback release day.

Standard Paid Subscribers - access in 3-6 months from date of this post

EPUB Edition — Platinum Supporters

An EPUB edition, readable on Kindle, Kobo, Apple Books, and any e-reader that supports the format. Platinum Supporters can download it below.

For the full paperback shelf

Both books sit on the Lulu shelf alongside the rest of the catalogue. The Boron Book. The Magnesium Handbook. No Autoimmunity. The Vaccine Books. The pet terrain titles.

lulu.com/spotlight/unbekoming

Thank you

Thank you for reading, for sharing, for buying, for lending, for recommending. The imprint runs on your attention and your word of mouth. Every book that goes out into the world does so because someone in this subscriber list decided it belonged on a shelf, in a library, on a coffee table, or in the hands of a friend.

Extraction is the longest of my books. If the architecture is to come apart, people have to be able to see it whole. That was the task.

With gratitude,

Unbekoming

Patrick Antonius is a Finnish professional poker player, resident of Monaco, with more than two decades at the highest levels of cash game poker and induction into the Poker Hall of Fame in 2024. In September 2026 he sat for a long interview with the podcaster JRB in which, nine minutes in, he began to describe his health in genetic terms. This essay examines what he actually said about his life, what the industry sold him as the explanation, and what the record of that industry contains. Establishment vocabulary (genes, variants, SNPs, “injury predisposition,” “autoimmune,” “genetic susceptibility”) appears here inside quotation and attribution, because that is where it lives. The terrain reading (mechanical overload, toxic exposure, nutritional depletion, the body’s intelligent response to injury) operates in the author’s own voice. Keeping the two registers separate is the only way to show both what the industry says and what the body had already told its owner.

The Interview

“I actually did some very deep genetic testing and I find out I have a g, I have we, I have very unusual genetics,” Patrick Antonius told the podcaster JRB in September 2026. “I have a gene that kind of makes it almost impossible to be a professional athlete, cuz when I try to push my body really hard I am, I’m very prone to like tendon injuries and disc injuries.”¹

He continued. “It’s scary how deep this gene stuff can go. It goes deep into your brain functioning, nutritioning, what, what it goes really deep. It goes even to specific foods.”²

He was now, he said, on “the very good program.” He had found a practitioner “specializing in all this autoimmune disease cancer which goes to the deepest level of health on the cellular level.” He was taking “kind of right supplements, right dietary things,” and feeling good. The timeline he described was lifelong, in exactly the way the industry’s marketing promises.³

Over the next ninety minutes of conversation he also, without noticing the connection, told JRB exactly what had happened to his body.

Audio Deep Dive (for Paid Subscribers)

What His Body Did

By age fifteen he was practicing tennis “four hours a day, five hours a day.” His back went. He described, in his own words, “a bulggin’s disc,” and an orthopedic doctor who told him he would never play tennis again. The physical therapy he received was poor. “That’s why it took so long to recover. One and a half years until I found like a good physical therapy, proper training and I recovered.”⁴

He returned. Two more years at the top of Finnish junior tennis, ranked top thirty nationally, training with players who would go on to professional careers. Another injury at nineteen ended tennis as a serious pursuit. Tennis, he said, is “a brutal sport when you practicing like 4 hours a day, 5 hours a day and you have shoulder elbow.”⁵

He then spent approximately twenty years sitting at card tables. In August 2026, after an unusually heavy stretch of poker during which he played “around the clock 24-hour sessions” for two weeks, he decided to return to competitive tennis. He developed a hip problem. He had been seeing a physiotherapist for two weeks when he spoke to JRB, limping, declining a weekend trip with friends.⁶

A boy was trained five hours a day until his spine ruptured. A teenager received eighteen months of bad physical therapy. A man came back to competitive sport after two decades of sitting at a card table and his hip complained. The pattern needs no further explanation. The body told the story each time. Patrick repeated the story accurately to his interviewer.

Then he reached for a gene.

The Discoverers’ Retreat

The gene story Patrick bought came from a small research network in Cape Town. In 2006, Gugu Mokone, Martin Schwellnus, Tim Noakes, and Malcolm Collins published a case-control study in the Scandinavian Journal of Medicine and Science in Sports. They compared 111 subjects with Achilles tendon pathology to 129 controls, all of European ancestry, in South Africa. They genotyped a particular variant in the COL5A1 gene, later catalogued as rs12722, and found that one allele was more common in the controls than in the cases. The odds ratio for the whole sample was 1.9, with a 95% confidence interval of 1.3 to 3.0. For a secondary analysis restricted to seventy-two subjects with chronic tendinopathy, the odds ratio rose to 2.6 (1.5 to 4.5). The paper concluded that individuals with the protective allele were “less likely of developing symptoms of chronic Achilles tendinopathy.”⁷

This is the paper that opened an entire athletic injury category inside the direct-to-consumer genetic testing industry. It is a candidate-gene study of 240 people, done in one city by one laboratory group. It is a reasonable starting hypothesis. It is not a clinical test.

In the years that followed, the same Cape Town network (Collins, Alison September, Michael Posthumus) ran further studies and added COL1A1 rs1800012 to the panel. Results were mixed. Some replicated. Some did not. Some pointed in opposite directions depending on how the alleles were coded. The COL1A1 genotype of commercial interest, the rare TT, appeared in approximately four percent of European controls. A rare homozygote does not sort the other ninety-six percent of customers.

By 2015, the Cape Town group was publishing cautions. In the British Journal of Sports Medicine that year, Collins, September, and Posthumus wrote that “many direct-to-consumer companies are currently marketing genetic tests directly to athletes without it being requested by an appropriately qualified healthcare professional, and without interpretation alongside other clinical indicators or lifestyle factors. These specific genetic tests are premature.”⁸

By 2023, in the same journal that had carried Mokone 2006, Collins and September published a review titled “Are commercial genetic injury tests premature?” Their answer, printed in the abstract: “the current evidence suggests that it is premature or even not viable to include these three polymorphisms as markers of injury risk.” The three polymorphisms they named: COL1A1 rs1800012, COL5A1 rs12722, GDF5 rs143383. These are the markers at the center of the commercial athletic genetics industry. The authors who discovered them, by name, told the industry to stop selling them.⁹

The industry did not stop.

What the Meta-Analyses Found

Pooled analyses accumulated. In 2022, Rui Guo and colleagues at Beijing Sport University published the largest synthesis in the literature, twenty-one observational studies on COL5A1 polymorphisms and musculoskeletal soft tissue injuries. For rs12722 overall: T versus C allele, OR 1.14 (95% confidence interval 1.03 to 1.28). An allelic odds ratio of 1.14 is a small shift in a noisy trait. It is not destiny. It is not a reason for a supplement.

The more consequential finding was in the stratified analysis. The authors wrote: “Stratified analyses by injury type suggested that rs12722 polymorphism was associated with an increased susceptibility to ligament injury under five genetic models. But the association was not found in tendon injury or muscle injury.”¹⁰

The marker that opened the field in 2006 as an Achilles tendinopathy finding does not, in the largest meta-analysis available in 2026, show a tendon-injury association. The literature has walked away from its own origin story.

Patrick is a tennis player with disc and tendon complaints. The marker sold for his profile has, in the best pool of evidence, no tendon association. He bought a lifetime of supplements against it anyway.

What the Industry Sells

The companies know all of this. They sell anyway.

3X4 Genetics operates out of Solana Beach, California. Its test is marketed as “35 pathway results across the 10 health areas,” at $299, available either direct to the consumer or through more than nine thousand associated clinicians. The muscle and skeletal pathway promises “Injury risk, recovery speed and bone health, train with your genes, not against them.” Every result “includes food, lifestyle and supplement guidance matched to your genes.” The lifelong frame is printed twice on the product page: “Yours for life, DNA doesn’t change” and “Never changes, test once, use for life.”¹¹ Patrick’s description to JRB of his supplements, his dietary rules, and his lifelong program could be lifted from the page.

SelfDecode sells a tendon-injury report for $59. The companion article, “You Train Hard, Yet Injuries Keep Sidelining You. Your Collagen Genes May Be Why,” is written by “the SelfDecode Research Team” and reviewed by Puya Yazdi, MD. It prescribes a protocol: “People with COL5A1 variants benefit from high-dose collagen peptides (10-15g daily of hydrolyzed collagen), combined with vitamin C (500mg daily), which is required for collagen cross-linking.” The article names Vital Proteins and Orgain as example brands. The adjacent frequency claim on the same page, that “roughly 30-35% of athletes carry the T allele” at rs12722, inverts Mokone’s own numbers. Mokone’s protective allele frequency was 29.8 percent in controls; the T allele was the majority. SelfDecode has published a frequency that reverses the reference paper’s data.¹²

Nutrigenomix is more careful on the surface. Its 2020 sample report, hosted on a laboratory website, names COL5A1 rs12722 by its official identifier, prints “Your variant: TT, Your risk: Elevated,” and cites a single paper to support the claim: September et al., British Journal of Sports Medicine 2009. That is one of the two main 2009 Cape Town papers. The sample does not cite Guo 2022, which found no tendon association. It does not cite Collins and September 2023, which told sellers to stop. The company’s recommendation in the sample case: “be mindful of activities requiring a surge of energy or overextension of this tendon through certain exercises such as uphill running. Preventive measures also include additional stretching of your calf muscles and increasing the duration of your warm up and cool down during exercise sessions.”¹³ Translated: warm up, stretch, strengthen your calves. The DNA test produced generic sports-medicine advice. The genotype did not change the advice. The genotype was the receipt.

DNAFit was once the UK brand name in this market. Its own domain, as of October 2026, redirects to CircleDNA. The company that was DNAFit has migrated. CircleDNA sells eighteen reports in its “sports and fitness” product, including “Injury Risk,” “Risk of Achilles Tendon Injury,” and “Risk of Anterior Cruciate Ligament Rupture.” It quotes an “analytical accuracy rate of 99.9%” for its sequencing. That is a claim about the lab chemistry. It is not a claim about the clinical accuracy of its injury-risk reports. The two numbers sit close together on the page.¹⁴

The MTHFR branch runs in parallel. Ben Lynch, ND, author of Dirty Genes, sells an “MTHFR Support Bundle” through Seeking Health, discounted to $73.60. The page opens: “You have an MTHFR variant. Here’s your starting point.” On duration: “If you carry significant variants, your body will likely always appreciate some level of support.”¹⁵ On an adjacent page on the same site, Lynch himself writes: “You do not base how much methylfolate you take based on which or how many MTHFR SNPs you have.”¹⁶ The company’s own site contradicts the company’s own product. Patrick’s second claim to JRB, that his gene goes into “brain functioning, nutritioning, specific foods,” is the MTHFR sales pitch almost verbatim.

Common population variants, often with weak or disputed effect sizes, become lifelong supplement protocols. The genotype provides the reason to start. “DNA doesn’t change” provides the reason never to stop. Where actionable advice appears, it is advice any competent coach or dietitian would already have given.

The Pattern Is Older Than Patrick

Patrick is not the first elite athlete to walk out of this industry with “high injury risk” written over his training history.

In March 2014, Runner’s World ran a piece on Jenny Meadows, the British 800-meter runner who had taken silver at the 2010 World Indoor Championships and then missed the 2012 Olympics with a tendon injury. After her injury she took a DNAFit test. “I only wish I’d had this information years ago. I could have trained more effectively,” she said. “The real eye-opener has been that I have a high risk of injury. This is the biggest fear of any athlete.”¹⁷

The magazine wrote that her DNAFit test “apparently revealed that she has an increased risk for soft-tendon injuries.” She modified her training to include fewer track workouts and more cycling. She became a DNAFit spokesperson. No gene name was published. No genotype. No lab report. The company had found a world-class athlete who had just suffered the exact injury the test’s output would frame as predicted.

The arrangement is structural. An elite athlete suffers an injury that threatens her career. She takes a test, which identifies that she has “high risk” for the kind of injury she just had. She adopts the finding as her own biography and tells the story in interviews, often as a paid spokesperson for the company that sold her the test. Her endorsement reaches the next injured athlete, who arrives at the test persuaded that someone like her found something useful. The test’s output is validated by her belief that it predicted something, when what it did was describe something after the fact. Greg Rutherford, the 2012 Olympic long jump champion, became a paid DNAFit spokesperson by 2016 under the same arrangement, promoting the test while winning further medals he attributed in part to its guidance.¹⁸

A decade after Meadows, Patrick Antonius told JRB: “I have very unusual genetics... I’m very prone to tendon injuries and disc injuries.” Two world-class athletes, ten years apart, arrived at the same self-description after a cheek swab, after the real injuries they had already sustained. The pattern is older than Patrick. He is the current example.

Seven in Ten

How unusual is “unusual”?

On October 15, 2020, a British runner writing under the name The PhD Runner published a review of her DNAFit experience. The company had sent her a report. Her injury result, as she rendered it: “I have a HIGH PREDISPOSITION to connective and soft tissue injuries. I am much more likely to develop tendinopathies and tendonitis with regular training.”¹⁹ She noted that the genes named “are most strongly linked to Achilles tendon, knee ligament, and shoulder injuries.”

She also noted something the company does not advertise. About seventy percent of DNAFit users had received the same injury result. A “high predisposition” shared by seven in ten customers is a marketing label, not a diagnosis.

Patrick’s “very unusual genetics” are, in the industry’s own commercial output, the ordinary result. The uniqueness he purchased for himself is the modal product the industry sells. Jenny Meadows got it in 2014. The PhD Runner got it in 2020. Patrick Antonius got it in time to talk about it on a podcast in 2026. The report is the product. The report is also the same report.

What the Mainstream Has Already Said

Mainstream medical genetics has been clear on this for more than a decade.

In 2013, the American College of Medical Genetics and Genomics published a practice guideline on MTHFR testing. The abstract concludes: “There is growing evidence that MTHFR polymorphism testing has minimal clinical utility and, therefore should not be ordered as a part of a routine evaluation for thrombophilia.”²⁰ A 2020 ACMG addendum reclassified the 2013 document from “evidence-based practice guideline” to “Clinical Practice Resource.” The clinical recommendation itself was not reversed.²¹

The CDC’s clinician page on folic acid, updated July 15, 2026, is addressed to the practitioner whose patient has walked in with a direct-to-consumer MTHFR result: “After testing with a direct-to-consumer genetic testing kit, patients may be seeking guidance on taking folic acid given their MTHFR genotype. There are no clinical recommendations at this time to test for MTHFR status or for consuming a different amount of folate or folic acid on the basis of the MTHFR genotype.”²²

The 2015 consensus statement from Webborn and colleagues in the British Journal of Sports Medicine, co-authored by fourteen sports scientists including Claude Bouchard, Yannis Pitsiladis, and Alun Williams, states: “The general consensus among sport and exercise genetics researchers is that genetic tests have no role to play in talent identification or the individualised prescription of training to maximise performance.” The same group warned about quality control failures, including samples from the same individual returning different results from different companies.²³

In November 2016, STAT journalist Rebecca Robbins published a long investigation into the athletic genetic testing industry. Robert Green, a geneticist at Harvard, told her: “The notion that they’re somehow tailoring these recommendations on the basis of your DNA is nonsense.”²⁴ Alun Williams, co-author of the Webborn consensus, told the same reporter that the companies cite the research “inappropriately,” with “selective quotations or taking little bit of information and extrapolating way beyond what we say.”²⁵

On March 31, 2021, the UK Advertising Standards Authority upheld a complaint against DNAFit. The ad in question had promised, “We’re DNA. We know all about your body.” The ruling: the ad “must not appear again in the form complained about.” The company was told its future marketing “must not state or imply they could provide consumers with effective personalised exercise and nutrition information or advice based on sequencing of their DNA that would result in improved health and fitness outcomes unless they held documentary evidence to that effect.”²⁶

The scientists who discovered the markers have called the tests premature. The sports science consensus says the same. Clinical geneticists have ruled MTHFR testing clinically useless. An advertising regulator forced DNAFit to pull an ad in 2021. The companies continue, operating under new brand names when the old ones become inconvenient.

The Same Device in Another Market

The gene story Patrick bought at retail is the same device used elsewhere. When connective tissue damage follows a pharmaceutical the medical system has conceded ground on, the admission is permitted; the CDC’s Pink Book acknowledges that up to twenty-five percent of adult women develop joint symptoms after MMR vaccination, attributed to the rubella component.²⁷ When connective tissue damage follows pharmaceuticals the medical system does not want investigated, the explanation migrates. The 2012 Institute of Medicine review parked reactive arthritis, rheumatoid arthritis, fibromyalgia, arthralgia, and brachial neuritis in the “inadequate evidence to accept or reject causation” bucket.²⁸ The post-vaccination literature attributes the chronic cases to “genetically susceptible individuals.” Pope’s 1998 Journal of Rheumatology case series of eleven hepatitis B recipients who developed rheumatoid arthritis used that framing,²⁹ as does Shoenfeld’s ASIA framework across dozens of vaccine-adjacent conditions.³⁰

The injury is real. The gene is where investigation stops. The industry Patrick walked into sells the retail version of that same stopping point. He is paying for it. People injured by pharmaceuticals they did not ask to think of as pharmaceuticals get the gene story imposed on them, often without being asked.

What Collagen Actually Needs, and What Damages It

Tendons and discs are made of collagen. Collagen is a protein. Proteins are built from amino acids, which come from food, and are assembled in the body with the help of specific cofactors, also from food. Type I collagen is built from glycine, proline, and lysine as its main amino acid inputs. Ascorbate (the molecule sold as vitamin C) is the cofactor for the enzymes that hydroxylate proline and lysine during fibril assembly. Copper is the cofactor for lysyl oxidase, the enzyme that produces the cross-links giving the fibril its tensile strength. Sulfur, zinc, and manganese contribute. Patrick could obtain all of these from a serving of beef liver and a bowl of bone broth, and would not need to buy them from Vital Proteins.

Collagen is damaged by what damages everything in the body: mechanical overload beyond recovery capacity, chronic inflammation from toxic exposure, nutritional depletion, and stress with its associated cortisol load. These are the four categories in which the terrain breaks down. Patrick’s injuries sit inside all four.

Mechanical overload: he trained five hours a day as an adolescent whose growth plates were still active. His spine responded by producing a bulging disc. His shoulder and elbow responded by producing inflammation and pain. These are intelligent responses. They are the body telling him to stop. He stopped at nineteen, not by choice but by injury.

Toxic exposure: the modern industrial food supply contains seed oils that generate inflammatory byproducts during metabolism, glyphosate residues on grains, pesticide and herbicide residues on produce, and preservatives, emulsifiers, and colorants the body spends energy clearing. The toxic burden begins earlier than food, with the pharmaceutical schedule administered across childhood. Patrick grew up on Finland’s. Patrick himself described his gluten story to JRB. He had been in a state of “inflammation, injuries, low energy levels, brain fog” for years. In 2011 he removed gluten and the symptoms resolved. “It only happened like few times in the first 6 months that I got some kind of symptoms when I quit gluten.”³¹ He explained his own transformation accurately. A food he had been eating was damaging his body. His body was responding with inflammation. When the insult was removed, the inflammation resolved. The gene story was not needed to make sense of any of it.

Nutritional depletion: soil mineral content has declined over the last century. Industrial processing strips remaining nutrients from grains. Modern eating patterns favor caloric density over nutrient density. The raw materials collagen needs are, for most people in industrial countries, in short supply.

Stress with cortisol load: cortisol breaks down collagen directly. Chronic sympathetic activation suppresses tissue repair. Patrick described to JRB a summer in which he played twenty-four-hour poker sessions back to back for two weeks before resuming hard tennis. He also described EMF, “stress,” and “overly stimulation” as causes of illness. He described how the body “heals itself” when given “right environment, right nutrition.”³² He stated the terrain framework in his own voice. He then handed it to a gene.

The honest explanation of his history is that his body was overworked as a child, inadequately rehabilitated as a teenager, poisoned by industrial food and specifically by gluten for the better part of two decades, then subjected to an abrupt return to high mechanical load after twenty years of sedentary work. The body produced the predictable responses at each stage: disc rupture at fifteen, chronic inflammation across his twenties, hip injury at forty-four. The gene did not cause these injuries. It was retailed to him as the terminal explanation for them, so the actual causes could remain unexamined and the supplement protocol could continue for life.

What the Gene Was For

A boy was trained past his recovery capacity until his spine broke. A teenager was given eighteen months of poor physical therapy and then sent back to the same training load that had broken him. A man came back to competitive sport after twenty years of sitting at a card table and his hip complained. These are not mysteries.

The industry that sold Patrick his explanation operates in open contradiction of the scientists who discovered its markers, the sports science consensus, the clinical geneticists, and the regulators who have examined its claims. The companies continue anyway, operating under new brand names when the old ones become inconvenient, selling the same product shape across different pathways. Seven in ten customers walk out “high risk.” Patrick walked out with the modal commercial result and announced his unusual genetics on a podcast.

The gene was a device for making the training log, the processed food, the childhood that preceded them both, and the industrial environment invisible. A lifetime supplement subscription was sold on their disappearance to a man who had already told his interviewer, in his own words, what had actually happened.

How to Explain It to a Six-Year-Old

Imagine a boy who runs around every day on concrete without proper shoes. His feet get sore. Then they get sore every day. Then one day they really hurt and he has to sit down.

A grown-up could tell him two different stories about why.

The first story: “The concrete is too hard. Your shoes are not good. Your feet needed a rest and did not get one. Let us fix the shoes, soften the ground, and give your feet time to heal.”

The second story: “You were born with special feet. Your genes make your feet weak. There is nothing you did and nothing you can change. Here is a little pill you must take every day forever, and here is a bowl of powder you must stir into your drink every morning. These will help your special feet. You will need them for the rest of your life. We also sell them.”

Both stories are told in the same friendly voice. One of them is true.

References

1. JRB (host). Interview with Patrick Antonius, Broke Living with JRB, September 2026, transcript at approximately 9:17.

2. Ibid., approximately 9:48.

3. Ibid., approximately 10:05 and 11:11.

4. Ibid., approximately 7:48 to 8:27.

5. Ibid., approximately 6:30 to 9:12.

6. Ibid., approximately 45:41 to 46:30.

7. Mokone GG, Schwellnus MP, Noakes TD, Collins M. “The COL5A1 gene and Achilles tendon pathology.” Scandinavian Journal of Medicine & Science in Sports 16, no. 1 (2006): 19–26. PMID 16430677. https://doi.org/10.1111/j.1600-0838.2005.00439.x

8. Collins M, September AV, Posthumus M. “Biological variation in musculoskeletal injuries: current knowledge, future research and practical implications.” British Journal of Sports Medicine 49, no. 23 (2015): 1497–1503. PMID 26504180. https://doi.org/10.1136/bjsports-2015-095180

9. Collins M, September AV. “Are commercial genetic injury tests premature?” Scandinavian Journal of Medicine & Science in Sports 33, no. 9 (2023): 1584–1597. PMID 37243491. https://doi.org/10.1111/sms.14406

10. Guo R, Ji Z, Gao S, et al. “Association of COL5A1 gene polymorphisms and musculoskeletal soft tissue injuries: a meta-analysis based on 21 observational studies.” Journal of Orthopaedic Surgery and Research 17 (2022): 129. PMID 35241120. https://doi.org/10.1186/s13018-022-03020-9

11. 3X4 Genetics. “3X4 Test + 3X4 Health app.” Product page, fetched October 4, 2026. https://3x4genetics.com/products/3x4-health

12. SelfDecode. “You Train Hard, Yet Injuries Keep Sidelining You. Your Collagen Genes May Be Why.” Article fetched October 4, 2026. https://selfdecode.com/en/pages/col5a1-gene-injury-risk/ ; and SelfDecode. “Tendon Injury” shop page. https://selfdecode.com/shop/injuries/tendon-injury/

13. Nutrigenomix. “70-Gene Sample Report.” PDF hosted at https://amc-lab.com/wp-content/uploads/2023/01/Nutrigenomix-70-gene-sample-report.pdf, copyright 2020, Achilles tendon injury page.

14. CircleDNA. “Sports & Fitness Report” and “Premium DNA Test” pages, fetched October 4, 2026. https://circledna.com/pages/sports-fitness-report ; https://circledna.com/products/premium-dna-test. The dnafit.com domain redirected to circledna.com as of the fetch date.

15. Seeking Health. “Dirty Genes - Super Seven - MTHFR.” Page fetched October 4, 2026. https://www.seekinghealth.com/pages/dirty-genes-super-seven-mthfr

16. Lynch, Ben. “Methylfolate Dosage for MTHFR: How Much Should I Take?” Seeking Health, fetched October 4, 2026. https://www.seekinghealth.com/blogs/education/methylfolate-dosage-for-mthfr-how-much-should-i-take

17. Burfoot, Amby. “British Runner Using DNA Tests to Improve Performance.” Runner’s World, March 18, 2014 (reporting the Associated Press). https://www.runnersworld.com/health-injuries/a20842360/british-runner-using-dna-tests-to-improve-performance/

18. DNAFit. “The Great Leap Forward in Training: Analyse Your DNA.” Press release via PR Newswire, April 14, 2016. https://www.prnewswire.com/news-releases/the-great-leap-forward-in-training--analyse-your-dna-575776611.html. Rutherford’s status as a paid spokesperson is reported in Robbins, Rebecca, “Genetic tests promise to help athletes train better. Can they deliver?”, STAT, November 2, 2016.

19. “Emma.” “DNAfit Test Review.” The PhD Runner blog, October 15, 2020. https://thephdrunner.com/2020/10/15/dnafit-test-review/

20. Hickey SE, Curry CJ, Toriello HV. “ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing.” Genetics in Medicine 15, no. 2 (2013): 153–156. PMID 23288205. https://doi.org/10.1038/gim.2012.165

21. Bashford MT, Hickey SE, Curry CJ, Toriello HV. Addendum to ACMG Practice Guideline. Genetics in Medicine 22 (2020): 2125. PMID 32533132. https://doi.org/10.1038/s41436-020-0843-0

22. Centers for Disease Control and Prevention. “Folic Acid: Facts for Clinicians.” Page dated July 15, 2026. https://www.cdc.gov/folic-acid/hcp/clinical-overview/index.html ; and CDC. “MTHFR Gene Variant and Folic Acid Facts.” Page dated July 16, 2026. https://www.cdc.gov/folic-acid/data-research/mthfr/index.html

23. Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, et al. “Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement.” British Journal of Sports Medicine 49, no. 23 (2015): 1486–1491. PMID 26582191. https://doi.org/10.1136/bjsports-2015-095343

24. Robert C. Green, quoted in Robbins, Rebecca. “Genetic tests promise to help athletes train better. Can they deliver?” STAT, November 2, 2016. https://www.statnews.com/2016/11/02/genetic-testing-sports/

25. Alun Williams, quoted in Robbins, ibid.

26. UK Advertising Standards Authority. “ASA Ruling on DNAfit Life Sciences Ltd t/a DNAfit.” Complaint A19-1036458, March 31, 2021. https://www.asa.org.uk/rulings/dnafit-life-sciences-ltd-a19-1036458-dnafit-life-sciences-limited.html

27. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), Rubella chapter. The up-to-25% figure for arthralgia and joint symptoms in adult women after rubella vaccination is cited in multiple editions; the attribution to the rubella component is explicit in the Pink Book text.

28. Institute of Medicine (Committee to Review Adverse Effects of Vaccines). Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: National Academies Press, 2012. Causality classifications for the conditions named appear in the summary tables of the chronic-joint and connective-tissue chapters. https://www.nationalacademies.org/read/13164

29. Pope JE, Stevens A, Howson W, Bell DA. “The development of rheumatoid arthritis after recombinant hepatitis B vaccination.” Journal of Rheumatology 25, no. 9 (1998): 1687–1693. PMID 9733447.

30. Shoenfeld Y, Agmon-Levin N. “’ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants.” Journal of Autoimmunity 36, no. 1 (2011): 4–8. PMID 20708902. https://doi.org/10.1016/j.jaut.2010.07.003

31. JRB, Interview with Patrick Antonius, approximately 14:34 to 15:44.

32. Ibid., approximately 13:40 to 14:26.

This essay tracks a documentary record. FDA approval dates, DSM diagnostic revisions, patent expirations, congressional investigations, and marketing campaigns all sit in the public archive. The clinical categories examined here (major depressive disorder, hypoactive sexual desire disorder, mild cognitive impairment, fibromyalgia, and the rest) appear in the vocabulary the manuals and package inserts use, because the argument concerns what those manuals did and when they did it. The mechanism being exposed is the mechanism the establishment built into its own paperwork. Readers who work from a terrain framework will notice the language of “disorders” and “conditions” is not endorsed here; it is being examined in its own words, because the record shows what those words were built for.

The Confession

The industry has a phrase for what it does.

“Every marketer’s dream is to find an unidentified or unknown market and develop it. That is what we were able to do with social anxiety disorder.”¹

Barry Brand, product director for Paxil at SmithKline Beecham, said that to Advertising Age. Paxil had received its FDA indication for social anxiety in May 1999. The condition existed in the diagnostic manual before the drug arrived. The market did not.

What follows are thirteen of these markets. Each began as an ordinary feature of human life: nervousness, sadness, aging, eating, sleeping, mourning, aching. Each acquired a clinical name at or near the moment a drug reached the shelves. The name created the patient. The patient created the prescription.

The suffering is real. The question is who named it a disease.

Every entry is verifiable in FDA approval records, DSM revisions, peer-reviewed research, and congressional reports. The pattern is not inference. It is a business model documented in its own paperwork.

Audio Deep Dive (for Paid Subscribers)

Related

1. Impulsive Eating → Binge Eating Disorder / Vyvanse (2015)

Shire Pharmaceuticals began developing lisdexamfetamine for binge eating in 2011.² The DSM did not yet recognize binge eating as a diagnosis. The DSM-5 promoted it from an appendix category to a standalone disorder in May 2013.³ In the eighteen months before FDA approval, Shire spent approximately $4 million on physician education about BED while cutting its ADHD education budget as that market exclusivity expired.⁴ The FDA approved Vyvanse for moderate to severe BED in January 2015, the first drug ever indicated for the condition.⁵

Jung and Fugh-Berman later documented in the Journal of the American Board of Family Medicine that all twenty-seven BED continuing-education modules in 2015 were Shire-funded, with seven of sixteen presenters disclosing financial ties to Shire. The modules framed Vyvanse as highly effective and quietly pitched it for weight loss, an off-label use for which amphetamines carry documented risks of addiction, cardiac events, and death.⁶ Shire hired tennis star Monica Seles to front the public awareness campaign.⁷ The authors of the peer-reviewed paper concluded that BED “may be an example of a disease created to sell a drug.” Overeating had become a diagnosis requiring a Schedule II amphetamine.

2. Puberty Distress → PMDD / Sarafem (2000)

Eli Lilly’s patent on Prozac was scheduled to expire in August 2001. In July 2000, Lilly received FDA approval for Sarafem, marketed for premenstrual dysphoric disorder.⁸ Sarafem was fluoxetine, the same molecule that had been Prozac since 1987, recolored pink and lavender in a new capsule with its own patent and sold in seven-day blister packs to help women “track” the condition.⁹ A Lilly marketing associate explained the brand split in simple terms: women did not look at their PMDD symptoms as depression, Prozac was closely associated with depression, and women told Lilly they wanted a treatment with “its own identity.”¹⁰

MIT held the use patent for fluoxetine in PMDD and had licensed it through Interneuron to Lilly, with royalties flowing back to the university.¹¹ PMDD had sat as a “provisional” category in DSM-IV’s appendix since 1994; it was promoted to a full diagnosis in DSM-5 in 2013.¹² The pink capsule did its work. Lilly retired the Sarafem brand once Prozac’s generic exposure was no longer the problem. The molecule, the manufacturer, the price, and the diagnosis had all served their purpose for the length of time the business required.

3. Shyness → Social Anxiety Disorder / Paxil (1999)

Paxil received its social anxiety indication in May 1999.¹³ SmithKline Beecham hired the public relations firm Cohn & Wolfe to run an awareness campaign built around the slogan “Imagine being allergic to people,” working through patient advocacy groups the firm helped organize.¹⁴ Social anxiety disorder had entered DSM-III-R in 1987 as a rare condition reserved for severe cases. The DSM-IV in 1994 broadened the criteria so dramatically that the American Psychiatric Association itself had to warn clinicians not to confuse the diagnosis with normal shyness.¹⁵

Prescriptions of Paxil for social anxiety rose from under 100,000 in 1998 to over one million within three years.¹⁶ The campaign placed stories about social anxiety in major newspapers and on television and set up help lines routing patients to physicians prepared to prescribe. A drug launch and a public relations campaign converted a rare diagnostic category into a condition carrying tens of millions of Americans and placed Paxil at the center of a new mass market. The condition existed in the manual before the drug arrived. The market did not.

4. Everyday Worry → Generalized Anxiety Disorder / Cymbalta (2007)

The GAD-7 screening tool was published in Archives of Internal Medicine in May 2006.¹⁷ Its seven questions include feeling nervous, worrying too much, and being unable to relax. A positive screen begins at five points out of twenty-one. In February 2007, Eli Lilly received FDA approval for Cymbalta in the treatment of generalized anxiety disorder.¹⁸

Lilly launched a direct-to-consumer campaign built around the phrase “Depression Hurts” and pushed the target population through primary care, where the GAD-7 could be administered in two minutes before the physician entered the room.¹⁹ Cymbalta reached annual sales exceeding $5 billion by 2013.²⁰ The screening tool and the indication arrived within nine months of each other. What both invited the physician to recognize was worry at a threshold most humans clear before breakfast.

5. Baldness → Androgenetic Alopecia / Propecia (1997)

Merck’s finasteride 5mg was approved as Proscar for enlarged prostate in 1992.²¹ In December 1997, Merck received a separate approval for finasteride 1mg as Propecia for male pattern baldness.²² The same molecule. One-fifth the dose. Substantially higher price per milligram than the identical drug for the prostate indication.²³ Going bald was reframed as androgenetic alopecia, a progressive medical condition requiring lifelong pharmaceutical management.

Post-finasteride syndrome, involving persistent sexual dysfunction, cognitive changes, and depression that continue after discontinuation, has been documented in the peer-reviewed literature since 2011.²⁴ A support foundation for post-finasteride syndrome maintains a registry of men who have died by suicide while suffering from it. Merck’s internal knowledge of the sexual side effect profile has been the subject of extended litigation.²⁵ The condition the drug was prescribed for was aging. The prescription was for life.

6. Male Aging → Low T / AndroGel (2000, DTC 2011)

AndroGel testosterone gel was approved by the FDA in February 2000.²⁶ Sales remained modest for a decade. In 2011, Abbott Laboratories launched the “Is It Low T?” direct-to-consumer campaign; Abbott spun off its pharmaceuticals as AbbVie in 2013.²⁷ The campaign was deliberately “unbranded,” meaning it never named AndroGel, while routing viewers to a quiz on IsItLowT.com whose results linked to the AndroGel website.²⁸ The ADAM questionnaire the quiz was built on had been developed by researchers funded by testosterone manufacturers; three yes answers out of ten suggested low testosterone.²⁹

Testosterone sales rose more than 1,800 percent in the three years after the campaign launched, reaching $1.9 billion in 2012.³⁰ A 2014 PLOS ONE study found a doubling of heart attack risk in men over sixty-five within ninety days of starting testosterone therapy.³¹ The FDA added a cardiovascular warning to testosterone product labels in 2015. AbbVie has paid substantial settlements through the testosterone products liability MDL.³² Getting older became a disease of the endocrine system.

7. Thinning Bones → Osteopenia / Fosamax (1995)

In 1992, a WHO study group meeting in Rome defined osteopenia as bone density between 1 and 2.5 standard deviations below the mean of a healthy thirty-year-old woman.³³ The comparison guarantees that virtually every woman over fifty falls short. “Osteopenia was never meant to be a disease in itself to be treated,” said Anna Tosteson of Dartmouth, who attended the Rome meeting.³⁴ Merck received FDA approval for Fosamax (alendronate) in September 1995.³⁵

Fosamax did not sell well at first because few women were being scanned. Merck hired a consultant named Jeremy Allen, created a nonprofit called the Bone Measurement Institute with Allen as its sole employee, financed the placement of portable DEXA scanners in physician offices, and lobbied through to passage the Bone Mass Measurement Act making the scans Medicare-reimbursable.³⁶ Diagnoses of osteopenia increased sevenfold.³⁷ Merck then launched a lower-dose Fosamax specifically for osteopenia.³⁸ Bisphosphonates cause osteonecrosis of the jaw and atypical femur fractures; absolute fracture reduction across major trials is one to two percent.³⁹ A statistical category became a diagnosis. The diagnosis became a drug that breaks the bones it was prescribed to protect.

8. Widespread Aches → Fibromyalgia / Lyrica (2007)

Fibromyalgia had been a contested rheumatology category since 1990, when the American College of Rheumatology established its diagnostic criteria.⁴⁰ Frederick Wolfe, who led that committee, later concluded fibromyalgia was a somatic response to emotional distress rather than a disease, and by 2008 was publicly calling it the product of “disease mongering.”⁴¹ Pfizer’s Lyrica (pregabalin), approved for epilepsy in 2004 and nerve pain in 2005, received the first FDA fibromyalgia indication in June 2007.⁴² Lilly’s Cymbalta followed in 2008 and Forest’s Savella in 2009.⁴³

Pfizer spent $138 million advertising Lyrica in 2008; Pfizer and Lilly together donated over $6 million to patient advocacy groups teaching physicians to recognize the diagnosis.⁴⁴ Daniel Clauw, the University of Michigan professor who became fibromyalgia’s leading academic voice, consulted for all three manufacturers.⁴⁵ Lyrica is a Schedule V controlled substance with documented withdrawal and dependence effects, as well as weight gain, dizziness, and edema.⁴⁶ It reached annual sales above $4 billion by 2012.⁴⁷ The man who wrote the diagnostic criteria had called it a label the drug companies made real.

9. Occasional Urgency → Overactive Bladder / Detrol (1998)

The term “overactive bladder” was popularized by Pharmacia & Upjohn’s marketing team in the late 1990s.⁴⁸ Detrol (tolterodine) received FDA approval in March 1998.⁴⁹ The condition was defined broadly enough that anyone experiencing sudden urges to urinate more than eight times daily could qualify.

The “Gotta Go” campaign for Detrol LA in 2001 taught the public to recognize the diagnosis in themselves and placed the question “Do you have overactive bladder?” into prime-time television slots.⁵⁰ Anticholinergic drugs like tolterodine have been associated with increased dementia risk in older adults in a dose-dependent relationship.⁵¹ Detrol became a billion-dollar franchise at its peak.⁵²

When Detrol’s patent expired and the anticholinergic dementia research grew clearer, newer OAB drugs took its place. Pfizer’s Toviaz and the first-in-class Myrbetriq promised fewer side effects than the drugs they replaced.⁵³ Each required the same diagnosis to prescribe. The urge to urinate, which every human recognizes without instruction, had become a syndrome requiring whatever drug the industry was selling that year.

10. Restlessness → Restless Legs Syndrome / Requip (2005)

GlaxoSmithKline received FDA approval for Requip (ropinirole) for restless legs syndrome in May 2005.⁵⁴ The condition described by Karl-Axel Ekbom in 1945 had sat in relative obscurity for sixty years before the launch. GSK spent $27 million advertising the new indication in the following year and funded the RLS Foundation with at least $850,000 between 2001 and 2006.⁵⁵ A prevalence survey funded by GSK reported that RLS affected one in ten adults; researchers unaffiliated with the company estimated actual prevalence well below three percent.⁵⁶

Requip sales doubled from $165 million in 2005 to nearly $330 million in 2006.⁵⁷ Ropinirole is a dopamine agonist. Its documented side effects include augmentation, in which the drug worsens the condition it was prescribed to treat, as well as impulse control disorders including pathological gambling and hypersexuality that have been the subject of extended litigation against the manufacturer.⁵⁸ A syndrome described in 1945 and left alone for six decades became a billion-dollar franchise within eighteen months of its first drug.

11. Low Libido → HSDD / Addyi (2015)

The FDA’s advisory committee voted unanimously against flibanserin in 2010 and again rejected the application in 2013.⁵⁹ Sprout Pharmaceuticals responded with a public relations campaign titled “Even the Score,” framing the rejections as a matter of gender equity and recruiting a coalition of twenty-six women’s organizations to lobby Congress and the FDA.⁶⁰ In August 2015, the FDA approved Addyi for hypoactive sexual desire disorder in premenopausal women.⁶¹

In the pivotal trial, women taking flibanserin daily reported approximately one additional sexually satisfying event per month over placebo.⁶² The alcohol interaction study submitted to the FDA used twenty-three men out of twenty-five participants, despite the drug being approved exclusively for women.⁶³ Addyi carries a black-box warning for severe hypotension and syncope with alcohol use. Two days after the approval, Valeant acquired Sprout for $1 billion.⁶⁴ Within two years Valeant handed Sprout back to its original shareholders as a failed asset.⁶⁵ A reluctant desire had been converted into a diagnosis requiring a drug the market itself refused.

12. Grief → Major Depression / SSRIs (DSM-5, 2013)

Before May 2013, the DSM excluded bereavement from major depressive disorder for the first two months following a loss.⁶⁶ A grieving widow could not be diagnosed with depression until she had grieved for at least eight weeks. The DSM-5 removed this exclusion.⁶⁷ A person who had just buried someone close could now be diagnosed with depression at the funeral and prescribed an SSRI on the way home.

Allen Frances, chair of the DSM-IV task force, had warned: “Making grief a mental disorder will be a bonanza for drug companies, but a disaster for grievers.”⁶⁸ Eli Lilly was already running clinical trials of Cymbalta for a proposed bereavement-related depression indication.⁶⁹ Antidepressant prescribing in the United States had already risen sharply through the 1990s and 2000s; the removal of the bereavement exclusion opened the newly bereaved to another decade of expansion.⁷⁰ The condition being treated is death.

13. Forgetfulness → Mild Cognitive Impairment / Aduhelm (2021)

Mild cognitive impairment was formalized as a diagnostic category through Mayo Clinic research in the late 1990s.⁷¹ In May 2019, after Biogen had abandoned its Alzheimer’s drug Aduhelm (aducanumab) over failed trials, Biogen’s chief scientist Al Sandrock met FDA neuroscience chief Billy Dunn off the books at a Philadelphia conference.⁷² Biogen then launched an internal campaign named “Project Onyx,” which produced at least 115 recorded contacts with the FDA over the following year.⁷³ In June 2021, the FDA granted accelerated approval to Aduhelm for Alzheimer’s disease including MCI.⁷⁴

None of the eleven members of the FDA advisory committee had recommended approval; three resigned in protest. Aaron Kesselheim called it “probably the worst drug approval decision in recent U.S. history.”⁷⁵ A congressional investigation later concluded that the FDA had “inappropriately collaborated” with Biogen on the briefing document the advisory committee had reviewed, and that Biogen had priced Aduhelm at $56,000 per year to “make history.”⁷⁶ Brain swelling and microhemorrhages appeared in roughly 40% of treated patients.⁷⁷ Biogen withdrew Aduhelm from the market in 2024. Billy Dunn had already resigned from the FDA in 2023.⁷⁸ The diagnostic category remained.

The Pattern

The mechanism behind these thirteen rebrands is a machine with three moving parts. A committee changes a definition. A drug arrives. A campaign teaches the population to recognize the diagnosis in themselves.

The committees are not independent. Cosgrove and Krimsky documented in PLOS Medicine in 2012 that 69% of DSM-5 task force members reported financial ties to the pharmaceutical industry, up from 57% on the DSM-IV task force before it.⁷⁹ Three-quarters of the DSM-5 work groups drafting the manual had majorities with such ties. The FDA that approves the drugs operates on pharmaceutical user fees that fund roughly two-thirds of its drug review budget.⁸⁰ The committees that invent the diagnoses and the agencies that approve the drugs are substantially paid by the same companies that sell them. This is not conspiracy. It is disclosed financial architecture.

The Aduhelm investigation showed what the architecture produces when it operates at full capacity. The FDA co-wrote with Biogen the briefing document that the advisory committee reviewed, met with Biogen more than a hundred times in a year, and approved the drug over the unanimous rejection of its own experts. The drug then failed in the market, Biogen withdrew it, and the diagnostic category it was approved to treat remained in the manual. That sequence is the pattern at full volume. The quieter cases in this essay are the same pattern at lower volume.

The DSM does not remove diagnoses. The FDA does not reverse indications. When a drug fails or its manufacturer withdraws it, the category remains in the manual. Physicians trained during the launch keep prescribing. The children whose parents were told they had ADHD grow up believing they have adult ADHD, and their children will be diagnosed with binge eating disorder. What began as a marketing campaign becomes clinical common sense within one professional generation.

Accepting any of these rebrands forces the frame across the rest. If PMDD and social anxiety and Low T and overactive bladder and fibromyalgia were built to sell drugs, the diagnostic labels a person holds about themselves are no longer observations. Some are advertising residue.

The pattern is not hidden. FDA approval dates sit in public databases, and DSM revision timelines and pharmaceutical patent schedules are a search away. The Barry Brand confession is in Advertising Age, and the Project Onyx documents are in the congressional record. The Jeremy Allen interview on how Merck’s Bone Measurement Institute built the osteopenia market was broadcast on NPR. The Jung and Fugh-Berman paper on how Shire paid for every continuing-education module on binge eating disorder in the year of Vyvanse’s approval is in the Journal of the American Board of Family Medicine. Frederick Wolfe’s disavowal of fibromyalgia as a disease was reported on the front page of the New York Times.

The next time a doctor offers a new name for something ordinary, look up when the name entered the manual and what drug reached the market that year. When the two align, the diagnosis is telling you what it was built for.

A companion essay, “The Thresholds That Weren’t,” examines the parallel mechanism of lowering numerical cutoffs for existing diagnoses (blood pressure, cholesterol, blood sugar, bone density) to manufacture millions of new patients overnight. The present essay examines the invention of names. The two mechanisms work the same way.

How to Explain It to a Six-Year-Old

Imagine you own a factory that makes umbrellas. You have too many umbrellas, and nobody is buying them because it is not raining much where you live. The umbrellas are stacking up in your warehouse. Your bills are coming due. You need to sell your umbrellas, and you cannot change the weather.

So you decide to change the weather in people’s heads instead. You start walking around telling people that a little drizzle is actually a very dangerous storm. You give it a scary name: Storm Anxiety Condition. You put up posters. You go on television. You get doctors to agree that Storm Anxiety Condition is real and that an umbrella is the only treatment. Soon your neighbors line up at your factory and buy your umbrellas, because they are afraid of the dangerous storm you told them about.

The drizzle did not change. Your factory did not change. The umbrellas did not change. You just gave the ordinary thing a scary new name and convinced everyone it was dangerous. That is what happened thirteen times in the pages above. Somebody had a new pill. Somebody gave the ordinary thing a scary new name. Everybody bought the pill. The drizzle was never the problem.

References

1. Brendan Koerner, “Disorders Made to Order,” Mother Jones, July/August 2002; Christopher Lane, Shyness: How Normal Behavior Became a Sickness (Yale University Press, 2007); Barry Brand quote to Advertising Age cited in both.

2. Public Citizen Health Research Group, “Vyvanse for Binge Eating: Old Pill, New ‘Disease,’” Health Letter, July 2015.

3. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 2013. Binge Eating Disorder promoted from Appendix B to a standalone diagnostic category.

4. Public Citizen Health Research Group, Health Letter, July 2015.

5. FDA News Release, “FDA expands uses of Vyvanse to treat binge-eating disorder,” January 30, 2015.

6. Jinhyun Jung and Adriane Fugh-Berman, “Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED),” Journal of the American Board of Family Medicine 33, no. 2 (March 2020): 240–251.

7. Shire plc press materials, January–February 2015, documented in Public Citizen Health Letter, July 2015.

8. FDA Approval Package for Sarafem (fluoxetine hydrochloride), NDA 21-107, approved July 6, 2000.

9. Melody Petersen, “Lilly’s Boost For Fluoxetine, With A Twist,” New York Times, October 22, 2000.

10. Nathan Greenslit, “Depression and Consumption: Psychopharmaceuticals, Branding, and New Identity Practices,” Culture, Medicine and Psychiatry 29, no. 4 (2005): 477–501; Lilly marketing associate quoted therein.

11. MIT News Office, “MIT-patented treatment approved by FDA for severe form of PMS,” July 2000. MIT held U.S. patent on serotonin-reuptake-inhibitor use for PMDD, licensed through Interneuron to Eli Lilly.

12. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 1994, Appendix B; DSM-5, 2013.

13. FDA Approval Package for Paxil (paroxetine hydrochloride) for Social Anxiety Disorder, NDA 20-031/S-024, approved May 11, 1999.

14. Brendan Koerner, “Disorders Made to Order,” Mother Jones (2002); Christopher Lane, Shyness (2007). Cohn & Wolfe campaign documented in both.

15. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 1994, Social Phobia criteria and clinician guidance.

16. IMS Health data cited in Koerner (2002) and Lane (2007).

17. Robert L. Spitzer et al., “A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7,” Archives of Internal Medicine 166, no. 10 (May 22, 2006): 1092–1097.

18. FDA Approval Package for Cymbalta (duloxetine hydrochloride) for Generalized Anxiety Disorder, NDA 21-427/S-015, approved February 26, 2007.

19. Eli Lilly direct-to-consumer campaign materials for Cymbalta, 2007–2013; “Depression Hurts” tagline.

20. Eli Lilly and Company, Annual Report 2013.

21. FDA Approval Package for Proscar (finasteride 5mg), NDA 20-180, approved June 19, 1992.

22. FDA Approval Package for Propecia (finasteride 1mg), NDA 20-788, approved December 19, 1997.

23. Retail pricing comparison for Proscar and Propecia at launch, documented in Martha Rosenberg, Born With a Junk Food Deficiency (Prometheus Books, 2012).

24. Michael S. Irwig and Swapna Kolukula, “Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss,” Journal of Sexual Medicine 8, no. 6 (June 2011): 1747–1753; Post-Finasteride Syndrome Foundation registry.

25. In re: Propecia (Finasteride) Products Liability Litigation, MDL No. 2331 (E.D.N.Y.).

26. FDA Approval Package for AndroGel 1% (testosterone gel), NDA 21-015, approved February 28, 2000.

27. “2013 All-Star Large Pharma Marketing Team of the Year: AndroGel,” Medical Marketing & Media, January 2013; corporate history per Abbott Laboratories and AbbVie Inc. Form 10-K filings; AbbVie spin-off completed January 1, 2013.

28. “Testosterone Marketing Frenzy Draws Skepticism,” NBC News, September 9, 2012; Lisa M. Schwartz and Steven Woloshin, “Low ‘T’ as in ‘template’: how to sell disease,” JAMA Internal Medicine 173, no. 15 (August 12, 2013): 1460–1462.

29. John E. Morley et al., “Validation of a screening questionnaire for androgen deficiency in aging males,” Metabolism 49, no. 9 (September 2000): 1239–1242; industry funding disclosed in publication.

30. Schwartz and Woloshin, JAMA Internal Medicine (2013); Kantar Media advertising-spend data cited in NBC News, September 9, 2012.

31. William D. Finkle et al., “Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men,” PLOS ONE 9, no. 1 (January 29, 2014): e85805.

32. In re: Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545 (N.D. Ill.); AbbVie Inc. Form 10-K filings; FDA Drug Safety Communication, March 3, 2015.

33. World Health Organization, “Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis,” WHO Technical Report Series 843, 1994, based on 1992 study group meeting in Rome.

34. Alix Spiegel, “How A Bone Disease Grew To Fit The Prescription,” NPR All Things Considered, December 21, 2009.

35. FDA Approval Package for Fosamax (alendronate sodium), NDA 20-560, approved September 29, 1995.

36. Spiegel, NPR, December 21, 2009; Ray Moynihan and Alan Cassels, Selling Sickness (Nation Books, 2005); “Merck to support DEXA scanner sales,” Diagnostic Imaging, 1995.

37. Spiegel, NPR, December 21, 2009.

38. Fosamax 35mg once-weekly approval for the prevention of osteoporosis, FDA 2000; Moynihan and Cassels (2005).

39. Documented in Unbekoming, “The Screening Trap” (2025), drawing on bisphosphonate trial meta-analyses; see also The Architecture of Deception (2025), chapter on bisphosphonates.

40. Frederick Wolfe et al., “The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia,” Arthritis & Rheumatism 33, no. 2 (February 1990): 160–172.

41. Alex Berenson, “Drug Approved. Is Disease Real?” New York Times, January 14, 2008; Associated Press investigation of fibromyalgia promotion, 2009, quoting Wolfe calling the Pfizer and Lilly campaigns “disease mongering.”

42. FDA News Release, “FDA Approves First Drug For Treating Fibromyalgia,” June 21, 2007.

43. FDA Approval Packages for Cymbalta fibromyalgia indication (June 13, 2008) and Savella/milnacipran (January 14, 2009).

44. Associated Press investigation of fibromyalgia promotion, 2009; TNS Media Intelligence advertising-spend data cited in multiple outlets.

45. Berenson, New York Times, January 14, 2008.

46. Lyrica (pregabalin) Prescribing Information, Pfizer Inc., Schedule V designation and adverse effect profile.

47. Pfizer Inc. Annual Report 2012; Lyrica revenue data.

48. Ray Moynihan, “The marketing of a disease: female sexual dysfunction,” BMJ 326 (2003): 45–47; Moynihan and Cassels, Selling Sickness (2005), chapter on OAB.

49. FDA Approval Package for Detrol (tolterodine tartrate), NDA 20-771, approved March 25, 1998.

50. Pharmacia Corporation, Detrol LA marketing materials, 2001; documented in Moynihan and Cassels, Selling Sickness (2005).

51. Shelly L. Gray et al., “Cumulative Use of Strong Anticholinergics and Incident Dementia,” JAMA Internal Medicine 175, no. 3 (March 2015): 401–407.

52. Pfizer Inc. Annual Reports, 2005–2010, following acquisition of Pharmacia.

53. FDA Approval Packages for Toviaz (fesoterodine fumarate), approved October 31, 2008, and Myrbetriq (mirabegron), approved June 28, 2012; Myrbetriq Prescribing Information, Astellas Pharma, cardiovascular warnings.

54. FDA Approval Package for Requip (ropinirole hydrochloride) for Restless Legs Syndrome, NDA 20-658/S-010, approved May 5, 2005.

55. Steven Woloshin and Lisa M. Schwartz, “Giving Legs to Restless Legs: A Case Study of How the Media Helps Make People Sick,” PLOS Medicine 3, no. 4 (April 11, 2006): e170; funding figures from Dartmouth Medicine coverage of the paper and Washington Post reporting.

56. Richard P. Allen et al., “Restless legs syndrome prevalence and impact: REST general population study,” Archives of Internal Medicine 165, no. 11 (June 13, 2005): 1286–1292, GlaxoSmithKline funding disclosed; Woloshin and Schwartz (2006) counter-estimate.

57. Requip sales growth documented in Public Citizen Worst Pills, Best Pills newsletter and NBC News coverage.

58. Requip (ropinirole) prescribing information, augmentation and impulse control disorder warnings; dopamine agonist impulse-control litigation.

59. FDA Advisory Committee minutes on flibanserin, June 18, 2010 (unanimous vote against approval), and FDA Complete Response Letter, October 2013.

60. Sprout Pharmaceuticals, “Even the Score” campaign materials, 2014; documented in Nature Reviews Drug Discovery 14 (October 2015): 669.

61. FDA News Release, “FDA approves first treatment for sexual desire disorder,” August 18, 2015.

62. Sprout Pharmaceuticals, Addyi (flibanserin) FDA Advisory Committee Briefing Document, June 4, 2015.

63. Addyi FDA labeling and advisory committee transcript, June 4, 2015; also Ms. Magazine, June 12, 2015, documenting the trial composition.

64. Andrew Pollack, “Valeant to Buy Sprout, Maker of Addyi Female Libido Pill, for $1 Billion,” New York Times, August 20, 2015.

65. Valeant Pharmaceuticals International press release, November 2017; Genetic Engineering & Biotechnology News coverage, November 2017.

66. American Psychiatric Association, DSM-IV, 1994, Major Depressive Episode criteria, bereavement exclusion.

67. American Psychiatric Association, DSM-5, 2013, Major Depressive Disorder criteria.

68. Allen Frances, “Last Plea To DSM-5: Save Grief From the Drug Companies,” Psychology Today, January 7, 2013; and Saving Normal (William Morrow, 2013).

69. Lilly duloxetine development pipeline documented in Patricia Pearson, “When did life itself become a treatable mental disorder?” Globe and Mail, April 2013.

70. Laura A. Pratt et al., “Antidepressant Use in Persons Aged 12 and Over: United States, 2005–2008,” NCHS Data Brief No. 76 (October 2011).

71. Ronald C. Petersen et al., “Mild Cognitive Impairment: Clinical Characterization and Outcome,” Archives of Neurology 56, no. 3 (March 1999): 303–308.

72. Damian Garde and Adam Feuerstein, “Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug,” STAT News, June 29, 2021.

73. House Committee on Oversight and Reform and Committee on Energy and Commerce, “The High Price of Aduhelm’s Approval: An Investigation into FDA’s Atypical Review Process and Biogen’s Aggressive Launch Plans,” December 2022.

74. FDA News Release, “FDA Grants Accelerated Approval for Alzheimer’s Drug,” June 7, 2021.

75. Peripheral and Central Nervous System Drugs Advisory Committee, FDA, November 6, 2020 meeting minutes; Adam Feuerstein and Damian Garde, “Three FDA advisers resign over agency’s approval of Aduhelm,” STAT News, June 10, 2021; Kesselheim resignation letter.

76. House Oversight and Energy and Commerce Committees, “The High Price of Aduhelm’s Approval,” December 2022.

77. Aduhelm (aducanumab-avwa) Prescribing Information, Biogen Inc., 2021; ARIA (amyloid-related imaging abnormalities) incidence data.

78. Biogen Inc. press release, “Biogen to Realign Resources for Alzheimer’s Disease Franchise,” January 31, 2024; Billy Dunn FDA departure announced February 2023.

79. Lisa Cosgrove and Sheldon Krimsky, “A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations with Industry: A Pernicious Problem Persists,” PLOS Medicine 9, no. 3 (March 13, 2012): e1001190.

80. FDA Prescription Drug User Fee Act (PDUFA) funding structure; see Government Accountability Office reports on FDA drug review budget composition.

This essay examines a clinical observation about blood pressure drugs and kidney failure, and the primary-text lineage that observation sits inside. Two registers of language operate here. The first is medicine’s own vocabulary. Hypertension as a diagnostic category, essential hypertension as a species of it, antihypertensive drugs as its correction, renoprotection as a protective effect established in trial endpoints: these terms appear in quotation, in trial names, and when the mainstream shelf is being described. The second register is the terrain reading in the author’s analytical voice. It treats elevated blood pressure as a response the body is making for a reason, and the drugs that force it down as interference with that response. The two registers describe the same physical events differently. Shifts between them are intentional. Nothing in this essay is medical advice. No reader should stop a prescribed medication unilaterally. The question posed here is a different one, and it belongs in a conversation with a physician who will engage it.

Kaufman’s Observation

In November 2017, 31 million Americans became hypertensive overnight. Their bodies had not changed. Two professional societies had moved the diagnostic threshold from 140/90 to 130/80 mmHg, and the population of the diseased expanded by fourteen percent of the adult population in a single publication cycle.¹⁷

The reading was unchanged. The name applied to it had migrated downward. The question underneath, what the body was doing when it raised the pressure, went unexamined in the publication cycle that moved the threshold, and continues to go unexamined in the practice that followed. The mainstream Cochrane literature has, meanwhile, already answered a related question: whether the drugs the new threshold brought under indication help the population the new threshold targeted.

Andrew Kaufman, a working clinician, says the most common cause of kidney failure in his practice is blood pressure medication. He makes a stronger claim: he has never seen a patient with kidney disease who was not taking an antihypertensive drug. When the body raises pressure at rest, Kaufman argues, something has reduced the flow of blood to the organs, and the higher pressure is the body’s correction. Lower the pressure chemically without addressing the reason it rose, and the organs return to the under-perfused state the body was trying to escape.¹

The strongest form of that observation collapses on inspection. Nearly every patient diagnosed with hypertension is prescribed an antihypertensive by current protocol. The correlation Kaufman reports is near-automatic. A physician who sees hundreds of hypertensive patients will see hundreds on medication, and the overlap with later kidney decline is confounded by indication from the moment the diagnosis is made.

What the pattern cannot do is close the question underneath. If the body raises blood pressure for reasons, lowering it chemically without identifying those reasons leaves the reasons in place. The organs that depended on the higher pressure for perfusion are now receiving less of it. Over time, in some patients, that reduction damages them. The mechanism does not depend on Kaufman’s census, and it is not his invention. Tilden described a version of it in 1921, Shelton a sharper version in 1964, Richard Moore a biophysics-adjacent version in 2001. Dawn Lester and David Parker synthesized the modern terrain reading in 2019. Twenty years of establishment pharmacovigilance has reached parts of the same mechanism from a different direction.

Audio Deep Dive (for Paid Subscribers)

Tilden, 1921

John Henry Tilden spent twenty-five years prescribing drugs. Then he stopped. He practiced for another thirty-three years without them, and in 1926 he gave his tally in Toxemia Explained: the drugs he had once prescribed were “unnecessary, and in most cases injurious.”²

His framework was toxemia. Toxic residues from imperfect digestion, inadequate elimination, and habits that drained nerve energy accumulated in the body for years. When the accumulation reached an organ already compromised, that organ gave way, and medicine named the organ’s failure. The toxemia was underneath all along.

In Impaired Health, published in 1921, he set out the drivers he had identified in his hypertensive patients. Tobacco. Tea. Coffee. Alcohol. Nervous overstimulation. Excessive eating of foods that putrefy in the intestine. These, he wrote, were “the most intense etiological factors” in arteriosclerosis.³ Elevated pressure was what the body did downstream of these habits, not a disease in its own right. Stop the stimulants, he claimed, and the arteries might soften, a timeline that overshoots what any controlled study could demonstrate but a doctrinal position that still holds. The leading orders in treatment, in his phrase, were proscriptions.

The sentence that reaches furthest into the question Kaufman raises comes from the epistaxis chapter. Tilden had observed that patients prone to apoplectic events sometimes bled from the nose, and that these bleeds were followed by lower pressure. He named the bleeding “conservative.” The body, he reasoned, was spending pressure through the easiest available outlet to protect something more valuable from losing it. Bleeding is not therapy. Modern stroke care has moved on. What Tilden named in 1921 language is the pattern Kaufman describes a century later. The pressure was doing something.

In the chapter on acute Bright’s disease, Tilden wrote that kidneys already weakened by toxic insult become “very susceptible” to the irritant drugs of his period: atropine, cantharides, potash, carbolic acid. The named agents are not antihypertensives. The pharmacology of ACE inhibition did not exist in 1921. The logic is what carries. Drugs act in the body. Weakened organs are more vulnerable to their side actions than healthy ones. A kidney already compromised by toxemia is a kidney that will be further compromised by whatever is added to the stream. Tilden’s response was removal of the toxic load. Elevated pressure sits downstream of a chain of insults, and drugs added to that chain extend it.

Shelton, 1964

Herbert Shelton reached for a garden hose. The hose at full flow. Water running out the open end. Now a nozzle at the tip, tightened until the opening narrows. The water still has to get through. The pressure behind the nozzle rises. Shelton applied the image to the body. When the arterioles throughout the body narrow under systemic irritation, pressure rises behind them, because the heart is still trying to deliver the same volume of blood to the same tissues.⁴

He called elevated pressure “an ending in a chain of causes” that reached back years into the life of the patient. The chain he named in that 1964 chapter: nervous strain, excessive eating, coffee, tea, tobacco, alcohol. Salt was a contributor, but not the whole story, and assigning everything to salt was a way of letting the rest of the chain go unexamined. Drugs that reduced the pressure without touching the chain produced what Shelton called a “forced reduction.” The pressure dropped only so long as the drug was taken. In his patients it often began to climb again despite the drug, because the chain was still intact and still generating the response.

“Genuine reduction” was pressure that fell because the causes had been removed. Shelton’s vehicle was fasting. Rest. Water. No further toxic load. The systemic irritation declined, and pressure declined with it. In his cases the lowered pressure tended to stay down after eating resumed, provided the eating did not rebuild the chain. The clinical observations were uncontrolled and should be read as such. The doctrinal distinction underneath, between pressure forced down by drugs and pressure that falls because its causes have gone, is what reaches into the modern argument.

The nephritis chapter is where the lineage becomes directly visible on the kidney. Bright’s disease, Shelton wrote, was a condition of people who ate heavily and continuously of foods that burdened the organs of elimination. The sentence that stands behind the whole kidney argument of this essay sits in that same chapter: “Many drugs produce inflammation of the kidneys.”⁵ He named the drugs of his period that did it. He also warned against the then-fashionable practice of forcing fluids on compromised kidneys. Excessive water drinking, he wrote, served no purpose for an organ already failing to process what it had.

Shelton closed the hypertension chapter with the formulation that frames the end of this essay. If we cut out causes instead of cutting out organs, he wrote, we secure a genuine elimination of effects. Modern pharmacology has, from a different direction, begun to confirm it.

Moore, 2001

Richard Moore held an MD from Indiana University and a biophysics PhD from Purdue. He taught biophysics at the State University of New York at Plattsburgh. His 2001 book The High Blood Pressure Solution took the Hygiene reading and translated it into cellular biophysics. His own mechanism was the potassium-to-sodium ratio inside the cell, which he called the K Factor. Diets heavy in sodium and poor in potassium disturbed the electrical balance of every cell. Elevated blood pressure was one visible marker of that disturbance.⁶ Moore overreached when he argued for the K Factor as a near-complete explanation; his claim that a Finnish salt-substitution program drove a sixty-percent decline in stroke and heart attack deaths compresses a multi-factor cardiovascular shift into a single story. The essay is not building on that part of his argument.

What Moore gave the lineage was a bridge. He said the thing Shelton had said, in a vocabulary modern readers could receive without rejecting on sight. Blood pressure, Moore wrote, was a marker, or a sign that something is out of balance. He compared it to body temperature. A fever is a sign that something is wrong, not the illness itself. Treating the fever without finding the inflammation it reports is treating a signal rather than its source.

The pharmacology paragraph is the one Lester and Parker extracted for their chapter on antihypertensives. Antihypertensive drugs, Moore wrote, produce side effects because they alter basic body functions, in the nervous system and kidneys as well as the blood vessels. They do not have a kidney side effect by accident. They alter kidney function by design, because the kidney is a central site of blood pressure regulation and the drugs operate on the mechanisms the kidney uses. Lester and Parker drew the inference Moore stopped short of: kidney disease could, on this reading, be a result of antihypertensive drugs rather than a prior cause of elevated pressure. Moore himself prescribed a program whose first step was “see your doctor.” His book is not a withdrawal pamphlet. Neither is this essay.

Moore remembered a 1950s pharmacology classroom. His instructors had told the students that every drug can also be a poison. Three decades later he sat in a lecture in which a side effect was named and a drug to manage that side effect was named in the next slide, with no reminder of the earlier teaching. The pharmacology of a drug and the pathology of a poison are two readings of the same molecule.

Moore’s framework found its modern physiological articulation in the work of Thomas Cowan, a cardiologist trained inside mainstream medicine. In Human Heart, Cosmic Heart, Cowan documented that roughly eighty percent of ischemic cardiac events are preceded by a chronic reduction in parasympathetic nervous system activity. The parasympathetic branch, mediated by the vagus nerve and acetylcholine, is the body’s restorative arm. When its tone collapses under sustained load, the sympathetic branch dominates. Vessels tighten. Pressure rises. Cowan listed what suppresses vagal activity: smoking, diabetes, sustained psychological strain, and hypertension itself.¹⁸ The reading called hypertension is one of the factors that produces the autonomic imbalance that produces the readings called hypertension.

Kaufman Today

Kaufman stands at the end of the lineage. His language is modern clinical informality rather than nineteenth-century prose or mid-century Hygiene doctrine, but the shape of what he describes is unchanged. Pressure rises because something is reducing flow. Flow is reduced either because volume is low or because the vessels have stiffened or narrowed. The pressure elevation is the body’s response to the reduction. Kaufman is a working clinician reproducing an argument whose primary-text evidence spans three previous generations and now converges with pharmacovigilance the establishment itself has published.

Lester and Parker, 2019

Dawn Lester and David Parker’s What Really Makes You Ill?, published in 2019, gathered the lineage for modern readers. On antihypertensive drugs they followed Moore’s pharmacology sentence to its conclusion: kidney disease, they argued, could be a result of the drugs rather than a prior cause of the elevated pressure the drugs were prescribed to lower.¹⁵ On hydration they declined to follow Batmanghelidj into his universal etiology; dehydration, they wrote, may be a contributing factor but cannot be regarded as the main cause of chronic conditions. They inherit the Hygiene reading, discipline its overreaches, and keep the mechanism intact for the modern pharmacovigilance.

How the Drugs Act on the Kidney

Each kidney holds about a million glomeruli, filtering units the size of a sand grain. A small artery feeds blood into each one. A second small artery carries the filtered blood out. The pressure inside the glomerulus is what drives the filtration. That pressure depends on how hard the blood arrives through the incoming arteriole and how much resistance the outgoing arteriole offers on the way out. The kidney adjusts both to keep filtration steady while the body’s systemic pressure moves around.

ACE inhibitors and angiotensin receptor blockers, the most widely prescribed antihypertensives in current practice, work on the outgoing arteriole. The renin-angiotensin system is the mechanism the kidney uses to tighten that outgoing vessel and preserve filtration pressure when the body’s systemic volume or pressure drops. The drugs block the system. The outgoing vessel relaxes. Filtration pressure falls. Systemic blood pressure falls with it, which is the clinical goal. Serum creatinine, a marker of what the kidney is clearing, typically rises in the first weeks on these drugs, because the kidney is doing less filtering per unit of blood received.⁷ Nephrology teaching has long treated rises up to roughly thirty percent as acceptable hemodynamic effects, provided they stabilize. More recent analyses have found that larger rises correlate with worse later outcomes, which complicates the picture rather than clarifying it. What is not disputed is the mechanism. The drug reduces the pressure the kidney is receiving. The kidney does less work.

In a patient with adequate volume and no additional stressors, this trade-off may be tolerated for a long time. In a patient without those conditions, the trade-off narrows. The National Institute of Diabetes and Digestive and Kidney Diseases publishes patient-facing guidance on what nephrologists call “sick-day rules.” When a person on an ACE inhibitor or ARB becomes dehydrated, or starts a non-steroidal anti-inflammatory drug, or combines these with a diuretic, the risk of acute kidney injury rises sharply. The combination of a RAS blocker, a diuretic, and an NSAID has a name in the nephrology literature: the triple whammy. Each component is defensible on its own. The combination can be enough to cross the autoregulatory floor and leave the kidney with too little perfusion to clear its load.⁸

Biff Palmer named the broader problem in a 2002 New England Journal of Medicine review on renal dysfunction complicating the treatment of hypertension. The autoregulatory window in which the kidney maintains filtration pressure across a range of systemic pressures is narrower in people with chronic hypertension and existing kidney disease than in healthy adults. Dropping systemic pressure in these patients can push filtration pressure below the floor. The resulting injury is often reversible if the drug is held or the dose reduced. Repeated exposure accumulates damage.⁹ The establishment has been describing this mechanism in its own journals for twenty years.

What the Renoprotection Trials Showed

Before the pharmacovigilance shelf is laid out, the case for antihypertensive renoprotection has to be stated in its strongest form. Edmund Lewis published a trial of captopril in type 1 diabetic patients with established nephropathy in 1993. Captopril slowed the doubling of serum creatinine and the progression to end-stage renal disease compared with placebo.¹⁰ Barry Brenner’s RENAAL trial, published in 2001, tested losartan against placebo in type 2 diabetic patients with nephropathy and reported similar renoprotective effects on hard renal endpoints.¹¹ A parallel trial of irbesartan, IDNT, reinforced the finding. Current clinical guidelines treat ACE inhibitors or ARBs as first-line therapy in patients with albuminuric diabetic kidney disease on the strength of this literature. The trials are real. The population they studied, patients with established diabetic nephropathy and significant proteinuria, is the population in which the renoprotective effect has been documented.

The scope of that documentation is where this reading reopens the question. The trials demonstrate that in patients with proteinuric diabetic kidney disease, these drugs slow progression on specific renal endpoints over several years. They do not demonstrate that lowering intraglomerular pressure is identical to restoring a healthy kidney. They do not demonstrate benefit in patients without proteinuria or without diabetes. They do not resolve what happens over the decades of exposure that current practice assumes.

The scope question has a second answer, more pointed, from the same mainstream literature. The population the 2017 threshold change expanded the diagnosis into is mild hypertension without prior cardiovascular disease. In 2012, Diao, Wright, Cundiff, and Gueyffier reviewed the randomized controlled trial evidence for exactly this group in a Cochrane analysis covering 8,912 participants across four trials. Four to five years of antihypertensive drug therapy compared to placebo did not reduce total mortality, did not reduce coronary heart disease, did not reduce stroke, and did not reduce total cardiovascular events. The intervention did increase withdrawals due to adverse effects.¹⁹

A 2015 meta-analytic update in the same tradition reported a number needed to harm of thirty-six. For every thirty-six patients started on antihypertensive drug therapy for mild hypertension, one withdrew because of a reaction severe enough to stop taking the drug.²⁰ The ones who continued despite the reaction, and metabolized whatever the drug did to them into some other category of illness, were not counted. On the mainstream’s own meta-analytic data, in the population the current threshold brought under indication, the drugs do not help on the hard endpoints and harm one in thirty-six at the rate the trials were able to measure. That finding sits beside the renoprotection trials, not against them. The two shelves describe different populations.

What the Pharmacovigilance Shelf Shows

In 2008, Johannes Mann and colleagues published the renal outcomes of the ONTARGET trial in the Lancet. The trial had tested whether combining an ACE inhibitor (ramipril) with an ARB (telmisartan) would be more protective than either alone in patients at high vascular risk. The combination increased the composite renal endpoint of dialysis, doubling of serum creatinine, or death, compared with ramipril alone. More blockade of the renin-angiotensin system was not more protection. It was more harm.¹² The ALTITUDE trial, testing the renin inhibitor aliskiren on top of standard RAS blockade, was terminated early for similar reasons. The VA NEPHRON-D trial of combined ACE inhibitor and ARB in diabetic nephropathy ended for safety concerns.

In 2015, the SPRINT trial reported that intensive systolic targets below 120 mm Hg reduced cardiovascular events and mortality compared with standard targets below 140. That result is real and has driven subsequent guideline revisions. In 2018, Michael Rocco and colleagues published the acute kidney injury data from the same trial. The intensive arm had a hazard ratio of 1.64 for acute kidney injury compared with the standard arm. The most common precipitant was volume depletion. Most events were mild and recovered toward baseline, but the signal was clear and the mechanism was the one the Hygiene writers had been describing: pressure forced lower than the body had set it, in conditions where the body needed what it had set.¹³

The most provocative modern finding sits in a 2021 paper by Hirofumi Watanabe and colleagues in JCI Insight. The authors examined kidney tissue from two sources. The first was mice given long-term renin-angiotensin inhibition. The second was human biopsies, from patients who had been taking these drugs for years. The finding was the same in both. The incoming arterioles, the small vessels that deliver blood into each individual glomerulus, had thickened concentrically. The walls had grown inward. The lumens, the hollow channels through which blood actually flows, had narrowed. Markers of renin-cell transformation were elevated. The vessels that fed the kidney’s filtering units were being remodeled over years of exposure to the drugs prescribed to protect those vessels from the pressure that had risen to compensate for narrowed vessels elsewhere in the body.¹⁴

The authors are careful. They do not recommend that patients benefiting from these drugs stop taking them. They note that prospective morphologic trials are needed. Those caveats are theirs. The finding stands.

Shelton wrote in 1964 that many drugs produce inflammation of the kidneys. Watanabe in 2021 photographed one of the ways that happens. Shelton did not have the microscope. He had the pattern.

The Hydration Question

Shelton’s warning from the nephritis chapter is the baseline the lineage holds. For a kidney already compromised by continuous insult, excessive water drinking serves no useful purpose. Flooding an organ that cannot process what it already receives does not restore it. That line sits uneasily with the popular hydration literature of the last three decades, which has gone in the opposite direction.

Fereydoon Batmanghelidj made the strongest version of the opposite case in Your Body’s Many Cries for Water and a long series of related publications. He proposed that chronic cellular dehydration was the primary cause of hypertension and of a long list of other conditions, that the body raised blood pressure specifically to force water across cell membranes against osmotic resistance, and that adequate water intake plus salt would eliminate hypertension altogether. The further claims he attached to this program, that it cures asthma within hours, prevents Alzheimer’s, and cures multiple sclerosis, are not supportable from the evidence he offered. Lester and Parker, writing from inside the terrain paradigm, declined to endorse him. Dehydration, they wrote, may be a contributory factor but cannot be regarded as the main cause of chronic conditions.¹⁵

A systematic review of what is called the osmopressor response, the rise in blood pressure that follows rapid water ingestion in patients with autonomic failure, has reported substantial systolic increases in that patient group. Drinking water, in those patients, raises pressure. The relationship between hydration and blood pressure is more variable than any single theory accommodates.

What remains after these qualifications is a smaller claim. Kaufman’s clinical anecdote about a patient who switched from tea and orange juice to water and whose chest pain resolved sits in the usual evidentiary category for a single case: suggestive, not demonstrative. The underlying beverage distinction, water rather than caffeinated or sugared drinks, is consistent with the Hygiene frame and with the mainstream nephrology literature on volume status. Habitual replacement of caffeinated and sugared drinks with water is not a universal cure for hypertension. Flooding a compromised kidney is not safe. Within those limits, the distinction is a plausible contribution to improved systemic conditions.

Goldhamer, 2001

A single modern cohort gives the Hygiene reading of hypertension a counted echo. Alan Goldhamer and colleagues at the TrueNorth Health Center in California published a 2001 case series of 174 consecutive hypertensive patients treated with medically supervised water-only fasting. The protocol was two to three days of fruits and vegetables, roughly ten to eleven days of water-only fasting, and six to seven days of refeeding on a low-fat, low-sodium vegan diet. Mean reduction in blood pressure across the cohort was 37/13 mm Hg. In stage 3 hypertensives, with systolic over 180 or diastolic over 110, the mean reduction was 60/17. About 90 percent of participants finished the protocol with blood pressures below 140/90. All 6.3 percent of participants who had entered on antihypertensive medication discontinued their medication under supervision during the study.¹⁶

The series is uncontrolled. There was no drug comparator. The setting was inpatient, with physician supervision, in a facility whose clinical philosophy is explicitly Hygienic. Funding included contributions from the American Natural Hygiene Society and the International Association of Hygienic Physicians. These disclosures are not disqualifications, and they are not substitutes for the controlled trial that has not been done. Water-only fasting of this duration is not safe without medical supervision and is contraindicated in several conditions. The point of including the data is to show that the terrain reading has a modern clinical datapoint, not to recommend a protocol. The pressure fell substantially when the inputs that had sustained it were removed.

Where This Leaves the Reader

Kaufman’s strong-form claim that the most common cause of kidney failure he sees is blood pressure medication is confounded by prescribing patterns and cannot be sustained. The weaker form of the argument stands. Elevated blood pressure is a response the body is making to conditions it is trying to manage. Lowering the response without changing the conditions returns the organs to the state the response was defending against. Over time, in some patients, that return damages the kidneys. The Hygiene writers reached this through clinical observation. Cowan has articulated the autonomic physiology that sits underneath. Modern pharmacovigilance has reached the kidney damage directly, through pathology.

The renoprotection trials are not wrong in their populations. Lewis, Brenner, and the IDNT investigators showed that in patients with proteinuric diabetic nephropathy, these drugs slow progression on specific endpoints over several years. The Cochrane literature on mild hypertension without prior cardiovascular disease shows no comparable benefit and documented harm. The two findings sit beside each other, describing different populations.

A medicated reader will want to know whether to stop. That question answers itself under a prescriber’s hand and is not the question this piece was built to pose. The question underneath, which the lineage has been asking for a hundred years, is what is being done to remove the reasons the pressure rose. Dehydration. Dietary burden on the organs of elimination. Sustained sympathetic activation. Arterial stiffening from accumulated insults. Environmental toxic load. Nothing in that list is mysterious. Each item was identified in the lineage texts walked through above, and each is removable with sustained effort and competent clinical support. The reasons were listed in 1921 and listed again in every generation that followed. The mainstream pharmacovigilance that confirmed parts of the mechanism was published in 2002, 2008, 2018, and 2021.

Shelton closed his hypertension chapter sixty years ago with the formulation that frames all of this. If we cut out causes instead of cutting out organs, he wrote, we secure a genuine and lasting elimination of effects. The organ-cutting in his sentence has a modern form. Watanabe’s biopsies show the kidney’s own feeding arterioles thickening and narrowing under the drugs prescribed to protect it. The under-perfusion the body raised the pressure to prevent is produced, in the organ the pressure was reaching for, by the pharmacology the number recruited. The drug cuts out the organ by inches, over years, in the vessels the organ depends on, while the doctor watches the number on the cuff.

How to Explain It to a Six-Year-Old

Imagine a garden hose watering some flowers. The pump at the tap is pushing the water through the hose, and the flowers at the end are getting the water they need. Now imagine someone has pinched the hose somewhere in the middle. The flowers start to droop because less water is reaching them. The pump senses this and pushes harder, which raises the pressure inside the hose. The water starts getting through again, and the flowers perk back up.

Now a visitor comes along, sees the high pressure in the hose, and says the pressure is too high. The visitor turns the pump down. The pressure in the hose drops, but the pinch is still there. The flowers at the end start drooping again, because less water is reaching them. If this goes on for long enough, the flowers die.

The pressure was high because the hose was pinched. The pump raised it to keep the flowers alive. To help the flowers, someone has to find the pinch and unpinch it. Turning down the pump makes the pressure number look better. It also makes the flowers die.

The kidneys are the flowers.

References

1. Kaufman, Andrew. Spoken clinical commentary on blood pressure medication and kidney function. Transcript provided to the author, 2026.

2. Tilden, John H. Toxemia Explained: The True Interpretation of the Cause of Disease. 1926. Public reprints and extracts via Horne, Ross, chapter 24, Soil and Health Library.

3. Tilden, John H. Impaired Health: Its Cause and Cure. Vols. 1 and 2. 1921. Public reprints, chestofbooks.com (Arteriosclerosis, Alimentary Poison, Acute Bright’s Disease, Chronic Bright’s Disease, Uremia, Epistaxis, Aneurism chapters).

4. Shelton, Herbert M. Fasting Can Save Your Life. Natural Hygiene Press, 1964. Chapters 26 (”High Blood Pressure”) and 33 (”Nephritis”).

5. Shelton, Herbert M. Fasting Can Save Your Life, chapter 33, “Nephritis,” ibid.

6. Moore, Richard D. The High Blood Pressure Solution: A Scientifically Proven Program for Preventing Strokes and Heart Disease. 2nd ed. Rochester, VT: Healing Arts Press, 2001. Preface and chapter extracts.

7. Bakris, George L., and Matthew R. Weir. “Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine: Is This a Cause for Concern?” Archives of Internal Medicine 160, no. 5 (2000): 685-693.

8. National Institute of Diabetes and Digestive and Kidney Diseases. “Keeping Kidneys Safe: Smart Choices about Medicines.” niddk.nih.gov.

9. Palmer, Biff F. “Renal Dysfunction Complicating the Treatment of Hypertension.” New England Journal of Medicine 347, no. 16 (2002): 1256-1261.

10. Lewis, Edmund J., et al. “The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy.” New England Journal of Medicine 329, no. 20 (1993): 1456-1462.

11. Brenner, Barry M., et al. “Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy.” New England Journal of Medicine 345, no. 12 (2001): 861-869.

12. Mann, Johannes F. E., et al. “Renal Outcomes with Telmisartan, Ramipril, or Both, in People at High Vascular Risk (the ONTARGET Study): A Multicentre, Randomised, Double-Blind, Controlled Trial.” Lancet 372, no. 9638 (2008): 547-553.

13. Rocco, Michael V., et al. “Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).” American Journal of Kidney Diseases 71, no. 3 (2018): 352-361.

14. Watanabe, Hirofumi, et al. “Inhibition of the Renin-Angiotensin System Causes Concentric Hypertrophy of Renal Arterioles in Mice and Humans.” JCI Insight 6, no. 24 (2021): e154337.

15. Lester, Dawn, and David Parker. What Really Makes You Ill? Why Everything You Thought You Knew About Disease Is Wrong. 2019. Chapters on hypertension, antihypertensive drugs, and hydration.

16. Goldhamer, Alan C., Douglas Lisle, Banoo Parpia, Scott V. Anderson, and T. Colin Campbell. “Medically Supervised Water-only Fasting in the Treatment of Hypertension.” Journal of Manipulative and Physiological Therapeutics 24, no. 5 (2001): 335-339.

17. Bakris, George, and Matthew Sorrentino. “Redefining Hypertension: Assessing the New Blood-Pressure Guidelines.” New England Journal of Medicine 378 (2018): 497-499. Muntner, Paul, et al. “Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.” Circulation 137, no. 2 (2018): 109-118.

18. Cowan, Thomas. Human Heart, Cosmic Heart: A Doctor’s Quest to Understand, Treat, and Prevent Cardiovascular Disease. White River Junction, VT: Chelsea Green Publishing, 2016.

19. Diao, Diana, James M. Wright, David K. Cundiff, and François Gueyffier. “Pharmacotherapy for Mild Hypertension.” Cochrane Database of Systematic Reviews 2012, no. 8: CD006742.

20. Sundström, Johan, et al. “Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis.” Annals of Internal Medicine 162, no. 3 (2015): 184-191.

In February 1891, Cecil Rhodes, the journalist William T. Stead, and Reginald Brett, later Lord Esher, drew up the organization of a secret society with an inner circle called the Society of the Elect and an outer circle called the Association of Helpers. Rhodes had written the plan into his first will at the age of twenty-four, naming the Jesuits as his model and the “ultimate recovery of the United States of America as an integral part of a British Empire” among his aims. Carroll Quigley’s The Anglo-American Establishment, completed in 1949 and published in 1981, traces what that society became under Alfred Milner after Rhodes’s death in 1902. Its record includes the Jameson Raid and the Boer War, the constitution of the Union of South Africa, control of The Times for most of fifty years, the founding of The Round Table and the Royal Institute of International Affairs, the drafting of the Balfour Declaration and the 1919 constitution for India, and a central hand in the appeasement of Germany from the Rhineland to Munich. It carried out all of this through a few dozen men drawn from three Oxford colleges, with no oaths and no formal membership, working on the opinions of a small circle of “important people” while the public saw only a series of unconnected institutions.

Quigley (1910-1977) taught at Georgetown University’s School of Foreign Service and had been an instructor at Princeton and Harvard. He served as a consultant to the U.S. Department of Defense, the House Committee on Astronautics and Space Exploration, and the U.S. Navy, and his other major works are The Evolution of Civilization and Tragedy and Hope. He wrote as a sympathizer. He agreed with the Group’s goals, regarded the British Commonwealth as one of the great achievements of history, and said so in his preface. His objection was to method: power placed in hands chosen by friendship over merit, blindness to other classes and other nations, and the Group’s habit of retreating to verbal clichés in a crisis. He relied partly on people close to the Group whom he could not name, used their information only where documents available to anyone confirmed it, and was told the story would be better left untold. A Georgetown professor with that record could not find a publisher for the manuscript. It sat for thirty-two years until Books in Focus released it in 1981.

The narrative closes in 1949, four years after the General Election that removed the Conservatives from office and cut off the Group’s political influence. By then Ireland had left the Commonwealth, India had been partitioned, Burma was drifting away, and South Africa was more distant from Britain than at any time since 1910. The popular explanation for appeasement was the “Cliveden set,” which Quigley treats as a caricature that caught one corner of a much larger structure. The accepted account of British imperial and foreign policy since the Boer War had been written largely by the Group itself. Its members edited the Dictionary of National Biography from 1921 to 1938, produced the annual Survey of International Affairs and the History of the Peace Conference, held the Oxford and London chairs in international relations, and had just published the first volumes of an official History of The Times that set out to refute the charge that the paper’s anti-German line from 1895 to 1914 helped bring on the First World War. Quigley was writing against a history composed by its own subjects.

The book reads as a study of how a small circle captures the institutions that form opinion and then the institutions that record what happened. The full summary follows several of its most specific findings. Ormsby-Gore told the House of Commons on 21 July 1937 that the Balfour Declaration had been drafted by Milner. Curtis’s private Round Table study group invented India’s system of “dyarchy” and sent its plan to the incoming Viceroy while withholding it from its own members, lest the public get hold of it. A German officers’ plot to remove Hitler, disclosed to Lord Halifax on 5 September 1938, was called off at noon on 28 September when word reached Berlin that Chamberlain was flying to Munich. Among all the members of the Milner Group and the Cecil Bloc, only Lord Phillimore had his entry in the Dictionary of National Biography written by an outsider, and his is the only one that is not wholeheartedly adulatory.

Related

Audio Deep Dive (for Paid Subscribers)

Read more

This is a companion to the terrain reading of shingles published earlier in this series. The general mechanism of nerve tissue expressing stored toxicity through the skin is developed there and will not be rebuilt from scratch here. What this essay focuses on is what distinguishes herpes from its sister conditions in what mainstream medicine groups as the Herpesviridae family: the metabolic clue that undoes the viral story on its own, the 1921 foundational citation that invented ganglia latency as a cover for failed transmission experiments, the daily pharmaceutical prescribed for life, and the manufactured shame that keeps the pharmaceutical selling.

A note on language. Where terms like “virus,” “viral infection,” “antiviral,” or “incurable” appear in these pages, they are the establishment’s terms, used in attribution, in quotation, or when the industry’s own evidence is turned against its own conclusions. In my own voice, the body is the self-healing organism it has always been. It does not catch herpes. It expresses something it has been carrying.

The Breakfast on the Plate

A woman in her mid-twenties sits in the examination room. She has had three cold sores over the past year and recently found a cluster of blisters in a new location. The test is positive. The physician tells her she has an incurable viral infection, that she will carry it for the rest of her life, that she must disclose her status to intimate partners from this day forward, and that a daily pill will reduce the frequency of her outbreaks and lower the risk of transmission. She leaves with a prescription for valacyclovir and a patient information leaflet tucked into the pharmacy bag.

This essay examines the leaflet, not the appointment.

Among the warnings and dosing instructions and small print, the leaflet acknowledges something that ought to end the conversation. Outbreaks diminish when the diet is weighted toward lysine. Outbreaks worsen when the diet is weighted toward arginine. Both are amino acids. The frequency and severity of what the leaflet calls a lifelong viral infection track the balance between two components of what the patient had for breakfast.

A DNA viral particle residing in nerve cells and emerging periodically to produce blisters on the skin would not be governed by the amino acid ratio in oats and almonds. Nothing in the mechanism described by virology provides a plausible pathway for a bowl of cereal to control the behavior of a pathogen. The dermatology literature has been aware of the clinical observation for decades. Griffith and colleagues ran an early clinical trial in 1978, finding that supplemental lysine shortened the duration of outbreaks and reduced their frequency.¹ The observation has been incorporated into the standard patient advice the woman in the examination room took home. The implication of the observation has not been incorporated into anything.

The implication is that whatever is producing the lesion is a metabolic event rather than an infectious one. Metabolism is governed by substrate availability in a way that pathogenic replication is not. Arginine fuels nitric oxide production, cellular replication, and the growth of tissues under stress. It is abundant in nuts, seeds, chocolate, coconut, grains, and most processed foods. Lysine serves connective tissue repair, calcium absorption, and the production of carnitine, which transports fat into mitochondria for the slow aerobic generation of energy. The two amino acids compete for the same transport proteins at the intestinal brush border and at the cell membrane. When the ratio tilts toward arginine, cellular metabolism tilts toward replication, oxidative load, and the kind of tissue stress that creates clearing demand. When the ratio tilts toward lysine, metabolism tilts toward repair and resolution. The outbreak tracks the ratio because the outbreak reports on the state of the metabolism.

The entire pharmaceutical structure built around the woman’s diagnosis rests on a claim her own leaflet quietly contradicts. The leaflet is still printed and tucked into every pharmacy bag. The implication is still unspoken. The pills are still prescribed daily, for life, to patients who will never be told that they can address what the pills are blocking by changing what they put on their plate.

Audio Deep Dive (for Paid Subscribers)

What the Handout Does Not Say

The companion essay on shingles develops the terrain reading of nerve-tissue expression through the skin. Blisters arrange along nerve pathways because nerve pathways drain the compartment where stored material lives. The dermatomal pattern is a drainage map. Herpes operates on the same logic. The herpes lesion follows nerve territory from the trigeminal ganglion to the lip, or from the sacral ganglion to the genitals, because these are the exits the stored load has access to.

What distinguishes herpes from shingles is the territory. Shingles tends to emerge on the trunk and extremities. Herpes concentrates on the mouth and the genitals. The difference matters. Mouth and genitals are the two most vascular, most innervated, most permeable mucosal boundaries the body has. They produce mucus and secretions that carry material outward continuously. They sit at the ends of the two nerve pathways that drain the two heaviest-storage compartments. The lip is downstream of the trigeminal territory, which absorbs mercury vapor rising from amalgam fillings and from the organic mercury injected in thimerosal-preserved vaccines. The genital region is downstream of the sacral territory, which collects the chemical burden of hormonal medications, antibiotic damage, candida overgrowth, and the pharmaceutical cascade typical of modern obstetrics and gynecology.

The eruption emerges where the pathway reaches the surface, and its timing follows the tipping of the terrain. When accumulated material exceeds the capacity to hold it quietly, the body uses whichever route is available to release the pressure. The trigger list on the patient handout documents the tipping events in the industry’s own words: sunlight, menstruation, stress, fever, surgery, dental work, immunosuppressive drugs. The list omits contact with another person. The industry calls herpes a sexually transmitted infection, assigns a lifetime disclosure obligation to anyone who tests positive, and acknowledges in the fine print that no event involving another person makes the triggers list.

The Ninety Percent

A reader currently committed to the viral framing will raise one objection before any other. The CDC estimates that approximately two-thirds of adults under 50 globally carry HSV-1, and about 13 percent carry HSV-2. If so many people are carriers, the transmission mechanism must be real. The sheer prevalence of the condition appears to settle the question before the question can be asked.

What the number actually measures is what antibody tests detect. Seroprevalence is not a measurement of viral particles found in human tissue. It is a measurement of binding patterns in laboratory assays run on blood samples. A test positive for HSV-1 antibodies does not establish that a viral particle entered the person, replicated, and set up residence in nerve ganglia. It establishes that the person’s blood produces proteins that bind to the specific laboratory antigen the test was built around. Antibody tests cross-react extensively. They were calibrated against the viral story they were designed to confirm. The reasoning is circular.

If the pattern the antibody test detects is in fact widespread, the terrain reading has a straightforward explanation. Humans in industrial societies share widespread exposure to the same toxic burden: dental amalgams, vaccine schedules, hormonal medications, antibiotic courses, industrial foods, environmental metals, electromagnetic radiation. That shared exposure produces shared patterns of eliminative response and shared patterns of what laboratory tests read as antibody markers. The 90 percent figure is as consistent with shared toxic terrain as it is with pervasive transmission. The two readings are not distinguishable by the antibody test, because the antibody test cannot tell them apart.

The industry built the transmission story first and then designed the tests that confirmed it. The tests measure what the industry needed them to measure. The seroprevalence number is the industry’s own circular evidence, not a demonstration that something is being passed between people. When a reader asks how transmission can be unreal if 90 percent of adults have it, she is asking a question the antibody test cannot answer in either direction.

The 1921 Citation

The foundational scientific document behind the modern herpes transmission story is a 1921 German-language monograph by the Austrian dermatologist Benjamin Lipschutz, titled Studien zur Ätiologie der Krankheiten der Herpesgruppe. Modern textbooks on sexually transmitted infection cite it as the source for the claim that genital herpes is transmitted between humans.² New Zealand physician Sam Bailey obtained a translation and walked through what the text actually describes.³ The experiments do not establish what the citation chain claims they establish. Lipschutz took fluid from the genital lesions of one patient, diluted it with saline, and injected the preparation into six other people. Observing them over several days, he recorded that nothing of interest occurred at the injection sites. Rather than treat this result as evidence against the transmission hypothesis, Lipschutz proposed that the virus must sometimes “remain latent in the perineural lymphatic sheaths for a longer period of time.” The entire modern justification for lifelong suppressive antiviral therapy, which rests on the claim that the alleged virus hides in nerve ganglia between outbreaks, originates in that sentence. The sentence functions as an excuse rather than a finding. It was written to protect the hypothesis from falsification by the experimental result that had just emerged on Lipschutz’s own observation records.

The pattern Lipschutz established in that treatise, assuming transmission then inventing a latency mechanism to patch the failure to demonstrate it, is the template on which the broader dormant-virus franchise was built. Shingles, mononucleosis, HPV, and HIV all operate on versions of the same move. A condition emerges in a person without any demonstrable transmission event, and the gap is filled with the explanation Lipschutz wrote first: the particle must have been there all along, waiting for the right conditions to reactivate. Lifetime pharmaceutical management follows from the lifetime hidden pathogen. The commercial architecture of chronic condition management rests on this 1921 move more extensively than any single textbook citation suggests.

The Daily Pill

The woman who left the examination room is almost always prescribed valacyclovir. The common long-term suppressive regimen is 500 milligrams or one gram once daily, taken indefinitely. The marketed purposes are to reduce the frequency of outbreaks and to lower the risk of transmitting the virus to sexual partners. The drug is a nucleoside analogue. Its mechanism is to insert itself into replicating DNA chains and terminate them. The manufacturer claims the mechanism is selective for viral DNA polymerase.

The label itself contains the admission that undoes the long-term prescribing pattern. Section 17.3 of the prescribing information states that no data exist on the safety or effectiveness of chronic suppressive therapy of more than one year’s duration in otherwise healthy patients, and no data exist on chronic suppressive therapy of more than six months’ duration in HIV-infected patients.⁴ Patients are prescribed this drug for years, often for decades, inside a safety envelope the manufacturer explicitly states has never been studied. The prescription continues past the edge of the evidence on the physician’s reassurance rather than on anything in the trial record.

Setting aside the question of whether the viral target exists, the drug accumulates in the kidneys and interferes with cellular replication wherever its concentration rises. The adverse effects listed on the label include acute renal failure, hallucinations, confusion, agitation, seizures, and reduced platelet counts, with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome documented at the eight-gram-per-day dose used in trials of patients with advanced HIV disease and recipients of bone marrow or kidney transplants, and also reported in postmarketing surveillance.⁴ The frequency of these effects rises with duration of use, and daily use continued over years is the exposure pattern most likely to produce them. The genotoxicity record sits on the same label. Valacyclovir produced positive results in two of the five standard genetic toxicity tests the manufacturer ran. One was a mouse micronucleus assay, which measures damage to chromosomes in bone-marrow cells. The other was a mouse lymphoma assay, which measures damage to cultured cells, with the positive result appearing after the drug converted to acyclovir, which is what happens in the body on first-pass metabolism. The drug damaged DNA in the standardized screens the industry itself designed to flag that kind of damage. The prescribing physician rarely dwells on any of this, because the alternative in the viral framing is life with uncontrolled outbreaks and the ethical obligation to disclose a lifelong infection to every new intimate partner.

Shelton’s description of the acute-to-chronic cascade applies with unusual clarity here.⁵ The body attempts to eliminate stored material through a skin eruption. The eruption is interrupted by a drug that interferes with the replication required to produce it. The stored material does not leave, and the drug itself contributes new material that the kidneys and liver must process. Over time the eruption stops, which the clinic reads as cure, but the stopping reflects exhaustion of the eliminative route rather than resolution of what was being eliminated. The downstream conditions that appear years later (reduced kidney function, neurological symptoms, chronic fatigue, cognitive changes) are reported as uncommon adverse events. In the terrain reading they are the predictable consequences of blocking a cleansing route for a decade while the cleansing demand continues to accumulate.

The Social Injury

The biological event of recurrent herpes, examined on its own terms, is modest. A cluster of blisters appears every few months at a specific site, lasts a week or two, and heals without intervention. The lesions are uncomfortable while they last. The frequency varies widely between people, with some experiencing one episode and never another, others six or more per year. Many carriers of what dermatology calls HSV-1 or HSV-2 are what the literature calls asymptomatic, meaning they have no symptoms and would never know of the diagnosis without a test. The modest biological event becomes, in the moment of diagnosis, something else entirely.

The diagnosis assigns an identity. The patient is told she has an incurable viral infection that will live in her nerves for the remainder of her life. She is told she is now potentially dangerous to future sexual partners. She is told she has an ethical obligation to disclose this status before any intimate contact. She is told that daily medication will reduce the frequency of her outbreaks and lower the risk of transmission. The identity, the disclosure requirement, and the medication prescription arrive together in a single clinical visit, often lasting fifteen minutes. The weight of what she walks out with falls heavily on how she will live every subsequent intimate moment of her adult life.

The disclosure requirement is itself a continuous source of anxiety. Every new relationship raises the question of when and how to tell. The telling produces fear of rejection, and the fear is often confirmed by actual rejection. The identity leaks into the sense of self. The clinical label becomes a personal attribute. A young woman learns at twenty-four that she “has herpes” and carries the label into every subsequent intimacy, every dating profile she chooses whether to annotate, every first conversation she decides whether to risk. The biological burden she actually carries is not proportionate to the weight of the label. The weight was assigned by the diagnosis.

The anxiety generated by the diagnosis has a direct biological consequence. Stress is on the trigger list. The cortisol rise associated with chronic worry suppresses digestion, depletes magnesium and B-complex nutrients, and reroutes energy from repair into the metabolic patterns of threat response. A woman anxious about her herpes status produces, through the mechanism of her anxiety, more frequent outbreaks of what she has been told is her herpes. The outbreaks confirm the diagnosis in her felt experience. The diagnosis renews her anxiety. The anxiety produces more outbreaks. The pattern locks in. The daily pill is then prescribed to interrupt the pattern, which it does by interfering with cellular replication at the site of eruption, which allows the stored load to continue accumulating in her tissues while the eruption fails to occur. The anxiety that drove the pattern is left untouched. The pill does not address it.

The nocebo loop is the business model. Revenue flows at every point in the cycle. The diagnosis is billable. The counseling that follows is billable. The disclosure training offered by patient advocacy organizations, often funded by the same pharmaceutical companies that make the suppressive medication, generates its own revenue streams. The daily pill is billable in perpetuity. The downstream complications, when they arrive, are each billable as separate conditions with separate specialist referrals and separate pharmaceutical interventions. The entire structure depends on the first move, the moment the patient accepts the framing that the eruption on her skin reports on a lifelong infection rather than on a terrain she has been carrying since the establishing event of her childhood. Once she accepts the framing, the business operates on autopilot. The pills refill, the anxiety sustains, the relationships adjust around the label, and life proceeds inside the architecture the diagnosis built.

The drug prescribed to interrupt the loop is itself documented to contribute to it. In the suppressive-therapy trial on which the one-gram daily dose was approved, the reported rate of depression was 7 percent on the active drug against 5 percent on placebo, and the reported rate of dysmenorrhea was 8 percent on the active drug against 4 percent on placebo.⁴ A woman taking the medication to reduce the anxiety her diagnosis produced is being treated with a substance that measurably raises her probability of experiencing depression and painful menstruation above the controlled baseline. The medication adds to the symptom burden it was prescribed to reduce.

The ethical weight of the disclosure requirement sits uneasily with the industry’s own evidence for the transmission risk it imposes. The reduction-of-transmission study on which the Valtrex label makes its transmission-reduction claim enrolled 1,484 discordant monogamous heterosexual couples in which the source partner had a history of nine or fewer outbreaks per year.⁴ Both partners were counseled on safer sex practices and advised to use condoms throughout the eight-month study. In the controlled conditions the industry designed itself, 27 out of 741 susceptible partners in the placebo arm (3.6 percent) developed what the trial counted as acquisition over the eight months of intimate partnership. The other 714 did not. In the Valtrex arm, 14 out of 743 (1.9 percent) did. The study population excluded multiple partners and non-heterosexual couples, and the label states explicitly that the efficacy claim has not been established in those populations. The lifetime disclosure mandate the diagnosis imposes on a young woman is being charged against a baseline the manufacturer’s own trial recorded at under four percent per eight-month period, in the specific population where the trial ran, and that the manufacturer declines to extend to any other population.

The 3.6 percent figure is also generous to the transmission hypothesis. The trial’s definition of acquisition relied on the appearance of lesions in the susceptible partner and on seroconversion in antibody tests, neither of which demonstrates that an infectious particle moved between the two bodies. What they demonstrate is that some susceptible partners developed lesions over the study period and that others showed changes in antibody tests. In both cases, the shared environment and shared lifestyle of a monogamous couple over eight months provides an alternative explanation the trial design cannot exclude. Human-to-human transmission of herpes has never been experimentally demonstrated outside the lancet-trauma protocols of Lipschutz’s 1921 work. Daniel Roytas reviewed the attempted contagion experiments across respiratory and herpetic conditions in Can You Catch a Cold? and documented a consistent pattern.⁶ When researchers try to transmit a condition between people under controlled conditions, they fail. The shame she is asked to carry is being charged against a debt the ledger does not show.

The Childhood Pattern

Most people who are told at some point in adult life that they have herpes developed their first lesion in childhood. The timing often follows the first bout of what was called chickenpox, or follows a febrile illness treated with pharmaceuticals, or follows a round of vaccinations, or follows the introduction of a childhood antibiotic. The clinical pattern is that the first eruption establishes a route the body returns to under subsequent terrain stress. The route is the one along which stored material can reach the surface. Once the body has used a route, it has learned the pathway, and the pathway becomes the default channel when similar conditions recur.

Charles Richet described the general mechanism in 1901. Injection of foreign protein into an organism produces a heightened response to any subsequent exposure to the same material. The response strengthens with repetition and persists for the life of the organism. Richet received the Nobel Prize for the discovery in 1913.⁷ The mechanism applies to all injected foreign material, whether proteins, adjuvants, metals, or preservatives. The childhood vaccine schedule injects multiple foreign proteins and adjuvant metals past the digestive and dermal barriers in the first two years of life, during the period when those barriers would otherwise be filtering and classifying what enters the organism. The sensitization produced is to material the body now carries and cannot easily clear. The lesion that appears years later during a moment of terrain stress is often the body processing a sensitized load it has carried since infancy.

The injection schedule is the dominant historical driver of what becomes, in adult life, the pattern of recurrent eruptions. The other three categories of insult, electromagnetic exposure, nutritional depletion, and emotional strain, operate as amplifiers on a terrain the schedule has already shaped. A child whose first two years contained no injections presents in adult life with a different baseline than a child whose first two years contained the current schedule. The baseline is set early and tracks forward. The daily pill prescribed in adulthood does not touch that baseline; it modifies the eruption that reports on it.

What Is Actually Needed

The question for a reader currently taking daily valacyclovir, or anxious about an upcoming disclosure conversation, or in the middle of a painful outbreak, is what to do with any of this. The practical answer runs through the four categories of insult that produce the terrain conditions driving the eruption, with the lysine-arginine clue at the center of the dietary approach because the metabolic signature is where herpes most clearly reveals itself as a condition of substrate and energy rather than of pathogen.

Diet and the amino acid balance. The clinical observation that lysine suppresses outbreaks and arginine triggers them translates into concrete food choices during active or anticipated flare periods. Arginine-dense foods to reduce during such periods include peanuts, almonds, walnuts, hazelnuts, cashews, sunflower seeds, sesame seeds, pumpkin seeds, chocolate, carob, coconut, oats, wheat germ, soy, and gelatin. Lysine-dense foods to emphasize include red meat from pastured animals, poultry, fish, eggs, dairy from grass-fed cows, and legumes paired with animal protein. Supplemental L-lysine at one to three grams daily during active outbreaks has been documented in multiple trials to reduce duration and severity. The dietary approach does not treat herpes in the sense of eliminating a pathogen. It shifts the metabolic substrate toward repair, which reduces the demand for eliminative eruption. Over months of consistent dietary emphasis on whole foods with favorable lysine-to-arginine ratios, outbreak frequency typically declines substantially. The reader who has been on daily suppressive medication for years and who begins eating this way will often find, if she is willing to taper the medication under appropriate guidance, that her outbreak frequency on the whole-food protocol is lower than it was on the pill.

Vaccine and medication history. The investigation of what the body is attempting to clear starts with the injection history. Every vaccine received, from the childhood schedule through adult travel vaccines, flu shots, and the COVID injections, has deposited material the body attempts to clear through its established routes. Every long course of antibiotic, every stretch on hormonal contraception, every SSRI prescription, every suppressive drug used for a prior condition contributes to the cumulative load. The history is not actionable in reverse. The injections already given cannot be ungiven. What understanding the history provides is reorientation. The eruption reports on the load. The load has specific sources. The reader can stop adding to it, which most readers who come to this framework begin doing almost immediately.

Dental terrain. The connection between mercury amalgam fillings and trigeminal nerve storage is particularly relevant for oral herpes. Chewing, hot drinks, and tooth brushing release mercury vapor continuously into the mouth and sinuses adjacent to the trigeminal nerve. Removal of amalgams under proper protocol, by a dentist trained in safe amalgam removal and using appropriate isolation equipment, has been reported anecdotally to reduce cold sore frequency over the subsequent months as the trigeminal load decreases. Root canals, if present, warrant discussion with a biological dentist, as chronic contamination in the root canal space can contribute to systemic toxic load. Fluoride exposure through municipal water and dental products should also be reviewed, as fluoride accumulates in nervous tissue and in the pineal gland.

Environmental and nutritional terrain. General support for the body’s eliminative capacity applies here as in all terrain-based approaches. Clean water free of fluoride and chlorine. Whole foods free of pesticide residues, with priority given to nutrient-dense traditional foods including liver, egg yolks from pastured hens, bone broth, raw dairy from grass-fed cows, and traditionally fermented vegetables. Mineral repletion with emphasis on magnesium, zinc, and selenium, which support the body’s clearing pathways. Removal of personal care products containing petroleum derivatives, parabens, phthalates, synthetic fragrances, and the other substances absorbed through the skin that add to the cumulative load.

Nervous system and electromagnetic environment. Chronic emotional strain produces chronic terrain compromise. Restorative sleep, time in nature, and grounding (direct skin contact with the earth, which has measurable effects on inflammation and nervous system regulation) support the body’s recovery capacity. Reduction of electromagnetic exposure in the sleeping environment supports the restorative work of the overnight hours. For the woman carrying the weight of the diagnosis itself, the work of unlearning the identity assigned by the clinical encounter is as important as any physical intervention. The anxiety is a trigger. The anxiety was manufactured. Addressing the anxiety at its source, by understanding what the eruption actually represents, breaks the loop the pharmaceutical business model relies on.

Continuing or discontinuing suppressive therapy. The decision to taper or stop daily valacyclovir is a medical decision each person must make in consultation with the practitioners she trusts. Abrupt discontinuation can produce rebound symptoms as the suppressed eliminative capacity returns. A thoughtful taper, supported by the dietary and terrain interventions above, allows the body to resume its work on its own schedule. The eruptions that follow the taper are generally the body completing work the drug prevented for the duration of use. They are not evidence of pathogen replication. They are evidence of long-postponed cleaning. Supporting them with topical approaches such as DMSO, which the companion essay on shingles discusses at length, can shorten their duration and improve resolution.

Close

The woman who left the examination room with her prescription was offered, at the moment of her diagnosis, a particular story. The story was that she had contracted an incurable virus that would live in her nerves for the remainder of her life and emerge periodically to produce blisters on her skin. The story told her the lesions were the virus. The story told her the daily pill would suppress the virus. The story told her she must disclose her status to every intimate partner. The story was coherent, and it rested on a 1921 excuse written to protect a hypothesis from the result of its own foundational experiment.

What the lesions actually report is the state of her terrain. The amino acids on her plate. The metals in her nervous tissue from the schedule of her first two years. The sensitization established in infancy. The chronic stress of carrying a diagnosis the clinic assigned. The daily pharmaceutical interfering with the only mechanism her body has to clear what it is carrying, and documented on its own label to raise her probability of depression, painful menstruation, DNA damage, kidney failure, and neuropsychiatric symptoms over the duration of use. The lesions have been telling her this since the first eruption. The pills ensure she will not hear them, and the disclosure requirement ensures she will not stop paying for them.

The incurable virus was never there in the way the story requires. What is there is a body that has been carrying a load since childhood, a nerve pathway that has learned the route out, a metabolism that responds to what she eats, and a diagnosis that has outsourced to her the cost of the industry’s continued revenue. The last of these is the one she can address today, without a prescription, by reconsidering the story she was told at the moment the industry acquired her as a customer.

How to Explain It to a Six-Year-Old

Sometimes you get a little blister on your lip or somewhere else on your skin. The blister looks a bit scary when it shows up, but it is really your body cleaning out something that it did not want inside anymore. Your skin is like a door. The door opens, the stuff comes out, and then the door closes again and your skin heals.

For a long time, grown-ups thought the blister was caused by a tiny bug that lived in your body forever. They thought the bug slept in your nerves most of the time and woke up now and then to make a blister. They never actually found the bug. The bug was just a story they told because they could not think of a better one.

The real reason blisters come back is that the body still has stuff inside it that needs to come out. If you eat lots of good food, especially food that gives your body what it needs to fix and clean, you will have fewer blisters. If you eat lots of things like nuts and chocolate at the same time, you might have more blisters, because those foods tell your body to grow and copy stuff instead of fixing stuff.

Doctors sell a pill that stops the blisters from showing up. The pill does not take anything out of your body. It just stops the door from opening. All the stuff that wanted to come out stays inside. That is not healing. That is hiding.

Think of it like a smoke alarm. If your smoke alarm starts beeping, the beeping means there is smoke somewhere in your house. The alarm is not the problem. The smoke is the problem. If someone puts a piece of tape over the alarm to stop the beeping, the alarm will be quiet. But the smoke will still be there. The alarm was trying to help.

The blister was never the enemy. The blister was the alarm. The pill is the tape over the alarm. The smoke is still there.

Medical Disclaimer

The content of this essay is for informational and educational purposes only. Nothing here constitutes medical advice. Readers currently taking valacyclovir or any other prescription medication should not alter their regimen without consulting qualified practitioners of their own choosing. Each person’s situation is individual and warrants individual consideration. The interpretive framework offered here is one the reader is invited to weigh against other frameworks and against her own experience, in collaboration with practitioners she trusts.

References

1. Griffith, R. S., DeLong, D. C., and Nelson, J. D. “A multicentered study of lysine therapy in Herpes simplex infection.” Dermatologica, vol. 156, no. 5, 1978, pp. 257–267.

2. Holmes, K. K., et al., editors. Sexually Transmitted Diseases. McGraw-Hill, multiple editions. The genital herpes chapter cites Lipschutz 1921 as foundational for the human transmission claim.

3. Bailey, Samantha. “What We Weren’t Taught About Herpes.” Video essay, 7 June 2022. Available at drsambailey.com and on alternative video platforms. Includes translation and analysis of the Lipschutz 1921 treatise.

4. Valtrex (valacyclovir hydrochloride) prescribing information. GlaxoSmithKline, 2008. Includes Warnings and Precautions (section 5), Adverse Reactions (section 6.1, including suppressive-therapy trial rates for dysmenorrhea, depression, and other events), Nonclinical Toxicology (section 13.1, genetic toxicity record), Clinical Studies (section 14.2 and Table 7, reduction-of-transmission trial), and Patient Counseling Information (section 17.3, including the admission that no safety or efficacy data exist for chronic suppressive therapy beyond one year in otherwise healthy patients).

5. Shelton, Herbert M. Natural Hygiene Articles. Shelton’s lifetime work on the acute-to-chronic cascade, eliminative crises, and the consequences of pharmaceutical suppression is distributed across his newsletters and books, including Orthopathy and Human Life: Its Philosophy and Laws.

6. Roytas, Daniel. Can You Catch a Cold? Untold History and Human Experiments. 2023. Comprehensive review of failed human-to-human transmission experiments across respiratory and herpetic conditions.

7. Richet, Charles. “Anaphylaxis.” Nobel Lecture, 11 December 1913. Full text available via nobelprize.org. Documents the mechanism by which injection of foreign protein produces lifelong heightened response to subsequent exposure.

Additional Sources

Bailey, Mark. The Final Pandemic: An Antidote to Germ Theory.

Cowan, Thomas, and Fallon Morell, Sally. The Contagion Myth.

Engelbrecht, Torsten, and Köhnlein, Claus. Virus Mania.

Gober, Mark, with Bailey, Samantha, Bailey, Mark, and Lanka, Stefan. An End to Upside Down Medicine.

Lester, Dawn, and Parker, David. What Really Makes You Ill?

Tilden, John H. Toxemia Explained.

Williams, Ulric, Bailey, Samantha, Bailey, Mark, et al. Terrain Therapy.

A twenty-seven-minute video produced by Ontario’s Ministry of Health is mandatory viewing for parents who wish to decline the childhood vaccination schedule on grounds of conscience or religious belief. Ted Kuntz of Vaccine Choice Canada sent me the video and made me aware of Ontario’s certification process. I had not previously known about it. The essay engages the video in the two registers the paradigm requires. Establishment vocabulary (immune system, virus, antibody, infection, contagion, herd immunity) appears when I am quoting the video or attributing a claim to the Ministry and its physicians. My analytical voice operates in the terrain register and does not endorse the framework under examination.

The Certificate

In Ontario, a parent cannot decline the childhood vaccination schedule simply by declining. The parent must obtain a Vaccine Education Certificate, issued by the local public health unit only after the parent has watched a twenty-seven-minute video produced by Ontario’s Ministry of Health.¹ The certificate accompanies a statement of conscience or religious belief submitted to the same unit. Without the certificate, the exemption cannot be processed. Without the exemption, the child can be suspended from school under the Immunization of School Pupils Act.²

A parent approaches the state to decline a product. The state responds by requiring the parent to watch state-produced speech about the product for twenty-five minutes before processing the decline. The viewing is mandatory, the content one-directional, and no companion video presents the vaccine-injury and risk record. The certificate is proof of exposure.

The West teaches its citizens to recognize state-run belief-correction programs when they appear in foreign jurisdictions. The Chinese Communist Party ran such programs on dissidents during the Cultural Revolution and operates them today in Xinjiang, where ethnic Uyghurs are detained in what Western governments call re-education camps. The structure is consistent across examples: the state identifies citizens whose beliefs diverge from state orthodoxy, compels them to submit to corrective content, issues a document confirming attendance, and conditions a civic benefit on that document. Scale, duration, and content vary. The structure does not.

Ontario’s Vaccine Education Certificate program is a re-education program for parents who know enough about pharmaceutical products to want to decline them for their children. The tone is polite, the enforcement runs through school attendance rather than labor camps, and the structure is unchanged.

What the video says matters: the state is attempting to transfer specific beliefs. If those beliefs are false against the record, the compulsion loses whatever justification it had, and what remains is the compulsion itself.

Audio Deep Dive (for Paid Subscribers)

The Parent Voice

The video stages twelve speakers. Three carry institutional authority: a Ministry voiceover, a male physician identified as a vaccinator, and a female physician who runs an immunization clinic. The remaining nine play parents who voice concerns a physician or Ministry voiceover then answers. The pattern repeats across all four chapters.

Five examples from the transcript, in order of appearance:

Parent: “Do our kids need all these vaccines? I thought some of these diseases don’t exist anymore, like polio.” Ministry: “All vaccines recommended by Ontario’s Ministry of Health are for diseases that still exist and are current threats.”¹

Parent: “I thought vaccines wipe out your immune system. If we give them to our child, does that mean he won’t develop his own natural resistance?” Ministry: “Some people believe that immunity you develop after getting an infection is better than the immunity provided from a vaccine, but infections can cause severe and lasting complications.”¹

Parent: “I’d like to breastfeed Jonas as much as possible, and if he takes it, then maybe we can wait and see what vaccines he really needs.” Ministry: “Breastfeeding is not a substitute for vaccination.”¹

Parent: “They keep giving kids all sorts of vaccines, and I’ve heard about bad side effects. I can’t help but wonder if they’re doing more harm than good.” Physician: “In my immunization clinic, I get a lot of referrals... their children can have had things after immunization that are not even related to the immunization themselves.”¹

Parent: “I had mumps when I was a kid. Aside from feeling kind of sick with a fever, it was no big deal.” Narrator: “Mumps can cause long-lasting complications like meningitis, deafness, and infertility.”¹

The staging is preemption. The parent arrives with questions the video has anticipated and written into the script, voiced by actors in parent register. She recognizes her own concern on screen and watches it answered. By the time she could voice it, the concern has already been voiced and answered. The device simulates acknowledgment.

The video does not refuse to hear the parent’s question; it voices the parent’s question to overwrite it. She experiences the overwriting as responsive. The felt experience is that the Ministry has heard her. The structural reality is that she was never speaking.

The walk-throughs that follow address the physician and Ministry claims directly.

Chapter One: The Basics

The chapter carries four Ministry-voiced claims: smallpox was eradicated by vaccination; polio was eradicated by vaccination; vaccines imitate infections so what the video calls the immune system learns to fight them; and breastfeeding offers nothing against the diseases vaccines target.

Smallpox. The physician says smallpox “disfigured people and killed millions of children” and that “because of vaccines, it’s no longer with us.”¹ Humphries and Bystrianyk’s Dissolving Illusions documents smallpox mortality in England and Europe from the 1700s onward. Sanitation, nutrition, and housing drove the decline. Vaccination did not.³ Leicester refused Jenner’s vaccine during the mandatory era and achieved lower smallpox mortality than nearby complying cities. Vaccination campaigns in the Philippines, Japan, and England produced smallpox case surges and mortality spikes during and after the drives.³ The WHO’s own 1988 publication Smallpox and Its Eradication reported that in 1976, two years after India was declared smallpox-free, surveillance teams found 63% of suspected cases were chickenpox, and that severe adult chickenpox could not be reliably distinguished from smallpox at any stage.²² What the WHO called eradication was diagnostic reclassification. The term was retired; the conditions were not.

Polio. The video reports that 11,000 Canadians were paralyzed by polio between 1949 and 1954, that 500 died at the 1953 peak, and that case numbers declined sharply after the vaccine’s 1955 introduction.¹ The dates are accurate. The attribution is not.

The paralysis called poliomyelitis is anterior horn cell damage in the spinal cord. Seguin documented this damage in 1882 in humans poisoned with arsenic; Popow reproduced it in animals a year later.²³ The lesions are the same because the cause is the same. Lead arsenate was sprayed on American orchards from the 1890s, sodium arsenite on Hawaiian sugar from 1915, and DDT on children, livestock, and crops after the Second World War. In 1949, the physician Morton Biskind documented DDT symptoms “nearly identical” to what was being diagnosed as polio. He testified to Congress in December 1950. Ralph Scobey followed in 1952, arguing poliomyelitis was a poisoning, not an infection.²⁴ Both were ignored. DDT was restricted beginning in the late 1960s. The waves of paralysis receded in parallel.

On May 12, 1955, coinciding with the Salk rollout, US diagnostic criteria changed. Before Salk, polio required a single clinical examination with paralysis lasting twenty-four hours. After, paralysis had to persist for sixty days, confirmed on two separate examinations. Cases that would have been counted as polio before 1955 were reclassified as aseptic meningitis, Coxsackie virus infection, or Guillain-Barré syndrome.³ ⁴ A 1958 Detroit study examined fecal samples from 869 clinically diagnosed polio patients and found poliovirus in 34%.²⁵ The alleged cause was absent from two-thirds of the cases attributed to it.

The CDC’s Pink Book notes that after wild polio was declared eradicated in the United States, 154 of 162 paralytic polio cases (95%) were caused by the oral polio vaccine itself.⁵ The Salk vaccine arrived while the pesticides were being phased out and the diagnostic criteria were being tightened. Credit went to the vaccine.

The dress rehearsal. A physician says a vaccine imitates an infection, the body produces a response, and this produces lifelong protection against the real pathogen.¹ Three assumptions in that sentence are false. The body does not conduct warfare against invaders; it maintains an internal environment and responds to insult.⁶ What medicine calls antibodies have never been purified from human serum for study; their protective function is inferred from laboratory binding assays. Injection does not imitate natural respiratory or oral exposure; it bypasses the mucosal, nasal, and gut barriers that mediate how the body processes foreign material. Charles Richet won the 1913 Nobel Prize for demonstrating that injection of foreign proteins produces sensitization, not tolerance.⁷ The “dress rehearsal” metaphor contradicts the Nobel laureate who established the actual effect of foreign protein injection.

Breastfeeding. “Breastfeeding is not a substitute for vaccination.”¹ Breast milk is characterized as useful against “some infections, such as colds, ear infections, and diarrhea” but not against the diseases vaccines target. The framing treats the schedule as the baseline and breast milk as a supplement. The historical sequence is the opposite. Humans fed infants exclusively by breast for the entire history of the species, and infant mortality from the diseases the modern schedule targets declined by 90% between 1900 and 1950 in Western populations, before most of the schedule existed.³ Clean water, nutrition, housing, and breastfeeding carried that decline.

Chapter Two: Vaccine Safety

The chapter frames everything in a vaccine as “designed to help make it safe and effective,”¹ then addresses the three ingredients that worry people, the question of adverse events, and the autism concern.

Purity. Vaccines are “highly purified to reduce the amount of foreign substances introduced to your immune system.”¹ Gatti and Montanari’s 2017 study examined forty-four samples of thirty different vaccines by electron microscopy and found micro and nano-sized particulate contamination in every sample. The particles included stainless steel, tungsten, gold, silver, zirconium, hafnium, lead, bismuth, iron, and chromium.⁸ None appeared on any package insert. “Highly purified” is a marketing phrase.

Aluminum. The Ministry voiceover describes aluminum salts as added to “strengthen the effectiveness of the vaccine” through adjuvant action producing “faster, stronger, and longer-lasting immunity.”¹ Aluminum is a known neurotoxicant that crosses the blood-brain barrier and accumulates in bone, kidney, and brain tissue. Mold, Umar, King, and Exley (2018) examined post-mortem brain tissue from individuals diagnosed with autism and found aluminum concentrations among the highest ever measured in human brain tissue, localized predominantly inside non-neuronal cells including microglia.⁹ Crépeaux et al. (2017) showed that aluminum hydroxide, the form used in most pediatric vaccines, translocates from the injection site to the brain in mice; low doses produced greater brain uptake than high doses because of how macrophages handle the metal.¹⁰ The Pink Book names aluminum adjuvant content in DTaP, hepatitis B, hepatitis A, Hib, HPV, and pneumococcal vaccines.⁵ The cumulative aluminum load delivered through the first year of the Canadian pediatric schedule exceeds the FDA’s parenteral aluminum safety threshold for premature infants. The Ministry does not mention the calculation.

Formaldehyde. The video defuses formaldehyde with a biological point: your body produces formaldehyde during metabolism, therefore trace vaccine formaldehyde is not harmful.¹ The move trades on a category confusion. Endogenous formaldehyde is generated inside cells for routine biochemistry and cleared through normal metabolism. Injected formaldehyde bypasses the gut and liver, enters the bloodstream directly, and is delivered to tissues as a complete foreign molecule. Formaldehyde is a Group 1 human carcinogen (IARC).¹¹ Saying trace vaccine formaldehyde is safe because the body makes formaldehyde is like saying injecting pond water is safe because the body makes water. The route of exposure determines everything.

Thimerosal. “Thimerosal has not been used in vaccines since 2001, with one exception. It is still used in some flu shots. There is no evidence of any harm caused to any person by thimerosal in vaccines.”¹ Each sentence is wrong. Thimerosal was not banned in 2001; the U.S. Public Health Service and the American Academy of Pediatrics recommended reduction, not elimination. The Pink Book’s 2020 ingredient tables confirm that multidose influenza vaccines still contain thimerosal, and those vials are routinely administered to pregnant women and infants over six months in the United States and Canada.⁵ The “no evidence of harm” claim ignores the Verstraeten CDC analysis presented at the Simpsonwood conference in June 2000, which found a statistically significant association between thimerosal exposure and neurodevelopmental outcomes. The analysis was reworked across subsequent iterations until the association disappeared in the published version. The Simpsonwood transcript is in the public record under FOIA.¹² “No evidence of harm” describes the published literature after selective publication, not the state of knowledge.

Anaphylaxis at one in a million. The video places serious reactions at this frequency.¹ VAERS receives about 30,000 reports per year according to the Pink Book itself.⁵ The CDC calls VAERS a passive surveillance system subject to underreporting. The 2010 Harvard Pilgrim/AHRQ study estimated that fewer than 1% of adverse vaccine events are reported through VAERS.¹³ A 1% reporting rate applied to 30,000 annual reports yields a true adverse event frequency three orders of magnitude higher than the one-in-a-million figure.

The autism paragraph. The Ministry voiceover states that the autism idea started in 1998 with a journal article, that there was “one study, and it was wrong,” that “dozens of studies since then” have “all disproven that link,” that Wakefield “lost his medical license after facing charges of professional misconduct,” and that the General Medical Council found he had engaged in “numerous things like falsifying data for the study.”¹

The 1998 Lancet paper was a case series of twelve children with gastrointestinal symptoms and developmental regression after MMR vaccination. A case series describes observations and asks whether a pattern warrants investigation; it does not establish causation. The paper itself stated: “We did not prove an association between measles, mumps, and rubella vaccine and the syndrome described.”¹⁴ The video presents the paper as a study claiming causation. It was neither.

The GMC inquiry addressed procedural ethics (ethics committee approval for invasive investigations, consent on certain blood draws), not data falsification. The “falsified data” claim entered public discourse through journalist Brian Deer’s 2011 BMJ reporting, which constitutes allegation, not scientific finding. The Lancet retracted the paper in 2010. Ten of thirteen co-authors had already signed a 2004 retraction of “an interpretation” stating that “no causal link was established between MMR vaccine and autism as the data were insufficient.” Wakefield did not sign. The retraction confirms the paper’s own disclaimer; it is nevertheless cited as evidence of fraud.

The studies cited as having “disproven” the MMR-autism link share two methodological limitations. Most compare MMR-vaccinated children to other-vaccine-vaccinated children, not to unvaccinated children. Most are population-level studies that cannot detect subset vulnerabilities. The DeStefano 2004 CDC study is widely cited; its senior author, William Thompson, publicly stated in August 2014 that he and his colleagues had omitted data showing a 3.4-fold elevated autism risk in African American boys who received MMR before thirty-six months. Representative Bill Posey read Thompson’s statement into the Congressional Record in July 2015.¹⁶ Handley’s How to End the Autism Epidemic catalogs the limitations of each cited study.¹⁵ The video’s phrase collapses a limited and compromised literature into a declaration of settled science.

Chapter Three: Safety in Numbers

A physician recounts a 2015 measles cluster that began at Disneyland and “spread to a number of locations all across North America.”¹ The point: illnesses that seem rare can appear anywhere, carried by unvaccinated travelers.

The CDC’s record of the 2015 episode is public. Of 110 confirmed California patients in the MMWR report, 49 (45%) were classified unvaccinated, 47 (43%) had unknown or undocumented vaccination status, and the remainder had received one or more MMR doses.¹⁷ The categories mislead. US MMR coverage runs above 90% by school age; a 45% “unvaccinated” slice does not exist in that population as a stable fact. “Unvaccinated” here names an administrative category, not a biological state. A patient classified unvaccinated for MMR has almost certainly received other vaccines on the schedule, and may well have received an earlier MMR dose whose record the health department could not verify to its own tightened standard. The 43% “unknown” bucket absorbs most of those cases. The fully vaccinated proportion of the outbreak is higher than the headline numbers make visible. The measles genotype identified was B3, a strain also present in the Philippines at the time. The index case was never identified. The physician’s object lesson in unvaccinated travelers importing illness is not what the epidemiological report establishes.

The 90% figure. “There is a 90% chance that someone who is not adequately protected against measles will acquire the disease if they are in contact with an infected person.”¹ The number comes from pre-vaccine-era observations of close domestic contact: how often, when one person in a household developed measles, others sharing the house over the following days also developed it. The video uses the figure to suggest that any public contact carries the same risk. The original observation does not support that extrapolation.

Herd immunity itself. The concept derives from A.W. Hedrich’s 1933 observations on measles outbreaks in Baltimore, where outbreaks occurred when the susceptible population reached a threshold through births and migration.¹⁸ Hedrich was describing naturally acquired immunity, which is lifelong in the case of measles. Vaccine policy imported the concept on the assumption that vaccine-induced immunity is functionally equivalent. It is not. Vaccine-induced immunity wanes; the Pink Book acknowledges waning for pertussis, tetanus, diphtheria, and hepatitis B.⁵ Two-dose MMR produces 88% effectiveness against mumps by the Pink Book’s own figures, meaning 12% of recipients remain susceptible.⁵ A population with 95% coverage and 12% breakthrough reaches the “herd” threshold in the model, not in the field.

Mumps complications. A parent speaker says mumps “was no big deal” when she was a child. The Ministry corrects her: mumps can cause “meningitis, deafness, and infertility” and “miscarriage” in pregnant women during the first trimester.¹ The parent was correct. During 1963-1968, US mumps mortality ran at approximately 1 death per 93,000 infections, and the deaths resulted from rare complications rather than the illness itself.⁵ The sterility fear attached to orchitis has driven much of the perceived seriousness. The clinical data contradicts it: orchitis occurs in 20-40% of post-pubertal cases, is unilateral in over 90% of those cases, and complete sterility is described by the CDC itself as “rare,” with no study definitively assessing permanent infertility risk.⁵ Childhood vaccination shifted the demographic profile toward older ages, where the complications are more frequent. The Pink Book notes that after two-dose MMR vaccination became standard, mumps outbreaks appeared in highly vaccinated populations, including university students and Orthodox Jewish communities with high MMR coverage.⁵ Herd immunity as applied to MMR has not matched field data for over a decade.

Vulnerable communities. The appeal: infants, the elderly, and those the video calls “immunocompromised” depend on the vaccinated majority for protection.¹ The appeal rests on the assumption that vaccinated people do not pass illness to others. The MMR licensing studies did not measure person-to-person passage. The data required to justify the moral logic of universal vaccination was never collected.

Chapter Four: What, When, and Why

The science-based schedule. A pediatrician describes the Ontario schedule as “science-based” and tells parents that following it ensures a child is “protected at each point along the way.”¹ No published safety study compares the full pediatric schedule against an alternative schedule or against no schedule. The Institute of Medicine’s 2013 report The Childhood Immunization Schedule and Safety concluded as much and called for such studies.¹⁹ They have not been funded at scale. The 2020 Thomas and Lyons-Weiler analysis of a single pediatric practice found higher rates of chronic illness in vaccinated versus relatively unvaccinated patients.²¹ “Science-based” describes the scheduling of individual products, not the safety of the combined cumulative load. The video uses the first meaning to imply the second.

Multiple vaccines. “Research has proven that people can safely receive multiple vaccines at once. This doesn’t increase the risk of adverse reactions.”¹ The claim rests on no cited study. The IOM’s 1994 report found inadequate evidence for most vaccine-outcome pairs, and the 2013 report identified the same gap for combined administration. Published work on simultaneous administration measures what the field calls antibody response rates, not neurological or developmental endpoints over time. “Proven” is a confidence statement the literature does not support.

Delay as risk. A parent says her child “is so tiny. Maybe we should wait.”¹ The narrator responds that delay “leaves children at risk of getting sick” because many diseases “pose a higher risk for babies and children.” The framing inverts the biology. Infants under six months are protected by factors transferred from the mother during pregnancy and through breast milk. The pediatric aluminum body burden peaks earliest in infancy, when the kidneys least efficiently clear it.⁹ ¹⁰ The developing brain is most vulnerable to neuroinflammatory insult in the window the schedule most heavily loads. “Delay creates risk” holds only if the current schedule is accepted as the baseline. Adjust the baseline for maternal protective factors, lower aluminum exposure, and a more mature blood-brain barrier, and the calculation inverts.

Record-keeping and revaccination. The video notes that incomplete records “may result in extra vaccinations that aren’t needed,”¹ reassuring that revaccination “is safe, but is unnecessary if your immunization records are up to date.” If the vaccine schedule carries the toxic load the record supports, revaccination is not a logistical inefficiency; it is an additive insult.⁹ ¹⁰ ²⁰ “Getting extra vaccines is safe” is the earlier safety claim restated for a different anxiety.

Exemptions. The Immunization of School Pupils Act requires children in school to show proof of immunization against nine diseases. Exemptions are available on medical, conscience, or religious grounds. Students without proof or an exemption “may be suspended from school.”² Children without immunization may also be excluded “during a disease outbreak.” The chapter does not mention the Vaccine Education Certificate requirement that gates the non-medical exemption. The video, itself the gatekeeping instrument, addresses the gate obliquely through a parent’s anxious question (”do you think they’ll really suspend my kids from school?”) and the Ministry’s confirmation.

The Statement of Conscience that accompanies the certificate is signed before a commissioner for taking affidavits. The document functions as liability transfer. If the child later develops a condition the schedule claims to prevent, the state can produce the parent’s signed affirmation that she was informed. The signed statement does for the state what a signed informed-consent form does for a hospital: it moves exposure from the institution to the family.

A parent in Hamilton closes her laptop at 10:34 on a Tuesday night. The video is over. Her youngest will start kindergarten in September. She prints the certificate confirmation, signs the statement of conscience, folds both into an envelope, and seals it. Nothing in the twenty-five minutes changed her mind. The state did not require that it should.

The Constitutional Question

A government that compels a citizen to watch state-produced speech as a condition of exercising a legal right engages in a specific civic transaction. The citizen is not persuaded; she is required. The transaction converts a right into a conditional benefit, and the condition is submission to the state’s view.

What the state compels the parent to watch is not information with a slant. The record contradicts the video at every substantive point: smallpox, polio, the autism paragraph, the ingredients section, the surveillance system, the schedule science, the Disneyland episode, the mumps mortality figures. Each is dismantled in the chapters above, against the Ministry’s own cited sources or against the record the Ministry omits. The video is a sequence of specific false statements delivered under state authority. The schedule it enforces consists of specific products from specific manufacturers. The parent is being compelled to sit through pharmaceutical marketing bearing the Ministry’s seal.

The video does not sit on its own. The philosopher Fabio Vighi has described capital in the current phase as having outsourced its reproduction to the state’s monopoly on violence.²⁶ The childhood vaccine schedule is a clear contemporary example. In the United States, the 1986 National Childhood Vaccine Injury Act removed manufacturer liability for the products on the schedule, converting the childhood vaccine market into a state-guaranteed revenue stream insulated from the ordinary legal consequences of selling an injurious product.²⁷ The schedule enforced in Ontario is coordinated with the American one and the manufacturers are the same global cartel. The Ontario Ministry of Health enforces, on Canadian parents, a schedule written for the benefit of that cartel. The compelled viewing is a grassroots manifestation of the industrial capture of the state’s monopoly on violence.

The parent seeking an exemption under Ontario’s Immunization of School Pupils Act is exercising a provision the Act itself preserves. Medical, conscience, and religious exemptions are not favors; they are statutory provisions. The Vaccine Education Certificate is an administrative requirement imposed on the exercise of those provisions. No equivalent requirement is imposed on parents who comply with the schedule. A parent who vaccinates is not required to watch a video about the vaccine-injury and risk record. The compulsion runs in one direction.

The Ministry defends the program by saying that informed decisions require exposure to accurate information, and that an uninformed exemption is not a real one. The defense carries two assumptions: that the Ministry is the only legitimate source of information on the subject, and that the parent seeking exemption is uninformed by default. Both are instructive about who the state believes should decide.

The Chinese Communist Party ran re-education programs on dissenting citizens during the Cultural Revolution and runs them today in Xinjiang. The Soviet Union ran its own versions. Western history teaching and current news coverage treat these programs as emblems of totalitarian overreach, teaching citizens to recognize the structure: identify dissenters, require them to submit to corrective instruction, document their compliance. Citizens find the structure disturbing when it appears in photographs from foreign countries, past or present. The same citizens, as parents, submit to a smaller-scale version in their own country and do not call it by its name.

Ontario’s version runs twenty-five minutes rather than months, through school attendance rather than labor camps, with cheerful paperwork rather than political humiliation. The differences are real.

The structure does not change. Ontario’s Vaccine Education Certificate program is a re-education program for parents who know enough about pharmaceutical products to want to decline them for their children, operating at small scale through school attendance in a democratic jurisdiction in Canada in 2026. The certificate is proof that the parent has sat through the state’s correction of her beliefs; the record of her exposure is kept.

The constitutional question is whether a province can condition a parent’s exercise of a legal right on the parent’s submission to state-produced belief content. The video that gatekeeps the exemption is the evidence of what the exemption now costs.

How to Explain It to a Six-Year-Old

Imagine a town where every family has to send their children to the same school. The school has a rule: before you can play on the playground, you have to drink a special drink the school makes. The drink is supposed to be good for you.

Some parents don’t want their children to drink it. They have looked at what is in the drink, and they don’t like the ingredients. They know that children who have drunk it have sometimes become very sick. They would like their children to be allowed to play on the playground without drinking it.

The town has a rule for parents like this. The parents can get special permission not to drink the drink, but only if they first sit in a room and watch a long video. The video is made by the people who want everyone to drink the drink. The video says the drink is safe. The video says the ingredients are good. The video says the parents who worry about the drink are confused and have been reading the wrong things on the internet. The video even shows other parents who were confused like them, and shows those confused parents being gently corrected by doctors. The video takes about as long as a cartoon.

When the video ends, a person at the door gives the parent a piece of paper. The paper says: “This parent has watched the video.” The parent takes the paper to the school. The school looks at the paper and says: “Yes, you are allowed not to give your child the drink.”

The paper does not say the parent changed her mind. The paper does not even ask whether she changed her mind. The paper only says that she sat through the video.

Now imagine someone from another country, where a different government does the same thing with a different drink, and we see it on the news. We think it is strange. We think the people are being made to sit through a video they did not ask for, and given a piece of paper that proves they watched it, before being allowed to do what they already had the right to do.

We find it strange when the other country does it. We do not find it strange when our own country does it, because our own country is polite about it and smiles when it hands you the paper.

The grown-up word for what the school is doing is called “compelled speech.” The children on the playground are not thinking about this. They are just playing on the playground. The grown-ups are the ones who have to notice.

References

1. Ontario Ministry of Health. Vaccine Education Video (transcript, 27:54 minutes). Available via Vaccine Education Certificate program, Ontario public health units. Source material for this essay.

2. Immunization of School Pupils Act, R.S.O. 1990, c. I.1 (Ontario).

3. Humphries, Suzanne and Bystrianyk, Roman. Dissolving Illusions: Disease, Vaccines, and the Forgotten History (2015).

4. Maready, Forrest. The Moth in the Iron Lung: A Biography of Polio (2018).

5. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book), 14th edition. See chapters on poliomyelitis (VAPP), pertussis, measles/mumps/rubella, influenza (thimerosal content in multidose vials), and Appendix D (VAERS, surveillance architecture).

6. Cowan, Thomas S. and Fallon Morell, Sally. Vaccines, Autoimmunity, and the Changing Nature of Childhood Illness (Chelsea Green, 2018).

7. Richet, Charles. “Anaphylaxis.” Nobel Lecture, December 11, 1913.

8. Gatti, Antonietta M. and Montanari, Stefano. “New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination.” International Journal of Vaccines & Vaccination 4(1), 2017.

9. Mold, Matthew; Umar, Dorcas; King, Andrew; and Exley, Christopher. “Aluminium in brain tissue in autism.” Journal of Trace Elements in Medicine and Biology 46 (2018): 76-82.

10. Crépeaux, Guillemette et al. “Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity.” Toxicology 375 (2017): 48-57.

11. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100F: Formaldehyde (classified as Group 1, carcinogenic to humans).

12. “Scientific Review of Vaccine Safety Datalink Information” (Simpsonwood Conference transcript), June 7-8, 2000. Released under the Freedom of Information Act.

13. Lazarus, Ross et al. Electronic Support for Public Health - Vaccine Adverse Event Reporting System (ESP:VAERS). Final report to the Agency for Healthcare Research and Quality (AHRQ), Grant No. R18 HS 017045, 2010.

14. Wakefield, A.J. et al. “Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.” The Lancet 351 (February 28, 1998): 637-641. (Retracted 2010; retraction note confirms original paper did not claim causation.)

15. Handley, J.B. How to End the Autism Epidemic (Chelsea Green, 2018). See chapters on the Thompson/DeStefano CDC whistleblower disclosure (August 2014) and methodological review of frequently cited MMR-autism epidemiological studies.

16. Statement of William W. Thompson, Ph.D., regarding the 2004 article examining the possibility of a relationship between MMR vaccine and autism, as entered into the Congressional Record by Rep. Bill Posey, July 29, 2015.

17. Zipprich, Jennifer et al. “Measles Outbreak in California, December 2014 to February 2015.” Morbidity and Mortality Weekly Report 64(6), February 20, 2015: 153-154.

18. Hedrich, A.W. “Monthly Estimates of the Child Population ‘Susceptible’ to Measles, 1900-1931, Baltimore, Maryland.” American Journal of Epidemiology 17(3) (1933): 613-636.

19. Institute of Medicine. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies (National Academies Press, 2013).

20. Miller, Neil Z. Miller’s Review of Critical Vaccine Studies (New Atlantean Press, 2016). See chapters on aluminum adjuvant neurotoxicity and cumulative exposure analysis.

21. Lyons-Weiler, James and Thomas, Paul. “Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination.” International Journal of Environmental Research and Public Health 17(22) (November 2020): 8674. The paper was withdrawn by the publisher post-publication under contested circumstances; the underlying dataset and analysis remain in the public record.

22. Fenner, F., Henderson, D.A., Arita, I., Ježek, Z., and Ladnyi, I.D. Smallpox and Its Eradication. World Health Organization (1988). See Chapter 1 on diagnostic difficulty and the 1976 post-eradication surveillance findings in India.

23. Seguin, E.C. “Myelitis Following Acute Arsenical Poisoning (By Paris Green or Schweinfurth Green).” Journal of Nervous and Mental Disease IX(4) (October 1882): 665-680. Popow, N. “Ueber die Veränderungen im Rückenmarke nach Vergiftung mit Arsen, Blei und Quecksilber.” Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 93 (1883): 351-366.

24. Biskind, Morton S., and Bieber, Irving. “DDT Poisoning: A New Symptom with Neuropsychiatric Manifestations.” American Journal of Psychotherapy (1949). Biskind, statement to the Select Committee to Investigate the Use of Chemicals in Food Products, U.S. House of Representatives, December 12, 1950. Scobey, Ralph R., statement to the same committee, 1952.

25. Brown, G.C., Lenz, W.R., and Agate, G.H. “Laboratory data on the Detroit poliomyelitis epidemic, 1958.” JAMA 172(8) (1960): 807-812.

26. Vighi, Fabio. Interview with Unbekoming, May 12, 2026. See also Vighi, “Bombs for Bonds: Iran and the Geopolitics of Refinancing,” The Philosophical Salon, March 9, 2026, and Vighi, “A Self-Fulfilling Prophecy: Systemic Collapse and Pandemic Simulation,” The Philosophical Salon, August 2021.

27. National Childhood Vaccine Injury Act of 1986, Public Law 99-660. See also Bruesewitz v. Wyeth, 562 U.S. 223 (2011), extending the Act’s preemption of state-law design-defect claims against vaccine manufacturers.

This essay examines a specific chemical ingredient on the childhood vaccine schedule. The case against formaldehyde can be built within the terms the regulatory system itself uses, and most of the evidence below is drawn from that system: the CDC’s own Pink Book, the WHO’s cancer research arm, the EPA’s exposure limits, OSHA’s workplace rules. These are quoted and attributed as what they are. My analytical voice operates within the terrain framework that governs this body of work. Where mainstream vocabulary appears in this essay (virus, antigen, immune response, antibody, infection), it belongs to the sources being quoted, not to me. The chemistry of formaldehyde is real. The regulatory documents are real. The question of what is in the vial, and what it does to the body it is injected into, can be answered without accepting the framework that put it there.

Two vials

The vial of embalming fluid at the funeral home and the vial of hepatitis B vaccine injected into the newborn contain the same chemical compound. Formaldehyde. The embalmer uses it to preserve tissue by cross-linking the proteins so that bacteria and fungi cannot break them down. The vaccine manufacturer uses it to kill bacterial contamination during production and to alter the biological material the industry labels as hepatitis B virus. The leftover formaldehyde stays in the vial. The vial goes into the muscle tissue of a child, often within hours of birth, before the first feed, before the mother has recovered from labor.

The ingredient is listed. The schedule is published. The CDC’s own 14th-edition Pink Book, in Appendix B, names formaldehyde as an excipient in Recombivax (hepatitis B), in Daptacel and Infanrix (DTaP), in Pediarix and Vaxelis and Pentacel (combination vaccines given at two, four, and six months), in Ipol (polio), in Boostrix and Adacel and Tenivac and TDVAX (tetanus-containing), in Fluzone and Fluarix and FluLaval and Fluad (influenza, administered annually from six months of age), in Menactra and MenQuadfi and Menveo (meningococcal), in Vaqta (hepatitis A), in ActHIB and Hiberix (Hib), in Ixiaro (Japanese encephalitis), in Biothrax (anthrax), in DT, and in Typhim Vi (typhoid). The same table lists Havrix (hepatitis A) and Twinrix (hepatitis A/B combination) under the term formalin, which is formaldehyde in aqueous solution.¹ The chemical appears on the schedule from the first day of life and recurs through adolescence.

The hepatitis B vaccine is administered within twenty-four hours of birth to the majority of infants born in American hospitals. The Pink Book reports that 75% of children born in 2015 and 2016 received the birth dose within three days of life, a figure that has climbed since.² The Recombivax formulation listed on the CDC’s excipient table contains formaldehyde, potassium aluminum sulfate, amorphous aluminum hydroxyphosphate sulfate, and yeast protein.¹ The child goes home from the hospital with these substances in her tissue.

Audio Deep Dive (for Paid Subscribers)

What it is

Formaldehyde is CH₂O, the simplest aldehyde. At room temperature it is a colorless gas with a sharp odor detectable at concentrations as low as 0.5 parts per million. Dissolved in water at approximately 37%, it becomes formalin, the liquid familiar to anatomy labs and funeral homes. The chemical was first synthesized in 1859 and patented for industrial use shortly after. Its utility across industry rests on two properties: it kills microorganisms, and it cross-links proteins.

The embalming industry built around chemical body preservation in the 1860s and 1870s used it for exactly these reasons. The chemical binds amino and thiol groups on tissue proteins and freezes them in place. Bacteria and fungi cannot digest cross-linked protein. Decomposition stops. The same two properties made formaldehyde useful across other industries: as a precursor for the resins that bind particleboard, plywood, and laminate; as a textile finish, including the permanent-press treatments on clothing; as a disinfectant in laboratories and mortuaries; as a preservative in some cosmetics and in some veterinary feeds.

Global production runs in the range of 30 million metric tons a year, placing it among the most-produced chemicals in the world. A modern home contains it in dozens of places. Pressed-wood furniture, kitchen cabinets, carpet backing, drywall adhesives, and the formaldehyde-releasing preservatives inside shampoo and body wash all off-gas the chemical slowly into indoor air. Measurements inside new homes commonly run five to ten times outdoor air concentrations. None of this changes what the chemical does to tissue.

In 2004, the International Agency for Research on Cancer, the cancer research arm of the World Health Organization, reclassified formaldehyde as Group 1: carcinogenic to humans.³ Group 1 is the highest category IARC uses, reserved for substances with sufficient evidence of causing cancer in people. The company it keeps in Group 1 includes asbestos, plutonium, tobacco smoke, and benzene. The classification was based on evidence of nasopharyngeal cancer in formaldehyde-exposed workers and of leukemia in industrial exposure cohorts. The pivotal cohort study by Hauptmann and colleagues at the National Cancer Institute, published in 2003, tracked more than 25,000 industrial workers across ten US plants and found a significant excess of myeloid leukemia mortality in the highest peak-exposure group.⁴

OSHA treats formaldehyde as a hazardous substance in American workplaces. Permissible airborne exposure is capped at 0.75 parts per million as an eight-hour time-weighted average, with a short-term limit of 2 parts per million for any fifteen-minute period.⁵ A workplace using the chemical must provide respiratory protection, local exhaust ventilation, eye protection, hazard training, and medical surveillance for exposed employees. The material safety data sheet lists it as toxic by inhalation, skin contact, and ingestion, with warnings for eye damage, respiratory sensitization, allergic skin reactions, and cancer risk.

Across all of this, no regulatory body has published a safety assessment for injected formaldehyde in human infants. The exposure routes the regulators studied are inhalation (workplace air, indoor air, cigarette smoke) and ingestion (drinking water, food). Intramuscular injection into a newborn is not among them.

What it does

Formaldehyde works on tissue the same way it works on an embalmed body. It cross-links proteins. The aldehyde carbon reacts with amino and thiol groups in amino acid side chains and forms covalent bonds between adjacent protein molecules. The cross-linked proteins lose their function. Enzymes that depended on folding and movement are frozen. Membrane proteins that transported ions or signaled across cells are immobilized. The mechanism is uncontroversial and documented across more than a century of biochemistry.

The same reactivity damages the cell’s nucleic acids. Formaldehyde cross-links the nucleic acid strand to the proteins packed around it, and the cell cannot easily repair the lesion. Cells carrying this damage die outright or divide producing further damaged cells. The IARC monograph cites this chemistry in its Group 1 classification. The link between workplace formaldehyde exposure and leukemia in exposed cohorts follows from the same reactions reaching bone marrow cells over years.

When formaldehyde reaches tissue at a concentration that overwhelms local clearing capacity, it kills cells. The embalmer relies on this cellular toxicity for preservation, and industrial safety limits are calibrated around it. The vaccine manufacturer uses the chemical for the same reason: to kill bacterial contamination during production and to alter the biological materials being prepared. The industry describes this as inactivating what it calls polio virus, as weakening diphtheria toxin into diphtheria toxoid, and as weakening tetanus toxin into tetanus toxoid. After formaldehyde treatment, the materials in the vial no longer produce the acute illness they are said to produce when fresh.

A newborn has approximately 240 milliliters of blood. Her liver, the primary site of formaldehyde metabolism in older humans, is immature at birth. The enzyme that clears the chemical (formaldehyde dehydrogenase, which converts the aldehyde to formic acid and then to carbon dioxide and water) is present at reduced levels in neonates compared to adults. Her blood-brain barrier is permeable in ways it will not be after the first year. Her kidneys concentrate and excrete at lower rates. The margin between a dose the body can clear and a dose it cannot is narrower in the first weeks than at any other time of life.

Into this biology, the hepatitis B vaccine delivers residual formaldehyde directly into muscle tissue. The chemical reaches systemic circulation before any clearing organ acts on it. The muscle at the injection site contains aluminum adjuvant, which keeps the local tissue inflamed for weeks. Inflamed tissue has altered blood flow and altered clearance kinetics. The formaldehyde acts on cells in that environment, not in the clean laboratory conditions of the inactivation chemistry performed inside the vial.

“Your body already makes it”

Every mainstream defense of formaldehyde in vaccines runs through the same argument. The CDC’s public-facing page states it, pediatric practice handouts repeat it, and fact-check articles reproduce it almost word for word. The argument runs: the human body produces formaldehyde endogenously as part of normal metabolism, at concentrations in the range of 2 to 3 micrograms per milliliter of blood; a vaccine dose of residual formaldehyde adds a trivially small amount to a background that is already larger; therefore no injury can occur.

The argument confuses four distinct biological facts. Each confusion closes a different door.

Endogenous production is not the same as exogenous delivery. Endogenous formaldehyde is generated inside cells, in regulated quantities, from one-carbon metabolism and from the oxidation of serine, glycine, and choline. It is produced by the same cell that clears it, in the same compartment, as part of a metabolic cycle the cell runs continuously. The formaldehyde never leaves the compartment that produced it. The body does not accumulate a free formaldehyde pool. The 2 to 3 micrograms per milliliter figure cited in the defense is a transient steady-state concentration maintained by enzymes clearing the chemical as fast as it is produced. Exogenous formaldehyde delivered as an injection enters tissue as a bolus. It is not produced by the cell that must clear it. It arrives in excess of local clearing capacity by definition, which is why the chemical acts on tissue at all.

Oral and inhalation routes are not the same as intramuscular injection. The EPA’s reference dose for formaldehyde in drinking water assumes oral ingestion.⁶ The oral route delivers the chemical to the portal circulation, which carries it directly to the liver before it reaches the rest of the body. The liver clears most of it on the first pass. OSHA’s workplace limit assumes inhalation. Inhaled formaldehyde is cleared in the upper airway by mucosal enzyme systems. Neither pathway resembles intramuscular injection, in which the chemical is deposited in muscle tissue and reaches systemic circulation before encountering any clearing organ. The regulators themselves distinguish between exposure routes. The vaccine defense treats them as interchangeable.

With cofactors is not the same as without. Endogenous formaldehyde is produced inside cells that contain the enzymes, cofactors, and substrates needed to clear it. The clearance system is integrated with the production system. Injected formaldehyde arrives in tissue without any of this. The muscle at the injection site contains no formaldehyde dehydrogenase at concentrations relevant to a bolus dose, and the aluminum adjuvant present in the same vial extends the inflammation window during which the chemical is acting on nearby cells.

Transient equilibrium is not the same as repeated pulses. Endogenous formaldehyde is produced continuously at low rates and cleared continuously at matching rates. The system is in dynamic balance. The vaccine schedule introduces formaldehyde on day one of life, again at two months, again at four months, again at six months, again at twelve to fifteen months, again at four to six years, and annually thereafter through the influenza schedule. Each injection is a pulse. The DTaP vaccine Infanrix, administered at two, four, and six months, specifies up to 100 micrograms of residual formaldehyde per 0.5 milliliter dose in its own package insert.¹⁶ The pulses stack across a developing body whose clearing systems are still maturing. No study has characterized the cumulative tissue exposure across the full schedule. The defense cites the endogenous steady state as if it absorbed the pulses, which it was never designed to do.

Behind the four confusions sits a deeper error. The defense treats a molecule as a context-free unit. A molecule of CH₂O with the formula CH₂O. Interchangeable regardless of where it came from, how it arrived, what came with it, or what the receiving tissue was prepared to do with it. The body does not treat molecules this way. The route of entry, the cofactor matrix, the timing, and the local tissue state are not incidental to biology. They are the biology. The body is a self-regulating organism that cleanses, repairs, and maintains the terrain within tolerances it has evolved to handle. The tolerances were not shaped by injection. The route did not exist until the needle created it.

How it got there and stayed

Formaldehyde entered vaccine production in the early twentieth century for a straightforward reason. It worked. It killed bacterial contamination in the production environment, and it altered the biological materials the industry worked with. The method was adopted at the Pasteur Institute in the early 1920s for the diphtheria toxoid. The CDC’s Pink Book states directly that “a method for inactivating tetanus toxin with formaldehyde was developed in the early 1920s. This led to the development of tetanus toxoid in 1924.”⁷ The chapter on polio describes the inactivated vaccine as containing “wild poliovirus strains grown individually in Vero cells and inactivated with formaldehyde.”⁸ The practice is openly described in the establishment’s own training materials.

The Salk polio history is instructive and documented. Suzanne Humphries, in Dissolving Illusions, assembles the record of warnings issued by senior scientists during the vaccine’s development. Swedish observations presented at the Rome Poliomyelitis Congress in September 1954 showed that formaldehyde did not inactivate at the rate Salk’s model assumed, and that the inactivation curve was not a straight line but a continuous curvature.⁹ Dr. Edwin Lennette, director of the California State Department of Health, later recounted a 1953 meeting with Thomas Rivers, whom Humphries describes as the mastermind of Rockefeller’s polio vaccine mission. The question of whether the vaccine was adequately inactivated at the chosen formaldehyde concentration was raised directly at that meeting. Rivers answered: “If you put any more formaldehyde in, you’ll make it so damn safe it won’t be any good.”¹⁰ The 1955 Cutter incident, in which Cutter Laboratories’ polio vaccine paralyzed children when the inactivation chemistry fell short, followed directly from this dismissal. The record shows 260 cases of paralysis documented between April 17 and June 30, 1955, after inoculation of roughly 400,000 persons with the Cutter vaccine. The official breakdown counted 94 cases among the vaccinated themselves, 126 among family contacts, and 40 among community contacts.¹¹

Wendell Stanley described what formaldehyde had actually done to the vaccine material. It “engendered a ‘tanning’ effect upon the outer coating of the virus,” reversible under subsequent conditions, so the material could test clean at fourteen days and reactivate at three or four weeks.¹² Stanley’s observation went into the record and was set aside. The vaccine stayed on the schedule. Manufacturers responded to the Cutter disaster by adding more filtration steps rather than reconsidering the inactivation chemistry. Dr. Sven Gard, a leading Swedish scientist working on the Salk problem, later wrote that the repeated filtrations were “only hunting ghosts” and that “the whole philosophy behind the Salk vaccine is wrong.”¹³

The point is not that formaldehyde was poorly chosen for inactivation chemistry. The point is that no one at the time asked, and no one since has adequately asked, what the residual formaldehyde did when it reached the recipient’s tissue. The inactivation was studied in the vial. The injection consequences were not studied in the body.

The regulatory framework that stabilized this arrangement rests on two words. “Residual” and “trace.” Formaldehyde in a vaccine is classified as a manufacturing-process residual rather than as an active ingredient. The distinction matters legally and practically. Active ingredients require safety and efficacy studies. Residuals do not, as long as the manufacturer certifies that remaining concentrations fall below a defined threshold. The threshold was set by reference to endogenous production levels, which recycles the confusion addressed in the previous section. The second category is Generally Recognized as Safe. GRAS is an FDA designation created for food additives with a long history of consumption. Formaldehyde carries GRAS status for certain food applications. GRAS was never designed as a safety determination for injection. The chemical’s presence on the food-additive list has functioned in regulatory practice as a general safety signal that transfers across contexts it was never evaluated against.

What was not done is more revealing than what was. No randomized trial has tested injected formaldehyde in human infants against a true saline placebo. No biodistribution study has tracked where injected formaldehyde actually travels in the body over time. The 2013 pharmacokinetic modeling paper by Mitkus and colleagues at the FDA, which the CDC and vaccine manufacturers cite in defense of injection safety, is a computational projection built on assumptions about absorption, distribution, and clearance in the injected infant.¹⁷ It is not empirical measurement; it is what the field has substituted for empirical measurement. No cumulative-dose study has characterized total formaldehyde exposure across the full childhood schedule. No study has examined formaldehyde in combination with the aluminum adjuvants it is injected alongside, even though the aluminum keeps the injection site inflamed for weeks and extends the window during which the formaldehyde acts on local tissue. Neil Miller’s catalog of critical vaccine studies states this directly: “No studies have been conducted to confirm the safety of combining aluminum with other toxic substances in vaccines, such as mercury, formaldehyde, phenoxyethanol, polysorbate 80, and glutaraldehyde.”¹⁴

These are not gaps. They are choices. The studies that would answer the questions have not been funded. The regulatory structure does not require them. The manufacturers are not liable for injuries caused by the ingredients they place in the vial, because the 1986 National Childhood Vaccine Injury Act removed that liability from the civil courts and replaced it with a federal compensation program funded by an excise tax on vaccines themselves.¹⁵ The arrangement is organized so that the questions are not asked. The structure that would answer them does not exist.

Two vials, again

I find it demonically poetic that we are injected with formaldehyde on our entry into the world, and wrapped in formaldehyde on our exit.

A deeper paradigm question sits beneath all of this. The body is not under constant assault by invading pathogens requiring pharmaceutical defense. Disease arises from toxic exposure, nutritional deficiency, electromagnetic burden, and psychological strain, acting on a terrain the body works continuously to maintain. The injection of embalming fluid into a healthy newborn is an insult to that terrain. The question of whether a specific dose of formaldehyde causes a particular identifiable injury in an individual child is secondary to the question of why embalming fluid is in the vial at all. Other essays in this series address the deeper layer. This one has stayed with the chemical.

Return to the vial at the funeral home and the vial injected into the newborn. The chemical compound is identical. The embalmer uses the chemical for a stated purpose: to stop decomposition by freezing proteins in place. The vaccine manufacturer uses the chemical for a stated purpose: to kill bacterial contamination in production and to alter the biological material in the vial. The leftover chemical, in both vials, is formaldehyde. Every US agency with jurisdiction has published something about it. The CDC’s Pink Book lists it (as formaldehyde or formalin) in twenty-nine vaccines. The IARC monograph classifies it as Group 1, carcinogenic to humans. OSHA regulates workplace airborne exposure at 0.75 parts per million. EPA calibrates a reference dose for drinking water. None of these documents concerns the route the schedule actually uses. The injection into the newborn’s muscle, bypassing every regulatory limit calibrated to any other exposure route, happens on the day of birth, under a schedule the parents have been told is safe because the body already makes small amounts of the compound itself.

The ingredient is listed. The studies are not.

Twelve points

1. Formaldehyde is the chemical compound CH₂O. In solution at approximately 37%, it is formalin, the fluid used in anatomy labs and funeral homes.

2. The International Agency for Research on Cancer classified formaldehyde as a Group 1 carcinogen in 2004. Group 1 means carcinogenic to humans, the highest category IARC uses.

3. OSHA regulates formaldehyde as a hazardous substance in American workplaces. Permissible airborne exposure is capped at 0.75 parts per million over an eight-hour day. Employers using the chemical must provide respiratory protection, ventilation, training, and medical surveillance.

4. The CDC’s own Pink Book, Appendix B, lists formaldehyde as an excipient in Recombivax, Daptacel, Infanrix, Pediarix, Vaxelis, Pentacel, Ipol, Boostrix, Adacel, Tenivac, TDVAX, Fluzone, Fluarix, FluLaval, Fluad, Menactra, MenQuadfi, Menveo, Vaqta, ActHIB, Hiberix, Ixiaro, Biothrax, DT, Typhim Vi, Kinrix, and Quadracel. The same table lists Havrix and Twinrix (hepatitis A vaccines) under the term formalin, which is formaldehyde in aqueous solution.

5. The chemical cross-links proteins and reacts with cellular nucleic acids. This is why it preserves tissue in embalming and alters vaccine materials in production. The same chemistry damages cells over time at exposure concentrations.

6. The childhood vaccine schedule introduces formaldehyde on day one of life (hepatitis B birth dose), at two months, four months, six months, twelve to fifteen months, four to six years, and annually thereafter through influenza vaccines.

7. The mainstream defense of formaldehyde in vaccines rests on the claim that the body produces the chemical endogenously. The defense conflates endogenous production with injected delivery, oral and inhalation routes with intramuscular injection, metabolically embedded production with isolated bolus doses, and continuous steady-state balance with repeated schedule pulses.

8. The EPA’s and OSHA’s exposure limits apply to ingestion and inhalation routes with full metabolic clearance available. No regulatory body has published a corresponding safety limit for injected formaldehyde in human infants.

9. Formaldehyde entered vaccine production in the early twentieth century because it killed bacterial contamination and altered biological materials in the vial. The Salk polio vaccine history records that senior scientists warned the inactivation chemistry was wrong, that the inactivation was incomplete and the material in the vials remained capable of causing paralysis, and that the warnings were set aside.

10. Formaldehyde is classified in vaccines as a manufacturing residual rather than as an active ingredient. Residuals are not required to be safety-tested the way active ingredients are. The GRAS designation that permits formaldehyde in some food applications has functioned as a general safety signal transferring to injection contexts it was never evaluated against.

11. No randomized trial, no biodistribution study, no cumulative-dose assessment, and no study of formaldehyde in combination with aluminum adjuvants has been performed in human infants on the childhood schedule. The absence is structural, not accidental.

12. The 1986 National Childhood Vaccine Injury Act removed vaccine manufacturers’ civil liability for injuries caused by ingredients in the vial. The regulatory structure that approved formaldehyde for injection, the industry that profits from the schedule, and the parents who must live with the consequences do not share equal access to the courts.

Questions you will be asked

“Isn’t the amount tiny?” Residual formaldehyde in a single vaccine dose is listed by manufacturers in the microgram range. The Infanrix (DTaP) package insert specifies up to 100 micrograms per 0.5 milliliter dose; Daptacel and other DTaP preparations fall in a similar range. Whether that amount is tiny depends on where it goes, how fast it is cleared, what accompanies it, and what the receiving body is prepared to handle. A microgram in a glass of water the liver clears on first pass is a different biological event from a microgram injected into muscle tissue of a six-pound newborn alongside an aluminum adjuvant. The question of whether the amount is small presupposes an exposure route the regulators never studied for injection.

“Doesn’t the body already produce formaldehyde?” The body produces endogenous formaldehyde in regulated quantities, inside cells, cleared by enzymes in the same cell, as part of a metabolic cycle in dynamic balance. Injected formaldehyde arrives from outside, as a bolus, in tissue that was not producing it, in the presence of aluminum adjuvant that extends local inflammation and alters clearance kinetics. The two are not interchangeable. The endogenous steady state is not a reservoir that absorbs injections.

“Hasn’t this been studied?” Formaldehyde’s toxicity has been studied extensively by the EPA, OSHA, and IARC in the contexts of inhalation and ingestion. No regulatory body has published a safety study of injected formaldehyde in human infants. No biodistribution study, no cumulative-dose study across the schedule, and no study of combination with aluminum adjuvants exists. The absence is documented in Neil Miller’s catalog of the published literature.

“If it were dangerous, wouldn’t we see it?” We do see it. The rise in neurodevelopmental conditions, chronic inflammation, pediatric conditions labeled autoimmune, SIDS, and the broader chronic illness profile of the vaccinated cohort is what harm from the schedule looks like at population scale. The comparison between fully vaccinated and genuinely unvaccinated children is the comparison the regulatory agencies have refused to fund. Independent researchers (Mawson, Lyons-Weiler, Thomas, Garner) have performed versions of it and found consistent and significant health gaps.

“But vaccines prevent disease, right?” The question of whether the childhood schedule produces net health benefit is addressed in other essays in this series. The formaldehyde question is prior to it. If embalming fluid is in the vial, and no one has studied what happens when it is injected into a newborn, the question of what the vial is for cannot settle the question of what the ingredient does.

“Why would doctors give it if it were harmful?” Doctors are trained in a system that treats the schedule as settled science and treats the ingredient list as a manufacturing matter outside their clinical responsibility. The pediatrician reading the chart does not read the manufacturer’s insert. The pharmacist filling the vial does not read the IARC monograph. The system is structured so that the people administering the injection are not the people trained in what is in it.

How to Explain It to a Six-Year-Old

Imagine your body is a garden. A real garden, with soil and roots and little pathways the water travels along to reach the plants. The garden has a tiny spray bottle it uses sometimes to clean up small messes between the leaves. The spray bottle holds a cleaner that is helpful in very small amounts, used in the right place at the right time by the gardener who lives inside you. The gardener knows how to make a little of the cleaner, use a little, and clean up a little. The garden has worked this way for a very long time.

One day someone comes to the fence with a big spray gun. The gun contains the same cleaner, except a lot of it, and a kind that was made in a factory far away. The person at the fence says, “Don’t worry. Your garden already uses this stuff.” Then they point the big gun past the fence, past the gate, past the little path the garden has for letting things in and out slowly, and they spray it straight into the dirt around the roots. The cleaner goes into the garden all at once, in a place it does not belong, in an amount the gardener was never prepared to handle. The gardener was not asked.

The person at the fence says the garden is fine because the garden makes a little bit of the same cleaner on its own. But the garden making a tiny amount in the right place, slowly, with its own helpers nearby, is not the same thing as the big gun spraying a lot in the wrong place, quickly, with no helpers in sight. The gardener knows the difference. The plants know the difference. Everyone except the person with the spray gun seems to know the difference. The garden is a living thing. It does not care what the cleaner is called. It cares about where it came from, how much there is, and whether it belongs there. The answer, every time it is sprayed, is that it does not.

References

1. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book), 14th edition. Appendix B: Vaccine Excipient Summary. Public Health Foundation, 2021.

2. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book), 14th edition. Chapter on Hepatitis B.

3. International Agency for Research on Cancer. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Volume 88: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol. Lyon: World Health Organization, 2006. Based on the June 2004 Working Group reclassification.

4. Hauptmann, M., Lubin, J. H., Stewart, P. A., Hayes, R. B., Blair, A. Mortality from Lymphohematopoietic Malignancies among Workers in Formaldehyde Industries. Journal of the National Cancer Institute, 2003; 95(21): 1615-1623. The National Cancer Institute cohort study on which the IARC 2004 Working Group drew heavily for the leukemia classification.

5. US Occupational Safety and Health Administration. 29 CFR 1910.1048: Formaldehyde Standard.

6. US Environmental Protection Agency. Integrated Risk Information System (IRIS): Formaldehyde (CASRN 50-00-0). Oral reference dose assessment.

7. Centers for Disease Control and Prevention. Pink Book, 14th edition. Chapter on Tetanus.

8. Centers for Disease Control and Prevention. Pink Book, 14th edition. Chapter on Poliomyelitis.

9. Humphries, S. and Bystrianyk, R. Dissolving Illusions: Disease, Vaccines, and the Forgotten History. 2013. On the Rome Poliomyelitis Congress, September 1954, and the inactivation curve observations.

10. Humphries and Bystrianyk, Dissolving Illusions, 2013. Edwin Lennette interview recounting the 1953 pre-trial meeting with Thomas Rivers.

11. Humphries and Bystrianyk, Dissolving Illusions, 2013. Documentation of the 1955 Cutter incident, April to June, 260 cases of paralysis following inoculation of approximately 400,000 persons.

12. Humphries and Bystrianyk, Dissolving Illusions, 2013. Dr. Wendell Stanley on the “tanning” effect of formaldehyde on the outer protein coating.

13. Humphries and Bystrianyk, Dissolving Illusions, 2013. Dr. Sven Gard on the Salk inactivation philosophy.

14. Miller, N. Z. Miller’s Review of Critical Vaccine Studies: 400 Important Scientific Papers Summarized for Parents and Researchers. New Atlantean Press, 2016.

15. National Childhood Vaccine Injury Act of 1986, Public Law 99-660, Title III of the Public Health Service Act.

16. GlaxoSmithKline. Infanrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Prescribing Information. Current revision. The package insert specifies ≤100 μg residual formaldehyde per 0.5 mL dose.

17. Mitkus, R. J., Hess, M. A., Schwartz, S. L. Pharmacokinetic modeling as an approach to assessing the safety of residual formaldehyde in infant vaccines. Vaccine, 2013; 31(25): 2738-2743. DOI: 10.1016/j.vaccine.2013.03.071. A PBPK (physiologically-based pharmacokinetic) model, not an empirical biodistribution study. Cited by the CDC and vaccine manufacturers as the principal defense of injected formaldehyde safety.

The man who co-edited the National Science Foundation’s 2002 landmark report Converging Technologies for Improving Human Performance, which set the federal research agenda for nanotechnology, biotechnology, information technology, and cognitive science, is the same man who, twenty years earlier, had called on his sociological colleagues to become “religious engineers” and deliberately construct new scientistic cults to displace Christianity. William Sims Bainbridge, Director of the Information and Intelligence Systems Division at the NSF, had spent five years embedded in the Process Church of the Final Judgement, a satanic cult that split from Scientology. He accepted a teaching role in its pantheon of Satan, Lucifer, Jehovah, and Christ, and published his ethnographic findings as Satan’s Power in 1978. Martin Erdmann’s The Spiritualization of Technology: The Quest for Human Perfection, published in German in 2015 and in updated English translation in 2024, documents the Bainbridge dossier and situates it within an intellectual lineage reaching from Hesiod to the Extropy Institute.

Erdmann holds a Master of Divinity from Columbia International University, a Master of Theology from the University of Basel and the University of Aberdeen, and a doctorate in Modern Church History from Brunel University London awarded in 1999. From January 2004 to December 2008 he served as resident ethicist and consultant to the surgeons of the cardiology unit at University Hospital Basel and to the medical personnel of the CLINAM Foundation, the European Foundation for Clinical Nanomedicine, now the International Society of Nanomedicine. The research he conducted over those five years became the basis of the Habilitation thesis in Systematic Theology that Károli Gáspár University of Budapest accepted in 2017; the book is that thesis. He has directed the Verax Institute for Christian apologetics since 2003. Patrick Hunziker, Deputy Head of Intensive Care Unit Cardiology at University Hospital Basel and now President of the International Society of Nanomedicine, contributed the foreword.

Erdmann presented a paper at the University of South Carolina’s nanomedicine conference arguing that the convergence project is a modern version of alchemy. The audience of seventy to eighty medical professors and doctors erupted in applause when he finished. The alchemical reading is not an outside interpretation imposed on the field. Working practitioners recognize what the project is. His stated purpose in publishing the book in both German and English, Erdmann writes, was to expose the open secret to a larger international audience.

The 2002 NSF and Department of Commerce report, 405 pages, moved the technological transformation of the human species from speculation into federal research policy. Mihail Roco, Director of NSF’s Nanotechnology Division, and Bainbridge, co-editing the volume, sympathetically credited Ray Kurzweil’s projections of machine consciousness, mind transfer, and reversible death. They proposed a “global brain” linking human nervous systems into a single transcendent collective intelligence. They projected a human body made “more durable, healthier, stronger, and easier to heal,” resistant to biological threats and the aging process. The executive summary declared the NBIC convergence would lead humanity to a “golden age” and recommended the US government make enhancement research a national priority. The scope of what was being proposed, bearing the imprimatur of the federal science establishment, is what gives the document its historical weight. Dissenting voices within the field, including Jeremy Rifkin, Bill Joy, and Phil Kuekes, did not alter the direction of the agenda.

This book belongs in the lineage of works that read modern technological utopianism as religious inheritance, continuous with Hermetic, Gnostic, Neoplatonic, and alchemical sources. It stands alongside Frances Yates on the Hermetic tradition, Eric Voegelin on Gnosticism and modernity, and C.S. Lewis’s The Abolition of Man. The summary unpacks the specific documentary record Erdmann assembles: Marsilio Ficino’s 1463 translation of the Corpus Hermeticum for Cosimo de’ Medici, prioritized over the completion of his Plato translation, which launched the Renaissance Hermetic revival that reaches to Francis Bacon; Walter Wilmshurst’s 1927 declaration in The Meaning of Masonry that “the evolution of man into superman” is the actual purpose of the Craft, stated sixty years before Max More formalized the Extropian Principles; and the seven Extropian Principles themselves, accompanied by an anonymous 1995 Extropy Journal manifesto demanding “Down with the laws of gravity” and declaring “We will become our own gods.” The Director of Information and Intelligence Systems at the National Science Foundation is on public record proposing a Church of God Galactic. His own published writings establish the fact. What has been seen in his dossier cannot be unseen.

I interviewed Dr. Erdmann in April 2026 and reviewed his earlier work The Greed for Gold and Glory, a 487-page documentary account of mercantilism from Venice to the present-day City of London. Both pieces are in the archive. He writes five days a week on Substack under Musings of the Court Jester. His scholarship is among the most consequential independent work being produced in this field, and I am a supporter of his work.

Audio Deep Dive (for Paid Subscribers)

Read more

A note on language. This essay engages a condition that mainstream cardiology describes in the vocabulary of lipid deposition, cholesterol infiltration, and genetic risk. Those terms appear here in quotation and attribution, within reference titles, and inside the names of official bodies. The author’s own analysis runs in a different register. Where mainstream cardiology sees an accumulating substance, this essay sees a repair process. Where it sees “bad cholesterol,” this essay sees red blood cells trapped in clots. The two registers do different work and the reader should feel the shifts between them.

This essay is a companion to “The Wrong Enemy: Blood Clots, Not Cholesterol,” which maps the full terrain of heart disease across history, politics, metabolism, stress, and treatment. The piece you are reading narrows the lens to one question that essay sketches but does not fully develop: what, physically, is an atherosclerotic plaque, and how is it built?

The vein that becomes an artery

A surgeon performing a coronary artery bypass graft strips a length of vein from the patient’s leg and sews it onto a coronary artery, bypassing a blockage. The vein served that leg for sixty years without a trace of atherosclerosis. Now it carries arterial pressure. It fills with plaque, sometimes severely, and sometimes within a few years.¹

The blood did not change. The LDL in that blood is the same LDL that passed through the vein every day of the patient’s life without harming it. What changed is the stress on the vessel wall.

A second oddity sits alongside this one. The pulmonary arteries, which carry blood from the right side of the heart through the lungs, almost never develop atherosclerosis. Neither do the pulmonary veins. The same blood circulates through them, with the same cholesterol, the same LDL, the same lipoproteins of every variety. Plaque almost never forms there.¹

If atherosclerosis were a disease of what circulates in the blood, the pulmonary arteries would be as diseased as the coronaries, and a vein grafted into arterial duty would stay as clean as the vein next to it in the thigh. Neither is true.

Mechanical stress on the arterial wall is the subject of this essay. Not what floats in the blood.

Audio Deep Dive (for Paid Subscribers)

Three figures the mainstream buried

Karl von Rokitansky (1804–1878). Viennese pathologist, prolific beyond belief, said to have performed or supervised tens of thousands of autopsies. He opened arteries for a living. In the 1840s he examined thousands of diseased arteries and saw the same thing again and again: fibrin, the sticky protein that binds blood clots, laid down in layers inside the plaques, in various stages of organization and repair. He proposed what he called the encrustation hypothesis: plaques are the remains of clots. He was describing what he found in the arteries of the dead, not theorizing beyond it.² His contemporary Rudolf Virchow pressed one question. If plaques form beneath the arterial lining, how does a blood clot get underneath that lining to begin with? Rokitansky had no answer. The answer was not available for another 140 years.

Elspeth Smith. Scottish pathologist at the University of Aberdeen. In a small-group teaching session there, she once told a room of fresh-faced medical students that LDL cannot cross the endothelium.³ For most of the students the sentence passed as a technical aside. For one of them, Malcolm Kendrick, it was the first visible crack in the façade of what they were being taught. Smith spent four decades documenting the role of the clotting system at every stage of plaque development, from initiation to growth to rupture. “After many years of neglect,” she wrote, “the role of thrombosis in myocardial infarction is being reassessed. It is increasingly clear that all aspects of the haemostatic system are involved: not only in the acute occlusive event, but also in all stages of atherosclerotic plaque development.”⁴ Her work was published, cited, and largely ignored by a research field with its attention fixed elsewhere.

Kilmer McCully (1933–2025). Harvard pathologist, trained at Massachusetts General Hospital. In 1968 he examined the arteries of two children who had died with severe arteriosclerosis. One was a boy who had died of stroke at age eight in 1933; the other was a two-month-old who had died of pneumonia. Both had the inherited condition homocystinuria, in which the amino acid homocysteine accumulates in the blood. Both children had severe arteriosclerosis throughout their bodies. In neither case did the plaques contain fat or cholesterol.⁵ The shared factor was elevated homocysteine. McCully proposed, in a paper published in 1969, that homocysteine damages the arterial wall and triggers the plaque-building process. By 1977 his laboratory at Massachusetts General had been taken from him. By 1979 his appointment was ended. He spent two years unemployed, then landed at the Veterans Administration hospital in Providence, Rhode Island, where he worked until his death in 2025.⁶

Three figures, each describing a facet of the same thing. Rokitansky buried by a question he could not yet answer. Smith buried by indifference. McCully buried by career destruction.

1. What the word means

Athero comes from the Greek for gruel or porridge, describing the soft, pulpy core of some advanced plaques. Sclerosis is Greek for hardening. The disease was named for what pathologists found when they cut diseased arteries open: hardened vessels containing areas of soft, yellowish material.

Where it forms matters. Plaques develop in large and medium-sized arteries. They cluster at branch points, at bends, and where arteries narrow. They do not form in the small arterioles or in the capillaries. They do not form in veins. They almost never form anywhere in the pulmonary circulation.¹

The pattern is a map of mechanical stress. Branch points are where flow becomes turbulent. Bends are where shear forces concentrate. The locations where plaque forms are the locations where the arterial lining takes the hardest hit.

2. What is actually inside a plaque

A standard list of plaque components reads as follows: fibrin, platelets, red blood cells, white blood cells, smooth muscle cells, lipoprotein(a), collagen, calcium, and cholesterol crystals.⁷

Every item on that list, except smooth muscle cells and calcium, is also found in a blood clot.

The American Heart Association’s 1995 scientific statement, the Stary classification of atherosclerotic lesions, examined advanced plaques directly. The findings are startling to anyone taught that plaque is accumulated cholesterol:

“...38% of persons with advanced lesions had thrombi on the surface of the lesion. These thrombi ranged in size from minimal to grossly visible deposits, and some consisted of layers of different ages. Immunohistochemistry revealed wavy bandlike deposits related to fibrin within the advanced lesion of an additional 29% of persons. Because of their structure, these were thought to represent the remnants of old thrombi. Similar data were reported by other authors.”⁸

Thrombi of different ages. Fibrin bands within the plaque body. Visible layers suggesting repeated deposition over months and years. The AHA’s own document continues:

“The architecture of some multi-layered fibroatheromas could also be explained by repeated disruptions of the lesion surface, hematomas, and thrombotic deposits.”⁸

Fibrin cannot cross an intact arterial lining. Red blood cells cannot cross it. Platelets cannot cross it. The presence of all three in layered formations inside advanced plaques is only explicable if those components were there from the beginning, as components of blood clots that were subsequently covered over and incorporated into the artery wall.

Look at an advanced plaque in cross-section and the layers can be visible to the naked eye. Pathologists have compared them to tree rings.⁸

3. The question Virchow asked

Rokitansky’s problem was that nineteenth-century pathology had no concept of how new arterial lining is generated. The lining, called the endothelium, was understood as a passive layer of tiles. If plaques sit beneath the endothelium, and clots form on top of the endothelium, how does the clot get underneath? Rokitansky could not answer. Virchow pressed the point and the encrustation hypothesis fell into disuse.

The answer arrived in the 1990s with the identification of endothelial progenitor cells, bone marrow–derived precursors that circulate in the bloodstream and respond to breaches in the arterial lining by generating new endothelial cells on site.⁹ When a clot forms over a damaged patch of lining, these cells arrive and build a new endothelium directly on top of the clot. The clot is thereby drawn into the artery wall.

A 1968 study of pig aortas, funded by a tobacco company, had already documented the process without knowing what it was watching. The researchers stripped the endothelium from sections of the pig aorta, waited varying numbers of days, and killed the pigs to examine the damaged area. They described a blood clot forming over the damage, then shrinking, then becoming covered by “flattened cells with darkly staining elongated nuclei and spindle shaped cytoplasm lying on the surface of these thrombi.”¹⁰ They had watched new endothelium grow over the clot. They did not know what the cells were.

Rokitansky, had the answer been available to him, could have told Virchow that the clot does not form beneath the endothelium. The endothelium grows back over the top.

The implication is severe. Plaques do not form by LDL seeping through the lining. Plaques form at breaches in the lining, where clots arise, and the lining then regrows over the clot.

4. Where the cholesterol crystals come from

Pathologists examining plaques do find cholesterol crystals, often in abundance. The crystals look like sharp white needles under the microscope. Rudolf Virchow identified them in the 1850s and the mainstream explanation has run the same way ever since: the crystals must have come from LDL, which carries cholesterol in the blood.

They did not.

LDL carries cholesterol in the form of cholesterol esters, in which a cholesterol molecule is bonded to a fatty acid. Cholesterol crystals cannot form from cholesterol esters. To crystallize, cholesterol must be in its free, unesterified form.¹¹

Red blood cells provide it. The membrane of a red blood cell is roughly 40% lipid, and that lipid contains the highest concentration of free cholesterol of any tissue in the body outside the brain. When a red blood cell is incorporated into a clot and its membrane degrades, the free cholesterol is released, and that free cholesterol is what crystallizes within plaque.¹² ¹³

A 2012 paper in the Upsala Journal of Medical Sciences reported directly:

“...erythrocyte membranes were present in the necrotic core of advanced atherosclerotic plaques. Further studies have shown that erythrocyte membranes contribute to a significant increase of cholesterol accumulation in atherosclerotic plaques, since these membranes contain large amounts of cholesterol.”¹³

Cholesterol crystals in a plaque are a signature of trapped red blood cells, which is a signature of a clot. They are not a signature of LDL infiltration.

5. Plaques grow in episodes

The common mental picture of plaque buildup is gradual accumulation, like limescale in a kettle. The picture is wrong.

Plaques grow in discrete episodes. A patch of lining is damaged. A clot forms. New lining grows over the clot. The same patch is damaged again, in days or in weeks or in years. Another clot forms on top of the first. New lining grows over the second clot. The process repeats.

The AHA’s 1995 document described it directly:

“The fissure and hematomas that underlies thrombotic deposits in many cases may recur, and small thrombi reform many times. Repeated incorporation of small recurrent hematomas and thrombi into a lesion over months or years contributes to gradual narrowing of the arterial lumen.”⁸

A 2000 paper in the journal Atherosclerosis reinforced the point: “plaque rupture and subsequent healing is recognized to be a major cause of further rapid plaque progression.”¹⁴

What makes a plaque dangerous is the final event in this sequence. The repeating cycle of damage, clot, and healing eventually fails. A rupture of the plaque surface triggers a very large clot, big enough to block the entire artery. The downstream tissue dies. If the artery is a coronary, that tissue is heart muscle, and the event is called a heart attack. If the artery feeds the brain, the event is called a stroke.

The same process that builds the plaque is the process that eventually kills.

6. The measurement that should have ended the debate

If cholesterol in the blood were the cause of plaque in the arteries, then people with more cholesterol in their blood should have more plaque in their arteries. The question is testable. The test was performed, repeatedly, in the twentieth century. The method was simple: measure the blood cholesterol of a deceased person and measure the amount of atherosclerosis in their arteries at autopsy, then look for a correlation.

The results have been remarkably consistent.

Landé and Sperry (1936), examining a large series of autopsies: no correlation.¹⁵

Paterson and colleagues in Canada, tracking the blood cholesterol of veterans for years before they died and then examining their arteries: no correlation.¹⁶

Mathur and colleagues in Agra, India, studying 200 people who had died suddenly by accident: no correlation.¹⁷

Studies in Poland, Guatemala, and the United States: no correlation.¹⁸ ¹⁹ ²⁰

The Framingham autopsy study did find a correlation. The correlation coefficient was 0.36.²¹ A coefficient of 1.0 would indicate a perfect correlation; 0.0 would indicate none at all. A coefficient of 0.36 indicates a very weak relationship. The paper offered no diagrams, no individual data points, and did not discuss the number. Framingham was a federally funded study, politically significant, and its weak autopsy correlation did not interrupt the growth of the cholesterol hypothesis.

The 1959 Gore paper comparing aortic atherosclerosis in the United States, Japan, and Guatemala found something more striking. The Japanese subjects had the same degree of aortic atherosclerosis as the American subjects, despite a Japanese heart disease death rate one-sixth of the American rate.²² Plaque burden and heart attack rate were not tracking together.

A disease hypothesis that fails this test, repeatedly and across continents, is a hypothesis in trouble. The hypothesis was retained anyway. The reasons the hypothesis survived its own counter-evidence — Ancel Keys and the Seven Countries Study, the sugar industry’s role in redirecting blame, the statin trade and the institutional capture that followed — are mapped in “The Wrong Enemy.” That history is not repeated here.

7. The experiment that misled everyone

In 1913, the Russian pathologist Nikolai Anitschkow fed enormous quantities of cholesterol to rabbits. The rabbits developed thickened, cholesterol-laden lesions in their arteries. The experiment was taken as confirmation that dietary cholesterol causes arterial disease, and the finding anchored the cholesterol hypothesis for the next century.²³

Rabbits are herbivores. They do not naturally consume cholesterol, which is found only in animal tissue. Force-fed cholesterol at levels no rabbit would ever encounter in nature, the rabbits’ blood cholesterol rose to 10 to 20 times higher than the highest ever recorded in a human being. Cholesterol accumulated throughout the body: in the liver, in the kidneys, in the fur, in the eyes. The animals eventually died of emaciation. The lesions in their arteries did not resemble human atherosclerotic plaques. Different locations, different microscopic structure, no thrombus formation, no haemorrhage, no rupture.²⁴

When the same experiment was repeated on dogs, which are omnivores and metabolize cholesterol as humans do, the dogs regulated the intake and excreted the excess.²⁵ The dog comparison was a better model for humans. The dog comparison was ignored. The rabbit experiment had already fixed cholesterol as the suspect.

The rabbit has not been retired. More than a century after Anitschkow, the cholesterol-fed rabbit remains the archetypal animal model in atherosclerosis research, cited in textbooks and reproduced in laboratories as the canonical image of a cholesterol-caused arterial lesion. A herbivore poisoned with a substance it has no mechanism to process is still being used to illustrate what happens to humans who eat eggs.

8. Clots alone build plaques

The strongest test of whether plaques are built from clots is to examine arteries exposed to clots but not to the usual risk factors, and see whether plaques form.

The pulmonary circulation provides the test. Patients with chronic pulmonary thromboembolism have small clots repeatedly lodging in their pulmonary arteries. These arteries are otherwise immune to atherosclerosis. If plaques are built from clots, these patients should develop plaques in their pulmonary arteries.

They do.

A 2002 paper in Heart by Arbustini and colleagues examined the pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension and compared them with patients with plexogenic pulmonary hypertension, in whom no chronic clots were present. The thromboembolic patients had plaques containing organizing thrombus, recent thrombotic material, calcifications, and cholesterol clefts. The plexogenic patients had fibrous thickening without the pultaceous (soft, lipid-containing) core. The authors wrote:

“Thromboembolic material is therefore sufficient on its own to induce plaque formation and influence its composition.”²⁶

They added that the coronary arteries of these same patients, examined by angiography and at surgery, were free of atherosclerosis. The patients were constitutionally resistant to coronary plaque. In their pulmonary arteries, where the clots were, the plaque developed anyway.

A 1955 paper by O’Neal and Thomas in Circulation, titled “The Role of Pulmonary Hypertension and Thromboembolism in the Production of Pulmonary Arteriosclerosis,” had found the same thing decades earlier. The authors studied children with congenital heart defects that threw clots from the heart into the lungs. These children were too young to have accumulated the risk factors medicine would later invoke, and they had developed full atherosclerotic plaques in their pulmonary arteries from the clots alone. The authors wrote that they “were able to demonstrate transition stages from clearly recognizable thrombi to arteriosclerotic lesions.”²⁷

The chain holds. Where clots repeatedly form, plaques develop. Where clots do not form, plaques do not develop. In a vessel bed famously resistant to atherosclerosis, the presence of chronic clots overrides that resistance.

9. What damages the lining

The remaining question is the only one left. If plaque is built from clots at sites of lining damage, what damages the lining?

The arterial lining is not a passive sheet of tiles. It is covered on the blood side by a layer called the glycocalyx, a fine mesh of sugars and proteins that keeps blood cells and clotting factors from touching the endothelial cells beneath.²⁸ The glycocalyx is where damage begins. Strip it away and the endothelial cells are exposed. Damage the endothelial cells and the tissue beneath is exposed, triggering clot formation.

The known insults are specific and well-documented.

Mechanical shear stress. The locations where plaque forms are the locations where blood flow becomes turbulent: branch points, bends, narrowings. Turbulence creates abnormal shear forces on the arterial lining. The glycocalyx tolerates normal, laminar flow and is stripped by chaotic flow. This is why the vein graft, suddenly asked to carry arterial pressure in a pattern it was never built for, begins failing where the pulse hits hardest. Mechanical stress is not just where damage happens. It is one of the things that does the damage.

Blood sugar spikes. A study published in Diabetes in 2006 directly measured what happens to the glycocalyx during a spike in blood glucose. The glycocalyx was stripped off, and fragments of it, including hyaluronan, could be measured floating in the bloodstream.²⁹ Any meal that spikes blood sugar does this. People who have been given the label diabetes do it chronically. People with the condition medicine calls prediabetes, often undiagnosed, do it chronically as well.

Sugar-damaged proteins. When excess sugar in the blood binds to proteins and fats, it damages them. The damaged molecules are called advanced glycation end products, or AGEs. Research has shown that AGEs can initiate and propagate atherosclerotic lesions independently of lipid status, meaning the damage is done directly, with no need for elevated cholesterol.³⁰

Homocysteine. The amino acid identified by McCully. Elevated homocysteine damages the lining directly. The B-complex nutrients folate, B6, and B12 are required for its metabolism, and intake of these through whole food is often inadequate on a modern processed diet. The fuller story of McCully’s discovery, its suppression, and the B-vitamin connection is told in “The Wrong Enemy.”

Smoking. The link between smoking and heart disease is one of the few that mainstream cardiology and this analysis agree on, and the mechanism is lining damage. Smoke damages the glycocalyx and the endothelium directly.

Heavy metals. Lead and cadmium, in particular, accumulate in the arterial wall and damage endothelial cells.³¹

Bacterial toxin. When bacterial fragments cross from the gut or the mouth into the bloodstream, as happens in leaky gut and in advanced gum disease, they trigger inflammation at the arterial lining. A 2018 study identified lipopolysaccharide, a bacterial toxin, embedded directly within atherosclerotic plaque.³²

Cortisol and adrenaline. Chronic stress, through the HPA axis, elevates these hormones chronically. Both damage the endothelium and increase clot formation.³³

Kidney disease. The condition medicine calls chronic kidney disease impairs nitric oxide synthesis, which is required to keep the endothelium healthy, and reduces the circulating supply of endothelial progenitor cells, which are needed to repair damage.³⁴

The list is not exhaustive, but the common thread is clear. These are insults that strip the glycocalyx, damage the endothelial cells, and either exceed the body’s capacity to repair the lining or exhaust the progenitor cell supply that performs the repair. Where the insult is intermittent, the lining heals and no plaque forms. Where the insult is chronic and the repair system is overwhelmed, the repair residue accumulates. That residue is what pathologists see on autopsy and name atherosclerosis.

The vein again

A vein in the leg, exposed for sixty years to the same blood as every other vessel in the body, does not develop plaque. Grafted onto a coronary artery and asked to carry arterial pressure, the same vein can fill with plaque within a few years.

Nothing in the blood changed. The oxygen tension did not change. The LDL did not change. The cholesterol did not change. The vein did not acquire a new disease.

What changed is the mechanical stress on the vessel wall. The vein, built for low-pressure drainage, is now being pulsed at systolic pressure. The glycocalyx and endothelium of a vein are not designed for that stress and begin to fail. Microscopic damage sites appear. Clots form over them. New lining grows over the clots. The next pulse creates the next damage. Clot layers on clot layers. Plaque.

A disease framework that identifies atherosclerosis as a condition of what circulates in the blood cannot accommodate this fact. A framework that identifies atherosclerosis as the residue of repeated damage can. The vein graft is a controlled experiment that the body performs on itself.

A reader who accepts this has to accept several things along with it. The cholesterol number on a routine blood panel is not the thing that matters. The statin a doctor is prescribing is addressing a measurement rather than a mechanism. The question “am I at risk” has to be asked in a different language than it has been asked in for seventy years, and the tests that answer it are not the tests ordered by default. These are not small adjustments. They are a different map, with the roads leading to different places. The reader is free to put the map down. The arteries will build what they build either way.

What to do with this

What follows is information, not medical advice. Nobody should alter or discontinue a prescribed medication without consulting their physician.

This essay does not engage two bodies of trial evidence that a sophisticated reader will raise. The B-vitamin trials (HOPE-2, NORVIT, VISP) lowered homocysteine with synthetic folic acid and did not reduce cardiac events; the question of whether that result bears on McCully’s thesis, or on the difference between whole-food folate and synthetic folic acid, deserves its own treatment. The PCSK9 outcome trials (FOURIER, ODYSSEY) showed small absolute reductions in events from LDL lowering, alongside their own mortality signals; the question of what those trials actually measured deserves its own treatment too. Both are owed essays of their own.

The pathology above identifies what damages the arterial lining. Avoid or reduce what strips the glycocalyx and damages the endothelium: blood sugar spikes from processed carbohydrates, industrial seed oils, periodontal infection and dysbiotic gut bacteria, smoking, chronic unmanaged stress, and environmental lead and cadmium. Do the inverse: steady blood sugar through whole foods, adequate high-quality animal protein to supply the amino acids from which the glycocalyx is rebuilt,³⁵ serious treatment of oral and gut problems, enough sleep for the HPA axis to reset, and movement that encourages circulation. The fuller prevention protocol, including specific nutrients and therapeutic interventions, is in “The Wrong Enemy.”

The tests that track these processes are different from the tests mainstream cardiology relies on. If a reader can ask a doctor for one test first, a coronary artery calcium score images the plaque burden directly, which total cholesterol and LDL do not. Fasting insulin and HbA1c capture the state of glucose regulation that total cholesterol ignores. Homocysteine measures the amino acid McCully identified. hs-CRP measures the inflammatory state. Lipoprotein(a) measures a particle genuinely bound up in clot formation. These tests exist. They are usually not ordered by default.

A reader convinced by the analysis above has one question left: what to tell a doctor. The honest answer is that most doctors are trained within the framework this essay rejects and will respond accordingly. Reading the sources listed in the references is the best preparation for that conversation.

How to Explain It to a Six-Year-Old

Imagine you scrape your knee. A scab forms. Underneath the scab, new skin grows. When the new skin is ready, the scab falls off, and your knee looks almost like it did before.

Now imagine the scab forms inside a tube that carries water, like a garden hose. If the scab fell off inside the tube, it would float along until the tube got narrow somewhere, and then it would get stuck. If it got stuck in the wrong place, like the pipe to your heart or your brain, that would be very bad.

So inside a blood vessel, the scab is not allowed to fall off. Instead, your body grows new skin on top of the scab, which pulls the scab into the wall of the tube. The scab is tucked away inside the wall where it cannot float off and cause trouble.

That works beautifully, as long as it only happens once.

But what if the same spot inside the tube gets scraped again? A new scab forms, in the same place. New skin grows over the top of that one too. Now you have two layers of tucked-away scab inside the wall. Scrape it again, and there are three layers. Then four. Then five.

After many years of scraping the same spot and tucking away the scabs, there is a lump inside the wall of the tube. The lump is made of all the old scabs piled up. The tube is narrower there now, because the wall has gotten thicker.

That lump is called a plaque. Doctors used to think the lump was fat that leaked in from the blood. It is not. It is scabs. It is what the body built to patch the wall every time something scraped it.

The question that matters is not what the scabs are made of. The question is what keeps scraping the same spot.

References

1. Kendrick, M. (2021). The Clot Thickens: The Enduring Mystery of Heart Disease. Columbus Publishing, chapters 2–3. On the absence of plaque in veins and the pulmonary circulation, and on vein grafts as coronary bypass grafts.

2. Ventura, H. O. (2000). “Rudolph Virchow and Cellular Pathology.” Clinical Cardiology 23(7): 550–552. https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.4960230717

3. Kendrick, M. (2021). The Clot Thickens, chapter 2. Kendrick recounts Smith’s teaching remark that LDL cannot cross the endothelium during a small-group session at Aberdeen University, which he identifies as his first exposure to a crack in conventional cardiovascular thinking.

4. Smith, E. B. and Thompson, W. D. (1994). “Fibrin as a factor in atherogenesis.” Thrombosis Research 73(1): 1–19. https://www.sciencedirect.com/science/article/pii/0049384894900493

5. McCully, K. S. (1969). “Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.” American Journal of Pathology 56(1): 111–128.

6. McCully, K. S. and McCully, M. (1999). The Heart Revolution: The Extraordinary Discovery That Finally Laid the Cholesterol Myth to Rest. HarperPerennial, foreword and pages 7–10.

7. Kendrick, M. (2021). The Clot Thickens, chapter 2, on plaque composition.

8. Stary, H. C., Chandler, A. B., Dinsmore, R. E., et al. (1995). “A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis. A Report From the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.” Circulation 92(5): 1355–1374. https://www.ahajournals.org/doi/full/10.1161/01.CIR.92.5.1355

9. Luttun, A. and Verfaillie, C. M. (2007). “Will the real EPC please stand up?” Blood 109(5): 1795–1796. https://ashpublications.org/blood/article/109/5/1795/23187/

10. Woolf, N., Bradley, J. W. P., Crawford, T., and Carstairs, K. C. (1968). “Experimental mural thrombi in the pig aorta. The early natural history.” British Journal of Experimental Pathology 49(3): 257–264. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2093824/

11. Kendrick, M. (2021). The Clot Thickens, chapter 2, on cholesterol esters versus free cholesterol.

12. Pasterkamp, G. and Virmani, R. (2002). “The erythrocyte: a new player in atheromatous core formation.” Heart 88(2): 115–116. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767211/

13. Zhong, Y., Tang, H., Zeng, Q., et al. (2012). “Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin.” Upsala Journal of Medical Sciences 117(4): 390–398. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497225/

14. Zaman, A. G., Helft, G., Worthley, S. G., and Badimon, J. J. (2000). “The role of plaque rupture and thrombosis in coronary artery disease.” Atherosclerosis 149(2): 251–266. https://www.sciencedirect.com/science/article/pii/S0021915099004797

15. Landé, K. E. and Sperry, W. M. (1936). “Human atherosclerosis in relation to the cholesterol content of the blood serum.” Archives of Pathology 22: 301–312.

16. Paterson, J. C., Armstrong, R., and Armstrong, E. C. (1963). “Serum lipid levels and the severity of coronary and cerebral atherosclerosis in adequately nourished men, 60 to 69 years of age.” Circulation 27: 229–236.

17. Mathur, K. S., Patney, N. L., Kumar, V., and Sharma, R. D. (1961). “Serum cholesterol and atherosclerosis in man.” Circulation 23: 847–852.

18. Marek, Z., Jaegermann, K., and Ciba, T. (1962). “Atherosclerosis and levels of serum cholesterol in postmortem investigations.” American Heart Journal 63: 768–774.

19. Méndez, J. and Tejada, C. (1967). “Relationship between serum lipids and aortic atherosclerotic lesions in sudden accidental deaths in Guatemala City.” American Journal of Clinical Nutrition 20: 1113–1117.

20. Cabin, H. S. and Roberts, W. C. (1982). “Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary arterial narrowing by atherosclerotic plaque in coronary heart disease.” American Journal of Medicine 73: 227–234.

21. Feinleib, M., Kannel, W. B., Tedeschi, C. G., Landau, T. K., and Garrison, R. J. (1979). “The relation of antemortem characteristics to cardiovascular findings at necropsy. The Framingham Study.” Atherosclerosis 34: 145–157.

22. Gore, I., Hirst, A. E., and Koseki, Y. (1959). “Comparison of aortic atherosclerosis in the United States, Japan, and Guatemala.” American Journal of Clinical Nutrition 7: 50–54.

23. Anitschkow, N., Chalatov, S., Müller, C., and Duguid, J. B. (1913). “Über experimentelle Cholesterinsteatose: Ihre Bedeutung für die Enstehung Einiger Pathologischer Prozessen.” Zentralblatt für Allgemeine Pathologie und Pathologische Anatomie 24: 1–9.

24. Ravnskov, U. (2000). The Cholesterol Myths: Exposing the Fallacy that Saturated Fat and Cholesterol Cause Heart Disease. NewTrends Publishing, chapter 7.

25. Gould, R. G., Taylor, C. B., Hagerman, J. S., Warner, I., and Campbell, D. J. (1953). “Cholesterol metabolism: I. Effect of dietary cholesterol on the synthesis of cholesterol in dog tissue in vitro.” Journal of Biological Chemistry 201(2): 519–528.

26. Arbustini, E., Morbini, P., D’Armini, A. M., et al. (2002). “Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation.” Heart 88(2): 177–182. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767204/

27. O’Neal, R. M. and Thomas, W. A. (1955). “The Role of Pulmonary Hypertension and Thromboembolism in the Production of Pulmonary Arteriosclerosis.” Circulation 12(3): 370–377. https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.12.3.370

28. Reitsma, S., Slaaf, D. W., Vink, H., van Zandvoort, M. A., and oude Egbrink, M. G. (2007). “The endothelial glycocalyx: composition, functions, and visualization.” Pflügers Archiv 454(3): 345–359.

29. Nieuwdorp, M., van Haeften, T. W., Gouverneur, M. C., et al. (2006). “Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.” Diabetes 55(2): 480–486.

30. Schleicher, E. and Friess, U. (2007). “Oxidative stress, AGE, and atherosclerosis.” Kidney International 72: S17–S26. https://doi.org/10.1038/sj.ki.5002382. As cited in Hussey, S. (2022). Understanding the Heart. Chelsea Green, chapter 7.

31. Alissa, E. M. and Ferns, G. A. (2011). “Heavy metal poisoning and cardiovascular disease.” Journal of Toxicology 2011: 870125.

32. Carnevale, R., Nocella, C., Petrozza, V., et al. (2018). “Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque.” Scientific Reports 8: 3598.

33. Steptoe, A. and Kivimäki, M. (2012). “Stress and cardiovascular disease.” Nature Reviews Cardiology 9(6): 360–370.

34. Baylis, C. (2008). “Nitric oxide deficiency in chronic kidney disease.” American Journal of Physiology: Renal Physiology 294(1): F1–F9.

35. Kendrick, M. (2021). The Clot Thickens, chapter 12, on albumin and glycocalyx maintenance.

On September 25, 2017, the US Court of Federal Claims ruled that Merck’s Gardasil vaccination killed Christina Tarsell, a twenty-one-year-old Bard College art student who died in her sleep eighteen days after her third dose. The government did not appeal. By letting the deadline expire on March 30, 2018, the US Department of Health and Human Services conceded by preponderance of evidence what Merck and the CDC had spent a decade denying: this product can cause death in healthy young women. The Tarsell ruling is the keystone finding of Shattered Dreams: The HPV Vaccine Exposed, Christina England’s 2019 compilation of fifteen contributors documenting what Gardasil, Gardasil 9, and Cervarix have done to teenage girls across the world. The book is anchored in court documents, FDA submissions, VAERS data, and clinical trial protocols obtained through freedom of information requests. The evidence is not anecdotal. It is procedural, documented, and publicly available to anyone who looks.

Christina England holds a BA Hons in Literature and Humanities and a Higher National Diploma in Journalism and Media Studies, and has spent over a decade researching vaccination for VacTruth, Health Impact News, GreenMedInfo, and The Truth About Vaccines. She has previously co-authored Shaken Baby Syndrome or Vaccine Induced Encephalitis — Are Parents Being Falsely Accused? with Dr. Harold Buttram, and Vaccination Policy and the UK Government: The Untold Truth with Dr. Lucija Tomljenovic PhD. Her co-author Amanda Dew holds a BSc Hons in Health Sciences, with a Masters-level literature research module in the same field; her sixteen-year-old daughter Brodie developed severe epilepsy, chronic fatigue, and ASIA syndrome after the HPV vaccination series. The contributors assembled for this volume include Professor Christopher Exley (bioinorganic chemistry, Keele University), Professor Yehuda Shoenfeld (immunology, Tel Aviv University), Dr. Sin Hang Lee (pathology, Milford Molecular Laboratory), Dr. Sarah Myhill, Désirée Röver, Viera Scheibner PhD, and attorney Alan Phillips. Their work has not been refuted. It has been ignored.

Gardasil received FDA fast-track approval in 2006, Cervarix followed in 2009, and Gardasil 9 was approved in December 2014 with more than double the aluminium adjuvant content of the original. The commercial context is specific. Merck was about to lose patent protection on Zocor and faced $18 billion in Vioxx injury claims from a cardiovascular drug the company had marketed while suppressing its own data showing a five-times increase in heart attacks. Analysts projected the global HPV vaccine market at $4 billion by 2011, contingent on government-funded national programs for teenage girls. The 1986 National Childhood Vaccine Injury Act had already granted manufacturers complete liability immunity. By 2013, Japan had withdrawn its HPV vaccine recommendation after cataloguing severe adverse reactions in hundreds of girls. No Western government followed. The establishment position across the UK, US, Australia, and most of Europe held, and still holds, that the vaccines are safe and effective, that reported injuries are coincidental, and that cervical cancer prevention justifies the program. The book was published into this position, not against a vacuum.

Shattered Dreams sits alongside Mary Holland’s The HPV Vaccine On Trial and Viera Scheibner’s foundational vaccination work as part of the documented record on what has been done to a generation of teenage girls under the banner of cancer prevention. The full summary unpacks three specific findings: that Merck used the aluminium adjuvant itself as the “placebo” control in 92.5% of trial subjects, making it structurally impossible to detect excess reactions from the adjuvant; that Dr. Sin Hang Lee found HPV DNA fragments bound to aluminium in every one of sixteen Gardasil samples tested, and in the blood and spleen of a New Zealand girl six months after her third dose; and that in every country with high vaccination coverage, including Australia, the UK, Norway, and Sweden, cervical cancer rates have stopped declining and started rising specifically in the vaccinated cohort. Martínez-Lavín’s 2017 calculation puts the number needed to seriously harm with Gardasil 9 at 140, and the number needed to vaccinate to prevent one case at 1,757. Thirteen young women are seriously harmed for every one who benefits. The vaccine was approved on the basis of trials that could not detect what the trials were supposed to detect, and it is still being given to twelve-year-olds today.

Related

Audio Deep Dive (for Paid Subscribers)

30 Q&As

Question 1: Who was Christina Tarsell, and what was the significance of the US Court of Federal Claims ruling in her case?

Answer: Christina Tarsell was a 21-year-old Bard College art student, athlete, and only child of Emily Tarsell. She died in her sleep on June 23, 2008, eighteen days after her third Gardasil vaccination. She had no known heart condition before her first Gardasil dose. Between her first and second shots, an EKG detected an arrhythmia that had never appeared in twenty years of regular athletic physicals. Her primary care doctor misdiagnosed the irregularity as premature atrial contractions and ordered the wrong follow-up test. The coroner, Dr. Keri Reiber, could find no structural cause of death and filed a VAERS report. The CDC obtained Christina’s medical records, ran one test for Staphylococcus aureus, and closed the investigation.

Emily Tarsell spent nearly a decade in the Vaccine Court. Leading cardiologist Professor Michael Eldar and immunologist Professor Yehuda Shoenfeld examined the case. Eldar established that the arrhythmia was malignant RVOT ventricular premature complexes, a form documented in the literature as capable of triggering fatal arrhythmias in otherwise healthy individuals. He showed that the arrhythmia was not present before the first Gardasil dose and that symptoms intensified with each successive shot, satisfying the challenge-rechallenge standard. Special Master Christian Moran initially denied compensation. Judge Mary Ellen Coster Williams overturned that ruling in 2017, documenting thirty specific medical appointments showing no prior arrhythmia and finding the Special Master had ignored the evidence. On remand, Moran reversed his own decision. The government did not appeal. By letting the deadline expire on March 30, 2018, the US Department of Health and Human Services conceded by preponderance of evidence that Gardasil killed Christina Tarsell. Her case is the first Gardasil death to win a judgment in federal court.

Question 2: What is the National Childhood Vaccine Injury Act of 1986, and how did it change the legal landscape for pharmaceutical manufacturers?

Answer: The National Childhood Vaccine Injury Act, signed by President Reagan in 1986, was the pharmaceutical industry’s response to a wave of lawsuits piling up against vaccine makers for serious injuries and deaths in the early 1980s. The pharmaceutical lobby pressured Congress to grant complete federal liability protection to vaccine manufacturers, doctors, and hospitals for any health damage, side effects, or deaths caused by vaccines they administered. The Act created the Vaccine Injury Compensation Program, often called the Vaccine Court, as the sole venue for claims. Injured parties cannot sue the manufacturer directly. The US Supreme Court reinforced this immunity in the 2011 Bruesewitz v. Wyeth decision, in which the court itself characterized vaccines as “unavoidably unsafe.”

The consequences of this liability shield are structural, not incidental. Without the threat of lawsuits, pharmaceutical companies lost the single most powerful commercial incentive to make safer vaccines, to investigate adverse reactions seriously, or to withdraw products that cause harm. By 2018, the US federal government had paid out $3.9 billion in compensation for vaccine injuries and deaths, with a payout of $282 million in fiscal year 2017 alone. Since the Department of Health and Human Services has acknowledged that fewer than 1% of vaccine adverse events are reported, these figures represent a tiny fraction of the actual harm. The 1986 Act created a market in which the manufacturers collect the profits and the taxpayers cover the damage. Vaccines are, in commercial terms, the only product category in modern pharmaceutical history where this arrangement exists.

Question 3: What was Kesia Lyng’s experience in Merck’s Future II clinical trial, and what does the phrase “new medical history” reveal about how adverse reactions were handled?

Answer: Kesia Lyng was eighteen when she enrolled in Merck’s Future II Gardasil trial in September 2002 at Hvidovre Hospital in Copenhagen. Her grandmother had died of cervical cancer the year before, and she wanted to help prevent the same fate for other women. Merck paid her 54 euros. After the first dose, she experienced pain and tingling in her arm. After the second dose in November 2002, she developed severe headaches, exhaustion, and flu-like symptoms that made simple tasks like biking to school impossible. When she reported these effects to Merck, they told her the symptoms could not have been caused by the vaccine, reassured her the product was safe, and persuaded her to continue. After the third dose, her condition deteriorated into chronic fatigue, insomnia, and unrelenting headaches. She was eventually diagnosed with chronic fatigue syndrome in 2016. Five other Danish trial participants told her they had become similarly ill.

The investigative journalist Frederik Joelving, in an eight-month investigation for Slate, obtained over 2,300 pages of trial documents through freedom of information requests. He confirmed that when trial participants reported serious health problems like Lyng’s, Merck investigators did not record them as adverse reactions. They recorded them as “new medical history,” placing them in a separate category outside the trial’s safety data. The 33-year-old participant interviewed by Joelving had been forced to drop out of school from overwhelming fatigue; her investigator recorded none of this and told her, “This is not the kind of side effect we see with the vaccine.” The “new medical history” category is the mechanism by which the trial produced its safety record. Reactions that occurred were not denied; they were reclassified. The published safety data reflects what the investigators chose to count as vaccine-related, not what actually happened to the people who received the shots.

Question 4: How did Brandy Vaughan’s time inside Merck selling Vioxx shape her understanding of the HPV vaccine program?

Answer: Brandy Vaughan joined Merck at twenty-five with a biochemistry background and the belief that she was going to help people around the world. She sold Vioxx, a pain medication so powerful it caused heart attacks and death. A Merck-funded study showed a five-times increase in heart attacks in the Vioxx group versus the placebo group. When Merck received the results, the company stopped the study but told neither the FDA nor the patients. Sales representatives were instructed to persuade doctors that the results did not reflect reality, and the drug continued to be prescribed. Vioxx was a blockbuster. By the time Merck withdrew it, an estimated 60,000 people had died. Merck paid a $321 million criminal fine. Vaughan saw from the inside how a pharmaceutical company twists information and data for its own gain, placing patients at huge risk.

When Vaughan’s pediatrician in California tried to pressure her into vaccinating her unvaccinated seven-month-old son, the doctor used a line Vaughan recognized immediately: “I’m the doctor, I’ve done the research for you. You can trust me.” She had trained sales representatives to coach doctors to say exactly that to parents who questioned prescriptions. Her response, that she knew where he got his research because she used to call on pediatricians for Merck, ended the appointment. Vaughan then applied the same analytical lens to Gardasil that she had learned to apply to Vioxx. Merck was facing the loss of patent protection on Zocor and $18 billion in Vioxx injury claims. Gardasil was the lifesaver for Merck’s sinking prospects, projected to reach a $4 billion global market by 2011. She founded Learn the Risk to warn parents. The Vioxx pattern (safety signals ignored, profits prioritized, injured patients abandoned, regulators compliant) is the pattern she recognized in the Gardasil program before most of the public had any idea it was happening.

Question 5: What is the Gillick competency doctrine, and how has it been used to vaccinate children against their parents’ wishes in the United Kingdom?

Answer: The Gillick competency doctrine comes from a 1985 House of Lords case in which Victoria Gillick challenged the right of doctors to give contraceptive advice to her daughters under sixteen without her consent. The court ruled that a child under sixteen could legally consent to medical treatment if the healthcare worker administering the treatment believed the child understood the benefits and risks. This standard was originally crafted around contraception, where a doctor might reasonably argue that preserving a young person’s confidentiality served their welfare. The Fraser Guidelines, drawn from the same case, set out specific conditions under which such consent could be accepted. Together they created a legal pathway that allows a child to receive a medical intervention without parental knowledge or against stated parental refusal.

In the context of HPV vaccination, this doctrine has been used in a way the original ruling never contemplated. Nurses in UK school settings have given the HPV vaccine to twelve- and thirteen-year-old girls after their parents had already signed forms refusing consent. Amanda Dew describes being “emotionally bullied” alongside her sixteen-year-old daughter by a nurse practitioner who conducted what Amanda calls an interrogation (”Why wouldn’t you want to protect your daughter against cervical cancer?”) despite Amanda’s signed refusal. For a twelve-year-old to meaningfully understand the benefits and risks of a vaccine involving a proprietary aluminium adjuvant, residual recombinant DNA fragments, Polysorbate 80, and documented links to autoimmune reactions, menstrual disruption, premature ovarian failure, and sudden death, the child would need a working grasp of immunology, molecular biology, trial design, pharmacovigilance, and the economics of pharmaceutical regulation. No twelve-year-old has this. The Gillick framework, applied this way, produces a legal fiction in which the state obtains consent from a child that the child cannot meaningfully give, overriding the one adult in the room who is legally responsible for the child’s welfare.

Question 6: What is aluminium adjuvant, what role does it play in HPV vaccines, and why did Merck more than double its quantity in Gardasil 9?

Answer: An adjuvant is a substance added to a vaccine to provoke a stronger inflammatory response, on the theory that the virus-like particles would otherwise produce too weak a reaction to generate measurable “antibody” levels. Merck’s HPV vaccines use a proprietary compound called Amorphous Aluminium Hydroxyphosphate Sulfate, abbreviated AAHS. Cervarix uses a different system called AS04, which combines aluminium hydroxide with Monophosphoryl Lipid A. The original Gardasil contained 225 micrograms of aluminium per dose. Gardasil 9, approved by the FDA in December 2014, contains 500 micrograms per dose, more than double the original. Cervarix contains 500 micrograms of aluminium hydroxide. These adjuvants are what the body actually responds to, which is why in the clinical trials the “placebo” group that received the adjuvant alone experienced adverse reaction rates comparable to those receiving the full vaccine.

Merck doubled the aluminium content in Gardasil 9 to drive a response against five additional HPV types (31, 33, 45, 52, and 58) added to the original four. The design logic was straightforward: more antigens require more inflammatory stimulus. SaneVax posed the obvious question: aluminium is a known neurotoxin with 1,652 peer-reviewed PubMed papers documenting its effects on biological systems, so why would a manufacturer double the dose in a product given to healthy adolescents? The answer lies in regulatory asymmetry. The FDA treats aluminium exposure through injection as equivalent to aluminium exposure through swallowing, even though swallowed aluminium is subject to stomach acid, enzyme breakdown, and excretion. Injected aluminium bypasses every one of these natural defenses. The GACVS statement endorsing aluminium safety relies on an FDA risk assessment calibrated to oral ingestion. No equivalent assessment for injected aluminium at the doses now used in Gardasil 9 exists in the published literature. The doubling went forward anyway.

Question 7: What did Professor Christopher Exley’s research reveal about aluminium accumulation in brain tissue, and what role does silicon-rich mineral water play in his treatment approach?

Answer: Christopher Exley is Professor of Bioinorganic Chemistry at Keele University, where he has studied aluminium in biological systems for over thirty years. His work with Matthew Mold and colleagues produced two findings that disturb the official narrative on aluminium safety. First, in 2017 they documented extremely high levels of aluminium in brain tissue samples from young people with autism spectrum disorder who had died. In one fifteen-year-old boy, aluminium was found at nearly three times the level considered significant, both within dying brain cells and clumped in the spaces between them. Second, their 2016 work on brains from patients with familial Alzheimer’s disease found aluminium concentrations high enough to suggest a causal role rather than a passive one. Exley has shown that the aluminium does not simply sit inert; it is carried into the brain inside immune cells (what medicine calls macrophages) that absorb the adjuvant at the injection site and travel across the blood-brain barrier, a mechanism Dr. Lucija Tomljenovic has described as a “Trojan horse.”

Exley’s therapeutic recommendation is deceptively simple. Silicon in its biologically available form, silicic acid, binds to aluminium in the body and enables its excretion through urine. Drinking 1.5 litres of silicon-rich mineral water each day for twelve weeks measurably reduces body aluminium burden. Amanda Dew put her daughter Brodie on this regimen after speaking with Exley directly. The Acilis brand of silicon-rich mineral water, drawn from Malaysian artesian sources and bottled at source, is one of the products used in Exley’s clinical trials. Testimonials from parents of autistic children describe improvements in eye contact, speech, and constipation after regular drinking. Exley’s position is straightforward: aluminium should not be used as a placebo in vaccine trials because it is not inert, and the burden of proof lies with manufacturers to demonstrate safety for a substance known to accumulate in brain tissue. His research continues to be published in mainstream peer-reviewed journals even as regulatory agencies ignore its implications.

Question 8: What did Dr. Sin Hang Lee discover when he analyzed Gardasil samples, and why does his finding about HPV DNA fragments bound to aluminium matter?

Answer: Dr. Sin Hang Lee is the director and pathologist of Milford Molecular Laboratory in Connecticut. In 2012 he analyzed sixteen Gardasil samples drawn from various countries. Every single sample contained residual DNA fragments from the HPV coating gene, in addition to the expected virus-like particles. In eleven samples, DNA from two HPV types was present. In each case, the DNA fragments were attached to an insoluble particle Lee could only conclude was the aluminium adjuvant. Merck’s position had been clear: the virus-like particles were produced in yeast cells using recombinant technology, contained no viral DNA, and were therefore non-infectious. Lee’s work showed this was not accurate. His findings were independently confirmed by Professor Laurent Belec at the European Hospital Georges Pompidou in Paris, who tested French Gardasil batches and found the same contamination. When SaneVax submitted the evidence to the FDA, the agency’s response was that residual DNA fragments were not contaminants but a normal consequence of vaccine manufacture, and that Gardasil continued to be safe and effective.

Lee’s work took on sharper significance when he was given post-mortem blood and spleen tissue from an eighteen-year-old girl in New Zealand who had died unexpectedly in her sleep six months after her third Gardasil dose. The autopsy had revealed no cause of death. Lee found HPV-16 DNA fragments firmly attached to the aluminium adjuvant in both her blood and spleen. The DNA was contorted out of its natural shape, which Lee believed rendered it impermeable to the enzymes that would normally break it down. Free-floating HPV DNA is cleared from the body within forty-eight hours. The adjuvant-bound DNA was still present six months later. HPV-16 normally infects only the cells lining mucous membranes, such as the genital tract; finding it in blood and spleen is itself unprecedented. The implications sit at the intersection of several categories of concern: a persistent foreign genetic material capable of being carried by macrophages to distant organs, bound to a known neurotoxin, with no study of its long-term effects on the recipient’s own tissues. This is what medicine calls autoimmune disease: the body responding to foreign material lodged in its own tissues, which is exactly what Dr. Lee’s findings describe.

Question 9: How were the clinical trials for Gardasil and Cervarix designed, and why is the use of aluminium adjuvant as a “placebo” scientifically indefensible?

Answer: The gold standard for establishing causation in medical research is the double-blind randomized placebo-controlled trial, in which the test substance is compared against an inert substance that produces no biological effect. A placebo is, by definition, inactive. The Gardasil clinical trials enrolled 18,083 subjects across seven studies, with 10,088 receiving Gardasil and 7,995 receiving what Merck called “placebo.” Of those 7,995, fully 92.5% received an injection containing the same aluminium adjuvant used in the vaccine itself. Only 7.5% (320 females and 274 males) received what was described as “saline placebo.” Even that saline placebo contained Polysorbate 80, a compound shown in Slovak research to cause ovarian disruption in rats. Cervarix was tested against hepatitis A vaccine, another biologically active substance, in trials involving fewer than 1,200 girls under fifteen.

The design produces exactly the result it was engineered to produce. When the aluminium-containing “placebo” group reports adverse reactions at rates close to the vaccine group (injection site pain at 75% versus 84%, swelling at 16% versus 25%, systemic effects comparable across both arms), the apparent conclusion is that the vaccine causes no excess reactions beyond background. The actual conclusion is that both groups received the same inflammatory substance. This is the mechanism by which Gardasil and Cervarix have been described as “placebo-controlled” and “safe” in regulatory submissions, in physician education materials, and in mainstream media coverage. When a member of the audience at a December 2017 Trinity College Dublin lecture asked a professor directly about the approval of Gardasil from trials that did not use inert controls, the question was not answered. A second professor bypassed it by referring to post-licensing research. This question has never received a satisfactory answer because none exists. The trial design made it impossible to detect what honest trials are supposed to detect.

Question 10: How were adverse events recorded, categorized, and dismissed during the 14-day post-vaccination monitoring window?

Answer: The European Medicines Agency’s 2006 guidance for clinical evaluation of new vaccines states that special attention should be paid to adverse events occurring within approximately five to seven days of each dose, with later events up to fourteen days collected by telephone contact. After day fourteen, only serious adverse events requiring hospitalization and judged by the investigator to be “possibly, probably, or definitely vaccine-related” were recorded. Everything else fell outside the trial’s safety data entirely. The architecture of this system produces predictable results. Autoimmune conditions take months or years to manifest. Ovarian failure may not become apparent until a young woman tries to conceive. Chronic fatigue syndrome develops over months. Neurological conditions emerge in patterns that the fourteen-day window is incapable of capturing. The Japanese researchers Ozawa and colleagues documented an average onset of 319 days between first vaccination and symptom appearance in their cohort of 163 patients.

The categorization scheme compounded the problem. The million-woman Danish and Swedish cohort study followed girls aged ten to seventeen for four years but recorded only hospital-diagnosed autoimmune, neurological, and venous thromboembolic events for six months after each dose. Even for serious adverse events during the fourteen-day window, trial protocols required that investigators make causality judgments based on “the test vaccine’s known profile,” which is a circular standard since the trial itself is supposed to establish that profile. The World Health Organization’s Uppsala Monitoring Centre researchers analyzed 39,953 HPV vaccine adverse event reports in VigiBase. They found that a mother describing her daughter sleeping twelve to twenty hours per day, missing lots of school with no energy, was coded as “non-serious.” A parent writing “it’s too late for my son whose life has been irrevocably altered” was coded as “non-serious.” The coding system does not reflect what happens to the recipient. It reflects what the pharmacovigilance infrastructure chooses to count as a reaction worth recording. By the Dwoskin Foundation and Dr. Lucija Tomljenovic’s calculations, the age-standardized death rate from cervical cancer in the US is 2.5 times lower than the rate of serious adverse reactions from Gardasil reported to VAERS. In the Netherlands, the serious adverse reaction rate from Cervarix is nearly four times higher than the age-standardized cervical cancer death rate.

Question 11: What has happened to cervical cancer rates in countries with high HPV vaccination coverage, and how does this contradict the vaccine’s stated purpose?

Answer: The pattern across every high-coverage country is the same. In Australia, cervical cancer incidence declined by almost 50% from 1995 to 2004, before the HPV vaccine was introduced. Since the national vaccination campaign began in 2007, achieving 85% coverage of Australian girls, the decline stopped. By 2017, cervical cancer mortality had increased by almost 15% in just three years. In Canada, cervical cancer incidence was halved between 1972 and 2008 through Pap screening alone. Once the HPV vaccine was introduced, the decline stagnated and incidence began trending upward. In Norway, before vaccination, the cervical cancer rate had fallen sharply between 1965 and 2004. Since the 2009 vaccination campaign, cervical cancer rates have nearly doubled between 2004 and 2015 and continue to trend upward. In Sweden, after four decades of steady decline, cervical cancer rates rose 20% in just two years from 2014 to 2015, concentrated specifically in the age range targeted by the vaccine.

The United Kingdom data is the sharpest. Between 2002 and 2008, the last year before the countrywide vaccination campaign, cervical cancer incidence in girls aged twenty to twenty-four decreased by 40%. In 2009, the year the school program reached 80% coverage, the decrease stopped. By 2011, rates began to rise. Between 2012 and 2015, cervical cancer rates in girls aged twenty to twenty-four increased by 45%, while rates in older women did not increase. The vaccine was supposed to reduce cervical cancer by 70%. Instead, in every country where coverage is high, the long-standing downward trend produced by Pap screening has either stopped or reversed, and the increases are concentrated in the vaccinated age cohort. Pap smear screening reduced cervical cancer mortality by 70% in the decades before any vaccine existed. The disease was already in retreat when Merck brought Gardasil to market. The vaccine’s measurable effect on cervical cancer rates in the populations where it has been most aggressively deployed is to end the retreat and reverse it.

Question 12: What arguments do Peter Duesberg, Christian Fiala, and other scientists make against the premise that HPV causes cervical cancer?

Answer: Peter Duesberg is a professor of molecular biology at the University of California, Berkeley. His 2013 paper in Molecular Cytogenetics, co-authored with McCormack, Fan, Bloomfield, and Fiala, titled “Individual karyotypes at the origins of cervical carcinomas,” argues that cervical cancers arise from chromosomal rearrangements induced by carcinogens, not from HPV. His position rests on three observations. First, if HPV were the direct cause, every cervical cancer cell would contain HPV genetic material; they do not. Second, around 30% of healthy American women carry HPV sequences without ever developing any pathology, which is inconsistent with the pathogen-causes-disease model. Third, if cervical carcinomas depended on HPV functions, they would be immunogenic and subject to what medicine calls anti-viral immunity, which is not observed. The occurrence of papillomavirus-free cervical carcinomas, in Duesberg’s words, “is by itself sufficient evidence that cervical carcinomas are virus-independent.” He describes HPV in cancer cells as a “passenger,” present but not causal.

Dr. Christian Fiala, an obstetrician and gynecologist in Vienna, states the position directly: “Nobody has shown that the HPV vaccine actually reduces the rate of cervical cancer. As long as we have no proof that cervical cancer is caused by HPV, it is fundamentally useless to vaccinate against HPV because the chances are the cancer will occur whether there is HPV or not.” Dr. Bernard Dalbergue, a former Gardasil marketing physician, has predicted the vaccine will become “the greatest medical scandal of all time.” Ryser and colleagues published a 2015 stochastic model showing that in immunocompetent adolescents with cervical HPV, the body’s cellular response may contribute less than 20% to viral clearance, with the rest handled by random cell dynamics in the basal layer. The actual contributing factors to cervical cancer are documented: smoking, long-term oral contraceptive use (which depletes folic acid, essential for cervical cell integrity), multiple sexual partners, and the carcinogen exposures of modern life. The germ theory framework insists on a single-pathogen cause for a single disease because that structure sells vaccines. The clinical reality is messier and does not require Merck’s product to address.

Question 13: What is ASIA syndrome, and how does Professor Yehuda Shoenfeld’s work connect vaccine adjuvants to conditions labelled autoimmune?

Answer: Professor Yehuda Shoenfeld is an immunologist at Sheba Medical Center and the Sackler Faculty of Medicine at Tel Aviv University. He has written twenty-six medical books in immunology, edits four medical journals including Autoimmunity Reviews, and founded the biennial International Congress on Autoimmunity. In 2011 he published a groundbreaking paper describing a phenomenon he called ASIA syndrome: Autoimmune/Inflammatory Syndrome Induced by Adjuvants. The syndrome encompasses a constellation of symptoms including muscle pain, chronic fatigue, cognitive impairment, memory loss, arthritis, and sleep disorders, often accompanied by auto-antibody detection and specific genetic susceptibility markers. Shoenfeld’s work documents what practitioners worldwide were already witnessing but could not categorize: an inflammatory response that persists long after exposure, producing damage that medicine then labels as the body attacking itself.

The mechanism Shoenfeld describes is Charles Richet’s sensitization pathway, discovered in 1901 and awarded the Nobel Prize in 1913. Injection of foreign proteins creates a heightened response to subsequent exposures. Aluminium adjuvants are specifically designed to provoke this response. The HPV vaccines over-stimulate the body’s antibody-producing capacity, generating levels thirty-six to seventy-eight times higher than those produced after natural exposure to the alleged virus. This hyper-stimulation increases the likelihood that proteins resembling the body’s own tissues will be targeted by what medicine calls the immune response. Darja Kanduc, a molecular biology professor at the University of Bari, has shown that HPV vaccine proteins share amino acid sequences with numerous human proteins, including those involved in reproductive function. This is molecular mimicry, the accepted immunological mechanism for what medicine calls autoimmunity. Shoenfeld served as expert immunologist in the Christina Tarsell case. His textbook The Mosaic of Autoimmunity has become foundational to the field. What medicine calls autoimmune disease is, in the terrain reading, the body responding to foreign material it cannot clear: toxic injury producing inflammatory repair, which the labeling then calls self-attack. Shoenfeld’s clinical work points directly at the injection as the trigger, which is the piece medicine most needs to not see.

Question 14: What evidence links HPV vaccines to premature ovarian failure, infertility, and menstrual disruption?

Answer: The evidence runs across multiple independent streams. In the US VAERS database, cases of amenorrhea, premature menopause, and ovarian failure were essentially flat through 2006. In 2007, the first full year of Gardasil administration, cases of amenorrhea jumped from three to twenty-eight. By 2016, the combined annual total reached sixty-seven cases. Of all VAERS reports involving these conditions since Gardasil’s licensure, 88% have been associated with Gardasil, and 76% solely with Gardasil. The American College of Pediatricians issued a formal 2016 statement raising concerns about this signal, noting that long-term ovarian function was not assessed in either the original rat safety studies or the human vaccine trials, and that the lack of saline placebos combined with high rates of hormonal contraception use among trial participants made meaningful assessment impossible. Dr. Gayle DeLong’s 2018 statistical analysis found that women who received the HPV vaccine were significantly less likely to have ever conceived. By her calculation, universal vaccination of the study population would have resulted in two million fewer conceptions.

The biological mechanisms are well documented. The aluminium adjuvant has been shown in rat studies by Fu and colleagues (2014) to disrupt ovarian structure and interfere with cellular respiration, inhibiting ovulation and corpus luteum development. Polysorbate 80 (Tween 80) was studied by Gajdová and colleagues in Bratislava in 1993; neonatal rats exposed to it showed rapid maturation followed by degeneration of the ovaries. European Medicines Agency documents for both Gardasil and Gardasil 9 acknowledge that “theoretically, the vaccine could give rise to antibodies, which cross-react to self-structures, resulting in autoimmune events.” Human ovaries are listed in the literature as common targets of what medicine calls autoimmune attack. The HPV vaccines generate what medicine calls antibody responses at levels thirty-six to seventy-eight times higher than natural exposure, dramatically increasing the probability of cross-reactivity with ovarian tissue. The clinical trials were not designed to detect ovarian problems. The follow-up window was fourteen days. Most participants were on hormonal contraception, which masks any menstrual irregularity. The signal only became visible after the product was in the general population, which is when the cases started appearing in VAERS, in the medical literature, and in the lives of young women who found they could not conceive.

Question 15: What is Polysorbate 80, and what did Slovak researchers find when they exposed young female rats to it?

Answer: Polysorbate 80, also known as Tween 80, is a surfactant and emulsifier used in Gardasil and Gardasil 9 (but not Cervarix). It appears on the ingredient list at 50 micrograms per dose. Its stated purpose is to help the active components disperse in solution. Beyond this technical role, Polysorbate 80 has specific biological properties. It increases the permeability of membranes, including the blood-brain barrier, which has made it useful in pharmaceutical formulations where drugs need to cross otherwise impermeable barriers. For a vaccine administered to adolescent girls, this property is not trivial. Polysorbate 80 was also present in the “saline placebo” given to the 7.5% of Gardasil trial participants who did not receive the aluminium-containing control, which means the trial compared the full vaccine against an injection containing a known reproductive toxin.

The reproductive toxicity was documented by Gajdová and colleagues at a Bratislava research center in 1993. They injected neonatal female rats with Polysorbate 80 at low doses and observed what happened to their reproductive organs over time. The exposed animals showed accelerated maturation of the reproductive system followed by progressive degeneration of the ovaries. The researchers concluded that neonatal Polysorbate 80 exposure caused delayed but definitive damage to female reproductive organs. The paper has been in the peer-reviewed literature for over three decades. Merck’s clinical trials did not test for the effects documented by Gajdová. The investigators were not looking for menstrual abnormalities, ovarian dysfunction, or infertility. The fourteen-day post-vaccination monitoring window would not have detected effects that develop over months or years. The signal that eventually appeared in VAERS, in the American College of Pediatricians statement, and in the DeLong fertility analysis is consistent with what Gajdová showed in rats twenty-five years before. The compound is still in Gardasil 9 at the same quantity. No pregnancy registries were established before the vaccine’s rollout. Young women receiving the vaccine today receive a substance known since 1993 to damage the ovaries of female mammals, with no human study designed to detect the same outcome in them.

Question 16: How does Leslie Carol Botha’s work on the menstrual cycle intersect with the HPV vaccination program and the use of birth control pills?

Answer: Leslie Carol Botha is a women’s health educator who has spent decades studying the menstrual cycle as a barometer of overall health. Her central observation is that women’s immune function fluctuates sharply across the cycle. In the postovulatory phase (the paramenstrum, roughly the week before menstruation), immune function drops as a biological consequence of the hormonal environment required to support potential conception. During this phase, tolerance to alcohol, drugs, surgical procedures, and vaccines is measurably reduced. Botha documented this through her work in detention facilities, where she found women consistently incarcerated during this same phase of their cycle for “disorderly conduct” and “disruptive behavior” triggered by altered alcohol tolerance. The medical establishment, Botha argues, has treated the menstrual cycle as either a nuisance or a joke. The result is that women receive medical interventions, including vaccines, with no consideration of where they are in their cycle.

The HPV vaccination program compounds this blindness in two ways. First, girls receive the vaccine with no attempt to track or document their cycle phase at the time of injection. Barbara Loe Fisher of the National Vaccine Information Center included a cycle-phase question on NVIC’s adverse injury survey; hardly any respondent could answer it. Second, girls are routinely encouraged (whether or not they are sexually active) to begin oral contraceptive pills at the same visit as HPV vaccination, often framed as a way to “regulate” their cycle. The contraceptive pill does not regulate the cycle; it suppresses ovulation and produces a withdrawal bleed. A girl taking the pill will appear to have regular periods regardless of whether her reproductive system is functioning. Any damage to ovarian function from the vaccine will be masked for as long as she stays on the pill, often not becoming apparent until she stops it years later and tries to conceive. The pill also depletes folic acid, magnesium, zinc, selenium, and B vitamins, as documented in Ross Pelton’s work. Folic acid depletion is specifically linked to cervical dysplasia, meaning the pill may contribute to the very condition the vaccine is sold to prevent. Botha’s framework exposes a medical system that disregards the menstrual cycle as data, which is one of the clearest signals a woman’s body provides about her state of health.

Question 17: What constellation of symptoms have been reported in HPV-vaccinated girls across the world, and what diagnostic labels have been applied to them?

Answer: The pattern is remarkably consistent across continents. The AHVID survey of 160 UK adolescents found that 97% reported fatigue, 77% headaches, and over 75% suffered concentration problems, brain fog, sleep disorders, dizziness, joint pain, mood changes, menstrual issues, and gastrointestinal problems. New onset seizures occurred in 23%. In Japan, Kinoshita’s case series of 44 teenage girls documented headaches, fatigue, cold fingers and toes, limb pain, and general weakness beginning five to ten months after vaccination; eighteen were diagnosed with Complex Regional Pain Syndrome. A quarter had orthostatic intolerance producing violent tremors. In Denmark, Postural Orthostatic Tachycardia Syndrome emerged as the signature presentation. In the Netherlands, long-lasting fatigue. In Italy, Mexico, Colombia, Ireland, Spain, and across Scandinavia, the same clusters appeared: autonomic nervous system dysfunction, cognitive decline, chronic pain, debilitating fatigue, seizures, menstrual disruption, and premature ovarian failure. Takahashi and colleagues documented thirty-two Japanese patients with prolonged nervous system symptoms. The World Health Organization’s Uppsala Monitoring Centre researchers found 39,953 HPV vaccine adverse event reports in VigiBase, with disproportionate reports of serious events even excluding the signal countries of Japan and Denmark.

The diagnostic labels applied to these girls form a litany: Chronic Fatigue Syndrome / Myalgic Encephalomyelitis, Postural Orthostatic Tachycardia Syndrome (POTS), Complex Regional Pain Syndrome (CRPS), fibromyalgia, Guillain-Barré syndrome, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Hashimoto’s thyroiditis, celiac disease, idiopathic epilepsy, functional neurological disorder, autoimmune encephalitis, premature ovarian failure, primary ovarian insufficiency, polycystic ovarian syndrome, and anaphylaxis. In addition to these diagnoses, girls have been labeled with psychiatric conditions: psychosomatic disorder, conversion disorder, fabrication disorder, Munchausen syndrome, and Munchausen by proxy aimed at the mothers. The Japanese researchers’ honest observation was that most girls were initially assessed as “psychosomatic” before diagnostic testing revealed real physical abnormalities including small fiber neuropathy, abnormal cerebral blood flow on SPECT imaging, and autoantibodies against neural receptors. The labels serve different purposes. The medical diagnoses carve the condition into departmental fragments, each managed by a different specialist with no one taking responsibility for the whole. The psychiatric labels transfer responsibility to the patient. What unites every one of these girls is the same injection, received in the same deltoid, containing the same aluminium-bound virus-like particles and residual DNA fragments. Only the Japanese researchers thought to investigate the pattern rather than disperse it into separate specialties.

Question 18: How did the Japanese government respond to the pattern of adverse reactions, and how does their approach compare with that of Western health authorities?

Answer: Japan did what no Western government has done. In June 2013, after mounting reports of severe adverse reactions in girls who had received Cervarix or Gardasil, the Japanese Ministry of Health, Labour and Welfare withdrew its recommendation for routine HPV vaccination. Medwatcher Japan published a 2015 report calculating that serious adverse events after HPV vaccines ran at 3.2%, and concluding that the risk of death from the vaccine exceeded the risk of death from cervical cancer. When 750 girls developed nervous system problems, Japanese officials did not require causation to be proven before investigating. They treated the girls. They took blood samples and spinal fluid, tested for autoantibodies, measured immune system chemicals, and documented what they found. They identified antibodies against NMDA receptors (correlating with cognitive problems in 81% of patients), elevated IL-17 (associated with pain sensation and nervous system disorders), and a wide range of specific markers that pointed to real, treatable pathology. The average time from vaccination to onset of cognitive symptoms was nearly two years. The researchers Kazuki Ozawa and colleagues documented 163 patients in their series.

The Western response could not be more different. The UK Medicines and Healthcare products Regulatory Agency received over 9,100 adverse event reports by 2018, with eight deaths, and concluded there were “no new safety issues.” The Joint Committee on Vaccination and Immunisation subcommittee, with thirty-five members present at its January 2017 meeting, had read none of the three major research papers warning of signals (Chandler’s WHO pharmacovigilance work on symptom clusters, Aratani’s mouse study showing central nervous system damage, and Takahashi’s case series) that the MHRA had dismissively summarized for them. The World Health Organization’s Global Advisory Committee on Vaccine Safety noted that “there were ongoing media reports in some countries in Europe which were undermining HPV programmes,” framing the problem as a public relations challenge rather than a safety signal. In Ireland, parents raising concerns were dismissed as spreaders of misinformation. In the UK, Amanda Dew’s daughter Brodie had hundreds of blood tests and autoantibody panels showing clear abnormalities (24% blood cell membrane loss, elevated receptor autoantibodies) which multiple neurologists refused to engage with. One consultant admitted her team had held a prior meeting at which they had already decided the vaccine was not responsible, before any examination. The Japanese response treated the girls as patients with real illness requiring investigation. The Western response treated the parents as problems requiring management.

Question 19: What happened to 30,000 girls in India who received HPV vaccines in 2009, and what did the Supreme Court case reveal?

Answer: In 2009, approximately 30,000 young girls in the Indian states of Andhra Pradesh and Gujarat were given HPV vaccines (Gardasil and Cervarix) in what was presented to them and their families as a routine immunization program. The girls were tribal children, drawn from vulnerable populations with no political voice and little access to information. What they and their families were not told was that they were being enrolled in a Phase IV clinical trial. The vaccines had not been proven safe in the Indian population. The informed consent that international medical ethics requires did not occur. Many of the girls suffered anaphylactic shock, seizures, paralysis, and conditions medicine classifies as immune system disorders. Six children died. The deaths were ruled unrelated to the vaccine without the kind of investigation that would have been required to establish causation. Parents who tried to raise concerns were ignored.

Activists Kalpana Mehta, Nalini Bhanot, and Dr. Rukmini Rao of the Gramya Resource Centre for Women filed a writ petition with the Supreme Court of India on October 29, 2012, under Article 32 of the Constitution. The petition was directed against the Drug Controller General of India, the Indian Council of Medical Research, the state governments of Andhra Pradesh and Gujarat, PATH International (the US-based NGO that organized the trial), GlaxoSmithKline Asia, and MSD Pharmaceuticals. The petition alleged that the HPV vaccines were illegally brought into the two states and administered to thousands of vulnerable Indian children before the vaccines were established as safe. In its April 2017 judgment, the Supreme Court referred the matter to the Constitution Bench under Article 145(3), citing substantial questions of law regarding constitutional interpretation. In February 2017, the Indian government took a further step: it severed all financial ties between the National Technical Advisory Group on Immunization and the Bill and Melinda Gates Foundation, citing conflict of interest concerns arising from the foundation’s connections with pharmaceutical companies. India had seen what happens when a Western philanthropic organization with pharmaceutical investments is allowed to shape a developing country’s vaccination policy, and it closed the door. No Western government has taken comparable action.

Question 20: What did Governor Rick Perry’s 2007 executive order mandating HPV vaccination in Texas expose about Merck’s political influence?

Answer: In early 2007, Texas Governor Rick Perry issued a surprise executive order making the HPV vaccine compulsory for all Texas schoolgirls. He framed the order in the language of public health protection, telling the Associated Press that the vaccine provided “an incredible opportunity to effectively target and prevent cervical cancer.” His spokeswoman emphasized that the governor wanted to protect young women “rich and poor, insured and uninsured.” Neither mentioned the governor’s financial relationship with Merck. When the connection surfaced, Perry acknowledged a $5,000 donation and framed questions about his motives as personal insult: “If you’re saying I can be bought for $5,000, I’m offended.” The actual figures emerged shortly thereafter. The watchdog group Texans for Public Justice revealed that Merck had given Perry $28,500 for his gubernatorial campaigns since January 2001. Since 2006, when Gardasil came to market, Merck had donated $377,500 to the Republican Governors Association, which was one of Perry’s campaign’s largest bankrollers. Perry chaired that association.

The investigation uncovered additional layers. Perry’s chief of staff, Mike Toomey, had moved through the revolving door from the governor’s office directly into a lobbying position for Merck in Texas, which he held while Perry issued the executive order. GlaxoSmithKline, whose Cervarix was then in late development, had donated similar sums to Perry’s campaigns and nearly four times as much to the Republican Governors Association. Novartis had donated more than $700,000 to the governor’s association between 2006 and 2009, and Perry had signed a bill mandating meningococcal vaccination for all Texas college students shortly before Novartis introduced its own meningococcal vaccine. The Texas HPV mandate was overturned by the state legislature a few months after Perry’s executive order. The same pattern was simultaneously unfolding in twenty other states. In Virginia, where the mandate for sixth-grade girls passed with little notice, legislators had received $135,750 in Merck campaign contributions. In Illinois, the senate’s majority leader introduced a mandate while serving as director of a Merck-funded national cancer organization. The Texas scandal taught Merck that direct mandate campaigns drew unwanted attention. The company announced it would halt its push for mandates, continuing instead through less visible channels: patient advocacy groups, medical societies, school-based programs, and political relationships that produce the same result without the paper trail. Merck’s annual lobbying budget, as reported by the Center for Responsive Politics, runs to $5.4 million.

Question 21: How did Merck and GlaxoSmithKline position themselves commercially around the HPV vaccine, and what did their cross-licensing agreement reveal about the appearance of competition?

Answer: The public narrative around HPV vaccination featured Merck’s Gardasil and GSK’s Cervarix as competing products in a “cancer war” between two pharmaceutical giants with rival technologies. News coverage framed the race in competitive terms, as though the two companies were pushing each other toward better products through market pressure. The reality was different. In early 2005, long before either vaccine reached the market, Merck and GSK settled their patent disputes through a cross-licensing agreement. GSK, which held key intellectual property through its partnership with MedImmune, took an upfront payment plus royalties from Merck’s future Gardasil sales. GSK was going to profit from every Gardasil dose Merck sold. The competition was theatrical. The commercial arrangement was collaborative. The two companies, which between them cover essentially the entire HPV vaccine market globally, had already divided the spoils before the public health campaigns began.

The commercial pressure to launch and maintain Gardasil as a blockbuster drug was substantial. Merck was about to lose patent protection on Zocor, its leading cholesterol drug, and faced $18 billion in injury claims from Vioxx. Analysts projected the global HPV vaccine market would reach $4 billion by 2011 if the vaccines were placed on national schedules and funded by governments. A 2006 review study noted explicitly that this projected revenue depended on “government-funded vaccination program[s] for teenage girls.” Gardasil generated $1.1 billion in sales in its first nine months. By 2016, US HPV vaccine sales reached $1.8 billion annually. The pattern established by the Merck-GSK agreement is standard in modern pharmaceutical markets. Apparent competitors share underlying intellectual property, cross-license their technologies, and present the appearance of market dynamics while coordinating on pricing, regulatory strategy, and public messaging. The former First Ladies, former Presidents, and bipartisan political figures who have lent their names to HPV vaccine promotion (Rosalynn Carter’s Every Child By Two, Bill Clinton’s Global Initiative, the George W. Bush Institute’s Pink Ribbon Red Ribbon, the Obama-Biden Cancer Moonshot) are not opposing Merck and GSK. They are extending the market for a product that both companies profit from, with regulatory protection from liability, government funding to buy the doses, and political cover from across the ideological spectrum.

Question 22: How does Kate Birch’s homeopathic framework describe HPV vaccine damage, and what does miasm theory contribute to understanding the pattern of injuries?

Answer: Kate Birch works within the classical homeopathic tradition established by Samuel Hahnemann and developed through two centuries of clinical practice. Her framework rests on observations that mainstream medicine has excluded from its model. Microorganisms, in the homeopathic reading, are pleomorphic: they change form in response to the conditions of their environment, as Antoine Béchamp documented. They are not fixed invaders. Vaccination, in this framework, is not immunization but rather the introduction of foreign material that provokes a specific kind of chronic disturbance Hahnemann called a miasm. The sycotic miasm (associated historically with gonorrheal infection) and the cancer miasm are the two most relevant to understanding HPV vaccine damage. Birch’s clinical observations connect the symptoms girls develop after HPV vaccination (chronic warts and overgrowths, ovarian dysfunction, hormonal disruption, autoimmune conditions, cancer susceptibility) to the activation of these miasmatic patterns by the vaccine’s foreign material.

The homeopathic treatment protocol works through several mechanisms simultaneously. Thuja is the classical remedy for vaccine damage and genital warts. Silica supports the body’s ability to break down and expel foreign material, including the aluminium adjuvant. Medorrhinum addresses the underlying sycotic miasm. Carcinosin addresses the cancer miasm activated by the vaccine. Alumina helps the body release stored aluminium. Potentized preparations of Gardasil and Cervarix themselves, used isopathically (same cures same), can trigger the body’s clearance of what it has retained from the original injection. Oophorinum, prepared from healthy ovarian tissue, supports the reactivation of ovulation. Folliculinum addresses hormonal cycle disruption. Birch’s clinical experience reveals a specific vulnerability: girls on hormonal contraception at the time of vaccination showed the most severe and persistent damage. The pill and the vaccine together create a double disruption of hormonal, immune, and cellular function that neither produces alone. The co-morbidity of oral contraceptives and HPV vaccination has never been studied. Birch’s clinical observations fill the gap medicine refuses to investigate. Her framework treats the body as self-regulating and self-healing, understanding symptoms as the body’s attempts to expel what has been imposed on it, and selecting remedies that support rather than suppress the restorative process.

Question 23: What is Dr. Sarah Myhill’s clinical approach to treating HPV vaccine damage, and what role do mitochondria, nutrition, and toxic metal detoxification play?

Answer: Sarah Myhill is a British physician whose clinical framework treats the body as an energy system. Fatigue, in her reading, arises when energy demand exceeds energy delivery. The mitochondria are the engines that produce energy at the cellular level. When they fail (whether from toxic blockade, nutritional deficiency, or metabolic disruption), every system that depends on them fails with them. Myhill’s analogy is the car: the mitochondria are the engine, diet is the fuel, micronutrients and good gut function are the oil, the lungs and heart deliver oxygen, the thyroid is the accelerator, and the adrenals are the gearbox. HPV vaccine damage, in this framework, strikes multiple parts of the system simultaneously. Aluminium accumulates in tissues and blocks mitochondrial function. Residual recombinant DNA fragments provoke chronic inflammation. The resulting fatigue reflects actual cellular energy failure, not psychological weakness.

Myhill’s treatment protocol works at multiple levels at once. A paleo-ketogenic diet eliminates the fermenting sugars that poison mitochondria and provides ketones, which mitochondria burn more cleanly than glucose. A basic package of nutritional supplements (magnesium, Coenzyme Q10 as ubiquinol, carnitine, niacinamide, D-ribose, and vitamin B12 by injection) supplies the raw materials mitochondria need to function. Vitamin C to bowel tolerance (typically five to fifteen grams daily for healthy humans, higher for the sick) donates electrons and supports the body’s natural clearance processes. DMSA chelation at 15 mg/kg weekly binds toxic metals and allows their excretion through urine. Heating regimens (traditional saunas, far infrared saunas, Epsom salt baths, sunbathing) mobilize toxins stored in subcutaneous fat so they can be washed off the skin surface. Fifty such regimens reduce the toxic load by approximately 50%. Correction of thyroid and adrenal function with natural desiccated thyroid addresses the downstream endocrine damage. In Myhill’s small sample of ten post-Gardasil patients, every single one showed significant aluminium burden. Her framework addresses the actual mechanisms: toxic metals blocking cellular energy production, nutritional deficiencies impairing detoxification capacity, and the chronic inflammation generated by foreign material the body cannot clear. The restoration of function follows from supporting the body’s own processes rather than suppressing the symptoms those processes produce.

Question 24: What does Dr. James Smith’s analysis reveal about relative versus absolute risk reduction in HPV vaccine studies?

Answer: Dr. James Smith, writing under a pseudonym because of professional restrictions on physicians who question vaccine policy, performed a careful statistical analysis of the research cited by the American Academy of Pediatrics in physician education materials promoting HPV vaccination. The paradigm case was a study presenting the vaccine’s efficacy in terms of relative risk reduction. Relative risk reduction compares the rate of a bad outcome in one group to the rate in another, expressed as a percentage. When relative risk reduction is high and the baseline rate of the bad outcome is low, the number sounds impressive while meaning very little. Absolute risk reduction, by contrast, measures the actual difference in outcomes between the two groups. For HPV vaccination, Smith’s analysis showed that the three-dose schedule, presented as highly effective in the paper used to educate physicians, overestimated its own benefit by 248.5 times when the figures were converted from relative to absolute risk reduction.

Martínez-Lavín and Amezcua-Guerra published a 2017 critical review of HPV vaccine serious adverse events in pre-licensure randomized trials and post-marketing case series. Their calculations produced a stark finding. For Gardasil 9, the number needed to seriously harm was 140 (95% confidence interval 79-653). The number needed to vaccinate to prevent one case was 1,757 (95% confidence interval 131 to infinity). In practical terms, Gardasil 9 was associated with serious harm in approximately one of every 140 recipients, while its benefit was approximately one in 1,757. Thirteen young women are seriously harmed for every one who benefits. Two of the largest HPV vaccine randomized trials found significantly more severe adverse events in the vaccine arm than in the aluminium “placebo” arm. One compared 2,881 women receiving the bivalent vaccine against 2,871 receiving aluminium placebo; the vaccine arm had fourteen deaths versus three in the control arm (p = 0.012). Despite this, “practically none of the serious adverse events occurring in any arm of both studies were judged to be vaccine-related.” The methodology for assigning causation was the same methodology that erased Kesia Lyng’s symptoms into “new medical history.” The arithmetic of the vaccine’s risk-benefit ratio has been in the literature for years. The physicians recommending it to healthy teenage girls, and the parents consenting on their behalf, almost never see these numbers.

Question 25: What is type replacement, and what evidence suggests that non-vaccine HPV strains are rising in vaccinated populations?

Answer: Type replacement is the ecological phenomenon in which pressure applied against specific strains of a microorganism creates space for other strains to expand. The principle is well established across pathogen biology. When antibiotics eliminate susceptible bacteria, resistant strains flourish. When vaccines target specific strains, non-targeted strains occupy the vacated niche. In the case of HPV, the original Gardasil targeted strains 6, 11, 16, and 18. There are over 100 known HPV strains, approximately thirty of which are sexually transmitted, and approximately fifteen of which have been associated with cervical cancer. By suppressing strains 16 and 18, the vaccine creates space for strains 31, 33, 45, 52, 58, 56, 39, 66, and others. The commercial response has been to add more strains to the vaccine: Gardasil 9 targets nine strains instead of four. The ecological response is predictable. Pressure against those nine will favor the hundred-plus others.

The evidence that type replacement is happening in vaccinated populations is accumulating. Fangjian Guo and colleagues published 2015 data showing significantly higher prevalence of non-vaccine high-risk HPV types in vaccinated US adult women compared to unvaccinated women across almost every demographic category. The prevalence ratio for all non-vaccine high-risk types in vaccinated women was 1.29. For non-Hispanic white women it was 1.40. For women with past smoking it was 1.93. Reyes-Rodriguez and colleagues produced mathematical models predicting the rise of non-vaccine HPV strains as vaccination pressure continues. The FUTURE II trial, one of the largest Merck-funded studies, found that while Gardasil was 98% effective against the specific strains in the vaccine among women with no prior HPV exposure, that efficacy dropped to 17% when all HPV-related disease was included. The rising cervical cancer rates in vaccinated populations across Australia, UK, Norway, and Sweden are consistent with type replacement. The teenagers like Jess Bradford who developed cervical cancer after full vaccination demonstrate individual cases of the pattern. Erin Crawford, who participated in one of the first US HPV vaccine trials, developed cervical cancer caused by the exact strain the vaccine was supposed to protect against, suggesting either vaccine failure or that the vaccine itself delivered the viral material she subsequently developed cancer from. The ecological reality is that pressure on specific strains does not reduce overall HPV presence in the population. It redistributes it toward strains that were previously unmeasured. The vaccine’s commercial model requires presenting it as a reduction in cancer risk. The ecological evidence suggests it is instead reshaping the distribution of HPV types in ways the vaccine’s targeted strains do not capture.

Question 26: What alternative or complementary risk factors for cervical cancer are being overshadowed by the focus on HPV vaccination?

Answer: The documented risk factors for cervical cancer are specific and well-established. Smoking is strongly associated with cervical cancer development, as the carcinogens in tobacco smoke concentrate in cervical mucus and damage cervical cells directly. The long-term use of combined oral contraceptive pills increases the risk of persistent HPV infection and cervical cancer; the pill depletes folic acid, which is essential for cervical cell integrity, and alters the hormonal environment in ways that favor cervical pathology. Multiple sexual partners increase the likelihood of exposure to HPV and other sexually transmitted factors. Ryser and colleagues’ 2015 stochastic model showed that estrogen stimulates cervical epithelial proliferation while progesterone inhibits it, which means progestin-dominant hormonal contraception may increase cervical cancer risk through its effects on cell dynamics. Suzy Cohen’s documentation of estrogen-based contraceptives disrupting gut flora, with downstream nutritional consequences, adds another layer. The Rockefeller-era shift of nutrition out of medical education left most physicians without the framework to recognize these connections.

The question of alternative causes becomes sharper when the ineffectiveness of the vaccine is considered. If HPV vaccination reduced cervical cancer rates in the vaccinated age cohort, there would be a legitimate (if still risk-laden) argument for the intervention. In every high-coverage country, cervical cancer rates in vaccinated age groups have either stagnated or risen. The pre-vaccine decline in cervical cancer was produced by Pap screening, which identifies and treats pre-cancerous lesions before they become invasive. Pap screening reduced cervical cancer mortality by 70% in high-income countries before the vaccine existed. The money spent on vaccination programs could fund earlier and more thorough Pap screening in young women, which would address cervical cancer where it actually occurs (predominantly in women over fifty) rather than vaccinating teenagers against a disease that is extraordinarily rare in their age group and may not be caused by HPV in the way the pharmaceutical industry has established. The real population-level intervention would address smoking cessation, caution about long-term hormonal contraception, information about safer sexual practices, and expanded screening. These interventions do not generate pharmaceutical revenue. They do not require patents. They do not create markets. The focus on HPV vaccination displaces attention from the modifiable risk factors that would actually reduce cervical cancer burden, in favor of a product that reduces nothing while generating serious adverse events in teenage girls.

Question 27: What did Amanda Dew’s daughter Brodie experience after her HPV vaccinations, and what pattern emerged when Amanda sought answers from the medical system?

Answer: Brodie Dew was sixteen when she and her mother Amanda were “emotionally bullied” (Amanda’s words) by a nurse practitioner into accepting the HPV vaccine, despite Amanda having signed a form refusing consent. Brodie had been a keen academic student who enjoyed studying. The first dose in October 2014 produced only mild flu-like symptoms. Before the second dose in January 2015, Amanda noticed unusual behavior: Brodie was stabbing a math textbook with her pencil in frustration at being unable to understand homework, something entirely out of character. After the second dose, Brodie began having full tonic-clonic seizures. Over two and a half years, she experienced forty-four documented seizures. Her blood tests showed autoantibodies against muscarinic and adrenergic receptors, a 24% loss of blood cell membranes, abnormally low levels of phospholipids, essential fatty acids, magnesium, chromium, selenium, zinc, vitamins C and B12, raised serum calprotectin, and a diagnosis of ASIA syndrome. She developed temporal lobe epilepsy, absence seizures, functional neurological disorder, cognitive impairment, tachycardia, chronic fatigue, exercise intolerance, sleep problems, skin lesions, and periodic severe abdominal pain. She missed significant portions of school. She could not run safely without triggering seizures. The person she had been before the vaccine was replaced by someone her mother barely recognized.

Amanda’s search for answers mapped the shape of institutional denial. The first neurologist dismissed any connection to the vaccine. The second neurologist, recommended as more open-minded, listened politely but produced only an invoice. The third, at Queen Square in London, dismissed Brodie’s hand tremors by saying her own hands shook too. When Amanda produced blood work showing 24% blood cell membrane loss, the consultant admitted that her team had met previously and already decided the vaccine was not responsible. The decision had been made before any examination. The MHRA’s response to Amanda’s safety queries consisted of a reference to a one-page GACVS document that discussed only two autism studies and relied on an FDA risk assessment calibrated to orally ingested rather than injected aluminium. The GP eventually offered a verbal apology but could never put anything in writing. Amanda’s local immunization team said they would improve the information letters to parents; the change amounted to lip service. The private meeting the school had held about the HPV vaccine had excluded the GP, who was also the school medical adviser. Amanda eventually located Professor Christopher Exley at Keele University, who gave her the silicon-rich mineral water protocol that reduced Brodie’s aluminium burden. The research journalist Christina England met Amanda at a product launch for Acilis mineral water, and the idea for this book was born there. Brodie’s story is the story of thousands of girls across the UK and the world. The deafening silence that gives Amanda’s chapter its title is the systematic refusal of medical institutions to investigate a signal they are structurally unable to see.

Question 28: What did Désirée Röver uncover about SV40 contamination in polio vaccines, and how does this historical precedent inform understanding of the HPV vaccine program?

Answer: Désirée Röver is a Dutch medical research journalist whose own son died of cancer at the age of three. Her research into vaccination led her to a 1950s precedent that remains largely absent from public awareness. The Merck polio vaccines put on the market in 1954 were produced using monkey kidney cells as the culture medium. Shortly after launch, Merck scientists Bernice Eddy and Sarah Stewart discovered that these vaccines were contaminated with a monkey virus they called Simian Virus 40, or SV40. Eddy’s hamsters injected with the vaccine developed malignant tumors. Eddy reported her findings. Merck’s response was to remove her from the project and seize her research papers and photographs. Maurice Hilleman, Merck’s chief vaccine developer, confirmed in a 1987 interview with medical historian Edward Shorter that “one in 10,000 particles [of SV40] is not inactivated by formaldehyde,” meaning the SV40 contamination survived every method used to prepare the vaccine. His response was clinical: “It was good science at the time because that’s what you did. You didn’t worry about these wild viruses.”

The implications continued to unfold for decades. In 1992, researcher Michele Carbone identified the same SV40 strains that had been in the 1950s polio vaccines in the brain tumors of adult Americans who had received those vaccines as children. The latency between vaccination and malignancy was forty years. The parallel to the HPV vaccine program is direct. Both vaccines use biological production methods that cannot guarantee the absence of foreign genetic material. In the HPV case, the recombinant DNA technology used to produce virus-like particles leaves residual DNA fragments (documented by Dr. Sin Hang Lee in every Gardasil sample tested). These fragments bind to the aluminium adjuvant and persist in the body, as shown in the New Zealand girl’s post-mortem analysis. The clinical observation that cancers can develop decades after a vaccine was taken seriously enough with SV40 to generate thousands of research papers, but the implications were buried and the vaccines were never recalled. The pattern repeats with HPV: contamination identified, dismissed by regulators as expected and harmless, with the long-term consequences not yet measurable because the exposed cohort is only beginning to reach the ages at which such effects would appear. Röver’s warning is that the pattern of discovery, suppression, delayed consequence, and institutional silence that characterized SV40 is already visible in the HPV vaccine program. The information is there. Whether it will be acted on before the forty-year window of latency expires is a different question.

Question 29: What did Dr. Jenny Goodman observe in her treatment of “Susanna” and “Laura,” and what therapeutic protocols did she apply?

Answer: Dr. Jenny Goodman is a British ecological physician whose clinical practice centers on the connections between environmental exposures and chronic illness. She contributed two detailed case histories to the book. Susanna was a previously healthy teenager who developed severe fatigue, cognitive problems, and widespread symptoms after her HPV vaccination series. Laura came to Goodman after HPV vaccination with symptoms including fatigue, inability to attend school, cognitive impairment, and physical weakness. Blood testing on Laura revealed very high aluminium levels. Goodman’s clinical approach treats these cases as what they clinically appear to be: toxic injury from a specific identifiable source, requiring removal of the toxin from the body and support for the tissues damaged by its presence. She does not accept the diagnostic erasure that redirects these cases into psychiatric categories or into chronic disease labels that imply unknown cause.

Goodman’s protocol for Laura began with aluminium removal. Silica, in its soluble silicic acid form, binds to aluminium and enables its excretion through urine. Horsetail, a herb that naturally concentrates silica from soil, provided additional silicic acid. Silicon-rich spring waters contributed further. Vegetable juicing supported the body’s natural detoxification pathways. Far infrared saunas initially, graduating to ordinary saunas as Laura regained strength, mobilized aluminium stored in subcutaneous fat so it could be washed from the skin surface. Over time, her aluminium levels dropped to a quarter of their initial measurement. Goodman also addressed sources of ongoing aluminium exposure: aluminium cookware, aluminium foil used for food storage, and the deodorants and antiperspirants that deliver aluminium directly through underarm skin into the lymphatic system. Laura returned to school part-time. She was not completely restored to her pre-vaccination health, but she was substantially improved. Her mother declined the second and third HPV doses. Goodman’s framework rejects the false dichotomy between acknowledging that the vaccine caused the damage and refusing to treat the patient. She treats the damage as what it is and addresses the mechanisms through which it continues to injure. Her case histories demonstrate that recovery is possible when the clinician is willing to recognize what has happened and work with the body’s capacity to restore itself when the ongoing insult is removed and the stored toxic burden is addressed.

Question 30: What do Alan Phillips, Brandy Vaughan, and the collective voice of the contributors recommend parents do when confronting the HPV vaccine program?

Answer: The practical recommendations across the contributors converge on several themes. Alan Phillips, as a vaccine rights attorney, counsels parents to learn the specific vaccination laws of their jurisdiction, to understand what exemptions exist (medical, religious, philosophical, personal belief), and to invoke them legally when they decide against vaccination. He warns against bringing someone up to speed all at once; the subconscious psychological barriers that protect existing beliefs will shut down a conversation that moves too fast. He recommends asking questions rather than hurling facts, since telling someone they are wrong triggers defensive closure, while asking a question leaves them in control. He offers eight concise, irrefutable facts that start a learning curve without demanding immediate acceptance: that the US Supreme Court itself has called vaccines “unavoidably unsafe,” that federal payouts for vaccine injury have exceeded $3.9 billion, that fewer than 1% of vaccine adverse events are reported, that manufacturers have no liability, that 95% of twentieth-century infectious disease mortality decline preceded vaccines, and that pharmaceutical companies have paid billions in criminal and civil fines for fraud.

Amanda Dew offers three questions every parent should ask before consenting to the HPV vaccine: Is it safe? Is it effective? Do the benefits outweigh the risks? If any answer is no, do not sign the form. If a parent decides to proceed, Dew recommends documenting the child’s baseline health in detail before vaccination (heart rate, appetite, energy, mental acuity, GP visit frequency) so that any post-vaccination changes can be objectively assessed. Report any suspected adverse events to the national pharmacovigilance system (MHRA in the UK, VAERS in the US). Connect with vaccine injury support groups: AHVID and Time for Action in the UK, REGRET in Ireland, SaneVax in the US, GANZ in New Zealand. Brandy Vaughan’s Learn the Risk, Claire Dwoskin’s CMSRI, and the National Vaccine Information Center provide independent information. The underlying principle, articulated across all the contributors, is that informed consent cannot be obtained from parents who have been given only Merck’s sales material and Public Health England’s reassurances. True informed consent requires access to the clinical trial data, the VAERS reports, the independent research, the family stories, and the alternatives (Pap screening, lifestyle factors, nutritional approaches). The programme survives only because this information is withheld. When parents access it, the deafening silence from the health authorities becomes audible as the sound of institutional interests overriding the welfare of the children the institutions are meant to protect. The recommendation is simple: do your own research, document everything, refuse to be bullied, support the injured families, and know that the burden of proof should lie with those administering the vaccine, not with the parents whose children bear the consequences.

Analogy

Imagine a small town built along a river. The river has flowed clean for generations because the townspeople take care of what they put into it: they screen their waste, they tend the banks, they teach their children not to foul the water. Cases of illness downstream have been declining for seventy years thanks to this careful stewardship.

A chemical company arrives with a product it says will stop a particular kind of contamination that occasionally shows up in the river. The company’s own tests, it says, prove the product safe. The town council meets. Representatives of the company explain that failing to use the product means children will die. The council votes to require the chemical be added to the water supply of every child in the town.

Within a year, children begin collapsing. Some have seizures that never stop. Some lose the ability to walk. Some die in their sleep. Their parents bring the evidence to the town’s doctors, who say the symptoms must be coincidental, that no connection has been proven. The parents bring the evidence to the town council, which responds that the chemical company has reviewed the reports and found no cause for concern. The parents bring the evidence to the newspapers, which print stories warning readers not to believe the “misinformation” being spread by “anti-chemical activists.”

A mother whose daughter has collapsed asks what the chemical actually contains. She discovers that the company’s “placebo” in its safety tests was the chemical itself, minus one ingredient. She discovers that the follow-up period after exposure was fourteen days, far shorter than the time it takes most symptoms to appear. She discovers that the company was granted immunity from lawsuits before the chemical came to market. She discovers that the clean-water trend downstream, which had been improving for seventy years, has now reversed in the children exposed to the chemical, with contamination levels rising instead of falling in exactly the population the product was supposed to protect.

She discovers that other mothers in neighboring towns are finding the same things. She discovers that one town, in a country far away, decided to stop using the chemical and start treating its injured children. She discovers that her own country’s health authorities received thousands of reports of injuries and recorded them all as unrelated. She discovers that the chemical company funds the medical schools, the professional journals, the patient advocacy groups, and the political campaigns of the officials who regulate it.

She tells her story. Other mothers tell theirs. They are called hysterical, uninformed, conspiracy theorists. They are told the chemical is safe because it has been tested, even though they can read the tests themselves and see what the tests actually measured. They are told the chemical is necessary to prevent a disease that was already in retreat before the chemical existed. They are told their children’s suffering must have other causes, though no one investigates those other causes either. Their daughters sleep sixteen hours a day. Their daughters cannot climb stairs. Their daughters cannot have children. The company’s revenue grows.

The HPV vaccine is the chemical. The river is the body. The town is every country where the program operates. The mothers are telling the truth.

The One-Minute Elevator Explanation

Shattered Dreams is a 2019 compilation of fifteen expert contributors documenting what has happened to teenage girls after HPV vaccination with Gardasil and Cervarix. The book opens with Christina Tarsell, a twenty-one-year-old who died eighteen days after her third dose; the US Vaccine Court ruled in 2017 that Merck’s product killed her. It documents Kesia Lyng, a Danish trial participant whose severe reactions were recorded as “new medical history” rather than adverse events. It documents Amanda Dew’s daughter Brodie, who has had forty-four seizures and lost 24% of her blood cell membranes.

The vaccines use an aluminium adjuvant called AAHS, which Merck doubled in Gardasil 9. The clinical trials used the aluminium adjuvant itself as the “placebo” in 92.5% of controls, making it impossible to detect excess reactions. The vaccines contain residual HPV DNA fragments bound to the aluminium, documented by Dr. Sin Hang Lee in every sample he tested. In every country with high vaccination coverage, including Australia, UK, Norway, and Sweden, cervical cancer rates have stopped declining and started rising specifically in the vaccinated cohort. The 1986 US National Childhood Vaccine Injury Act gave manufacturers complete immunity from liability. Fewer than 1% of adverse events are reported, and even obvious serious reactions have been coded as “non-serious” in the WHO databases.

Thirteen women are seriously harmed for every one who benefits from Gardasil 9, according to Martínez-Lavín’s 2017 calculation. Japan withdrew its recommendation in 2013 and started treating the injured girls. No Western government has done the same.

[Elevator dings]

For further research: look into Dr. Sin Hang Lee’s HPV DNA contamination studies published in Advances in Bioscience and Biotechnology; the Christina Tarsell case documents at the US Court of Federal Claims; and the Slate magazine investigation by Frederik Joelving titled “What the Gardasil Testing May Have Missed.”

12-Point Summary

1. The Christina Tarsell Precedent. On September 25, 2017, the US Court of Federal Claims ruled that the Gardasil vaccination killed Christina Tarsell, a twenty-one-year-old Bard College student who died in her sleep eighteen days after her third dose. The government did not appeal, allowing the deadline to expire on March 30, 2018, thereby conceding by preponderance of evidence that Merck’s product caused her death. Her mother Emily Tarsell spent nearly a decade in the Vaccine Court, with cardiologist Professor Michael Eldar demonstrating that Christina’s fatal arrhythmia was not present before her first Gardasil dose and that symptoms intensified with each successive shot. The ruling established legal precedent that Gardasil can cause death, a fact systematically denied by health authorities globally.

2. The Clinical Trial Fraud. Merck’s Gardasil clinical trials enrolled 18,083 subjects. Of the 7,995 “placebo” recipients, 92.5% received an injection containing the same aluminium adjuvant used in the vaccine itself. The remaining 7.5% received a “saline placebo” that contained Polysorbate 80, a compound shown to cause ovarian damage in young female rats. The gold standard for establishing causation requires comparison against an inert substance. By using the aluminium adjuvant as the control, Merck engineered a trial design that could not detect reactions caused by the adjuvant, which is the component producing most of the inflammatory damage. The vaccine was approved and marketed as “placebo-controlled” and “safe” on the basis of this design.

3. The Fourteen-Day Window and “New Medical History.” Adverse event monitoring in HPV vaccine trials was limited to fourteen days after each dose. After day fourteen, only hospital-diagnosed serious events judged by investigators to be vaccine-related were recorded. Kesia Lyng, a Danish Future II trial participant, documented how Merck recorded severe post-vaccination symptoms in trial participants as “new medical history” rather than adverse reactions. The architecture guarantees that autoimmune conditions, ovarian failure, chronic fatigue, and neurological disorders (all of which develop over months or years) do not appear in the safety data. The published trial safety profiles reflect what the investigators chose to count, not what happened to the people who received the shots.

4. The Rising Cervical Cancer Rates. In every country with high HPV vaccination coverage, the decades-long decline in cervical cancer produced by Pap screening has stopped or reversed in the vaccinated cohort. Australia saw a 15% increase in cervical cancer mortality from 2014 to 2017. The UK saw a 45% increase in cervical cancer rates in girls aged twenty to twenty-four between 2012 and 2015. Norway’s rates nearly doubled between 2004 and 2015. Sweden’s rose 20% in just two years from 2014 to 2015. Pap screening alone had reduced cervical cancer mortality by 70% in high-income countries before any vaccine existed. The vaccine’s measurable population-level effect is to reverse the pre-existing improvement.

5. The Aluminium Adjuvant and Brain Accumulation. HPV vaccines use proprietary aluminium adjuvants (AAHS in Gardasil, aluminium hydroxide with Monophosphoryl Lipid A in Cervarix). Gardasil 9 contains 500 micrograms of aluminium per dose, more than double the original Gardasil. Professor Christopher Exley at Keele University has documented aluminium accumulation in brain tissue, including nearly triple the significant threshold in a fifteen-year-old boy with autism who had died. Macrophages carry the aluminium across the blood-brain barrier (the “Trojan horse” mechanism described by Dr. Lucija Tomljenovic). Silicon-rich mineral water (such as Acilis) can reduce body aluminium burden through urinary excretion, a protocol Exley recommends and Amanda Dew applied with her daughter Brodie.

6. The HPV DNA Contamination. Dr. Sin Hang Lee analyzed sixteen Gardasil samples from around the world and found HPV DNA fragments bound to the aluminium adjuvant in every single sample. Professor Laurent Belec at the European Hospital Georges Pompidou independently confirmed the finding in French Gardasil batches. In the post-mortem analysis of an eighteen-year-old New Zealand girl who died unexpectedly six months after her third dose, Lee found HPV-16 DNA bound to aluminium in both her blood and spleen. The contorted DNA could not be broken down by the enzymes that would normally clear free-floating DNA within forty-eight hours. The FDA’s response was to declare residual DNA fragments a normal consequence of vaccine manufacture.

7. The Fertility Signal. VAERS reports of amenorrhea, premature menopause, and ovarian failure were flat through 2006, then jumped sharply after Gardasil’s introduction. 88% of all such reports since licensure have been associated with Gardasil, 76% solely with Gardasil. Dr. Gayle DeLong’s 2018 statistical analysis found that women who received the HPV vaccine were significantly less likely to have ever conceived, with universal vaccination of her study population projected to produce two million fewer pregnancies. The American College of Pediatricians issued a 2016 warning statement. The biological mechanisms include aluminium disruption of ovarian function (Fu 2014), Polysorbate 80 damage to ovaries in rats (Gajdová 1993), and cross-reactivity between vaccine proteins and ovarian tissue (molecular mimicry documented by Darja Kanduc).

8. The Japanese Response Versus the Western Silence. Japan withdrew its HPV vaccine recommendation in June 2013 after mounting reports of severe adverse reactions. Japanese researchers treated the affected girls, taking blood samples and spinal fluid, testing for autoantibodies, and documenting what they found. They identified antibodies against NMDA receptors (correlating with cognitive problems in 81% of patients), elevated IL-17, abnormal cerebral blood flow on SPECT imaging, and small fiber neuropathy. The average time from vaccination to onset of cognitive symptoms was nearly two years. In the UK, MHRA received over 9,100 adverse event reports by 2018 with eight deaths and concluded there were “no new safety issues.” The thirty-five members of the January 2017 JCVI subcommittee had read none of the three major research papers warning of signals.

9. The India Case and the Gates Foundation. In 2009, approximately 30,000 tribal girls in Andhra Pradesh and Gujarat were enrolled without informed consent in a Phase IV clinical trial of Gardasil and Cervarix organized by PATH International. Many suffered anaphylactic shock, seizures, paralysis, and immune system disorders; six died. Activists filed a writ petition with the Indian Supreme Court in October 2012. In February 2017, the Indian government severed all financial ties between the National Technical Advisory Group on Immunization and the Bill and Melinda Gates Foundation, citing conflict of interest concerns arising from the foundation’s connections with pharmaceutical companies. India closed the door that the West has kept open.

10. The Political Capture. Governor Rick Perry’s 2007 Texas executive order mandating HPV vaccination for all schoolgirls was revealed to be backed by $28,500 in Merck donations to his campaigns and $377,500 to the Republican Governors Association he chaired. His chief of staff Mike Toomey moved directly from the governor’s office into a Merck lobbying position. Similar patterns were documented in Virginia ($135,750 in Merck contributions to legislators), Illinois (the mandate’s lead sponsor directed a Merck-funded cancer organization), and twenty other states. Merck’s annual lobbying budget runs to $5.4 million. Former Presidents Carter, Clinton, Bush, Obama, and Vice President Biden have all lent their names to HPV vaccine promotion through foundations and initiatives, providing bipartisan political cover for the program.

11. The 1986 Vaccine Act and the Liability Shield. The National Childhood Vaccine Injury Act, signed by President Reagan in 1986, granted complete federal liability immunity to vaccine manufacturers, doctors, and hospitals for harm caused by vaccines. Injured parties cannot sue the manufacturer directly; they must go through the Vaccine Court. The US Supreme Court reinforced this immunity in Bruesewitz v. Wyeth (2011), characterizing vaccines as “unavoidably unsafe.” By 2018, federal payouts for vaccine injuries totaled $3.9 billion. Since fewer than 1% of adverse events are reported, actual harm vastly exceeds this figure. The commercial consequence is that pharmaceutical companies collect the profits while taxpayers cover the damage, with no financial incentive remaining to make safer vaccines.

12. The Pattern of Institutional Denial. The response from medical institutions follows a consistent pattern across every country. Doctors tell parents the symptoms must be coincidental. Health authorities dismiss adverse event reports as background noise. Mainstream media characterizes parents raising concerns as spreaders of misinformation. Specialists refuse to investigate even when presented with clear clinical findings (Brodie Dew’s 24% blood cell membrane loss, documented autoantibodies, and ASIA syndrome diagnosis were met with “I never heard of HPV vaccine causing problems”). Regulatory committees meet with members who have read none of the critical research. The 1,145 adverse event reports in Spain, the 125 Japanese lawsuits, the 700 Colombian women suing Merck for $160 million, the Spanish court ruling on Andrea’s death, and the thousands of injured girls globally are met with the same institutional response: there is no evidence, there has been no proof, the parents are mistaken, the vaccine is safe. The silence is deafening because it is deliberate.

The Golden Nugget

The single most profound idea in the book, and the one fewest people would know, is this: Merck used its own experimental aluminium adjuvant as the “placebo” control in the Gardasil clinical trials, and no regulatory body in the world has required this to change.

This is not a minor methodological quirk. It is the architectural flaw that makes everything else possible. A placebo, by definition, is an inactive substance used to measure what the test substance causes above baseline. The aluminium adjuvant is the component of the vaccine that produces most of the inflammatory damage. By injecting the aluminium adjuvant into the “control” group, Merck guaranteed that the control group would experience adverse reactions at rates comparable to the vaccine group. When the comparison yielded no statistical difference, Merck declared the vaccine safe. The trial was designed to produce exactly this result. The 92.5% of control subjects who received the aluminium placebo had injection site pain at 75% versus 84% in the vaccine group, systemic reactions comparable across both arms, and the entire safety profile distorted by the inclusion of the inflammatory substance in both groups.

The reason this is the golden nugget is that it is simultaneously the most damning piece of evidence against the HPV vaccine program and the piece most invisible to the public. Parents consenting to the vaccine have never been told this. Doctors recommending it have almost never seen this. Regulatory agencies defending it have never addressed this. When a member of the audience at a December 2017 Trinity College Dublin lecture asked a professor directly about the approval of Gardasil from trials that did not use inert controls, the question was not answered. A second professor bypassed it by referring to post-licensing research. This question has never received a satisfactory answer in any public forum because none exists. The entire safety case for Gardasil, Cervarix, and Gardasil 9 collapses the moment this architectural flaw is understood. The vaccine was never tested against a placebo. It was tested against itself.

How to Explain It to a 6-Year-Old

Imagine you have a lemonade stand. You want to prove your lemonade is the best in the neighborhood. So you set up a taste test. On one side of the table, you put a cup of your lemonade. On the other side, you also put a cup of your lemonade. Then you ask everyone, “Which one tastes better?” People take a sip from each cup and say they taste about the same. You smile and tell everyone, “See? My lemonade is just as good as any other lemonade!”

That is a silly test. You cannot prove your lemonade is good by comparing it to itself. You have to compare it to something different, like water, or juice from another stand. Otherwise, you have not really tested anything.

A big company made a medicine shot called Gardasil. They said it would help girls not get sick when they grow up. They had to test it to show it was safe. But they did a test like the lemonade test. They gave almost everyone the shot with all the strong stuff inside it, and told people that the “pretend shot” (the one that was supposed to be plain) also had the strong stuff inside. Then they said, “See? The real shot and the pretend shot cause the same amount of problems. So the real shot must be fine.”

But that is not fine at all. Lots of girls got very sick after the shot. Some could not go to school anymore. Some had seizures. Some could not have babies when they grew up. A few even died. Their mommies and daddies told the doctors, but the doctors said it was just a coincidence, like saying the rain had nothing to do with your sneakers being wet.

The grown-ups who made the shot are still selling it to lots and lots of girls all over the world. They make billions of dollars. The people who are supposed to check if medicines are safe keep saying it is safe, even though mommies and daddies are saying their daughters got sick right after the shot. The book is telling the truth about what happened, so other families will know before they decide.

This essay tracks twelve committee decisions between 2011 and 2024 that lowered the recommended starting age for a screening test, a vaccination, or a drug intervention. It stands as a companion to the earlier essay on diagnostic thresholds, which examined how the numerical cutoffs that define disease have been quietly reset. That piece looked at where the line is drawn. This one looks at when it is drawn, meaning the age in a life at which the measurement first takes place. The two operations do the same work on different axes. A lowered threshold and a lowered starting age each enlarge the pool of official candidates for intervention. The committees produce candidates by signature, and the result is market-making in its purest form: an ever-growing share of the population becomes officially eligible for the product, and the product has nowhere else to go for its growth. The chair of each committee, the date of each vote, and the wording of each guideline can be traced back to a publicly available document.

On April 30, 2024, the United States Preventive Services Task Force finalized its recommendation that women begin mammography screening at age 40 rather than 50.¹ A single number had shifted: fifty became forty. Approximately 20 million American women who had been outside the screening pool the day before were inside it the day after.²

Their breasts were unchanged; what had changed was a USPSTF modeling exercise.

The panel did not cite new biological discoveries. It cited a rebalancing of existing evidence, decision-analytic projections, and a shift in how the panel weighed the harms of screening against the harms of not screening.³ The number of women aged 39 to 49 who must be invited to screening to prevent one breast cancer death stands at approximately 1,904, compared with 377 at ages 60 to 69.⁴ The USPSTF’s own draft acknowledged that mammography detects cancers that would never have progressed, delivers ionizing radiation to breast tissue, and produces false-positive rates approaching 60 percent over a decade of annual scans.⁵ The final document lowered the age anyway.

The committees’ public rationale is familiar: earlier screening catches disease earlier, and catching disease earlier saves lives. The trial data that has arrived since each of the twelve recommendations below complicates that claim.

Between 2011 and 2024, twelve committee decisions in the United States lowered the recommended starting age for a screening test, a vaccination, or a drug intervention. The population classified as needing medical evaluation has expanded by tens of millions. No new disease appeared and no epidemic emerged. What changed was the number below which a healthy person is called healthy.

The twelve ages below trace the arc, moving from adult thresholds to pediatric thresholds across the same thirteen-year window. In each case, a named panel chair signed a document, a vote was recorded, and a population that had been outside the medical system found itself inside it. The documents remain publicly available, and the bodies to which the guidelines have been applied received no vote.

Audio Deep Dive (for Paid Subscribers)

Related Essays

1. Mammography: 50 to 40 (USPSTF, 2024)

The 2024 USPSTF recommendation lowered the starting age for mammography from 50 to 40 and set the interval at every two years.⁶ The 2016 recommendation had left ages 40 to 49 as an individual decision. The 2024 revision made screening the default. The USPSTF’s own modeling report projected that initiating biennial screening at age 40 rather than 50 reduces the breast cancer death rate by an additional 3 percent (plausible range 1 to 6 percent), set against roughly 1,500 false positives per 1,000 women screened over a lifetime, additional unnecessary biopsies, and documented overdiagnosis.⁷ The document’s expression of the tradeoff was that averting the deaths was worth the harms. The document did not explain why the same reweighting was not persuasive in 2016.

The American College of Radiology, whose members are the primary financial beneficiaries of expanded mammographic screening, had campaigned for the age reduction for over a decade through position statements and lobbying for the USPSTF Transparency and Accountability Act.⁸ The 2024 USPSTF revision aligned federal policy with the professional body whose income depends on that policy. The defense that earlier detection reduces disparities in Black women does not survive the aggregate numbers: NNS at 1,904 means over 99.9 percent of women screened in the new age bracket receive no mortality benefit from the test itself.

2. Colorectal screening: 50 to 45 (USPSTF, 2021)

In May 2021, the USPSTF lowered the starting age for colorectal cancer screening from 50 to 45, citing modeling data suggesting a marginal benefit at earlier ages.⁹ The recommendation added approximately 21 million Americans to the screening pool. The following year, the NordICC trial, the first randomized controlled study of colonoscopy screening ever conducted, followed 84,585 people for ten years and reported an 18 percent reduction in cancer incidence and no statistically significant reduction in cancer deaths.¹⁰ The trial also found that 455 people had to be invited for screening to prevent one case of cancer. The number needed to prevent one death was indistinguishable from infinity within the trial’s statistical power.

The 2021 USPSTF revision preceded the NordICC results by one year. The task force has not withdrawn the recommendation in the years since the trial’s publication, and gastroenterology societies continued to recommend colonoscopy as the default screening modality for Americans aged 45 to 49. The defense that polyp removal prevents cancer runs into the trial’s finding that polyp removal does not prevent deaths at a scale a randomized study could detect. The defense that the trial measured the wrong outcome requires explaining why the outcome measured was the one the screening is marketed as preventing.

3. Type 2 diabetes: 40 to 35 (USPSTF, 2021)

The USPSTF’s August 2021 recommendation lowered the age for screening asymptomatic adults with overweight or obesity from 40 to 35.¹¹ The clinical significance compounds with a diagnostic threshold change made two decades earlier. In 2003, the American Diabetes Association lowered the fasting glucose cutoff for pre-diabetes from 110 to 100 mg/dL, adding millions to the pre-diabetic rolls without a single fasting reading changing.¹² The 2021 age reduction feeds the screening pipeline into the 2003 threshold. A 35-year-old with a fasting glucose of 101 mg/dL is now a candidate for metformin, counseling, and lifetime monitoring for a category that did not exist as a clinical entity when her parents were 35.

The screening expansion creates the recruitment layer for pre-diabetes interventions, including off-label metformin prescribing to asymptomatic adults flagged by a single laboratory reading. The defense that early detection prevents diabetes progression collides with two facts in the ADA’s own data: the category of pre-diabetes is itself an administrative construct whose threshold moved by committee vote in 2003, and the majority of people labeled pre-diabetic will never progress to clinical diabetes within a decade. The 35-year-old flagged by the new screening age inherits a label whose predictive value is marginal and a monitoring schedule that persists for life.

4. Lung cancer: 55 to 50 (USPSTF, 2021)

The March 2021 USPSTF revision lowered the recommended starting age for annual low-dose CT screening from 55 to 50 and cut the smoking history threshold from 30 pack-years to 20, where a pack-year equals one pack per day for one year.¹³ The dual change roughly doubled the eligible screening population. Each low-dose CT delivers ionizing radiation to lung tissue, radiosensitive bone marrow, and the breast tissue adjacent to the chest wall. The USPSTF’s own harm calculations acknowledged the radiation-induced cancer risk and the risk of invasive follow-up for benign nodules detected by the scan.

Projections published by Smith-Bindman and colleagues in JAMA Internal Medicine in 2025 estimated that CT scans performed in the United States in 2023 alone would produce approximately 103,000 future cancers, indistinguishable at autopsy from cancers attributed to other causes.¹⁴ Low-dose lung screening is a subset of this total, but the lowered age and relaxed smoking threshold mean the subset is growing. The defense that screening finds lung cancer earlier concedes the point: the screening finds some cancers earlier while causing others later, and the cancers it causes will not be attributed to it when they appear.

5. Hepatitis C testing: 45 to 18 (USPSTF, 2020)

In March 2020, the USPSTF issued its strongest recommendation for universal one-time hepatitis C testing of all adults aged 18 to 79.¹⁵ The 2013 recommendation had targeted a single birth cohort, Americans born between 1945 and 1965, approximately 76 million people. The 2020 revision took the age of first testing from 45 down to 18 and expanded the eligible population to roughly 240 million.¹⁶ The laboratory test looks for what mainstream virology calls hepatitis C viral RNA. A positive result triggers confirmatory testing, hepatology referral, and consideration of twelve weeks of direct-acting antiviral treatment.

The antiviral pipeline is where the screening expansion delivers its market. Gilead’s two leading HCV drugs, Sovaldi and Harvoni, generated approximately $22 billion in sales between launch in late 2013 and mid-2015 alone, with Sovaldi priced at $84,000 for a twelve-week course and Harvoni at $94,500.¹⁷ The U.S. Senate Finance Committee’s 2015 bipartisan investigation of Gilead’s internal documents concluded that the pricing strategy was designed to maximize revenue rather than reflect manufacturing cost or research investment. The 2020 USPSTF expansion from 76 million to 240 million eligible test recipients is the intake stage of a pipeline whose per-patient revenue is already demonstrated.

6. Statin therapy: consideration from age 40 (ACC/AHA 2013 and USPSTF 2016)

The 2013 American College of Cardiology and American Heart Association (ACC/AHA) cholesterol guideline, chaired by Neil J. Stone with vice-chairs Jennifer Robinson and Alice Lichtenstein, replaced the previous LDL-target model with a risk-calculator model that identified a much larger fraction of adults aged 40 to 75 as statin candidates.¹⁸ The panel’s own risk calculator was flagged in the peer-reviewed literature as overestimating cardiovascular risk by 75 to 150 percent.¹⁹ The USPSTF in 2016 aligned its recommendation with the ACC/AHA framework, endorsing statin therapy for adults aged 40 to 75 with elevated calculated risk.²⁰ Routine statin consideration for an American now begins at 40.

Of the 2013 ACC/AHA writing panel of 16 members, approximately half had disclosed financial ties to statin manufacturers, replicating the pattern first documented by Jeanne Lenzer in the BMJ for the 2004 cholesterol panel.²¹ A 2014 analysis by Pencina and colleagues in the New England Journal of Medicine estimated that the 2013 guidelines added approximately 12.8 million Americans to the recommended-statin pool compared with the prior framework, bringing total statin eligibility to roughly 56 million adults.²² The defense that statins reduce cardiovascular events in high-risk patients does not justify extending the drug class to lower-risk 40-year-olds whose risk is calculated by a model the panel itself designed to classify them as candidates.

Each of the six adult reductions was issued by the United States Preventive Services Task Force or a joint cardiology committee, published between 2013 and 2024, and produced by a documented recommendation process.²³ The same institutional architecture that lowered the mammography age from 50 to 40 has been applied to bodies that have not yet reached their tenth birthday.

The pediatric committees are different bodies with overlapping membership. The American Academy of Pediatrics writes the schedules that pediatricians follow. The Advisory Committee on Immunization Practices sets the childhood vaccination schedule and is housed within the CDC. The National Heart, Lung, and Blood Institute convened the 2011 expert panel that produced the pediatric cardiovascular guidelines, chaired by Stephen R. Daniels, pediatrician-in-chief at the University of Colorado School of Medicine, whose disclosures in the guideline document itself included consulting for Abbott.²⁴ The USPSTF issues pediatric recommendations covering mental health screening and obesity intervention. Cross-membership between adult and pediatric guideline bodies is routine. Daniels, for example, sat on the pediatric guidelines panel while also contributing to AHA scientific statements on adult cardiovascular health.²⁵

The mechanism is identical to the adult case. A panel meets. Evidence is reweighted. A threshold falls. A guideline document is published. Insurance reimbursement follows. Pediatric practices integrate the guideline into their electronic health record prompts. Parents arrive for a well-child visit and are told what their child’s age now requires.

The pediatric changes are less visible for a specific reason. Children do not read guideline documents. Parents defer to the pediatrician, who relies on the AAP, which in turn cites the panel that wrote the guideline. Between the panel decision and the child in the chair, no accountable interface exists. The parent who asks why a nine-year-old is getting a cholesterol test is answered with “it’s the guideline,” and the guideline sits in a database few parents have ever opened.

The six pediatric ages below are the current state of that pipeline.

7. HPV vaccination: from 11-12 to age 9 (AAP Red Book, 2018 edition)

The American Academy of Pediatrics shifted its recommended HPV vaccination starting age from the ACIP-defined 11 or 12 years down to 9 years in the 2018-2021 edition of its Red Book, the standard clinical reference for pediatricians, and reinforced the recommendation in a 2022 policy explanation published in Human Vaccines and Immunotherapeutics.²⁶ The Advisory Committee on Immunization Practices had permitted vaccination as early as age 9 since 2019, but the AAP recommendation moved age 9 from permitted to preferred, on the stated reasoning that earlier initiation improved series completion rates and avoided linking the vaccine to a conversation about sexual activity.²⁷ The AAP framed the age reduction as a “cancer prevention” measure, administered against what mainstream virology calls human papillomavirus to prevent cervical cancers four to six decades later.

Post-licensure case series have documented a pattern of adverse outcomes labeled autoimmune and neurological. Blitshteyn’s 2014 case series in European Journal of Neurology reported six previously healthy girls aged 12 to 22 who developed postural orthostatic tachycardia syndrome within six days to two months of Gardasil vaccination.²⁸ Tomljenovic and colleagues published a detailed case report of a 14-year-old girl who developed POTS with chronic fatigue two months after her second Gardasil dose.²⁹ Louise Brinth’s 2015 Danish Syncope Unit series prompted the Danish Health and Medicines Authority to request a European Medicines Agency safety review.³⁰ Little and colleagues reported premature ovarian insufficiency three years after menarche in a 16-year-old following HPV vaccination.³¹ A 2022 review documented more than 150 published post-vaccination cases of POTS and complex regional pain syndrome.³²

A vaccine originally marketed to adolescent girls approaching sexual activity is now administered to nine-year-old children of both sexes in a routine well-child visit. The parent is asked whether the child is up to date on shots. The specific vaccine and the specific condition it targets are frequently not named at the point of administration. The defense that the vaccine prevents cervical cancer four to six decades later must engage the case series above, which the AAP’s 2018 age reduction did not address and which the manufacturer’s post-licensure surveillance system is structurally not designed to detect at individual-case resolution.

8. Anxiety screening: age 8 (USPSTF, 2022)

In October 2022, the USPSTF issued a Grade B recommendation for anxiety screening in all children and adolescents aged 8 to 18.³³ No prior USPSTF recommendation for pediatric anxiety screening had existed. The document created the recommendation and set the minimum age simultaneously. For children aged 7 and younger, the panel issued an “I” statement, meaning the evidence to recommend or oppose screening was insufficient. The age-8 line is the panel’s selection, not a biological threshold. Endorsed screening tools include the Screen for Child Anxiety Related Emotional Disorders and the Patient Health Questionnaire–Adolescent, both relying on parent or self-report of behavioral traits.³⁴ A score above threshold triggers a referral, which produces an evaluation, which produces a diagnostic label, which produces access to services and, in many practice settings, a prescription.

The pharmaceutical pipeline the recommendation feeds is documented in pharmacy surveillance data. Chua and colleagues, publishing in Pediatrics in February 2024, analyzed 221 million antidepressant prescriptions and found that monthly dispensing to Americans aged 12 to 25 rose 66.3 percent between January 2016 and December 2022, with the rate rising 63.5 percent faster after March 2020 than before.³⁵ Among female adolescents aged 12 to 17, the post-pandemic rate rose 129.6 percent faster than the pre-pandemic trendline. Among male adolescents, dispensing declined. The defense that early intervention improves outcomes requires evidence that the screening leads to interventions that improve outcomes, which the USPSTF evidence report itself describes as sparse for the age range the recommendation covers.

9. Depression screening: age 12 (USPSTF, 2009, reaffirmed 2022)

The USPSTF first recommended universal depression screening for adolescents aged 12 to 18 in 2009 and reaffirmed the recommendation in 2016 and 2022.³⁶ The 2022 reaffirmation considered but did not endorse extending the screening down to children under 12, issuing an “I” statement for the under-12 group. The parallel 2022 anxiety recommendation set the minimum anxiety screening age at 8. An American child now enters a formal psychiatric screening regime at age 8 for anxiety and age 12 for depression, filed under separate USPSTF documents issued the same year. The screening tool is the Patient Health Questionnaire modified for adolescents, a nine-question instrument scored on the frequency of nine symptoms over the previous two weeks.³⁷ A twelve-year-old reporting sad, tired, or unfocused feelings for two consecutive weeks meets threshold.

The screening framework operates in schools as well as clinics. State laws in California, Illinois, New York, and several other jurisdictions require or permit school-based mental health screening, with results shared with parents and, in some jurisdictions, with school administrators.³⁸ Pediatric antidepressant use in the United States rose steadily through the 2010s and accelerated during and after 2020, despite an FDA black-box warning on increased suicidal ideation in patients under 25.³⁹ The defense that screening identifies children who benefit from treatment runs into the FDA’s own warning that the treatment increases suicidality, the outcome the screening is designed to detect.

10. Universal cholesterol screening: age 9 (NHLBI/AAP, 2011)

In November 2011, the National Heart, Lung, and Blood Institute published the Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, chaired by Stephen R. Daniels and endorsed by the American Academy of Pediatrics.⁴⁰ The document recommended universal lipid screening for all children aged 9 to 11, regardless of family history, weight, or risk factors. The 1992 NHLBI guideline it replaced had recommended selective screening only for children with a family history of premature cardiovascular disease. Before 2011, cholesterol testing in an asymptomatic nine-year-old was considered inappropriate by most pediatric practice standards.⁴¹ After the guideline, it became standard of care.

In August 2012, three UCSF researchers, Thomas Newman, Mark Pletcher, and Stephen Hulley, published a commentary in Pediatrics titled “Overly Aggressive New Guidelines for Lipid Screening in Children: Evidence of a Broken Process.”⁴² They argued the panel’s evidence base did not support universal pediatric screening, that the recommendation would convert millions of healthy children into patients labeled with “dyslipidemia,” and that panel members’ financial relationships with drug manufacturers raised questions about the process. “The panel made no attempt to estimate the magnitude of the health benefits or harms of attaching this diagnosis at this young age,” Newman wrote.⁴³ The AAP endorsed the guideline anyway. The defense that early identification of familial hypercholesterolemia justifies universal screening ignores that only roughly 0.3 percent of children carry the condition, while the test is applied to all.

11. Statin candidacy: from age 8 (NHLBI/AAP 2011; FDA labels)

The same 2011 NHLBI expert panel established statin therapy as an option for children aged 10 and older with LDL cholesterol above 190 mg/dL, or above 160 mg/dL with a family history of premature cardiovascular disease.⁴⁰ For children with a diagnosis of familial hypercholesterolemia, treatment could begin at age 8 with rosuvastatin (Crestor) or simvastatin (Zocor), or at age 10 with atorvastatin (Lipitor), pravastatin (Pravachol), or lovastatin (Mevacor), per the FDA labels approved through the pediatric indication.⁴⁴ Lovastatin’s label states that “the long-term efficacy of lovastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.”⁴⁵ Simvastatin carries identical language. No statin has been studied in prepubertal children in trials adequate to assess mortality, fertility, or endocrine outcomes.

Buonuomo and colleagues reported in the Journal of Pediatrics in 2017 a 10-year-old boy with familial hypercholesterolemia who presented with severe myalgia, generalized weakness, and darkened urine approximately ten days after starting atorvastatin at 10 mg per day, with creatine kinase at 1,951 units per liter against a normal upper limit around 200.⁴⁶ Oberhoffer and colleagues published in Translational Pediatrics in 2025 the case of a 17-year-old male on rosuvastatin at 5 mg per day whose creatine kinase at admission was 20,108 units per liter, approximately 100 times the upper limit of normal.⁴⁷ Vijayakanthi and colleagues reported in 2021 a 13-year-old girl on rosuvastatin whose creatine kinase reached 53,000 units per liter.⁴⁸

Conte and colleagues, reviewing the World Health Organization global database in 2020, identified 311 pediatric statin adverse drug reactions including 11 cases of rhabdomyolysis.⁴⁹ Cholesterol is the precursor for every steroid hormone in the body, and suppressing its synthesis in an eight-year-old suppresses the substrate for the pubertal hormonal cascade the child has not yet begun. Familial hypercholesterolemia affects approximately one in 311 people.⁵⁰ The 2011 recommendation nonetheless established the precedent that lifelong cholesterol-lowering therapy in a prepubertal child was defensible clinical practice. The defense that rare adverse events are the cost of population-level benefit requires evidence that the population-level benefit exists in children, which the FDA labels themselves state has never been demonstrated.

12. Blood pressure at 3, autism screening at 18 months (AAP)

The American Academy of Pediatrics recommends blood pressure measurement at every well-child visit beginning at age 3.⁵¹ The measurement produces a percentile against age, sex, and height. A percentile above the 95th generates a “hypertension” designation. A three-year-old above threshold enters a diagnostic pathway that can include repeat measurements, ambulatory monitoring, echocardiogram, renal imaging, and pharmacological treatment.⁵² The blood pressure of a three-year-old is exquisitely sensitive to the moment of measurement, the cuff size, the child’s crying, and the calibration of the device. The pathway does not stop for those variables.

The screening age below three is autism. The AAP recommends universal autism screening at the 18-month and 24-month well-child visits, using the Modified Checklist for Autism in Toddlers, Revised.⁵³ The M-CHAT-R is a 20-item questionnaire scored on the parent’s answers to whether the child points, makes eye contact, responds to name, and imitates gestures. A score of 3 or more triggers referral for evaluation. Guthrie and colleagues, publishing in Pediatrics in 2019, examined M-CHAT-R performance in a large pediatric network and found a positive predictive value of around 14 to 15 percent in general population screening, meaning roughly six of seven referrals will not result in an autism diagnosis after full evaluation.⁵⁴ Families in the false-positive group have already entered the specialist referral pipeline and the parental anxiety cascade before the diagnostic evaluation is complete.

The AAP’s 18-month screening recommendation was reaffirmed in 2020, over the objections of researchers who noted that autism screening at that age had not been shown to improve long-term outcomes.⁵⁵ The USPSTF in 2016 examined the same body of evidence and concluded the data were insufficient to recommend universal toddler autism screening either for or against.⁵⁶ The AAP continued to recommend it. The defense that early identification helps children who need help requires acknowledging that six of seven children screened enter the referral system without needing help, and that the harm of unnecessary identification is treated by the AAP as acceptable collateral in service of case-finding.

Twelve committee decisions, stacked into one life, produce a schedule. The American child born in 2025 enters a screening regime at 18 months and does not exit it until death. Between 18 months and age 3, her autism status is surveyed. From age 3 forward, her blood pressure is charted at every well-child visit. By age 8, her anxiety is scored on a nine-item instrument. The HPV series begins at 9. The first cholesterol draw occurs that same year. By 10, she is a candidate for statin therapy if the number comes back above threshold. Her depression gets its first formal score at 12. She then enters the adult schedule: hepatitis C testing at 18, diabetes screening at 35, statin consideration at 40, mammography at 40, colorectal screening at 45, lung CT at 50 if she smoked. The screenings do not stop.

No single panel designed this schedule. It emerged committee by committee, guideline by guideline, over thirteen years of recommendations, publications, and integrations into electronic health records. Each decision had a rationale. Each rationale was defensible within its own frame. The aggregate result is a life span in which no year is unscreened, no threshold is unmonitored, and no body is presumed well without a laboratory document confirming it.

The guideline documents remain publicly available, with their chairs named at the top and their panelists listed in appendices showing financial relationships with the manufacturers of the drugs the guidelines recommend. The votes are on the record. The child in the chair does not know the names of Stephen Daniels, Neil Stone, or the chairs of the USPSTF panels whose decisions now define what her healthy body will be tested for at every stage of the life ahead of her.

How to Explain It to a Six-Year-Old

Imagine a game where the grown-ups keep changing the rules to catch more kids in freeze tag.

The first rule was that you got tagged if you crossed the red line. Then the grown-ups moved the red line closer to home base. More kids got tagged. So they moved the line closer again. Even more kids got tagged. After a while they said toddlers had to play too. Then babies. Nobody runs faster or slower than before. The line just keeps moving in.

The line keeps moving because the store next to the playground sells medicine for tagged kids, and the store wants more customers. The grown-ups who move the line are friends with the people at the store. Some of them used to work at the store, and some are still being paid by the store on the side. They say that is fine because they wrote it down on a piece of paper that nobody reads.

Every kid on the playground is tagged now. The grown-ups say the game is working really well. Business is booming. Nobody ever asked the kids whether they wanted to play.

References

1. U.S. Preventive Services Task Force. “Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA. 2024;331(22):1918-1930. Published April 30, 2024.

2. Population estimate derived from U.S. Census Bureau data on female residents aged 40-49, approximately 20 million as of 2024.

3. USPSTF Final Recommendation Statement, Breast Cancer: Screening, April 30, 2024. Accompanying evidence and decision analysis reports.

4. Nelson HD, et al. “Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force.” USPSTF Evidence Report, 2024. NNS figures also cited in Nasser SM, Stafford RS. “Annual mammography starting at age 40: more talk, less action?” Cleveland Clinic Journal of Medicine, 2010.

5. Gøtzsche PC, Jørgensen KJ. “Screening for breast cancer with mammography.” Cochrane Database of Systematic Reviews, 2013; updated 2024 in medRxiv preprint 2024.06.06.24308542.

6. USPSTF 2024 Breast Cancer Screening Recommendation Statement (see reference 1).

7. Trentham-Dietz A, et al. “Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.” JAMA. 2024;331(22):1947-1960. The additional 3 percent mortality reduction figure is from Welch HG and Passow HJ’s analysis of CISNET modeling, cited in Nasser and Stafford, 2010.

8. American College of Radiology. Position statements on breast cancer screening, 2015-2024. ACR and Society of Breast Imaging advocacy documented in USPSTF Transparency and Accountability Act lobbying records, 2015.

9. USPSTF. “Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA. 2021;325(19):1965-1977.

10. Bretthauer M, et al. “Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death (NordICC trial).” New England Journal of Medicine. 2022;387:1547-1556.

11. USPSTF. “Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement.” JAMA. 2021;326(8):736-743.

12. Genuth S, et al. “Follow-up Report on the Diagnosis of Diabetes Mellitus.” Diabetes Care. 2003;26(11):3160-3167.

13. USPSTF. “Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA. 2021;325(10):962-970.

14. Smith-Bindman R, et al. “Projected Lifetime Cancer Risks From Current Computed Tomography Imaging.” JAMA Internal Medicine. 2025;185(4):385-396.

15. USPSTF. “Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.” JAMA. 2020;323(10):970-975.

16. Ibid.

17. Gilead Sciences SEC Form 10-K, FY2015 and FY2014; U.S. Senate Finance Committee bipartisan investigation report, “The Price of Sovaldi and Its Impact on the U.S. Health Care System,” December 2015. Harvoni price per 12-week course documented in Becker’s Hospital Review coverage of Gilead Q3 2014 earnings, October 2014.

18. Stone NJ, et al. “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.” Circulation. 2014;129(25 Suppl 2):S1-S45. Panel composition: 13 writing members and 3 ex-officio members; chair Neil J. Stone; vice-chairs Jennifer G. Robinson and Alice H. Lichtenstein.

19. Ridker PM, Cook NR. “Statins: new American guidelines for prevention of cardiovascular disease.” Lancet. 2013;382(9907):1762-1765.

20. USPSTF. “Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.” JAMA. 2016;316(19):1997-2007.

21. Lenzer J. “Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers.” BMJ. 2013;347:f6989. See also Lenzer J. “Majority of panelists on cholesterol guidelines have current or recent ties to drug industry.” BMJ. 2004;328(7452):8. A 2024 reanalysis published in a peer-reviewed journal, covered by TCTMD, examined the 2013 ACC/AHA panel composition and documented substantial industry relationships among the writing group.

22. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, et al. “Application of New Cholesterol Guidelines to a Population-Based Sample.” New England Journal of Medicine. 2014;370:1422-1431.

23. USPSTF Procedure Manual. Available at uspreventiveservicestaskforce.org.

24. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute Full Report, NIH Publication No. 12-7486, October 2012. Stephen R. Daniels, M.D., Ph.D., Panel Chair. Disclosures section notes Daniels served as a consultant for Abbott Laboratories.

25. Daniels SR cross-authorship on AHA scientific statements documented in multiple pediatric cardiology position papers of the American Heart Association.

26. American Academy of Pediatrics Red Book, 2018-2021 edition and subsequent editions, which recommend HPV vaccination initiation between ages 9 and 12. Rationale documented in “Why the American Academy of Pediatrics recommends initiating HPV vaccine at age 9.” Human Vaccines & Immunotherapeutics. 2022.

27. Meites E, et al. “Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.” MMWR. 2019;68:698-702.

28. Blitshteyn S. “Postural tachycardia syndrome following human papillomavirus vaccination.” European Journal of Neurology. 2014;21(1):135-139. Case series of six previously healthy women aged 12-22 developing POTS 6 days to 2 months after Gardasil.

29. Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y. “Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the ‘Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants’: Case Report and Literature Review.” Journal of Investigative Medicine High Impact Case Reports. 2014;2(1).

30. Brinth LS, et al. “Suspected side effects to the quadrivalent human papillomavirus vaccine.” Danish Medical Journal. 2015;62(4):A5064. Case series from the Danish Syncope Unit that prompted European Medicines Agency safety review.

31. Little DT, Ward HR. “Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination.” BMJ Case Reports. 2012.

32. Afrin LB, et al. “Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?” International Journal of Molecular Sciences. 2022;23(2):818.

33. USPSTF. “Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.” JAMA. 2022;328(14):1438-1444. Published October 11, 2022.

34. Ibid. Endorsed instruments described in evidence report.

35. Chua KP, Volerman A, Zhang J, et al. “Trends in Antidepressant Dispensing to US Adolescents and Young Adults, 2016-2022.” Pediatrics. 2024;153(3):e2023064245. Published February 26, 2024.

36. USPSTF. “Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.” JAMA. 2016;315(4):380-387. First issued 2009; reaffirmed 2016 and October 11, 2022.

37. Johnson JG, et al. “The Patient Health Questionnaire for Adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients.” Journal of Adolescent Health. 2002;30(3):196-204.

38. State legislation on school-based mental health screening: California AB 2246 (2016); Illinois PA 100-0356; New York Mental Hygiene Law provisions. National Alliance on Mental Illness state policy database.

39. U.S. Food and Drug Administration. “Suicidality in Children and Adolescents Being Treated With Antidepressant Medications.” Black Box Warning, 2004.

40. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute. Summary report. Pediatrics. 2011;128(Suppl 5):S213-S256.

41. Kavey RE, et al. “American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood.” Circulation. 2003;107(11):1562-1566. The 1992 NHLBI guideline it replaced recommended selective screening on family-history basis only.

42. Newman TB, Pletcher MJ, Hulley SB. “Overly Aggressive New Guidelines for Lipid Screening in Children: Evidence of a Broken Process.” Pediatrics. 2012;130(2):349-352. Published online July 23, 2012.

43. Newman quoted in UCSF news release, “New Lipid Screening Guidelines for Children Overly Aggressive, UCSF Researchers Say,” July 23, 2012.

44. FDA-approved prescribing information for rosuvastatin (Crestor), simvastatin (Zocor), atorvastatin (Lipitor), pravastatin (Pravachol), and lovastatin (Mevacor). Pediatric indications and age ranges as of current labeling.

45. Lovastatin (Mevacor) FDA-approved prescribing information, Section 8.4 Pediatric Use. Simvastatin (Zocor) FDA prescribing information carries identical language regarding pediatric long-term efficacy.

46. Buonuomo PS, Macchiaiolo M, Mastrogiorgio G, et al. “Statin-associated myopathy in pediatric settings: Myth or fact?” Journal of Pediatrics. 2017;191:279.

47. Oberhoffer FS, Rieger E, Schenk S, Hauer J, Chmiel R, Steinhauser M. “Statin-associated rhabdomyolysis: an exemplary case report and a mini-review of therapeutic management.” Translational Pediatrics. 2025;14(4):763-768.

48. Vijayakanthi N, Felner EI, Romero R, et al. “Rhabdomyolysis due to rosuvastatin in a patient with ROHHAD syndrome.” Journal of Clinical Lipidology. 2021;15(6):789-792.

49. Conte C, Rousseau V, Vert C, et al. “Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.” Fundamental and Clinical Pharmacology. 2020;34(4):518-520.

50. “Familial Hypercholesterolaemia in Children and Adolescents from 48 Countries: A Cross-Sectional Study.” Lancet. 2024;403:55-66. Prevalence estimate approximately 1 in 311.

51. Flynn JT, et al. “Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.” American Academy of Pediatrics. Pediatrics. 2017;140(3):e20171904.

52. Flynn JT, et al. 2017 (see reference 52). Diagnostic pathway details in sections on confirmed hypertension evaluation.

53. American Academy of Pediatrics Council on Children with Disabilities and Section on Developmental and Behavioral Pediatrics. “Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.” Pediatrics. 2020;145(1):e20193447.

54. Guthrie W, et al. “Accuracy of Autism Screening in a Large Pediatric Network.” Pediatrics. 2019;144(4):e20183963. Positive predictive value in general population screening approximately 14-15 percent.

55. Guthrie W, et al. (2019). See reference 55. Discussion of outcome evidence and screening justification.

56. USPSTF. “Screening for Autism Spectrum Disorder in Young Children: US Preventive Services Task Force Recommendation Statement.” JAMA. 2016;315(7):691-696.

This essay is practical. Aluminum has been introduced into human food, drinking water, cosmetics, medications, and vaccines on an industrial scale since the 1890s, and the body carries no built-in route for clearing it from brain tissue. One documented route exists. The chemistry has been confirmed in radioactive-tracer studies and in peer-reviewed clinical trials. The protocol is simple, the materials are either on the supermarket shelf or on the kitchen counter, and the cost is roughly ten dollars a gallon for imported mineral water or forty-three cents a gallon for the homemade equivalent. Most readers will not have heard of either of the two researchers whose work this essay draws on. That absence is itself part of the story.

The essay operates in two registers. The author’s analytical voice sits within a terrain framework in which disease arises from toxic exposure, nutritional depletion, electromagnetic burden, and psychological strain, and the body’s processes work to restore equilibrium once the insult is removed. Terms carried over from establishment medicine, including “autoimmune,” “immune system,” and “antibodies,” appear in quotation, attribution, or published study titles. Multiple sclerosis and Alzheimer’s are referred to by their names, which is how the conditions are known, without accepting the establishment’s causal explanations for them. The case against aluminum as a toxin, built independently by Christopher Exley and Dennis Crouse over four decades of combined work, sits comfortably within the terrain frame.

In 2006, fifteen patients with Alzheimer’s disease drank up to 1.5 liters a day of a silicon-rich mineral water for twelve weeks. Three of them, twenty percent, showed clinically significant improvements in cognitive function by the end of the trial. The result was published in the Journal of Alzheimer’s Disease.¹ Christopher Exley, who ran the trial at Keele University in the United Kingdom, has issued a standing challenge for anyone to identify a pharmaceutical trial for Alzheimer’s that has produced an equivalent result. Twenty years later the challenge is still open. No pharmaceutical intervention for Alzheimer’s has matched it.

Dennis Crouse’s mother was eighty-five when she was diagnosed with mild cognitive impairment and sundowners syndrome. She could not balance her checkbook. She could not thread her sewing machine. By mid-afternoon she could not hold a conversation. Her son, a Harvard-trained chemist who had retired a year earlier, started her on one liter per day of Fiji water, which carries 146 parts per million of orthosilicic acid, and systematically eliminated her aluminum exposures. Within twelve months her MMSE scores had improved. Her sundowners stopped. Her short-term memory returned to the point that she was once again talking about things that had happened in the last few days rather than only the distant past.² She lived to ninety-seven. She did not reach end-stage Alzheimer’s.

William Miller followed the same approach and reported his results in a separate interview published in April 2025. Diagnosed with Alzheimer’s. One liter of Fiji per day. Aluminum sources eliminated. After a year on the protocol his MMSE score was 29 out of 30, which his physician described as high normal. He has stayed in that range since.¹⁷

These three accounts rest on the same chemistry. A specific form of silicon dissolved in water, orthosilicic acid or OSA, binds aluminum in the body and facilitates its excretion in urine and sweat. OSA is the only non-invasive method of removing aluminum from humans with confirming evidence that spans isotope tracer studies, peer-reviewed clinical trials, and more than a decade of self-tracked biomarker data in individual cases. The protocol is one liter a day, continued for years. The materials are either imported mineral water or a homemade equivalent at forty-three cents a US gallon. Which route to take is the only question that remains.

Audio Deep Dive (for Paid Subscribers)

The problem

Aluminum is the third most abundant element in the earth’s crust. No known organism uses it for anything. Living systems sustain themselves in the presence of enormous quantities of aluminum in rocks and soil and keep it out of their own chemistry entirely. Industrial production of aluminum metal began in the 1890s, and in the century and a quarter since, aluminum has been placed in municipal drinking water as a coagulant, in cookware, in food additives, in antiperspirants, in antacids, in vaccines as an adjuvant, in cosmetics, in medications, and in food packaging.³ The body carries no built-in route for clearing aluminum from brain tissue. Nothing in the human body is set up to remove something that was never meant to be inside it.

The exposures are chronic and additive. Approximately sixty percent of the body’s aluminum ends up stored in bone, which turns over slowly. The remainder distributes through soft tissue, with brain accumulation rising with age. Exley’s measurements show elevated aluminum in one hundred percent of brain tissue from Alzheimer’s donors, and the brain regions carrying the most aluminum show the most severe degeneration.⁴ Donors with a diagnosis of multiple sclerosis carry pathologically significant brain aluminum in at least one brain region each.⁵ Crouse’s analysis using Sir Austin Bradford Hill’s criteria for causality concludes that aluminum satisfies every criterion for being a cause of Alzheimer’s.⁶ Exley’s work, built from an entirely different starting point in fish gill toxicity and aquatic chemistry, reached the same conclusion.⁷

Reducing new exposure stops the accumulation from growing. It does nothing about what has already arrived. For that, an elimination route is required.

How the chemistry works

When rainwater percolates through rock, silicon dissolves out of the mineral matrix as orthosilicic acid, a central silicon atom bonded to four hydroxyl groups.⁸ OSA is soluble in water up to about 200 parts per million; above that, it polymerizes into solid silica. In regions where volcanic activity or recent glaciation has exposed fresh rock to weathering, surface and spring waters carry OSA at concentrations between 50 and 150 ppm. Volvic from the Auvergne volcanic region of France, Spritzer from the Malaysian highlands, Fiji from the Pacific island of Viti Levu, and Gerolsteiner from Germany all fall in this range. In heavily eroded regions, including most of the United Kingdom, most of Australia, and the eastern United States, surface and tap waters carry almost no OSA. People drinking from streams in volcanic or recently glaciated country drank OSA-rich water as a matter of daily habit. In the industrialized world, most tap water carries almost none.

OSA that reaches the gut follows water into the bloodstream. Blood plasma OSA is tightly regulated by the kidneys between 5 and 10 micromoles per liter, well below the concentration required for OSA to react with aluminum. The regulation exists for good reason. If plasma OSA rose above approximately 40 micromoles per liter throughout the body, OSA would react with aluminum hydroxide in general circulation and form solid hydroxyaluminosilicate particles in blood vessels. The homeostatic set point prevents that.⁹

In the proximal convoluted tubules of the kidney, local OSA concentration is driven higher than the systemic level by specialized membrane transporters. Local phosphate and citrate concentrations drop. Three conditions are then met simultaneously: OSA concentration above 40 micromoles per liter, pH above 4.5, and aluminum hydroxide available. Under those conditions, OSA undergoes an irreversible condensation reaction with aluminum hydroxide, forming Al-O-Si bonds and producing stable, non-toxic hydroxyaluminosilicates.¹⁰ These particles are small enough to be filtered into the pre-urine and excreted. The same process occurs in the eccrine sweat glands, which is why sweating also enhances aluminum elimination.¹¹

The arrangement is unusual. Most body regulatory systems distribute their signals widely at useful concentrations. The OSA system works the other way: it keeps OSA well below its reactive threshold everywhere in the body, and concentrates it above that threshold only at the two sites where aluminum removal happens. The reaction that would be dangerous in a blood vessel is the same reaction that is useful in a renal tubule or a sweat gland. The body solves the compartmentalization problem by preventing the reaction from occurring anywhere else.

The reaction is specific to aluminum. OSA does not bind iron, calcium, or magnesium at physiological pH, which distinguishes it sharply from classical chelators such as deferoxamine, which pulls iron out of the body alongside aluminum and requires close monitoring to prevent anemia. OSA has no such liability.

The mechanism was demonstrated in 1996 by Bellia, Birchall, and Roberts. They dosed a healthy volunteer with radioactive ²⁶Al, waited forty-eight hours for the aluminum to equilibrate with short-term tissue reservoirs, then gave the volunteer OSA in beer at 51 ppm. Plasma aluminum dropped more than fivefold within hours, with concomitant increases in urinary silicon and aluminum excretion.¹² King and colleagues confirmed the dose-response in 1997 with a more detailed protocol.¹³ Exley’s group then documented the effect in Alzheimer’s and multiple sclerosis patients in two separate clinical trials.

The question of whether OSA also acts on aluminum already deposited in brain tissue is less fully resolved. Rat studies show that oral OSA facilitates aluminum elimination from the cortex, hippocampus, striatum, cerebellum, thalamus, and olfactory bulb.¹⁴ The cognitive improvements observed in Exley’s twelve-week Alzheimer’s trial, the sustained MMSE improvements in Crouse’s mother, and the many anecdotal reports of cognitive recovery in people drinking OSA-rich water all point in the same direction. The precise transit mechanism across the blood-brain barrier has not been fully worked out, which both Crouse and Exley acknowledge. The effect is reproducible.

The evidence

Exley’s 2006 clinical trial, published in the Journal of Alzheimer’s Disease, recruited fifteen individuals with a diagnosis of Alzheimer’s together with their caregivers. All participants drank up to 1.5 liters per day of Spritzer mineral water, approximately 119 ppm OSA, for twelve weeks. At the end of the trial, three of the fifteen patients, twenty percent, showed clinically significant improvements in cognitive function as measured by standardized instruments.¹ The other twelve were cognitively stable. The challenge Exley has repeatedly issued since publication, that anyone identify a pharmaceutical Alzheimer’s trial producing an equivalent twenty percent clinically significant cognitive improvement, has not been met.

A follow-up multiple sclerosis trial recruited fifteen individuals with progressive MS. For the first twelve weeks, baseline urinary aluminum excretion was measured. The result confirmed what Exley’s group had already seen: MS patients, particularly women, excrete abnormally high amounts of aluminum, consistent with an abnormally high body burden. For the second twelve weeks, participants drank 1.5 liters per day of Spritzer. Urinary aluminum excretion rose significantly for every participant. By the final week, roughly half were beginning to show falling excretion, interpreted as the body burden beginning to decline.¹⁵ A year after the trial ended, Exley was contacted by a consultant neurologist whose patient had continued drinking silicon-rich mineral water on her own initiative. The neurologist reported that her MS was no longer progressing. The neurologist did not contact Exley again.

Crouse’s mother is the longest-running single case. Diagnosed with mild cognitive impairment and sundowners at eighty-five, started on one liter per day of Fiji water combined with systematic aluminum source elimination. Over the following year her MMSE scores improved; her sundowners resolved; her memory consolidation returned.² She continued the protocol for the remaining twelve years of her life. She died at ninety-seven without reaching end-stage Alzheimer’s.

Crouse himself, with his wife Laurie Adamson, has been drinking three to four cups per day of homemade silica water for ten years. The biomarkers are documented in his 2026 book, Discovering Magic in Water that Makes Life Possible on Earth. In their mid-seventies, their 24-hour urinary aluminum levels sit below the Mayo Clinic healthy maximum reference for adults, 0.48 micromoles per 24 hours. Their blood pressure is normal. Their high-sensitivity CRP is below 1 mg/L. Their pTau217, a blood biomarker associated with Alzheimer’s pathology, is very low.¹⁶ A reader whose case Crouse records in the book shows what happens when the protocol stops. After four years of drinking Silicade, his 24-hour urinary aluminum had come down to 0.33 μmol/24hr at age sixty-seven, in the healthy young-adult range. He stopped drinking the water for a year, and the level doubled to 0.67. He restarted.

Beyond the trials and the named cases in the opening, Crouse has collected a substantial body of reader-reported outcomes. An eighty-nine-year-old man with Alzheimer’s goes from MMSE 19 to MMSE 25 after two months on 32 ounces per day of Fiji water. A woman diagnosed in 2020 describes six weeks on Fiji water producing a sense that her brain was starting to work more smoothly. A European reader on Volvic for six months reports the sensation that a fog had lifted. A seventy-year-old father whose memory had deteriorated to the point of not knowing where he was while driving returns to normal within a week on silica water combined with aluminum source elimination.¹⁸ These are not controlled trials. What they report matches the published trial results, lines up with the chemistry, and lines up with the pattern across other cases.

A twelve-week trial in which twenty percent of Alzheimer’s patients drinking silicon-rich mineral water showed cognitive improvement is the single most striking published result in the entire Alzheimer’s clinical literature. It has never been scaled up because funding for scaling it up has never been granted. Exley attempted to secure such funding and was blocked at every turn, including by Danone, Volvic’s parent company, which signed a research contract with Keele University and then pulled out six months later with no stated reason beyond a reference to Danone’s “other research on Alzheimer’s disease.”¹⁹ The gap between what has been demonstrated and what has been pursued is itself one of the clearest pieces of evidence in this field.

Three of fifteen patients in Exley’s twelve-week Alzheimer’s trial showed cognitive improvement. Twelve did not. Crouse’s mother did not recover her prior cognition; she stopped deteriorating and preserved what she had. William Miller did recover to high normal, on a protocol he has sustained for years. The pattern across the trials, the long cases, and the reader reports is consistent: OSA intake reliably reduces body aluminum burden in those who stay on the protocol, and cognitive outcomes depend on how much damage has already accumulated and how long the protocol runs. The intervention is a sustained aluminum-management strategy. It is not a short-course cure. The narrower claim is the one the evidence supports, and it is enough to act on.

What does not work

OSA is specific. Not all forms of silicon in water, food, or supplements convert to OSA at concentrations sufficient to react with aluminum. Exley is explicit on this point. Silica supplements that claim to remove aluminum are, in his view, selling a story that peer-reviewed evidence does not support, and the fact that several such supplements cite his research in their marketing material is one of the standing irritations of his working life.²⁰

Crouse has tested fourteen silica supplements in his own laboratory using the Coradin blue silicomolybdic spectrophotometric assay to measure OSA release under simulated gastric conditions. Most released too little OSA to be useful. Choline-stabilized OSA, which is the most commonly marketed OSA supplement, has approximately 17 percent bioavailability compared with 43 percent for OSA in mineral water, and the dosing recommendation of ten drops a day delivers only a small fraction of the OSA in a single liter of Fiji. Crouse’s mother took choline-stabilized OSA for a year with no observable improvement before being switched to Fiji water.²¹

Sodium meta-silicate, sold as Metso Pentabead 10 by the PQ Corporation, polymerizes in water at pH 6.5 and will not form OSA at the concentration required.²² Colloidal silica, diatomaceous earth, and silica supplements based on insoluble silicon dioxide do not release OSA at useful concentrations. Horsetail and bamboo-extract silicon products have not been shown to deliver measurable OSA to the bloodstream.

Three sources have been demonstrated to work: natural mineral waters with OSA above approximately 30 ppm, Crouse’s homemade silica water, and beer, which is where the Bellia-Birchall-Roberts study first demonstrated the effect in 1996 and which is not recommended as the primary vehicle for obvious reasons.

Exposure reduction, the other pillar

Both Exley and Crouse treat exposure reduction and OSA intake as co-equal. Drinking a liter a day of Fiji water while continuing to cook in aluminum pans, apply aluminum antiperspirant daily, eat baked goods raised with aluminum phosphate, and drink from aluminum cans is pouring water into a bucket with a hole in it. The hole has to be closed first, or at least substantially narrowed, for OSA intake to do its real work.

The sources, roughly ranked by typical daily exposure load:

Municipal drinking water. Most urban water supplies add aluminum salts (alum, sodium aluminate, or polyaluminum chloride) as coagulants to settle out organic matter. The US EPA's secondary standard caps aluminum in drinking water at 200 ppb, though 180 ppb has been shown to roughly double Alzheimer's risk.²³ Residual aluminum sits in the water that comes out of the kitchen faucet. Filtering through a Brita pitcher removes a portion of this; filtering at pH 4 to 5, as in the Silicade preparation below, removes substantially more. A bone char filter downstream of a Brita removes fluoride and arsenic without removing OSA. One category of fluoride filter to avoid: activated-alumina filters, including the Berkey PF-2 and similar products, use aluminum oxide as the removal medium. Fluoride in the input water reacts with the alumina and releases aluminum fluorides into the output, so the filter adds aluminum rather than removing it, and the effect is worse the more fluoride is in the input. These should not be used anywhere in a drinking-water system where aluminum reduction is the goal, and should especially not be used in combination with silica water. Fluoride in drinking water is itself a problem because fluoride increases the absorption of aluminum across the gut, which is Exley's explanation for most of fluoride's documented cognitive toxicity.²⁴

Aluminum cookware. Aluminum pots, pans, baking trays, and foil leach aluminum into food, particularly when the food is acidic (tomato sauce, lemon-based marinades, vinegar-based dressings) or salted. Cast iron, stainless steel, ceramic, and glass alternatives are available. Discard aluminum foil for cooking and food storage; parchment paper and glass containers do the same jobs. Non-stick cookware with intact coatings is safer than bare aluminum, but any scratch exposes the metal beneath.²⁵

Antiperspirants. Antiperspirants (as distinct from deodorants) are aluminum chlorohydrate, aluminum zirconium tetrachlorohydrex glycine, or similar aluminum salts, formulated specifically to be absorbed through skin and plug sweat ducts. "Natural" crystal deodorants marketed as safer alternatives are typically potassium alum (potassium aluminum sulfate) and deliver aluminum through the same route. Exley's measurements show accumulated aluminum in the upper outer quadrant of breast tissue from mastectomies, the region closest to the axilla where antiperspirant is applied. His published work on young regular users of antiperspirants shows an elevated risk of breast cancer.²⁶ Genuinely aluminum-free deodorants are widely available, but the label is essential: the word "natural" on its own does not mean aluminum-free. The daily use of an aluminum antiperspirant is one of the heaviest sustained exposures most adults experience.

Baking powder and commercially baked goods. Sodium aluminum phosphate is the leavening agent in most commercial baking powder and in the great majority of commercially baked goods. Rumford, Bob’s Red Mill, Clabber Girl’s aluminum-free line, and Hain Pure Foods make aluminum-free baking powder. Many store-bought cakes, muffins, and breads list only “leavening” on the label without specifying; the safer assumption is that any such product contains it.

Antacids. Aluminum hydroxide is a common active ingredient in over-the-counter antacids (Maalox, Mylanta, some Gaviscon formulations) and in prescription drugs for peptic ulcers. In gastric acid, aluminum hydroxide releases aluminum ions, which absorb across the gut. Exley’s unpublished analysis of UK General Practitioners Research Database data found that children prescribed an antacid before age six were 69 percent more likely to be diagnosed with an allergy; Exley describes this as a “look-and-see exercise” rather than a formal study.²⁷ Aluminum-free alternatives (calcium carbonate, magnesium hydroxide) are widely available.

Food coloring and processed foods. Aluminum lakes (chemical variants of aluminum hydroxide bonded to a dye) are the colorants in blue and purple sweets, in cake decorations, in processed cheese slices, and in some pharmaceutical coatings. Aluminum salts are added to milk powders to prevent clumping. Modified food starch in processed foods often contains aluminum starch octenylsuccinate. Reading labels catches most of these; eating fewer processed foods catches more.

Aluminum cans and foil-lined packaging. Soft drinks, beer, and juice sold in aluminum cans leach aluminum into the liquid, more so if the can is dented or has been stored for a long period. Foil-lined cardboard cartons present a similar issue over the shelf life. Glass bottles are the clean choice.

Vaccines. Aluminum adjuvants (aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate) are present in a wide range of childhood and adult vaccines. Injected intramuscularly, this aluminum bypasses the gut and bypasses first-pass metabolism by the liver. Exley’s published work on vaccine aluminum, and the body of research from Angrand and colleagues published in Toxics and other journals in 2022 and 2025, documents the toxicological consequences in detail.²⁸,²⁹ Reducing exposure from this source is harder than from the others and requires a conversation with a provider that goes well beyond label-reading.

Smaller sources. Aluminum salts appear in sunscreens, lipsticks, and a range of cosmetics as processing aids or active ingredients. Lipsticks in particular reach a surface that is routinely licked, swallowed, or kissed; aluminum-free alternatives exist. Some dental cements, implant surfaces, and craniofacial prostheses contain or leach aluminum, and titanium alloys, zirconia, or aluminum-free cements are the better options where they are available.

Laurie Adamson has compiled a working list of aluminum sources and recommended alternatives on the Crouse website at prevent-alzheimers-autism-stroke.com. Exley’s substack covers much of the same material from a UK and European starting point. The practical sequence is to identify the sources used daily first and replace them, then work through the sources used weekly or occasionally. The order matters because daily exposures do most of the damage. The water does the rest once the exposures have been reduced.

Where to buy, and what to look for

Exley’s practical recommendation for everyday use is a mineral water with silicon content above 30 mg/L when expressed as silica, or above 14 mg/L when expressed as silicon or silicic acid, drunk at approximately one liter per day.³⁰

Fiji water. 146 ppm OSA, labeled as 93 mg/L silica on the bottle. Sourced from an artesian aquifer in Viti Levu that filters through volcanic rock. Widely available in US and Canadian grocery stores and online. Current retail runs roughly two to three dollars per liter, which makes daily use expensive over a multi-year protocol.

Volvic. 51 ppm OSA. Sourced from the Auvergne volcanic region of France. This is the water Exley used in his first proof-of-concept trial.⁷ Widely available in the United Kingdom and continental Europe, selectively available in the United States. A liter of Volvic delivers roughly a third of the OSA of a liter of Fiji, so a larger daily volume is required for equivalent effect.

Spritzer and Acilis. Approximately 119 ppm OSA. Spritzer is the Malaysian mineral water Exley used in both his Alzheimer’s and MS clinical trials.¹,¹⁵ In the United Kingdom, Europe, and South Africa it is imported and sold under the name Acilis by SilicaWaters Ltd, a social enterprise run by Rex Garratt. Acilis is explicitly marketed with Exley’s clinical trial evidence behind it.³¹

Gerolsteiner. Approximately 64 ppm OSA. German, widely available across Europe, selectively available in North America. The high overall mineral content also makes it a useful calcium and magnesium source.

Various smaller spring waters in Iceland, Norway, Poland, and parts of central Europe carry high OSA concentrations and are regionally available. Appendix I of Crouse’s 2026 book has a complete international table of OSA content across commercially available mineral waters.¹⁶

For Australian readers specifically, the commercial options are limited. Most Australian spring waters are drawn from aged geology and carry low OSA. Fiji is the main commercially available option carrying clinically relevant OSA, and even that comes at a substantial price per liter sustained over years. The accessibility question is one of the reasons Crouse developed a homemade route.

Exley says you cannot make it. Crouse has been making it for ten years.

Exley and Crouse agree on the mechanism, on the evidence from the clinical trials, on the futility of silica supplements, on the preventative value of daily silicon-rich water, and on the primary indications where OSA intake is useful. Crouse’s first book, Preventing Alzheimer’s, Autism, and Stroke, was peer-reviewed by Exley prior to publication. The alignment on the science is substantial.

The disagreement is on whether a person can safely make silicon-rich water at home.

Exley’s position is categorical. From the final chapter of Imagine You Are an Aluminum Atom: “Specifically relating to safety, I want to take this opportunity to warn you against suggestions on the Internet that you can make your own silicon-rich mineral water. You cannot. Preparation of something equivalent to a silicon-rich mineral water requires sophisticated laboratory equipment. In my laboratory we prepare water that is high in dissolved silicon, silicic acid, for research purposes. However, under no circumstances would I advocate drinking this water. Unless water is made or bottled under conditions that have been proven to be biologically safe, you cannot produce a drinking water that is safe for human consumption. Even in a sophisticated laboratory such as my own. Do not believe what you read and watch on the Internet: you cannot make a silicon-rich mineral water. Only Nature can do this.”³²

Crouse’s position is that Exley is wrong on this point, and that he has demonstrated it is wrong over a decade of self-tracked biomarker data. In 2012 he built a laboratory to measure aluminum down to parts per billion and OSA down to parts per million. He tested a range of sodium silicate preparations and identified one specific formulation, low-alkalinity hydrous sodium silicate powder manufactured by the PQ Corporation under the name Product G, which is used worldwide to add silicate to drinking water under American Water Works Association Standard B104-98.¹⁶ The powder is 99.5 percent pure, is sold through chemical supply houses, and is safe to measure and handle with standard kitchen tools. Crouse’s recipe uses this powder together with sodium bisulfate, a swimming-pool pH adjuster also sold on Amazon by LoudWolf. The result is one US gallon of water containing 127 ppm OSA at output, rising to a stable 146 ppm after 72 hours. The cost per gallon is approximately forty-three cents and the active work time is about five minutes. He and his wife Laurie have been drinking it, three to four cups per day, for ten years.

Crouse's own view on water glass, from an eighth-grade experiment lining a flowerpot furnace with hardware-store water glass, is that the liquid form is hard to measure accurately with kitchen tools and dangerous to clean up after a spill. His recipe uses a low-alkalinity powder instead. His laboratory testing of other silicate preparations, including the case of sodium meta-silicate (Metso Pentabead 10), found that most do not release OSA at the concentrations required because they polymerize at or near neutral pH. One specific formulation does, and that is the one his recipe uses.

Exley’s warning assumes that the person reading it will attempt to use water glass or an uncharacterized silicate from an undocumented source. If that were the only route, the warning would be justified. Crouse’s recipe uses a specific drinking-water-grade product at specific pH steps with specific filtration to remove the small amount of residual aluminum introduced by the ingredients and the tap water base. His biomarker data, including 24-hour urinary aluminum below the Mayo Clinic healthy reference after ten years of use, is the strongest available answer to the question of whether the resulting water is safe to drink long-term.

A reader weighing this disagreement has three options: buy a documented silicon-rich mineral water and accept the cost; make silica water at home using Crouse’s recipe, published free on his website and demonstrated step by step in his YouTube video; or do nothing. The third option is a decision to leave the aluminum already in the body where it is. For readers in markets where imported mineral waters are expensive or scarce, which includes most of Australia, the home-preparation route is the only practical answer to a protocol that has to continue for years.

Crouse has written two books on this subject. His 2016 book, Preventing Alzheimer's, Autism, and Stroke, laid out the foundational case for aluminum as a cause of neurological disease. His 2026 book, Discovering Magic in Water that Makes Life Possible on Earth, is the culmination of his life's work on this subject and the authoritative source for the full chemistry, the biomarker data, and the recipe with all its options and troubleshooting notes. Readers new to his work can start with either. Buying either supports his continued work: [BOOK LINK 2026] and [BOOK LINK 2016].

How to make silica water at home: Crouse’s recipe

What follows is Crouse’s own recipe, published free on his website at prevent-alzheimers-autism-stroke.com and demonstrated step by step in his YouTube video. It is reproduced here so readers have the procedure in one place with the essay. Readers planning to make Silicade should treat Crouse’s 2026 book, Discovering Magic in Water that Makes Life Possible on Earth, as the authoritative source: it contains the complete chemistry, the impurity tables, the troubleshooting notes, the testing protocols, and detail that cannot be fitted into an essay-length summary. Buying the book supports his continued work:

Ingredients

Low-alkalinity hydrous sodium silicate powder, 99.5 percent pure, with an SiO₂ to Na₂O ratio of 3.22. This is PQ Corporation’s Product G, sold through ChemicalStore.com or Zchemicals.com in 2-, 10-, or 50-pound containers. Order “sodium silicate, low alkalinity.” Do not order “sodium silicate, alkaline” and do not use sodium meta-silicate (sold as Metso Pentabead 10).

Sodium bisulfate (also called sodium hydrogen sulfate), 99.5 percent pure, as microprills (small round beads). The recommended source is Professor Fullwood’s product sold by LoudWolf Ltd on Amazon.

Baking soda, standard grocery-store sodium bicarbonate.

Tools

A set of mini measuring spoons including a dash (1/8 teaspoon) and a smidgen (1/32 teaspoon). Crouse recommends Beryler, Yellrin, or Dostien sets because other brands and antique spoons are not reliably calibrated.

A 1-cup Pyrex measuring cup.

A 1-gallon container with a 1-gallon mark.

A pitcher-style Brita filter with a standard filter, a refillable Brita filter, or a Brita Maxtra+ filter. These three remove aluminum at low pH without removing OSA.

A spatula for leveling the spoons, and a stirring utensil.

The steps

1. Place one level dash and two level smidgens of sodium silicate powder (3/16 teaspoon total, approximately 600 mg) into the Pyrex cup.

2. Add 1/8 cup of tap water. Do not add more water at this stage; higher volume lowers the pH and reduces the silicate’s solubility.

3. Heat to boiling in the microwave or on the stovetop and boil for 30 seconds. Small insoluble residue is normal; the powder is 99.5 percent soluble sodium silicate and 0.5 percent insoluble impurity.

4. Dilute immediately with a small amount of cool tap water.

5. Pour the full contents of the Pyrex cup into the 1-gallon container.

6. Fill the gallon container to the mark with unheated tap water. The resulting solution is OSA at approximately pH 9.8.

7. Add one level dash (approximately 830 mg) of sodium bisulfate microprills. This acidifies the solution to pH 4 to 5. If the tap water is unusually alkaline (above pH 8.5), use a pH meter to add a little more sodium bisulfate until the pH reaches 4.0 to 5.0.

8. Stir thoroughly, then pour the acidified solution through the Brita pitcher filter. At pH 4 to 5, aluminum from the tap water and the ingredients is in a form the Brita filter removes. Above pH 5 it is not. This step is critical. Skipping it leaves residual aluminum in the finished product.

9. Add two level smidgens of baking soda to the filtered gallon. This brings the pH back up to approximately 6.5, which is comfortable to drink and stable in storage.

10. Stir to dissolve.

11. Store in the dark at room temperature or in the refrigerator. Freshly made Silicade contains approximately 127 ppm OSA. The concentration rises and stabilizes at 146 ppm after 72 hours at room temperature, and remains at that level for years.

Why each step matters

The boiling step in step 3 gets sodium silicate into solution; sodium silicate does not dissolve in cold tap water. The 1/8 cup limit in step 2 is because higher water volumes drop the pH during boiling and prevent the silicate from dissolving.

The acidification in step 7 serves two purposes. It brings the solution into a stable OSA concentration well below OSA’s saturation level, which prevents polymerization into solid silica. More importantly for the finished product’s safety, it converts any aluminum present (from the ingredients, from the tap water) into a labile form that the Brita filter removes in step 8.

The filtration step brings the aluminum level down to a safe range. Starting from tap water containing up to 42 micrograms per liter of aluminum, the Brita filter operating at pH 4 to 5 reduces aluminum in the finished Silicade to less than 10 micrograms per liter. The US EPA’s secondary standard for aluminum in drinking water, by comparison, is 200 micrograms per liter.¹⁶

The baking soda addition in step 9 neutralizes the acidity back to drinking pH without reversing any of the previous steps.

What not to do

Do not use distilled, deionized, or reverse osmosis water as the base. The trace minerals in tap water matter for the finished product’s electrolyte profile.

Do not use liquid water glass. Do not use sodium meta-silicate. Do not skip the Brita filtration step.

Do not heat the finished water above approximately 94°C / 202°F. Above that temperature, OSA concentrates at nucleate boiling sites and crystallizes on surfaces, which depletes the solution. For coffee or tea, keep the brewing temperature at or below this limit. And do not brew in an aluminum coffee maker, which will add aluminum back to the water you just took the trouble to filter out of.

Optional additions

If local tap water is low in calcium, two level dashes of calcium chloride (99 percent pure, from LoudWolf on Amazon) raise calcium by 80 ppm. Calcium above 75 ppm has a documented protective effect on cognition.¹⁶

If local tap water is low in magnesium, a dash of magnesium chloride hexahydrate (also from LoudWolf) raises magnesium by 20 ppm.

For a sparkling version, carbonate the finished water. The result is a pH 4.5 sparkling beverage.

Sourcing outside the United States

The suppliers Crouse names are based in the United States. ChemicalStore.com and ZChemicals.com ship PQ Product G sodium silicate internationally. LoudWolf’s sodium bisulfate, calcium chloride, and magnesium chloride are sold through Amazon in Australia, the United Kingdom, Canada, and most European markets. Brita pitcher filters are widely available locally in Australia, the UK, and continental Europe. Local chemical supply houses sometimes carry drinking-water-grade sodium silicate, but the specific low-alkalinity PQ Product G that Crouse validated and tested is worth sourcing from the named US suppliers rather than substituting an uncharacterized local product. The main variable is shipping cost on the chemicals; a 2-pound container of sodium silicate is enough for several hundred gallons of Silicade and lasts a household years, so the per-gallon cost including international shipping remains well below the price of a liter of Fiji.

How much, how often, for how long

Exley and Crouse agree that approximately one liter per day is the target intake. They differ slightly on timing.

Exley recommends one liter of silicon-rich mineral water per day, taken either in several small volumes throughout the day or in two or three larger volumes. He drinks one bottle of Acilis per day himself. His framing is explicit: “I consider silicon-rich mineral waters as a philosophy for living in the Aluminum Age as opposed to a classical ‘detox’ therapy for aluminum.”³³

Crouse recommends three to four cups per day of OSA-rich water, taken around mealtimes, based on measured OSA kinetics. The functional half-life of OSA’s aluminum-removing activity is approximately two hours. Spreading the dose maintains elevated OSA at the renal tubules for a longer fraction of the day than a single large volume does. Three to four cups of silica water per day delivers roughly seven to ten times the OSA intake that was shown in Rondeau’s French epidemiological study to reduce Alzheimer’s risk by a factor of 0.69.³⁴

Both schedules work. The Crouse schedule is slightly more efficient on paper and matters more for someone with a known heavy body burden.

The time course is years, not weeks or months. Approximately sixty percent of the body’s aluminum is stored in bone, which turns over slowly. In an elderly person who has accumulated aluminum over seventy or eighty years, bringing 24-hour urinary aluminum below the Mayo Clinic healthy reference of 0.48 micromoles per 24 hours is a six-to-ten-year project. Crouse and his wife reached that reference level after approximately that interval of consistent daily use.¹⁶

The relevant biomarker for tracking progress is 24-hour urinary aluminum. In the United States, Quest Diagnostics offers the test with a doctor’s prescription; one reader of Crouse’s used Quest for exactly this purpose and documented a measurable drop in aluminum after four months on three to four cups of Fiji per day. In other markets, functional medicine practitioners can order the test through specialty laboratories. Hair aluminum is not a reliable biomarker; Exley’s position is that aluminum in hair reflects external contamination from shampoos, dyes, and conditioners more than it reflects body burden.³⁵

In the first few weeks of starting silicon-rich water, urinary aluminum excretion will rise as OSA begins pulling aluminum out of the blood and short-term tissue reservoirs. This has been documented in healthy volunteers, in Alzheimer’s patients, and in MS patients. Cognitive improvement, where it occurs, has shown up at twelve weeks in roughly one in five Alzheimer’s patients in Exley’s trial. In Crouse’s documented cases, improvements in sundowners, in driving ability, in short-term memory, and in daily function often appear in the first one to three months, with more substantial change over six to twelve months. The protocol has to continue after the first visible improvement; stopping drops OSA levels back to baseline within hours, and bone-stored aluminum gradually redistributes into soft tissue if the elimination pressure is removed.

The whole protocol sits on top of exposure reduction, not in place of it. Water removing aluminum while the sources keep delivering more cancels out. Reduce the exposure, then drink the water, every day, for years.

Closing

One liter a day, for years, tracked by 24-hour urinary aluminum. The chemistry was established in isotope studies in 1996 and reproduced in a peer-reviewed Alzheimer’s clinical trial in 2006 in which twenty percent of participants recorded clinically significant cognitive improvement. Twenty years later, no funded replication has been attempted. The silence from the funding bodies is itself a form of evidence about which research questions are permitted and which are not.

Crouse’s mother was eighty-five when she was told she would die of Alzheimer’s. She lived to ninety-seven. She was still herself.

How to Explain It to a Six-Year-Old

A bad metal called aluminum gets into people a little at a time, from food and water and from the stuff grown-ups put under their arms. It is too small to see, but it builds up. When too much of it builds up in your head, it makes it harder for grown-ups to remember things.

A special kind of water comes out of some rocks. It has tiny invisible pieces in it that fit onto aluminum like a key fits into a lock. The pieces do not fit onto anything else in your body, only aluminum. When you drink the water, the pieces travel through you, find the aluminum, and lock onto it. Once they are locked together, they make a new tiny thing that goes down the pipes when you go to the bathroom.

If you drink this water every day for a long time, more and more of the bad metal leaves. That is why some grandmas and grandpas who were starting to forget things started to remember them again.

References

1. Exley C, Korchazhkina O, Job D, Strekopytov S, Polwart A, Crome P. “Non-invasive therapy to reduce the body burden of aluminium in Alzheimer’s disease.” Journal of Alzheimer’s Disease 10, no. 1 (2006): 17–24.

2. Interview with Dennis N. Crouse, PhD. Unbekoming, September 4, 2024. https://www.unbekoming.com

3. Exley, Christopher. Imagine You Are an Aluminum Atom: Discussions with Mr. Aluminum. Chapter 8, “Live Safely and Effectively in the Aluminum Age.”

4. Mold M, Umar D, King A, Exley C. “Aluminium in brain tissue in familial Alzheimer’s disease.” Journal of Trace Elements in Medicine and Biology 40 (March 2017): 30–36.

5. Exley C. Quantitative and qualitative measurements of aluminum in brain tissue from donors with multiple sclerosis, as reported in Imagine You Are an Aluminum Atom, chapter on multiple sclerosis.

6. Crouse, Dennis N. Preventing Alzheimer’s, Autism, and Stroke (2016). Application of Bradford Hill’s criteria to aluminum and Alzheimer’s.

7. Birchall JD, Exley C, Chappell JS, Phillips MJ. “Acute toxicity of aluminium to fish eliminated in silicon-rich acid waters.” Nature 338 (March 9, 1989): 146–148.

8. Exley C, Guerriero G, Lopez X. “Silicic acid: The omniscient molecule.” Science of The Total Environment 665 (May 15, 2019): 432–437.

9. Crouse, Dennis N. Discovering Magic in Water that Makes Life Possible on Earth (2026). Chapter 2, on OSA homeostasis and plasma regulation.

10. Beardmore J, Lopez X, Mujika JI, Exley C. “What is the mechanism of formation of hydroxyaluminosilicates?” Scientific Reports 6 (August 1, 2016): 30913.

11. Crouse, Dennis N. Discovering Magic in Water that Makes Life Possible on Earth (2026). Chapter 3, on sweat gland OSA transport.

12. Bellia JP, Birchall JD, Roberts NB. “Beer: a dietary source of silicon and its effect on aluminium absorption and excretion in man.” Study with radioactive ²⁶Al tracer, 1996.

13. King SJ, et al. Confirmation of OSA dose-response for aluminum excretion, 1997.

14. Rat brain OSA studies showing aluminum elimination from six brain regions, as reviewed in Crouse 2026, chapter 6.

15. Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S, Polwart A, Hawkins C. “Elevated urinary excretion of aluminium and iron in multiple sclerosis.” Multiple Sclerosis Journal 12 (2006): 533–540. Follow-up MS trial reported in EBioMedicine.

16. Crouse, Dennis N. Discovering Magic in Water that Makes Life Possible on Earth (2026). Chapter 7 (recipe and biomarker data) and Chapter 10 (ADOR calculation and Mayo Clinic reference).

17. Interview with William Miller: Defying Alzheimer’s: One Man’s Triumph Over a Trillion-Dollar Lie. Unbekoming, April 25, 2025.

18. Reader-reported cases collected in Crouse, Discovering Magic in Water (2026), chapter on anecdotal cognitive improvements.

19. Exley, Christopher. Imagine You Are an Aluminum Atom. Account of the Danone/Volvic research contract and its termination.

20. Exley, Christopher. Imagine You Are an Aluminum Atom. Warning on silica supplements and groundless citations of his research.

21. Interview with Dennis N. Crouse, PhD (No. 2). Unbekoming, March 24, 2026. On supplement testing and choline-stabilized OSA bioavailability.

22. Crouse, Discovering Magic in Water (2026). Chapter 7, warning on sodium meta-silicate.

23. Crouse, Discovering Magic in Water (2026). Chapter 10, aluminum dose-response for Alzheimer’s risk at 180 ppb in drinking water.

24. Interview with Dr. Christopher Exley. Unbekoming, April 6, 2024. On fluoride-aluminum interaction.

25. Exley, Christopher. Imagine You Are an Aluminum Atom. Chapter 8, on cookware.

26. Linhart C, Talasz H, Morandi EM, Exley C, Lindner HH, Taucher S, Egle D, Brunner C, Concin N. “Use of underarm cosmetic products in relation to risk of breast cancer: a case-control study.” EBioMedicine 21 (July 2017): 79–85.

27. Exley, Christopher. UK General Practitioners Research Database analysis of antacid prescriptions and childhood allergy diagnoses, reported in Imagine You Are an Aluminum Atom.

28. Angrand L, et al. 2022 paper on aluminum adjuvants published in Toxics.

29. Angrand L, et al. 2025 paper on aluminum adjuvants and neurological outcomes.

30. Exley, Christopher. Imagine You Are an Aluminum Atom. Silicon Fact Sheet, dosing recommendations.

31. SilicaWaters Ltd (UK). Acilis mineral water product information. https://www.silicawaters.com

32. Exley, Christopher. Imagine You Are an Aluminum Atom. Warning against homemade silicon-rich water, final chapter.

33. Exley, Christopher. Imagine You Are an Aluminum Atom. Framing of silicon-rich mineral water as a daily practice.

34. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. “Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort.” American Journal of Epidemiology 169, no. 4 (February 2009): 489–496.

35. Exley, Christopher. Imagine You Are an Aluminum Atom. Chapter on aluminum testing in hair, blood, and urine.

Most of the writing against childhood vaccination operates in the mode of telling. The ingredient lists. The documented harms. The corrupted trials. The captured regulators. The record is there, it is damning, and the writers who have done that work over the decades have done it well. The poisoning argument is true. It is also what has moved most of the people who are already with us. Without the telling, no one would be in the room at all.

What I have tried to bring to this space is the complement: showing. The reveal of the unvaccinated cohort as the healthiest group of children in the country, not the sickest. Parents on camera describing their own children. The data from four independent studies, presented as it stands, not interpreted into submission. Showing works where telling has stopped working. Not because telling is wrong. Because the audience we are now trying to reach has heard the telling, has already decided what to do with it, and needs something else to open the question again.

The establishment story on vaccination is simple. Vaccines are how children stay healthy. Without them, children are sick, disabled, and dying. The schedule is the floor beneath which no responsible parent would let their child fall.

If that story is true, then the unvaccinated cohort is the sickest, most disabled, most at-risk group of children in the country. That is the testable claim buried inside the establishment position. It is not an edge case. It is the central prediction of the entire framework.

The claim is not merely untested. It is inverted. The unvaccinated cohort is not the sickest. It is dramatically the healthiest. Four independent studies, across different methodologies, different populations, and different decades, all arrive at the same picture. One of them was presented to the United States Senate one year ago this week. The parents of those children, filmed in the final twenty-one minutes of Vaxxed 2, are not describing marginal differences. They are describing children the surrounding culture has forgotten are possible.

That inversion is the argument. Not that the vials are full of poisons, though they are. Not that the trials were corrupted, though they were. The argument is that the cohort the establishment implicitly promised would be the sickest, is in fact the healthiest, and that this one fact collapses the moral authority of the entire schedule.

I believe this is the most effective way to communicate with the curious middle. The parent who has not vaccinated yet. The parent who stopped partway. The parent who feels the question has not actually been answered, only pronounced upon. They do not need another list of toxins. They need to see the children who were spared.

Everything below is for that person, in the order I would walk them through it.

1. Watch the 42-minute presentation above.

The 42-minute presentation on The Unvaccinated, recently delivered and now free for anyone to watch. It sits in the masthead at the top of this post. The presentation walks through the four independent studies that converge on the same picture, the mechanism by which the central question has been avoided for a hundred years, the inversion at the heart of the establishment claim about the unvaccinated cohort, and the strategic position of the vitamin K shot as the first injection in the childhood schedule. Forty-two minutes of continuous argument, delivered as a single piece.

Of everything on this page, the presentation is the shortest path into the full argument. The essays below develop specific pieces of the case. The digital book and the paperback build it out at length. The Garner interview takes the reader to the source. The presentation compresses all of it into one shareable artifact that costs the viewer nothing, requires no login, and asks no commitment beyond the forty-two minutes it takes to watch. For most readers landing on this page, this is where the body of work makes its strongest first impression. If you watch nothing else today, watch this. If you share nothing else from this post, share this.

2. Watch the last twenty-one minutes of Vaxxed 2.

The vital appendix to the presentation above. Vaxxed 2: The People's Truth is the 2019 follow-up to the original Vaxxed documentary. The last twenty-one minutes are the piece that matters for this body of work. Parents of unvaccinated children, one family at a time, sitting for the camera and describing what their children are actually like. The calm. The focus. The groundedness. The absence of the conditions the surrounding culture now treats as unremarkable features of childhood. The footage does its own work. It is testimony. Twenty-one minutes of film.

Of everything on this page, this is the resource that embodies the showing frame most completely, and it is the one that completes the presentation above. There is no number to debate, no study to pick apart, no author to attack. There are only parents and their children, and the viewer’s own capacity to see what is in front of them. For the parent in the curious middle who has read enough telling to last a lifetime, this is the piece that opens the question again. I have never been able to improve on it with words. Twenty-one minutes of film does what writing on this subject cannot.

3. Read “The Vaccinated 60% vs. Unvaccinated 2.64%.”

The essay introduces the Control Group Survey, conducted by Joy Garner across forty-eight states and published in 2022. The survey did what the Centers for Disease Control, the Food and Drug Administration, and the National Institutes of Health have declined to do for decades. It compared the health outcomes of vaccinated Americans against those of people who had never been vaccinated. The result was a chronic condition prevalence of sixty percent in the vaccinated adult population, against two point six four percent in those with zero exposures. A tenfold difference. Published on this Substack in September 2024.

If you are going to persuade someone of only one thing on this subject, this is the number. Sixty versus two point six four. It is simple enough to repeat in a conversation at a dinner table, specific enough to withstand a search for its source, and large enough that no argument about methodology or sample bias can reduce it to noise. Everything else in this post builds around it. If the person you are trying to reach has fifteen minutes to spend before they move on with their day, send them this essay. It is the shortest written path into the full argument.

4. Read “The Unvaccinated: Proof of What We Lost.”

Published August 2025. Where the 60% versus 2.64% essay establishes the headline number, this essay develops what the number means. It is longer, slower, and asks more of the reader. The headline essay introduces the finding. This essay sits with it. It takes the reader past the shock of the comparison and into what it implies about the state of health in the vaccinated population, and about the children who were spared it. For readers who want the fuller argument around the central number, and the breathing room to absorb what it says about the condition of a generation, this is where it lives.

This is the most-read essay I have written on vaccination. It reaches readers the headline essay primes but does not satisfy, the reader who has registered the shock of sixty versus two point six four and wants to understand how it is possible. The essay does not argue for the data. It arranges it. It presents what is already there and lets the reader see it. The reader who finishes it does not need to be told what to think. They have already seen it. This is the piece most likely to turn a sympathetic reader into a committed one, and the one most responsible for whatever reach this body of work has achieved.

5. Read my October 2024 interview with Joy Garner.

Joy Garner is the researcher behind the Control Group Survey, the survey the federal health agencies have declined to conduct for a hundred years, and that produced the sixty versus two point six four number. In October 2024, I interviewed her for this Substack. The format is written, not video. Garner takes the reader through why she ran the survey, how it came together, and what the data actually shows. It is the primary source conversation on the central number in this entire body of work: her own account, in her own words, of how the study came to exist and what it means.

For the reader who has encountered the number through the two essays above and wants to go to the source, this interview is that source. It is the difference between reading a report of a conversation and sitting in on the conversation itself. Garner is not a researcher trying to protect her reputation inside an establishment framework. She did the work precisely because that framework refused to. The interview matters because the number matters, and the number matters because of the person who had the independence of mind to produce it. Readers who go here come away understanding that the Control Group Survey is not a dataset. It is an act of refusal.

6. Download The Unvaccinated as a free digital book.

Published May 2025. Everything the essays above cover, assembled as a book. The PDF is free. It gathers the Control Group Survey findings, the surrounding evidence, and the broader argument about the unvaccinated cohort into a single document the reader can hold, annotate, print, or forward. For the reader who prefers long-form over the pace of a Substack feed, or who wants a single file they can send to another parent without asking that parent to subscribe to anything or follow a sequence of links, this is the format.

A book is a different commitment than an essay. The reader who downloads a book has signaled, by doing so, that they are prepared to spend serious time with the material. That changes what the book can do that the essays cannot. It can build the full case at its own pace. It can repeat the central move, show not tell, across chapters and across evidence streams until the pattern becomes undeniable. The free PDF exists because this work should not be gated by whether a reader can afford a book or can be convinced to buy one. For many readers, the digital book is the first place they encounter the full argument intact.

7. Order The Unvaccinated paperback.

The paperback edition of The Unvaccinated, available on Lulu. Same content as the free digital book, in a format designed to persist. A physical object that sits on a shelf, that can be lent, borrowed, handed over at the end of a difficult conversation, and left with someone who is not quite ready to read it today but might be in six months. The paperback exists for readers who want the work out of the digital feed and into the physical world. Their own home. Their own hands. Their own capacity to put it in front of someone else without a link, a login, or a screen.

The presentation at the top is the highest-conversion entry point into this argument. The paperback is the long-term companion to it. The attention economy forgets everything within a week. A physical artifact does not. The paperback is the piece most likely to be waiting on a bookshelf when the question becomes urgent for a specific person, long after this post has scrolled off anyone’s feed. Of everything on this page, these two bookends are the ones I would ask you to remember. They do different work, and both are needed.

The Unvaccinated - Order paperback at Lulu

8. Download the presentation and help it travel further.

The 42-minute presentation is available as a direct MP4 download. The English version is in the masthead above and can be downloaded from there. Three subtitled versions, in French, Spanish, and Arabic, are available at the link below. The files are hosted on Proton for anyone to grab, with no login or sign-up required. If you run a channel, a Substack, a podcast, a Telegram group, a WhatsApp network, or any other platform where this argument might reach a parent it has not yet reached, download the file and upload it to your own feed.

The showing frame does not travel if it only lives in one place. It travels when the people who find it decide to put it in front of someone else, in their own language, through their own channels. For readers in countries where the mainstream vaccine narrative is especially entrenched, or where the curious middle speaks a language other than English, the subtitled versions exist for exactly that purpose. The more mirrors the presentation has, the harder it is to make it disappear.

Link to MP4 downloads: English, French, Spanish, Arabic

Everything above is one argument, assembled in the order I would walk a thoughtful person through it. The presentation at the top is the shortest path. The paperback at the bottom is the longest. Everything in between is a step on the same staircase.

If you have been reading me for a while, this post is probably not for you. You already know this material. You already know where you stand.

It is for the one parent in your life who has not landed yet. The friend who stopped vaccinating partway and is quietly carrying the question. The sister-in-law who asked you something awkward at Christmas and has not raised it since. The colleague whose child was recently diagnosed with something nobody can explain.

If you know that person, send them the video. That is who it was made for.

Patrick Pillow, who writes as Libertarian Overwatch on Substack and at the Libertarian Institute, has been documenting individual regime-change operations one at a time. His piece is a synthesis of that work: the recurring elements across a dozen colour revolutions from Belgrade in 2000 to Tunisia in 2011. He works in the register of Mark MacKinnon and Matthew Collin, close to the ground-level record of what happened, who did it, and how the pieces travelled between operations.

“Colour Revolutions Decoded,” which I published earlier this year, asked a different question of the same material: what strategic system these operations belong to and what it serves. Patrick’s essay asks what the operations were and how they were built. Both questions are worth asking, and readers who take on both pieces will finish with a picture neither offers alone. If you’ve read mine, his gives you the granular record I compressed. If you’re coming to the topic through his, mine gives you the strategic frame his register leaves for the reader to draw.

Libertarian Overwatch

Covering U.S. foreign/domestic policy, political book reviews, pop culture all through Libertarian lens.

Audio Deep Dive (for Paid Subscribers)

The Tenets of a Color Revolution

By Patrick Pillow at Libertarian Overwatch

On October 5, 2000, hundreds of thousands of protesters arrived in Belgrade demanding the removal of Yugoslav President Slobodan Milošević.

Among those protesting were members of Otpor, a Serbian youth movement whose black clenched fist would go on to become iconic in revolutionary movements. Seen on walls, T-shirts, posters, and through millions of stickers which carried a simple message: Gotov je—“He’s finished.”

Then came the bulldozer.

Ljubisav Đokić, perhaps known best as “Joe the Bulldozer,” drove a front-end loader into the headquarters of Radio Television Serbia. Protesters stormed the building while occupying it, as police resistance largely collapsed. A day later, Milošević had conceded defeat.

The scenes in the streets of Serbia were dramatic, but it was the unseen movements that provided even more intrigue.

According to a Washington Post investigation, the United States spent approximately $41 million supporting the Serbian opposition in the year leading up to Milošević’s removal. American assistance helped support independent media, polling, opposition parties, election monitoring, and Otpor itself. Notably, the U.S. even helped pay for 5,000 cans of spray paint and 2.5 million stickers to flood the Serbian streets with.

Serbia was just the start of a multi-year revolutionary process.

In 2003, protesters arrived with roses as Eduard Shevardnadze was removed from power in Georgia. The next year, the streets of Kyiv were filled with orange as hundreds of thousands met on the Maidan to protest the second round of elections. Kyrgyzstan’s 2005 Tulip Revolution followed suit, as the Belarusian opposition prepared for the 2006 election after years of planning with denim serving as their symbol.

After Serbia, the model was set. Activists traveled country to country, shared non-violence strategies, translated revolutionary books, all while watching Serbia’s documentary of a successful protest, Bringing Down a Dictator.

After 2000, the revolutions had started to span the globe.

I. The Grievance Comes First

While foreign involvement plays a large role across these movements, the protesters didn’t require outside help to be angry in the first place.

In Serbia, years of war, sanctions, and economic concerns caused a movement to arise. In Georgia, the country faced issues with corruption, conflicts emerged in the provinces of Abkhazia and South Ossetia causing displacement, and electricity blackouts hit during the winter. During Kyrgyzstan’s 2010 revolution—the second revolution in the span of five years—heating prices increased by 200%, leading to the violent conflict that would soon unfold out in the streets.

Similar concerns were raised during the 2010s. Years before Egyptians occupied Tahrir Square in 2011, the Kefaya opposition movement had protested against the Iraq War, while labor unrest and concerns over police abuses continued. Tunisia had its own issues that overlapped with the countries of the 2000s: unemployment, corruption, and regional inequalities all existed well before 26-year-old Mohamed Bouazizi set himself on fire in December 2010, helping spark the Arab Spring.

Former USAID official Krishna Kumar has described Serbia’s overthrow of Milošević as a “case study” and a transferable model. Still, in most cases, these revolutions were not simply invented in Washington, as the “color revolutions” also required the infrastructure in place to support the movements on the ground.

Serbia had both.

American support extended beyond the youth group Otpor. The U.S. aided and funded Serbia’s independent media, trained political parties, and supported civil society in a crucial way in the lead-up to the revolution. An example of this was seen through the International Republican Institute, which reportedly trained around 400 Serbian election monitors, who then trained an additional 15,000 in the country.

When the September 2000 presidential election arrived, that level of support became crucial.

After Milošević claimed that opposition candidate Vojislav Koštunica had not reached the 50% threshold needed to avoid a runoff, the opposition pointed to its own vote count to support its position.

The political crisis in Serbia had now moved from the voting booths and into the streets.

II. The Revolutionaries Learn From One Another

But long before the September election, Otpor had already received another kind of assistance.

During the campaign against Milošević, retired U.S. Army Colonel Robert Helvey taught members of the Serbian youth movement how to organize, while the works of Gene Sharp remained highly influential as he spent decades writing about non-violent resistance.

Sharp argued that governments depend on people and institutions to follow the rules provided for them. If these institutions stop cooperating—especially when that includes the military or security forces—the opposition can achieve its goals.

Otpor put these methods to the test and received worldwide recognition.

The youth group employed a variety of tactics to spread its message including the use of humor, theatrical performances, graffiti, and the ever-present methods of nonviolence. Instead of trying to simply overpower the Milošević government, they attacked it directly in novel ways with authorities unsure of how to respond.

After October 2000, the Serbians had something else: a successful revolution.

Georgia was paying attention.

Before the 2003 Rose Revolution, members of the Georgian youth movement Kmara met with veterans of Otpor and learned about the Serbian experience. Georgia’s influential Rustavi-2 television station repeatedly aired Bringing Down a Dictator, a documentary detailing Otpor’s campaign against Milošević.

The influence was not particularly subtle.

One Georgian activist later described the uprising as a “copy of that revolution—only louder.”

The model would soon spread even further. During Lebanon’s 2005 Cedar Revolution, activists used similar tactics from earlier movements including overnight encampments and handing flowers to soldiers.

Ukraine, however, was paying even closer attention.

As the Rose Revolution unfolded, future Ukrainian Pora activist Mykhailo Svystovych watched the events on CNN. In his words, the Georgian success “gave us faith.” If it could happen there, he concluded, “it would definitely be possible here.”

During the spring of 2004, Ukrainians attended a multi-day workshop in Novi Sad, Serbia. Former Otpor activist Siniša Šikman later recalled teaching them fundraising, teamwork, negotiation, media relations, door-to-door campaigning, and methods for motivating students. Journalists Mark MacKinnon and Matthew Collin reported that the seminars were funded by Britain’s Westminster Foundation for Democracy.

The Ukrainians soon created their own identity.

Otpor had its fist and the slogan “He’s Finished.” Pora—“It’s Time”—used a clock for its visuals with slogans noting that “the clock is ticking.” Split into two branches—Yellow Pora and Black Pora—the black branch described its objective as creating a “social lightning bolt” across the country.

The connection between the groups remained strong. Youth from Belarus, Serbia, and Georgia held training sessions while sharing their personal experiences with Ukrainian activists. Black Pora’s website noted how the youth groups in Serbia, Georgia, Ukraine, Belarus, and Albania were its “friends and/or spiritual partners.”

Before the election, Pora held a week-long camp in Crimea consisting of more than 300 regional leaders. Pora later noted how they had received around $130,000 from the German Marshall Fund, Freedom House, and the Canadian International Development Agency.

The following month, representatives from nearly all of Pora’s 80-plus regional branches attended a seminar hosted by the U.S.-funded National Democratic Institute.

When Pora filled the streets of Kyiv in November, it was not a spontaneous movement. This was a plan that was months in the making.

III. Building the Infrastructure

Foreign funding remains the most controversial element of the “Color Revolutions.” Regarding the role of some of these organizations, Allen Weinstein, who helped establish the National Endowment for Democracy, described in The Washington Post how “A lot of what we do today was done covertly 25 years ago by the CIA.”

The support that followed was generally far less secretive, reaching civil society groups, independent journalism, election-monitoring efforts, and NGOs.

Among the most important organizations involved during the “Color Revolutions” are the U.S. Agency for International Development (USAID), the National Endowment for Democracy (NED), Freedom House, George Soros’s Open Society foundations, and two organizations affiliated with NED—the National Democratic Institute and International Republican Institute.

From country to country and year to year, the influence of these organizations was seen in different ways, with Ukraine in 2004 providing a key example.

The Western-funded Znayu campaign maintained a range of roles: developing voter education, running hotlines, training activists, and distributing millions of leaflets. Freedom House helped fund the campaign, though one official from its Kyiv office later noted that Znayu was “really just a small part of our whole work” and that “the variety of projects we funded was huge.”

Freedom House seminars also brought in veterans of Otpor, while the Albert Einstein Institution helped distribute Gene Sharp’s From Dictatorship to Democracy. Pora activist Oleh Kiriyenko later described Sharp’s book as “the bible of Pora.”

Exit polling and independent vote counts also became common during the revolutions. Before Georgia’s 2003 election, the election-monitoring group ISFED sent thousands of observers across the country to conduct their own vote count. Their results showed the opposition National Movement ahead, conflicting with the early results released by the government, with the findings then broadcast on the opposition-friendly Rustavi-2.

Similar methods would soon appear in Ukraine where independent exit polling received significant foreign support. With American, Canadian, British, Dutch, Norwegian, Swedish, Danish, and other international sources providing support for polling, the results were heavily monitored. As the exit polls contrasted with the official runoff results, hundreds of thousands of leaflets carrying the polling figures were passed around on the Maidan.

USAID itself would later highlight its role in these movements. In its September 2005 Democracy Rising pamphlet, the agency discussed the Rose, Orange, Cedar, and Tulip Revolutions while stating that “the colorful revolutions were created by citizens from Ukraine to Lebanon, with U.S. and other support.”

None of this shows that foreign sources controlled the events on the ground, but it does show how much infrastructure had been built around these movements before protesters entered the streets.

One of the most important parts of that infrastructure was independent media.

IV. Winning the Information War

With state-run media having a large market share in many of these countries, support for independent media became essential.

Serbia had support for both independent radio and television. Georgia had the widely popular opposition channel Rustavi-2. Ukraine had Channel 5, the online newspaper Ukrainska Pravda, and the website Maidan.org.ua.

By 2004, Maidan.org.ua started to become seen as a “virtual meeting place” for opposition movements. The website received millions of visits, reported on election discrepancies, and even published telephone numbers to reach authorities when activists were detained.

Channel 5 was known for its openly favorable coverage of Yushchenko, and as the Maidan crowds swelled, the station moved to 24-hour “marathon” coverage of the demonstrations while attracting journalists from other networks.

One of the first visible signs of cracks in the regime was seen through the media. During a broadcast on state television, sign-language interpreter Natalia Dmytruk told deaf viewers that the official election results “are all lies.”

Other journalists soon refused to follow the government topic lists provided to the stations known as temnyky, and the rest is history.

Kyrgyzstan had its own example. With support from the U.S. government, Freedom House established a printing press that produced as many as 28 independent newspapers. When electricity to the facility was cut during the 2005 election campaign, the U.S. brought in two generators allowing the printing to continue. The next issue of the opposition newspaper MSN carried a simple headline: “Your Time Has Run Out—Step Down.”

Modern advances in technology also changed the methods used by revolutionaries as the movements continued.

In the Philippines in 2001, text messaging played a major factor during the demonstrations that removed President Joseph Estrada. By 2009, the Moldova uprising became known by some as the “Twitter Revolution.” Tunisia and Egypt similarly benefited from the use of social media, with Facebook serving an important purpose.

A similar role was played by BahrainOnline, a popular opposition forum that became a gathering place for activists before Bahrain’s 2011 Pearl Revolution. As demonstrations spread in February, one user noticed only 126 people were viewing the forum and took it as a good sign: “most people are outside demonstrating.”

As methods started to evolve, governments responded accordingly. Hosni Mubarak’s government shut down most of Egypt’s internet during the 2011 uprising in an attempt to limit gatherings.

The plan backfired, with activist Samar El Hussieny calling it a “fatal mistake.” With the internet down, the only way to get information on what was happening in the country was to go outside.

The trend continued during Ukraine’s Euromaidan nearly a decade after the Orange Revolution. On November 21, 2013, journalist Mustafa Nayyem called on his Facebook followers to meet at Independence Square. The Euromaidan Facebook page that followed became another organizing tool, providing protesters with everything from meeting locations to maps showing where they could find free tea and warm spaces.

But getting the message out was only part of the challenge. Protest movements also had to give people a reason to stay involved.

V. Making Revolution Cool

Getting people into the streets was one thing. Keeping them engaged was another.

A key reason for Otpor’s success was the low stakes and entertaining methods used to encourage engagement.

In one of its more notable moments, activists from the group put a picture of Milošević on an oil barrel with a baseball bat left beside it, with customers from a nearby shopping district taking the opportunity to vent their frustrations.

When police arrived, the only thing they could do was drag the barrel away.

As Otpor’s Srđa Popović described it, this was the event that made the group a household name.

The humor first employed in Serbia continued for many years to come.

During Ukraine’s 2004 campaign, opposition leader Viktor Yushchenko was poisoned by dioxin during the campaign season. Shortly thereafter, the other candidate, Viktor Yanukovych, collapsed dramatically after being struck by some at-the-time unidentified object.

Yanukovych supporters claimed he had been hit by a stone or video-camera battery, with his campaign describing the incident as a “terrorist act.”

Then video of the incident eventually emerged and showed that the candidate had instead been hit by a simple egg thrown by a seventeen-year-old student.

It didn’t take long for activists to seize on the event.

Pora developed a theatrical street performance known as “The Egg-Traveler,” featuring the recently cracked egg’s supposed relatives, before handing out boiled eggs to the crowd.

Other activists took it upon themselves to develop a cartoon series and a satirical video game where players launched eggs at a spider with Yanukovych’s head.

Symbols meanwhile helped give the revolutions a recognizable image.

Of the “flower revolutions,” there was the Rose in Georgia, Tulip in Kyrgyzstan, Lotus in Egypt, and Jasmine in Tunisia. There were also the revolutions associated with a certain color including Yellow for the Philippines, Orange for Ukraine, Purple in Iraq, Pink in Kyrgyzstan, Blue in Kuwait, and Green in Iran. Lebanon added the Cedar Revolution, though inside the country the movement was also known as the “Independence Intifada.”

The branding worked. In Ukraine, orange was so prominent that markets started to sell the color at an upcharge. For Iran, opposition members of the national soccer team even wore green wristbands during a 2009 World Cup qualifier match.

The festival-like atmosphere of the protests also helped increase interest in the movements. The Maidan was compared by one newspaper to Woodstock. Ukrainian bands performed all night long, celebrities appeared on the Maidan stage, while the radio station Gala FM even opened its own press center in the tent city. At one point, demonstrators chanted “Yush-chen-ko!” along to the beat of songs by Kylie Minogue and The Prodigy.

Nearly a decade later, many of the same scenes returned during Euromaidan. Protesters once again occupied Independence Square as music played from a large stage, food was handed out, volunteers provided medical care, and supplies poured into the growing encampment.

Politics had become a culture.

VI. Governments Learn Too

The governments were watching as well.

Belarus took notes as Milošević fell in Serbia, Shevardnadze was overthrown in Georgia, and Akayev departed in Kyrgyzstan. Ahead of its 2006 presidential election, the government restricted NGOs, arrested activists, and prevented the establishment of a tent city like the one seen in Ukraine two years prior.

Kyrgyzstan had an entirely different approach. As the opposition formed a youth movement called KelKel before the 2005 Tulip Revolution, pro-government forces created their own organization with the exact same name to confuse the message.

Russia took a more preemptive approach. After witnessing revolutions spread through neighboring countries, the Kremlin supported the youth movement Nashi as a counterweight to any Russian version of Pora.

By the 2007 election, Nashi was preparing thousands of activists across locations where protests and tent encampments were expected. Even the opposition recognized the problem, with Oborona noting that the government understood Gene Sharp’s theories and that their task was “more difficult than that faced by democrats in Serbia, Georgia, and Ukraine.”

With government preparation, it became evident that using the Otpor model did not necessarily guarantee success. Belarus had Zubr, its own Otpor-inspired youth movement that was formed all the way back in 2001, yet Alexander Lukashenko remained in power as the state response crushed attempts at revolution.

Azerbaijan provided another example. Youth activists borrowed Ukraine’s orange branding, translated Gene Sharp’s From Dictatorship to Democracy, and trained with members of Otpor, Kmara, and Pora.

This time however, the government was ready.

When protesters attempted to establish a sit-in following the 2005 election, authorities moved quickly to disperse the crowd, fearful of a repeat of Ukraine’s Orange Revolution. Activists later argued in the documentary How to Plan a Revolution? that they also lacked the level of outside support seen in places such as Serbia and Ukraine.

Burma followed two years later with 2007’s Saffron Revolution, where monks and thousands of civilians took to the streets. Sharp’s work had been translated into Burmese, while monk organizer Ashin Kovida later pointed to Bringing Down a Dictator and Otpor as influences. The protests were ultimately suppressed.

Then came Iran where the Green Movement brought massive crowds to the streets in 2009, but the Iranian government had spent years warning about the possibility of its own “color revolution.”

Those concerns had even made their way onto Iranian television. In 2008, a cartoon produced by Iranian intelligence was aired on Khozestan TV, depicting Gene Sharp, George Soros, John McCain, and others sitting around a table supposedly discussing plans to destabilize Iran.

Before the election, Revolutionary Guards spokesman Reza Saraj pointed directly to the earlier movements. “In all those countries where they have had ‘color’ revolutions, they didn’t have a Revolutionary Guards Corps,” he stated. “We do.”

Gene Sharp’s work had made its way to Iran as well. Farsi downloads of From Dictatorship to Democracy increased from just 79 in May 2009 to 3,487 in June as the protests spread. Former Revolutionary Guard member turned opposition activist Mohsen Sazegara also promoted Sharp’s ideas through daily videos while providing Farsi translations of his work online.

The Iranian government was paying attention. During the trial of around 100 opposition figures, prosecutors claimed that more than 100 of Sharp’s 198 methods of nonviolent action had appeared during the unrest. The indictment even pointed back to Serbia, Georgia, Ukraine, and Kyrgyzstan.

Iranian authorities had even requested and received copies of Sharp’s work years earlier. By 2009, they had also closely studied previous “velvet revolutions.”

Still, months of protests were not enough.

It may have taken years to see it, but it became evident: the playbook had limits.

VII. The Geopolitics Behind the Revolution

Behind these revolutions remained another factor: geopolitics.

With the Baku-Tbilisi-Ceyhan (BTC) pipeline running through Georgia—which carried Caspian oil and bypassed Russia—pipeline politics remained a point of contention throughout the early 2000s.

Ukraine’s geographic location between Russia and Europe led to increased discussions over NATO integration, relations with the European Union, and energy projects like the Odessa-Brody pipeline.

Those tensions remained nearly a decade later when protesters returned to the Maidan in 2013. Assistant Secretary of State Victoria Nuland and U.S. Ambassador Geoffrey Pyatt visited Independence Square while handing out food to protesters and security forces. Months later, a leaked conversation between the two revealed them privately discussing Ukraine’s opposition leaders, with Nuland famously remarking that “Yats is the guy.”

In Kyrgyzstan, air bases created new tensions as the U.S. maintained the Manas airbase while Russia had the Kant base. Monetary promises were made as arguments continued over who should remain in the region.

The situation became more complicated in Egypt as former Secretary of State Hillary Clinton maintained friendly relations with Hosni Mubarak, even going so far as to consider him “a friend of my family.”

The possibility of unrest in Egypt had also caught Washington’s attention. In August 2010, Obama issued Presidential Study Directive 11 (PSD-11), leading to a classified review of potential unrest across the Arab world. Advisers reportedly studied previous uprisings to determine why some succeeded and others failed, with Egypt identified as a major flashpoint.

The directive itself has never been publicly released.

Once the uprising actually began, the White House attempted to reach out to the opposition and even developed a “matrix” of over 100 officials and leaders to contact about the situation in the country.

Region to region, the geopolitics differ, but U.S. involvement rarely occurs without some objective in mind.

Still, foreign governments can provide money, training, political support, or diplomatic pressure, but once protesters enter the streets another institution becomes considerably more important.

VIII. Who Holds the Power?

While there is no denying the role NGOs, financial support, youth movements, election observers, and independent media play in the success or failure of these revolutions, something even more basic also plays a factor: will the state still continue to support the person at the top when challenged?

In Serbia, when workers at the Kolubara coal complex began to protest at the end of September, police didn’t stop them and one activist declared “the battle for Serbia was won here.” When hundreds of thousands arrived in Belgrade days later on October 5, the standard set in Kolubara continued at a mass scale and Milošević was defeated.

Ukraine came very close to a violent suppression. On November 28, more than 10,000 Interior Ministry troops were reportedly prepared to use live ammunition, but the military and SBU refused to act. Later accounts described SBU chief Ihor Smeshko as a key player in preventing the confrontation, with advancing Interior Ministry forces eventually ordered back.

Tunisia’s military was unable to save President Zine El Abidine Ben Ali’s presidency in 2011. In Egypt, the military recognized the “legitimate” demands of the protesters and noted they would not use force against the people of Cairo.

Sometimes it becomes as simple as this: does the person at the top still control the people with the guns?

IX. What Comes After?

Changing the government was one thing. What came next was another.

Georgia initially looked like one of the success stories. Under Saakashvili, state revenues increased, pensions were paid, tax reforms were launched, and the government reasserted control over Adjara.

In less than five years however, protesters were once again gathering outside Parliament. Police violently dispersed the crowds, hunger strikers were beaten, journalists were told to stop filming, and the opposition station Imedi TV was raided before a state of emergency was declared.

While the state of emergency was lifted after just over a week, the damage was already done.

By 2008, Georgia was at war with Russia, leaving hundreds dead and thousands displaced. The crisis led to one of the lasting images of Saakashvili: the president caught by the BBC chewing on his tie as events unraveled around him.

Then, just weeks before the 2012 parliamentary election, videos emerged showing prison officers beating and sexually abusing inmates. Saakashvili’s party was decisively defeated weeks later, falling from 119 seats in parliament to just 65 as the opposition Georgian Dream coalition won 85.

Saakashvili eventually left the country and served as governor of Odesa in Ukraine. He returned to Georgia in 2021 where he was arrested and remains imprisoned.

Ukraine unraveled even faster as the Orange coalition started to split almost immediately. In September 2005, Yushchenko fired his entire cabinet, as accusations of corruption ran rampant. It was in this environment that Viktor Yanukovych returned to the government as prime minister.

By 2010, Yushchenko was receiving just over 5% of the vote in the first round of the presidential election. Tymoshenko advanced to the second round instead, only to lose to Yanukovych. Five years after protesters filled Independence Square to prevent him from taking office, Yanukovych had finally become president.

In one of his final acts as president, Yushchenko also awarded Stepan Bandera, the controversial nationalist leader whose Organization of Ukrainian Nationalists collaborated with Nazi Germany, the title “Hero of Ukraine.” The award was later annulled by a Ukrainian court.

Kyrgyzstan would see similar outcomes. Bakiyev, who came to power following the Tulip Revolution, soon faced many of the same accusations that had followed Akayev. Opposition newspapers were confiscated, NGOs faced new restrictions, and corruption remained rampant. Roza Otunbayeva, one of the leading figures of the 2005 uprising, later summed up the result bluntly: “we witnessed only how one clan was changed for another one.”

The disappointment came quickly. By September 2006, just eighteen months after the Tulip Revolution, Antiwar.com columnist Justin Raimondo was already declaring that the revolution had “wilted” as increased political instability, attacks on independent media, and growing concerns over Bakiyev’s government continued.

Five years after Akayev fled the country, Bakiyev followed suit. Another uprising erupted in April 2010, this time leaving nearly 90 people dead as protesters stormed government buildings and Bakiyev eventually fled to Belarus. Kyrgyzstan adopted a new constitution that weakened the presidency and shifted power toward parliament, but the cycle was not over. Another political upheaval would follow in 2020.

Even those who had been most hopeful about the revolutions were left disappointed. Edil Baisalov, a prominent member of the opposition during the 2005 uprising who later joined the interim government following the second revolution in 2010, resigned only months later.

“Nothing has changed,” he argued. “It’s the same old corrupt schemes.”

The hope that these revolutions would change things for the better rarely matched what came afterward.

X. A Playbook

There was no single formula for a “color revolution,” but by the mid-2000s a playbook had been established.

Serbia was the model. Georgia followed Belgrade’s lead, while Ukrainians studied the methods used by both Serbia and Georgia. Gene Sharp supplied influential pieces of literature, former revolutionaries provided training, and foreign organizations helped provide funding and infrastructure. Independent media, election monitoring, branding, humor, and eventually social media all became recurring parts of the movements.

Former Otpor members eventually formed the Center for Applied NonViolent Actions and Strategies (CANVAS), continuing international seminars and trainings long after Milošević was gone.

Still, not every piece of the playbook appeared in every country, and having them never guaranteed success.

The grievances were not invented. Elections presented some serious concerns. Protesters had their own motivations, and movements that had similar forms of foreign assistance sometimes failed completely.

The Orange Revolution reflects the tug-of-war between domestic and foreign relations. Pora maintained direct contact with foreign organizations and Serbian activists, while its members also built a nationwide movement as branches expanded across Ukraine.

Foreign governments supported exit polling, but Ukrainians physically occupied the Maidan and remained overnight. Western organizations funded democracy programs, while Russia provided significant funding to support Yanukovych. Ultimately, it was Ukraine’s Supreme Court that overturned the disputed runoff results, which they described as filled with “systemic and massive violations.”

While the revolution may not be made in Washington, its influence is frequently seen. In Egypt, it was seen even in the deployment of tear gas which was emblazoned with the marking of “Made in the U.S.A.,” leading demonstrator Aly Eltayeb to declare “the way I see it the U.S. administration supports dictators.”

With grievances seen in India, the Philippines, Serbia, Albania, and Nepal just to name a few—the question becomes where will we see the playbook used next?

The genetic story of disease is a cover story.

The twenty-first century runs on it. Paediatric clinics. Cancer centres. Forensic laboratories. Family-planning counsel. It is used to explain illness, to assign blame, to foreclose questions. It protects the industries whose products and practices are what actually caused the harm.

It isn’t true.

In 2010, Jonathan Latham and Allison Wilson looked at over seven hundred genome-wide association studies covering some eighty common diseases. The genes the field had promised were not there. The field invented a term, “missing heritability”, to explain the absence, and has quietly worked to bury the finding ever since.

The Genetic Deception is a book about what Latham and Wilson found. What the field did with it. And what the public was told instead.

The digital only first edition went out in May. The paperback — Second Edition, revised and expanded — is now live.

The Genetic Deception

How a Failed Science Conceals the Real Causes of Disease

Second Edition, revised and expanded. 406 pages, paperback.

Across nineteen chapters and six appendices, the book works through the conditions where the genetic framework collapses on inspection. Cystic fibrosis, where the environmental trigger is omitted. Down’s syndrome, where the toxic exposures are known but not acknowledged. Dravet syndrome, where vaccine injury is renamed as inherited fate. BRCA. FH. Alpha-1. The forensic DNA story the public has never been told.

Long-form interviews with Jamie Andrews and Leon Karmameleon of the Telestai Network. Close engagement with the work of Dr Thomas Cowan, Elizabeth Nickson, and Latham and Wilson. A resource library at the back. An appendix on what to say when the doctor says “it’s genetic.”

What the book exposes is a procedure. A procedure for converting environmental injury, pharmaceutical damage, and industrial poisoning into inherited destiny. The procedure works on the patient. It works on the doctor. It works because most people who encounter it have never been shown what it conceals.

→ Order the paperback on Lulu

New in the Second Edition:

Three chapters not in the digital edition. The first is a long treatment of cystic fibrosis, the textbook example of a single-gene disease and the case that falls apart hardest on inspection. The second catalogues ten of the conditions currently labelled “genetic” and shows, one by one, what the label forecloses. The third asks where family resemblance actually comes from if not from genes, and what the Human Genome Project’s failure means for the question.

Expanded appendices, including an expanded vocabulary for the terms the framework uses to protect itself. New Notes and Sources across nine chapters, cited to the primary literature rather than to the field’s own summaries.

A full back-of-book index covering the people, institutions, conditions, and concepts named in the book, cross-referenced so the paperback works as a reference and not just a read-through. Any term the reader has seen in a clinic or in a news article — missing heritability, Dravet, CFTR, BRCA — can be looked up and traced to every place the book addresses it.

Table of Contents

1. Introduction

2. Genetics: The Ultimate Cover Story

3. Genetics Was Built on Bad Chemistry

4. The Fifth Wall: Genetics as the Final Fortress of Medical Extraction

5. Fool’s Gold Standard: The Unvalidated Science of DNA

6. Interview with Jamie Andrews

7. Interview with Leon Karmameleon (Telestai Network)

8. Your Genetic Heart Disease Isn’t Genetic

9. The Great DNA Data Deficit

10. The DNA Paradox: How Unseen Molecules Became Unquestioned Facts

11. How to Create a Genetic Condition

12. What is Cystic Fibrosis?

13. Down’s Syndrome: Environmental Poisoning Disguised as Genetic Fate

14. The Genetic Alibi: How Wayne Bennett’s Family Tragedy Exposes the Dravet Syndrome Cover Story

15. The Great Extinction Lie: How Genetics and Environmental Fraud are Destroying Rural Populations

16. The Emperor’s New Genes

17. The DNA Myth: What the Peer-Reviewed Literature Actually Shows About Forensic and Paternity Testing

18. The Ten “Genetic” Diseases That Aren’t Genetic

19. Heredity Without Genes

Appendix 1: The Vocabulary of Genetic Deception

Appendix 2: What to Say When the Doctor Says “It’s Genetic”

Appendix 3: The Four Real Causes

Appendix 4: The Conditions Currently Labelled “Genetic”

Appendix 5: The Eugenics Continuity

Appendix 6: The Curated Resource Library

Index

Who this book is for:

The reader who has watched a diagnosis arrive in their family and sensed that the explanation did not fit. The reader who wants to know what the research actually says instead of what the press release claims. The reader who is ready to ask what happened to the person before they were handed the gene.

For those who want a pigeon pair:

No Autoimmunity: The Body Doesn’t Attack Itself takes apart the companion deception. The claim that the body turns on itself has done to immunology what the genetic story has done to disease causation. Same method. Same voice. Same conclusion. The two books together are the full argument.

Order No Autoimmunity

Audio Deep Dive (for Paid Subscribers)

Digital Edition of this paperback

Platinum Supporters - immediate access

Want access now? Upgrade to Platinum Supporter to receive digital editions on paperback release day.

Standard Paid Subscribers - access in 3-6 months from date of this post

EPUB Edition — Platinum Supporters

Readable on Kindle, Kobo, Apple Books, and any e-reader that supports the format. Platinum Supporters can download it below.

The paperback shelf:

The Unbekoming catalogue covers terrain medicine. Virology dismantled. Dentistry, veterinary practice, psychiatry. The vaccination record. The books are written to be read in a sitting, shared without permission, and used as a reference. The full catalogue is here.

Thank you to every reader who has carried these books forward. The work only matters because you read it, pass it on, and bring the questions home to the people who need them.

Unbekoming

In September 2026, Robert Winston sat down on a podcast couch and told his hosts what his profession has spent forty years concealing. He is eighty-five years old. He is Lord Winston, one of the pioneers who built British in vitro fertilization from an academic curiosity in the late 1970s into what he now calls a twenty-three billion dollar global industry. This essay walks through what he actually said, in his own words, and then names what he did not say. The paradigm this project works within holds that failure to conceive is a symptom, not a disease. Most modern reproductive breakdown traces back to the categories of insult that produce all disease: toxic exposure, nutritional depletion, and unrelenting stress. Where the essay quotes fertility medicine’s own vocabulary, that vocabulary sits inside attribution. In the author’s voice, it does not.

The confession

“We as a profession are not telling the truth.”¹

Winston said that to Konstantin Kisin and Francis Foster on their program Triggernometry, in September 2026. He said it in the context of a question about IVF success rates. He is not a critic of fertility medicine. He built the field. He performed some of the earliest work on preimplantation genetic diagnosis in Britain. He ran one of the first laboratories to secure reliable pregnancies at Hammersmith Hospital in the 1980s. He served as one of the public faces of assisted reproduction for four decades. The Prince of Wales visited his lab in the early years, when Winston was still trying to persuade the country that any of this was worth doing.¹

An admission of this kind, from this source, does not require interpretation. It requires only that the listener notice what he said, keep noticing, and then read what he said next.

He said the industry now sits at roughly twenty-three billion dollars globally.¹ He said the fees have become huge in every country. He said young researchers no longer go into real academic work because private clinics pay five or six times more. He said research on the culture medium in which embryos spend their first five days of life is “negligible,” because commercial clinics have no incentive to fund it and there is no other funder.¹

Then he began to describe the numbers.

Audio Deep Dive (for Paid Subscribers)

The rate the industry does not quote

Winston said, more than once during the interview, that his profession does not tell patients the cumulative success rate. The industry advertises a per-cycle number. The number a patient actually needs to plan her life around is the cumulative number: her real chance of having a live baby after completing her whole course of treatment, however many cycles that turns out to be.

The largest population study of that number in the UK is McLernon and colleagues, 2016, published in Human Reproduction. It followed 178,898 women through the national IVF registry between 1992 and 2011.⁸ The study reports three cumulative live-birth rates depending on statistical assumption. The conservative estimate, which assumes women who dropped out of treatment would never have succeeded, is around forty-four percent after six full cycles. The prognosis-adjusted estimate, which is the figure the mainstream press typically reports, is 65.3 percent after six cycles. The optimistic estimate is higher again.⁸

Whichever number you take, the pattern is the same. Even on the most flattering possible reading of the data, one in three women who enters IVF and completes six full cycles will leave without a baby. At the more conservative end, more than half will. Six cycles is not a small commitment. At five to ten thousand pounds per cycle in the private British clinics, and fifteen to twenty-five thousand dollars per cycle in the American ones once medications and monitoring are counted, six cycles is a mortgage payment.¹ The physical toll is separate and cumulative. Ovarian suppression, ovarian hyperstimulation, egg retrieval under sedation, embryo transfer, hormonal support, the two-week wait, then failure, then start again.

For women aged forty to forty-two, the McLernon paper reports a cumulative live-birth rate after six cycles of 31.5 percent.⁸ That is the age group that most closely tracks what corporate egg freezing programs are actually selling: the woman who freezes at twenty-eight and returns to attempt pregnancy at forty. The industry does not quote the McLernon age-adjusted number to her. It quotes the per-cycle rate at intake.

Winston said in the interview that he does not believe the twenty percent per-attempt rate the industry advertises is what the industry actually delivers.¹ He was more direct in the House of Lords on June 4, 2026, three months before the interview: “clinics are telling patients, I hear this again and again, that if you come to the clinic you have a sixty percent chance of having your eggs frozen, with a successful baby afterwards.”⁹ That is the pitch. It bears essentially no relation to what the data show for any age group in any published study.

Cycle by cycle, this is what her body actually goes through. First, drugs to shut down her natural cycle so the clinic can control the timing. Then, daily injections of hormones designed to force her ovaries to mature many eggs at once rather than the usual one. Then, days of transvaginal ultrasound monitoring to watch how the follicles develop.² A “trigger shot” tells her body to release the eggs. Then, under sedation, a needle is threaded through her vaginal wall into each ovary to extract the eggs. She returns days later for the embryo transfer, more hormonal support, and the two-week wait.² Ovarian hyperstimulation syndrome, the condition in which pharmacologically stimulated ovaries leak fluid into the abdominal cavity and can produce anything from bloating to renal failure to death,⁶ appeared nowhere in the Triggernometry interview. It rarely does.

The egg-freezing numbers the HFEA does not publish

Winston moved from cycles to eggs. Specifically to frozen eggs, the product currently being marketed to women in their late twenties and early thirties as insurance against career-driven delay.

He has been submitting written parliamentary questions on egg-freezing outcomes to the Minister for Health for over a decade, roughly every three years, because the Human Fertilisation and Embryology Authority does not publish the data any other way.⁹ ¹⁰ The most recent question was answered in December 2025.¹⁰ In the June 2026 Lords debate on fertility treatment regulation, he laid out the current numbers in the clearest form he had ever given them publicly.

Approximately 250,000 frozen eggs are currently held in storage in the United Kingdom.⁹ Over the five years leading up to the pandemic, 75,958 of those eggs were subjected to thawing for attempts at pregnancy. Roughly 13,000 of them survived the thaw process. Of those 13,000, 11,400 were fertilized. Of those fertilized eggs, 7,257 produced an embryo. Of those embryos, 1,695 were considered suitable for transfer. Of those transfers, 288 women became pregnant. Of those pregnancies, 205 resulted in a live birth. Eighty ended in miscarriage.⁹

The two numbers that follow from those figures are the ones the industry does not put in front of a patient at intake. Less than 0.2 percent of eggs subjected to thawing produce a live birth. Only 1.7 percent of eggs that are successfully fertilized produce a baby.⁹

Winston said in the Lords, and repeated in the interview, that the HFEA’s public messaging tells a different story. The HFEA states on its website that egg freezing success rates are improving. A senior HFEA figure recently gave the number on BBC radio as 18 percent per egg.⁹ The HFEA’s own data, provided in response to Winston’s written questions, contradicts both claims. The public number and the filed number are not the same number, and there is no institutional accountability for the gap.

Vitrification, the flash-freezing method now standard in the industry, subjects the cell to a massive temperature drop in a fraction of a second. The antifreeze medium is a toxic solvent that “you would not drink, for obvious reasons.”¹ Because clinics tend to stimulate hard in order to bank many eggs at once, and because batches must be thawed together, women who freeze eggs at twenty-eight are not banking a linear insurance policy. They are banking a probabilistic long shot in which the odds against any individual egg are overwhelming, and the odds against the whole batch producing a live baby are worse than the industry’s marketing implies.

Corporate wellness programs at technology firms now offer egg freezing as an employee benefit. The pitch is straightforward. Delay children, focus on career, freeze in your twenties, unfreeze in your late thirties or early forties. A curious skeptic sent this pitch by their employer may reasonably assume the underlying success rate is at least broadly reasonable. It is not. Winston noted, as an aside, that after age thirty-five, egg freezing is “probably not worth doing” because the technology’s slim margin collapses further with age.¹

The general failure to distinguish between a frozen egg, a thawed egg, a fertilized egg, a viable embryo, and a live-born child is not a public misunderstanding. It is a marketing achievement. Winston mentioned, in a moment of surprise even to him, a stranger at a party telling his wife, “Yeah, we have kids. We have two frozen ones.”¹

The message being sold to a twenty-eight-year-old woman is that she can safely prioritize her career because when she comes back at forty her frozen eggs will be waiting to become her children. That message is a lie. Not a marketing exaggeration. A lie. The eggs she is freezing at twenty-eight have less than a one-in-five-hundred chance per thawed egg of becoming a live baby.⁹ By the age at which she is likely to use them, her cumulative chance of a live birth even across six full IVF cycles is 31.5 percent.⁸ The technology is being sold to her as insurance. It functions as a lottery ticket. The odds are concealed at the point of sale, and the sale is being made by an employer that has packaged the lie as a benefit.

The black box

The five days that follow fertilization are, in Winston’s own words, “critical to the development of a human being when genes are being switched on and being programmed by the environment.”¹

Those five days, in IVF, are spent in a dish of commercial fluid in a dark container.

Winston was direct. The composition of the culture media is proprietary. Almost no serious research is being done on how these media affect the earliest embryonic development. Different clinics use different media. The Human Fertilisation and Embryology Authority does not record which are used, in what quantities, with what outcomes. Which media a given clinic buys and whether it changes suppliers is a commercial decision made largely without oversight.¹

The reason this matters, in Winston’s own framing, is a body of research he calls epigenetics: the observation that environmental information changes how the body develops, and that this changed development can carry forward into offspring. He described the Överkalix cohort study from Sweden, which found that boys who experienced abundance around age nine had grandsons who died younger.¹ The environment during a specific critical window in one generation showed up in the health of a generation the boy would never meet.

Winston then acknowledged that the entire earliest window of development in IVF children takes place in commercial fluid that has not been properly studied, and that these children are not being followed long-term in any systematic way.¹ He said, with characteristic understatement, “I don’t want to say IVF is dangerous because there is no evidence that it is.” He then added that when the Överkalix pattern was first described, nobody could see why it mattered either.¹

The reporting in Everything Below the Waist adds context Winston did not supply. Babies conceived through assisted reproductive technology have roughly double the rate of birth defects, even among singletons who are not premature.³ Dish embryos twin at four times the natural rate.³ ICSI, the procedure in which an embryologist selects a single sperm and injects it directly through the egg’s outer membrane with a glass needle, is now used in about three-quarters of American cycles regardless of whether a male-factor diagnosis exists.³ It has been in widespread use for fifteen years. The children conceived by it are only now becoming old enough to have children of their own.

Judith Stern, professor at Dartmouth Geisel School of Medicine, told Block: “We really do not know anything about the long-term effects, not only on the kids but on the women who undergo treatment.”³ Cancer, diabetes, and cardiovascular disease all sit on the list of open questions.

Diagnosis avoidance

Winston described a pattern he had observed for decades. A couple presents with a period of failure to conceive. The clinic offers IVF. Basic diagnostic work is skipped. Sometimes a simple structural problem is present, such as a uterine polyp or a tubal adhesion. Sometimes the underlying issue is hormonal or nutritional or the residue of years on hormonal contraception. Sometimes the male partner has a treatable condition and has never been examined. Sometimes the couple would have conceived on their own within a few more months.

“Once you make a diagnosis, you often don’t need in vitro fertilization,” Winston said. “And the truth is that a vast amount of in vitro fertilization is unnecessary. It fails. But then a few months later, somebody gets pregnant spontaneously.”¹

He explained that couples typically become panicked, seek a private clinic, and enter a treatment cycle before any investigation has taken place. The clinic has no financial incentive to spend clinician time discovering that the couple has a straightforward, cheap, correctable problem. It has every incentive to move them into a stimulation cycle.

Winston was blunt about what this means for the women who never conceive by IVF and who eventually conceive spontaneously after treatment fails. The industry books their eventual pregnancies as vindication of some prior intervention. The statistics look better than they are. The couples themselves rarely understand what happened.¹

He also described what he called “professional patients.” Women who go through eighteen cycles because they can afford to. Women who know every acronym in the field but cannot get an answer to the underlying question of why their bodies are not doing what bodies are largely built to do. Women whose relationships fracture under the strain of scheduled sex, injection sites, hormonal swings, and repeated grief. Marriages that end at cycle fifteen.¹

The Block reporting names this pattern from a different angle. Paul Turek, a urologist in California, gave her the field’s shorthand for it. “The gynecologists happen to have the perfect technology for things you can’t fix, which is IVF.”³ Turek’s own data show that fewer than one in five infertile men in the United States receive a urologic evaluation. The other four in five are handed a semen analysis and the woman is booked for a cycle.³

Winston’s version of the same complaint, delivered as an insider: fertility clinics doing regular in vitro fertilization do not subject themselves often enough to advice from male experts. He believes there should be more andrology in these clinics. There is not.¹

The label that hides the terrain

“Unexplained infertility” is the diagnostic category into which somewhere between one third and one half of couples entering IVF are placed. Winston did not attack the category directly. He worked around it. He spent much of the interview describing what he thought was actually going on.

He described a woman he had treated for years. Every test came back normal. Her husband’s tests came back normal. She never conceived. Eventually she left her husband, took up with a new partner, and continued to fail to conceive in England for a further two years. She then moved to Australia and became pregnant within weeks.¹

He described a lecture by a senior endocrinologist who insisted that in some cases, stress was a driver of ovulation rather than a suppressor of it, and that the effect of stress on fertility is not linear or well understood.¹

He described work he supervised in his own laboratory, never published, that suggested women who experienced orgasm during intercourse were somewhat more likely to conceive when the couple’s infertility was otherwise unexplained.¹

None of this is offered as a paradigm. Winston reaches for these fragments because he does not have a model for what is actually happening in most of his “unexplained” patients. The category is a placeholder for missing information. It is used to move a patient from diagnostic work into a treatment cycle without having to answer the question that patient is actually asking.

The woman with the shovel

Consider Holly. Not her full name; she asked Jennifer Block to use only her first name in Everything Below the Waist. Holly lives in Reston, Virginia. She was diagnosed with “unexplained infertility” at thirty-two, after her OB-GYN prescribed Clomid without further investigation. Holly endured “every side effect they listed, and then some.” Hot flashes. Nausea. Nightmares. Paranoia. She lost her ability to distinguish left from right. She cried every day for a week and could not explain why.³

Snowzilla arrived in January 2016. Twenty-nine inches of snow fell on Holly’s cul-de-sac. Her clinic, twenty-four miles away, had stationed doctors in nearby hotels to keep the schedule going. Holly’s husband suggested rescheduling. Holly refused. She had booked the injection, taken the trigger shot, done the ultrasounds. She spent six hours shoveling her driveway the day before her appointment. She woke before dawn the next morning and shoveled two more hours.³

Her husband had produced one semen sample, at the start. His count was low. He did not want to provide another. Nobody suggested that his low count might be the treatable problem. Holly took the drugs. Holly did the shoveling. Holly received the diagnosis. Holly went to the appointment.

Multiply Holly by several million women. This is what Winston means when he refers to “professional patients” whose marriages end at cycle fifteen. It is not abstract.

What Winston does not say

Failure to conceive is a symptom, not a disease. The couple in the clinic is not a broken machine. It is a body responding to accumulated conditions, and there is nothing mysterious about which conditions.

Winston has never quite said this. He has come close. He has described the interior of the industry with unusual candor: the numbers, the missing data, the market incentives, the ways clinics avoid diagnosis. He stops there. He has never denied that IVF produces real babies for real couples, particularly where a clear structural obstacle has been diagnosed. His argument is with an industry that has scaled a narrow application into a mass-market treatment of first resort for problems it was not designed to fix. The question sitting under his testimony is what those problems actually are.

Consider what the modern woman brings to the clinic at thirty-four.

She has spent between ten and fifteen years on a pharmaceutical that suppresses ovulation, thins the uterine lining, and elevates a binding protein that ties up her available testosterone long after the drug is discontinued. Eighty percent of American women born after 1945 have used the pill.⁴ Many began in adolescence for acne or menstrual irregularity rather than pregnancy prevention. One study of women entering IVF found that those with ten years of pill use had significantly thinner uterine linings than those with six.⁵ A separate study of some 900 women aged 19 to 40 found that current pill users had ovaries half the size of non-users and significantly lower markers of what fertility medicine calls ovarian reserve.⁵ The long-term study that would answer this question conclusively has never been funded.⁵

Layered onto that are the medications no one calls contraception. A decade of antidepressants. Repeated courses of antibiotics for acne, sinus infections, or the flu-that-was-not-the-flu. Non-steroidal anti-inflammatories for the periods that hurt more each year. Thyroid replacement, metformin, statins by thirty-five. And the exposures nobody has measured on her: mercury amalgams still in her teeth, glyphosate in her urine, phthalates from personal care products, BPA from a childhood spent drinking from plastic, ambient electromagnetic exposure orders of magnitude beyond what her mother lived with, carried in her pocket and held against her abdomen when she uses her phone.

Layered onto that are the meals. She has eaten what a modern professional woman eats: low-fat processed food, coffee, sugar, seed oils. She has never eaten the fat-soluble activators dense in organ meats, pastured egg yolks, and traditional fermented dairy that Weston Price documented in fourteen traditional populations that had no fertility problems and no chronic disease. Her thyroid function is likely marginal. Her adrenals are likely fatigued. Her mineral status has never been assessed by anyone.

Layered onto that are the conditions in which she has lived. Chronic overwork. Chronic sleep debt. Chronic low-grade anxiety that never resolves because the phone never stops. Sustained cortisol elevation disrupts the signaling between brain and ovary directly. As Kalish, cited in Block, puts it: “The ovaries are the victim in this. The ovaries are responding with abnormal hormonal output because of emotional, dietary, or inflammatory stress. It’s not the other way around.”³

This is the couple that walks through the clinic door. She is not a woman in equilibrium whose reproductive system has spontaneously and unaccountably failed. She is a woman in whom toxic exposure, nutritional depletion, and unrelenting stress have accumulated for a decade or two before the attempt to conceive begins. Her body has been telling her something for years. She has been medicated for each of the symptoms in turn.

The clinic does not investigate any of this. It cannot. The investigation is not billable, the diagnosis is not clean, and the treatment is not a treatment the clinic sells. The clinic sells stimulation, extraction, laboratory manipulation, and transfer. It adds those to a system already burdened, and books a per-cycle success rate as a triumph of technology, even though the cumulative outcome across a full course of treatment leaves most patients without a baby.

Modern life produces the exhausted, chemically saturated, depleted body. The fertility industry then processes that body without ever asking why it arrived. This is what Winston is circling when he mentions that clinics do not encourage patients to lose weight because “patients want to have IVF rather than losing weight.”¹ Weight is one variable. It stands in for many.

The missing statistics

Sex selection is now openly sold to British patients through clinics in Cyprus and Spain, Winston noted, and he was clear that he believes selection for other inherited traits is already happening in the United States. “That’s already happening. We’re not saying it’s happening, but I’m sure it is happening.”¹ The technology is here. The regulatory perimeter is porous. The financial incentive is enormous.

Return to the statutory obligation.

The Human Fertilisation and Embryology Authority was set up with a specific requirement to provide better information to patients.¹ Winston identified this as one of his largest complaints about the current situation. He put it this way in the Lords in June 2026, quoting his most recent exchange with the Authority directly: “when I recently asked the HFEA to write to the Minister, I was told that we do not know how many eggs are being frozen, how many end up fertilised, how many become embryos or what happens to those embryos, we only know the number of embryos transferred to uteruses and the number of pregnancies.”⁹

The Authority does not record how many eggs are stimulated per cycle across the industry. It does not record how many are frozen. It does not record how many are thawed. It does not record how many of those thawed eggs fertilize. It does not record how many of those fertilizations produce a viable embryo. It does not follow up the children born from these procedures over the long term. It does not require clinics to publish their outcomes by choice of culture media. It does not track ovarian hyperstimulation syndrome as a systematic outcome.

These are not accidental omissions. They are choices. They are the choices of a regulatory body that has decided, cycle after cycle, year after year, act after act, that the information the couple in the clinic actually needs is information that will not be collected. And in the meantime, the same regulator publishes on its website that egg-freezing success rates are improving, and a senior member of the Authority tells the BBC that the per-egg success rate is 18 percent. The number filed in response to a parliamentary question is 1.8 percent.⁹ The regulator has one number for the public and another for Parliament.

Informed consent, in the sense the medical profession claims it, is not possible in this data environment. A woman offered egg freezing at twenty-eight is not being told the 0.2 percent per-thawed-egg live birth figure because the authority that would have to compel that disclosure has declined to compel it. A couple offered a cycle at cycle four is not being told the cumulative outcome data because the industry does not want them to see the actual number. A woman handed a diagnosis of “unexplained infertility” is not being investigated because the investigation would cut into the clinic’s revenue and would not, in the current data environment, produce a legally defensible protocol.

The pioneer knows. He has been saying so, in the House of Lords, on the BBC, in the Daily Mail, and now on a podcast with an audience of hundreds of thousands. He said the industry lies. He said the regulator will not measure what needs to be measured. He said the market has swallowed the research. He said the technology is being sold to women on terms that do not match what the data actually show.

Whether the industry he built continues to lie about its results depends on whether the couples who walk into its clinics start asking questions that Winston himself has now, at last, put on the public record. The numbers he cited, and the numbers the regulator has chosen not to collect, are enough to begin.

How to Explain It to a Six-Year-Old

Imagine a factory that promises to make you a puppy. You pay them a lot of money. First, they give the mother dog a lot of shots to make her body do something it does not normally do. Then they take some tiny pieces out of her that could one day become puppies. Then they put those tiny pieces in a dark box for five days, with a special drink that nobody has really tested. Then they hand you the box.

Most of the time, when you open the box, there is no puppy.

But the factory does not tell you that. They tell you the puppy is almost definitely inside. And when you come back for a second box, and a third, and a fourth, and there is still no puppy, they tell you it is not their fault and you should try again. Some people try six times. Some people try eighteen times. Even after six tries, at least a third of people never get a puppy at all. And each box costs about the same as a used car.

The people who own the factory make twenty-three billion dollars a year selling boxes.

The man who invented the factory is very old now. He sat on a couch on television and said, “We are not telling the truth about the puppies.” Then he explained the numbers. Then he pointed out that the rules say the factory has to keep track of how many puppies actually come out of the boxes, and the factory has decided not to keep track. So nobody knows the real number.

The puppies that do come out sometimes have things wrong with them, and nobody knows how many, because the factory does not follow up.

The old man said all of this out loud. Now we have to decide what to do with what he said.

References

1. Winston, Robert, interviewed by Konstantin Kisin and Francis Foster, “The IVF Pioneer Who Says His Own Industry Is Lying: Professor Robert Winston,” Triggernometry, September 27, 2026.

1. Direct quotations and material from the transcript, including: the “we as a profession are not telling the truth” admission; the twenty-three billion dollar industry estimate; Winston’s biographical details and history at Hammersmith Hospital; his description of culture media research as “negligible”; his account of clinics avoiding basic diagnostic investigation before offering IVF; his description of “professional patients” who complete eighteen cycles; his account of the woman who conceived in Australia after failing in England; his remark that stress may in some cases drive rather than suppress ovulation; his laboratory observation about female orgasm and unexplained infertility; his description of the vitrification antifreeze; his remark that egg freezing after age 35 is “probably not worth doing”; his account of the party guest referring to “two frozen ones”; his description of the mechanics of the standard IVF cycle; his admission that clinics stimulate ovaries hard for freezing at the expense of proper egg maturation; his estimate of clinic fees between five and ten thousand pounds in Britain; his account of sex selection now sold through overseas clinics; and his belief that trait selection is already happening in the United States.

2. Chen, Serena, reproductive endocrinologist at Institute for Reproductive Medicine and Science, St. Barnabas Medical Center, quoted in Jennifer Block, Everything Below the Waist: Why Health Care Needs a Feminist Revolution (St. Martin’s Press, 2019), on the standard IVF protocol sequence: pituitary suppression with a GnRH analogue, ovarian stimulation with follicle-stimulating hormone and luteinizing hormone, monitored follicle development, hCG trigger shot, transvaginal ultrasound monitoring, and egg retrieval.

3. Block, Jennifer, Everything Below the Waist: Why Health Care Needs a Feminist Revolution (St. Martin’s Press, 2019). Chapter 2, “Fertility Insurance.” Sources include: doubled rate of birth defects in ART singletons; dish-effect twinning at four times the natural rate; ICSI used in approximately 75 percent of American cycles regardless of male-factor diagnosis; Judith Stern of Dartmouth Geisel on the absence of long-term outcome data for women and children; Paul Turek on IVF as the “perfect technology for things you can’t fix”; Turek’s finding that fewer than 20 percent of infertile American men receive urologic evaluation; Daniel Kalish on the ovary as victim of upstream metabolic, emotional, and inflammatory stress.

4. Grigg-Spall, Holly, Sweetening the Pill: or How We Got Hooked on Hormonal Birth Control (Zero Books, 2013). On the prevalence of pill use in successive cohorts, the sustained elevation of sex hormone binding globulin following discontinuation, and the pattern of women being labeled infertile while in recovery from years of hormonal suppression.

5. Block, Jennifer, Everything Below the Waist, on the relationship between duration of hormonal contraceptive use and endometrial lining thickness at IVF embryo transfer; on the study of approximately 900 women aged 19-40 showing hormonal contraceptive users had ovaries half the size and significantly lower ovarian reserve markers than non-users; on the observation by the endometrial-lining study authors that long-term contraceptive use may represent a “previously unidentified side effect” of importance in counseling.

6. Weschler, Toni, Taking Charge of Your Fertility: The Definitive Guide to Natural Birth Control, Pregnancy Achievement, and Reproductive Health, revised edition (William Morrow, 2015). On IVF protocol steps including GnRH suppression, gonadotropin stimulation, and the risk of ovarian hyperstimulation syndrome; on the acknowledgment that egg freezing success rates remain “quite low” with no extensive long-term studies of children conceived from thawed eggs.

7. Hill, Sarah E., This Is Your Brain on Birth Control: The Surprising Science of Women, Hormones, and the Law of Unintended Consequences (Avery, 2019). On the connection between pill-driven delay of childbearing and the growth of the infertility treatment industry (”as it goes with the pill, so it goes with IVF”).

8. McLernon, David J., Abha Maheshwari, Amanda J. Lee, and Siladitya Bhattacharya, “Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178 898 women,” Human Reproduction, Volume 31, Issue 3, March 2016, pages 572 to 581. Funded by the Wellcome Trust and the Medical Research Council. Reports cumulative live-birth rates in the UK IVF registry between 1992 and 2011: conservative estimate approximately 44 percent after six full cycles, prognosis-adjusted estimate 65.3 percent after six cycles, and optimistic estimate higher. For women aged 40 to 42, the prognosis-adjusted cumulative live-birth rate after six cycles was 31.5 percent.

9. Winston, Robert (Lord Winston), speech during the “Fertility Treatment Regulation” debate, Lords Chamber, Hansard, June 4, 2026. https://hansard.parliament.uk/lords/2026-06-04/debates/EDD1C1D5-A58E-4017-A20B-B3E2D1A1E943/FertilityTreatmentRegulation. Direct quotations and specific numbers used in this essay, including: approximately 250,000 frozen eggs held in UK storage; the five-year pre-pandemic data of 75,958 eggs subjected to thawing, with approximately 13,000 surviving the thaw, 11,400 fertilized, 7,257 producing an embryo, 1,695 suitable for transfer, 288 pregnancies, 205 live births, 80 miscarriages; the 0.2 percent per-thawed-egg and 1.7 percent per-fertilized-egg live birth figures; the discrepancy between the HFEA’s public messaging of 18 percent and its filed data of 1.8 percent; the HFEA’s admission to the Minister that it does not know how many eggs are frozen, fertilized, or become embryos, only how many are transferred; the clinic pitch of 60 percent success; the £915 embryo freezing fee and £325 annual storage cost.

10. Winston, Robert (Lord Winston), written parliamentary questions on egg freezing outcomes, House of Lords, submitted approximately every three years since 2013. Most recent set answered by Baroness Merron, Parliamentary Under-Secretary of State (Department of Health and Social Care), December 2025, using HFEA register data as of December 17, 2025. Public record via UK Parliament Hansard and compiled at parallelparliament.co.uk/lord/lord-winston.

A five-year-old silver filling contains 27 percent mercury instead of the 50 percent it started with. A twenty-year-old filling can contain less than 5 percent. Nearly half the mercury has departed within five years, and the person carrying the filling is where it went. Autopsy work published in the Journal of Prosthetic Dentistry found brain mercury concentrations correlating linearly with the number of amalgam surfaces in the mouth. A Bacharach industrial mercury detector held above the fillings of a university psychologist in ordinary conversation registered 90 micrograms per cubic meter of air. OSHA closes a workplace and issues a $10,000 fine at 51. The 1993 book It’s All in Your Head: The Link Between Mercury Amalgams and Illness sets out this evidence across twenty years of clinical work with over 7,000 patients. Double-blind testing of 3,500 of them returned reactivity to mercury in 90.2 percent of the patients tested. The American Dental Association’s official position, published in Science Digest in 1984, put the figure at 5 percent. Within a month it had been revised to 1 percent. By 1989 it stood at one in a million. By 1991 it was back to 3 percent. No supporting studies were cited for any of these numbers.

Hal A. Huggins received his dental degree from the University of Nebraska in 1962 and practiced conventional dentistry for the next eleven years, ghostwriting Atlas of Occlusal Analysis with Arne Lauritzen and lecturing internationally on blood chemistry and nutrition. His encounter with the mercury question came in 1973 at a Mexico City conference, when Brazilian dentist Olympio Pinto explained that certain blood chemistry abnormalities Huggins could not account for resulted from sulfhydryl blockage by mercury leaching from amalgam fillings. Pinto’s own master’s thesis on mercury toxicity at Georgetown University had been shut down a decade earlier by the National Institute of Dental Research, which forced the university to stop the work. Huggins spent the next twenty years documenting what Pinto had described. He returned to the University of Colorado at Colorado Springs at age 48 to study under experimental pathologist Douglas Swartzendruber, completing a master’s degree in 1989 with a thesis titled “The Medical and Legal Implications of Components of Dental Materials.” He founded the Huggins Diagnostic Center in 1990. By the early 1990s the center was receiving 5,000 calls per month. Robert Atkins, M.D., wrote the foreword.

The mercury fight was already 150 years old when the book appeared. In the 1830s and 1840s, the National Association of Dental Surgeons banned amalgam as unethical. When half the profession used it anyway, the organization disintegrated. The American Dental Association was founded in 1899 to replace it, and it endorsed amalgam from its first meeting. In the 1920s, German chemist Alfred Stock published over thirty scientific articles documenting mercury toxicity from fillings using research methods that rival the sophistication of any 1990s laboratory. The dental community attacked him personally. His laboratory was destroyed by a bombing raid in World War II, and he died in near obscurity. In the same decade, Weston Price served as director of research for the ADA for fourteen years and published extensively on the dangers of root-filled teeth. His work is now nearly impossible to find. Huggins wrote in 1993 into an environment in which the ADA was still telling the public that reactivity to mercury was rare. The new high-copper amalgams releasing mercury fifty times faster than earlier formulations were being sold as state-of-the-art. Young women were ending up in wheelchairs within three years of MS diagnosis instead of the twenty years it had taken a generation earlier. Nearly one million mercury fillings were being placed by American dentists every day.

The book belongs to the toxic-exposure lineage in the terrain canon, the tradition that traces named diseases to specific documented environmental sources. Huggins is a convergent witness. He works within the establishment’s own methodology and vocabulary, using clinical blood chemistry, laboratory reactivity testing, and porphyrin excretion assays to demonstrate that conditions medicine classifies as “autoimmune” frequently trace to a single toxic material placed in the mouth by trained professionals under regulatory endorsement. The full summary unpacks the four-question framework by which the case was built; the sequential removal protocol that raised response rates from 10 percent to over 50 percent by taking negative-current fillings out first; the calcium-manganese-mercury triad found in hair analysis of the toxic patient; the mechanism by which Streptococcus mutans, the bacterium living in every mouth, converts mercury into methyl mercury on the fillings themselves; and the case of eleven-year-old Susan, given three months to live with seizures every fifteen minutes, who walked downstairs on Christmas morning five days after her three small pit fillings were removed. In all states except California, a dentist who tells a patient any of this can lose the license he spent eight years training for.

Related

Audio Deep Dive (for Paid Subscribers)

Read more

A large freshwater flatworm starved for ninety-one days shrinks from twenty-five millimeters to seven, its survival time in potassium cyanide falls from seven hours and forty-five minutes to two hours, and its carbon-dioxide production per unit weight matches that of newly hatched worms of the same small size. When fed again, it grows, differentiates, and passes through the entire life history as if beginning at postembryonic life. The animal has become young in its own body, without cutting, without fission, without fertilization, without any reproductive process at all. This is the central experimental finding of Senescence and Rejuvenescence (1915), and the point on which its author, Charles Manning Child, rested his claim that the young organism arises from the old, not from a self-perpetuating reservoir of youth locked away in the sex cells.

Child worked in the Department of Zoology at the University of Chicago and directed his experiments from the Hull Zoological Laboratory. The book compiles fifteen years of laboratory work on flatworms of the genus Planaria, hydra and marine hydroids, ciliate infusoria, sea urchin and starfish embryos, and various fish, amphibian, and annelid larvae. About half of it presents his own unpublished data, developed with colleagues including the biochemist S. Tashiro (whose biometer measured carbon-dioxide production in the experimental animals) and the zoologist L. H. Hyman, whose parallel work on oligochete annelids confirmed his findings. The susceptibility method — a physiological ruler for age built from standardized measurements of survival time in cyanide, alcohol, and ether — was his own instrument, and it gave him something biology had lacked: a laboratory measure of aging.

The book appeared into a discipline dominated by August Weismann’s germ plasm doctrine, which held that reproductive cells constituted an immortal hereditary substance sequestered from the aging body and passed intact from generation to generation. Neo-vitalism, in the form of Hans Driesch’s Aristotelian entelechy, had reappeared to argue that living processes required a directive principle outside physics and chemistry. Corpuscular theories of heredity — Weismann’s biophores, De Vries’s pangenes, Spencer’s physiological units — proposed hidden units carrying the characteristics of the species. The German botanist Alexander Braun had described rejuvenescence in the vegetable kingdom in 1851, in one of the pre-Darwinian statements of evolution, and his work had been substantially forgotten by the time Child began his own experiments. Child discovered Braun’s book only after reaching his own conclusions in the laboratory. The coincidence of two independent arrivals at the same position across sixty years, with the earlier one already buried, was itself part of what he was writing into.

Child’s book was then buried for a century in its turn. It came back into view in September 2026 through Sasha Latypova’s essay at Due Diligence and Art, which read Child as an early witness to a position the biochemical model of life has since made unspeakable: that living tissue is not a bag of chemicals in water, that “proteins,” “genes,” and “enzymes” are labels on the dead residues of destructive laboratory tests, and that whatever life is, it is not what modern biology says it is. Latypova, whose earlier work documented pharmaceutical R&D fraud in the covid vaccine contracts, used Child to connect a 1915 zoology text to Robert Becker’s mid-century bioelectric research and to a 2025 study out of Tufts and the Wyss Institute showing that human skin cells undergo membrane depolarization as they age. The lineage she traces runs from the flatworm on Child’s laboratory bench to the electrical current in the tissue that Becker measured, and from there to the loss of coordinated bioelectric domains that Sediqi and Levin now describe as the physical signature of cellular senescence.

Child sits at the head of this lineage: physiological rather than genetic, terrain rather than germ-line, reversible rather than fated. The full summary unpacks the ninety-one-day starvation experiment and the metabolic evidence that accompanies it; the fifteen generations of Planaria velata bred asexually across three years with no cumulative senescence; and the six- to seven-fold increase in oxygen consumption in the sea urchin egg after fertilization, which Child reads as evidence that egg and sperm are physiologically OLD cells and that fertilization initiates rejuvenescence in the zygote, reversing the direction the received biology had assigned to the reproductive process. In 1915, Child described the organism as a flowing stream and the visible body as the sediment the stream had laid down. In 2025, that stream turned out to be literal — an electrical current, ionic rather than metallic, running through the water in the tissue.

Audio Deep Dive (for Paid Subscribers)

Read more